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Abstract 
Haemopoietic  stem  cells  (HSC)  in  vivo  are  generally  accepted  to  be  quiescent, 
entering  cell  cycle  relatively  infrequently.  However,  their  capacity  for  self-renewal 
and  multilineage  differentiation  renders  them  a  formidable  target  when 
transformation  occurs.  Chronic  myeloid  leukaemia  (CML),  characterised  by  the 
presence  of  the  BCR-ABL  fusion  gene,  arises  in  a  pluripotent  HSC  and  also 
features  a  population  of  quiescent  stem  cells.  Recent  data  on  the  effectiveness  of 
a  targeted  therapy  for  CML,  STI571  (STI),  designed  to  inhibit  the  tyrosine  kinase 
activity  of  the  oncoprotein,  has  cast  doubt  on  the  success  and  durability  of  clinical 
responses  to  this  treatment.  The  work  contained  in  this  thesis  was  aimed  at 
isolation  of  quiescent  stem  cells  from  both  normal  and  CML  samples  and 
characterisation  of  the  properties  of  these  rare  populations,  the  response  of  CML 
stem  cells  to  STI  treatment  in  vitro  was  also  examined;  and  finally  a  microarray 
study  was  undertaken  in  an  effort  to  elucidate  the  gene  expression  profiles  of  both 
normal  and  CML  quiescent  cells  compared  to  their  cycling  counterparts. 
To  isolate  these  specific  cell  populations,  enrichment  of  the  stem  cell  fraction  was 
achieved  by  selection  methods  based  on  the  stem  cell  marker  CD34.  Positive  or 
negative  CD34  selection  yielded  up  to  99%  pure  CD34+  cell  populations.  A 
fluorescent  activated  cell-sorting  (FACS)  strategy  was  developed  to  allow  isolation 
of  quiescent  and  cycling  stem  cells.  Using  Hoechst  (HST)  and  Pyronin  Y  (Py)  to 
stain  the  DNA  and  RNA  respectively  and  gating  on  the  viable,  Propidium  Iodide 
(PI)",  CD34+  population,  it  was  possible  to  isolate  viable  stem  cells  in  GO,  G1  and 
S/G2/M  phases  of  the  cell  cycle. 
Success  of  the  sorting  strategy  was  demonstrated  by  PCR  analysis  of  differential 
cell  cycle  gene  expression  in  the  sorted  populations.  Further  development  of 
FACS  methodology  allowed  the  division  history  and  stem  cell  status,  as  defined  by 
CD34  expression,  to  be  monitored  under  a  range  of  conditions.  By  staining  cells 
with  a  non-toxic  permanent  cytoplasmic  dye,  carboxyfluorescein  diacetate 
succinimidyl  ester  (CFSE),  combined  with  a  sorting  strategy  to  enhance  division 
peaks,  high  resolution  tracking  of  cell  division  was  possible.  Growth  factor 
independence  was  established  for  CML  stem  cells  and  was  used  to  identify 
leukaemic  stem  cell  proliferation,  as  normal  cells  failed  to  divide  under  these 
conditions. 3 
Using  this  experimental  strategy,  it  was  shown  that  a  number  of  CML  stem  cells 
were  able  to  survive  exposure  to  concentrations  of  STI  in  excess  of  those 
achievable  in  vivo,  and  that  the  surviving  cells  were  undivided  or  quiescent.  A 
range  of  sensitivities  to  STI  between  patient  samples  was  shown,  however  in  all 
cases  a  population  of  viable,  undivided  stem  cells  was  observed.  In  addition,  STI 
was  also  shown  to  exhibit  antiproliferative  activity  causing  the  number  of  quiescent 
cells  to  increase  following  treatment  in  vitro.  It  is  possible  that  these  observations 
may  contribute  to  the  lack  of  disease  eradication  in  vivo  by  STI,  which  is  rare  with 
most  patients  harbouring  detectable  BCR-ABL  transcripts,  despite  significant 
clinical  responses. 
In  an  effort  to  further  characterise  quiescent  stem  cells,  the  HST/Py  FACS  strategy 
was  used  to  isolate  quiescent  and  cycling  stem  cell  populations  from  both  normal 
and  CML  samples,  which  were  then  processed  for  microarray  studies.  The 
analysis  of  these  very  specific  stem  cell  populations  has  yielded  a  significant 
amount  of  new  data. 
Firstly,  the  results  have  shown  a  differential  gene  expression  profile  between 
normal  GO  and  cycling  cells  that  fully  validates  the  sorting  strategy.  Significant  up- 
regulation  of  known  cell  cycle  genes  was  observed  between  normal  GO  and 
cycling  cells.  In  contrast,  CML  GO  cells  exhibited  aberrant  expression  of  a  number 
of  cell  cycle  genes  in  the  GO  fraction,  representing  a  gene  profile  closer  to  that  of 
cycling  cells.  The  most  significant  differential  gene  expression  was  in  a  set  of 
chemokine  genes,  which  were  up-regulated  in  both  normal  and  CML  GO  cells 
compared  to  cycling  cells.  This  has  not  been  previously  reported  and  represents  a 
novel  finding.  Additional  data  analysis  is  ongoing  and  may,  in  time,  yield 
therapeutic  targets  for  CML  disease  eradication. 
In  summary,  isolation  of  specific  CML  stem  cell  populations  has  enabled  the 
identification  of  a  quiescent  population  of  cells  that  are  able  to  escape  the  effects 
of  a  targeted  therapy  in  vitro.  These  results  may  have  significant  clinical 
importance  as  mechanisms  of  disease  persistence,  already  observed  in  vivo,  are 
elucidated.  Furthermore,  identification  of  gene  differences  between  quiescent  and 
cycling  cells  has  validated  the  FACS  strategy  for  isolation  of  these  rare  quiescent 
stem  cell  populations.  In  addition,  data  analysis  has  identified  unique  differences  in 
gene  expression  of  a  set  of  chemokine  genes,  up-regulated  in  quiescent  cells, from  both  normal  and  CML  populations.  These  data  will  have  significant 
importance  in  our  understanding  of  quiescent  HSC  behaviour. 5 
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Chapter  1  Introduction 
1.1  The  Normal  Haemopoietic  System. 
The  integrity  and  functional  capacity  of  the  immuno-haemopoietic  system  is 
maintained  throughout  the  lifetime  of  an  animal  by  a  pool  of  pluripotent  stem  cells 
residing  in  the  bone  marrow.  These  cells  have  the  capacity  to  both  self  renew  and 
to  differentiate  into  all  haemopoietic  cell  types,  preserving  the  stem  cell  pool  and 
sustaining  a  functioning  haemopoietic  system.  In  order  to  achieve  this  a 
hierarchical  structure  exists,  which  results  in  progressive  lineage  commitment  of 
haemopoietic  stem  and  progenitor  cells  with  successive  division  in  response  to 
demand  for  mature  functional  cell  types.  Simply  to  maintain  the  status  quo  the 
haemopoietic  system  has  to  produce  around  2x1011  erythrocytes  and  1010  white 
blood  cells  each  day.  Terminally  differentiated  cells  are  generally  unable  to  divide 
further  and  are  continuously  replaced  by  the  differentiation  and  proliferation  of 
more  primitive  progenitors. 
By  definition  all  stem  cells,  regardless  of  their  origin,  must  possess  the  intrinsic 
properties  of  self-renewal,  differentiation  and  proliferation.  HSC  are  rare  (-1  in  105 
total  bone  marrow  cells),  relatively  quiescent,  and  are  defined  as  those  cells 
whose  replicative  potential  is  capable  of  restoring  haemopoiesis  after  marrow 
ablation,  therefore  possessing  the  capacity  to  generate  every  cell  of  the  immuno- 
haemopoietic  system.  Clearly  this  means  that  the  proliferative  potential  of  these 
cells  is  immense  and  must  be  tightly  controlled  to  prevent  excessive  numbers  of 
cells  accumulating  in  the  circulation.  The  control  of  the  HSC  compartment  is 
closely  associated  with  the  bone  marrow  microenvironment,  where  the  cells  are 
influenced  by  regulatory  factors  and  adhesive  interactions. 
1.1.1  Organisation  of  the  Stem  Cell  Compartment 
HSCs  are  closely  associated  with  the  bone  marrow  where  stromal  cells  interact 
with  stem  cells  and  transmit  signals  that  influence  their  behaviour.  Two  types  of 
HSC  have  been  identified;  long-term  repopulating  cells  (LTRC)  and  short-term 
repopulating  cells  (STRC).  STRC's  are  capable  of  reconstituting  myeloid  and/or 
lymphoid  haemopoiesis  for  a  short  period  of  time,  around  4  months  in  mice 
(Morrison  SJ,  Weissman  IL.  1994;  Morrison  SJ,  Wandycz  AM  et  al.  1997).  In Susan  M  Graham,  2005  Chapter  1,18 
contrast  LTRC  are  capable  of  rescuing  an  ablated  host  for  the  lifetime  of  the 
animal  and  of  producing  cells  that  can  reconstitute  a  secondary  host  (Harrison  DE 
and  Zhong  RK.  1992;  Morrison  SJ  and  Weissman  IL  1994).  The  initial 
reconstitution  by  STRC  is  thought  to  be  a  necessary  prerequisite  to  long-term 
engraftment  (Szilvassy  SJ,  Humphries  RK  et  al.  1990) 
Stem  cells  give  rise  to  an  array  of  terminally  differentiated  cells  via  a  pool  of 
committed  progenitors.  The  primary  function  of  the  progenitor  population  is  to 
vastly  increase  the  numbers  of  differentiated  cells,  thereby  reducing  the 
requirement  for  extensive  proliferation  of  primitive  stem  cells,  minimising  the 
chance  of  a  mutation  being  perpetuated  in  a  cell  with  self-renewal  capacity 
(Abkowitz  JL,  Catlin  SN  et  al.  2002;  Gordon  MY,  Lewis  JL  et  al.  2002).  As  HSC 
divide  and  move  toward  lineage  commitment  their  self-renewal  capacity  is  lost. 
Their  immediate  progeny,  although  multiipotent,  have  limited  self-renewal  potential 
and  comprise  common  myeloid  precursors  (CMP)  and  common  lymphoid 
precursors  (CLP).  CMP  in  turn  give  rise  to  committed  myeloid  progenitors 
including  erythrocyte/megakaryocytes  and  granulocyte/macrophages.  CLP  give 
rise  to  B  and  T  lymphocytes  and  NK  cells  (Akashi  K,  Traver  D  et  al.  2000;  Hao  QL, 
Zhu  J  et  al.  2001).  However,  the  boundaries  may  not  be  as  clear-cut  as  first 
thought,  as  an  early  T-cell  progenitor  (ETP)  which  retained  some  myeloid  potential 
has  been  identified  in  the  Thymus.  This  is  distinct  from  the  CLP  in  the  bone 
marrow,  which  has  no  myeloid  potential  (Allman  D,  Sambandam  A  et  al.  2003).  In 
addition  a  bi-potential  B-cell/macrophage  progenitor  has  been  described  as  being 
present  in  small  numbers  in  adult  murine  bone  marrow  that  has  the  capacity  to 
develop  into  both  lineages  under  the  correct  conditions  (Montecino-Rodriguez  E, 
Leathers  H  et  al.  2001).  A  diagrammatic  representation  of  haemopoietic  cell 
development  is  shown  in  figure  1.1. Susan  M  Graham,  2005  Chapter  1,19 
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Figure  1-1  A  diagrammatic  representation  of  the  haemopoietic  cell  hierarchy. Susan  M  Graham,  2005  Chapter  1,20 
The  classic  model  of  haemopoiesis  is  a  stochastic  one,  where  stem  cells  produce 
progenitors  that  in  turn  produce  differentiated  functionally  mature  progeny  in  a 
hierarchical  fashion.  As  cells  divide  they  lose  their  "sternness"  and  gain 
characteristics  of  differentiated  cells.  It  has  also  been  accepted  that  stem  cells  are 
largely  quiescent  residing  in  the  GO/G1  phase  of  the  cell  cycle.  However,  emerging 
evidence  has  suggested  there  maybe  phenotypic  changes  related  to  cell  cycle 
position,  and  more  recent  models  propose  an  organisation  that  is  more  akin  to  a 
continuum,  with  cells  responding  to  the  environmental  stimuli  they  encounter  in  a 
way  that  is  dependent  upon  their  cell  cycle  status.  Most  assays  that  examine  stem 
cells  do  not  take  account  of  the  continuous  functioning  and  adaptation  that  stem 
cells  undergo  in  the  course  of  their  lifespan. 
Studies  of  stem  cells  that  attempt  to  evaluate  their  behaviour  over  time  produce 
some  intriguing  results.  It  is  estimated  that  around  90-95%  of  our  multipotent  stem 
cells  are  in  GO-G1  at  any  one  time.  Analysis  of  long  term  repopulating  cells 
(LTRC)  in  mice  in  the  presence  of  continuous  BrdU  (which  substitutes  for 
thymidine  in  newly  synthesised  DNA)  has  shown  that  in  fact  90%  of  these  primitive 
cells  had  incorporated  BrdU  into  their  DNA  by  12  weeks.  It  was  calculated  that 
these  cells  cycle  around  once  every  30  days  (Bradford  GB,  Williams  B  et  al.  1997). 
Using  a  similar  strategy  Cheshier  et  al  were  able  to  show  that  by  6  months  99%  of 
LTRC  had  entered  cell  cycle  and  calculated  that  approximately  8%  of  stem  cells 
enter  cell  cycle  daily  (Cheshier  SH,  Morrison  SJ  et  al.  1999).  However  stem  cell 
kinetics  in  the  murine  system  may  not  be  mirrored  for  human  stem  cells,  and 
clearly  similar  experiments  in  human  subjects  are  not  feasible.  An  interesting  set 
of  experiments  using  non-human  primates  (with  similar  transplantation  kinetics  to 
humans)  showed  that  primitive  stem  cells  do  enter  cell  cycle  although  at  a  much 
slower  rate  than  those  of  rodent  stem  cells  (Mahmud  N,  Devine  SM  et  al.  2001). 
Quiescent  cells  are  not  inert;  whilst  they  may  not  be  transiting  the  cell  cycle  they 
are  transcriptionally  active  including  DNA  repair.  Synthesis  of  newly  repaired 
fragments  of  DNA  will  also  incorporate  BrdU,  albeit  at  a  much  lower  level  than 
replicated  DNA,  and  this  should  be  excluded  from  measurements  of  incorporation 
due  to  proliferation  (Pang  L,  Reddy  PV  et  at.  2003). 
1.1.2  Haemopoietic  Stem  Cell  and  Progenitor  Assays 
All  haemopoietic  stem  and  progenitor  assays  generally  determine  two  factors; 
differentiation  potential  and  proliferation.  This  necessitated  that  each  assay  was Susan  M  Graham,  2005  Chapter  1,21 
specific  for  the  cell  population  being  measured.  Clonogenic  assays  have  been 
designed  to  identify  the  progeny  of  each  progenitor  and  usually  take  the  form  of 
cells  seeded  in  semi-solid  medium  containing  growth  factors  specific  for  the 
population  of  interest.  The  read  out  from  these  assays  is  no  longer  than  3  weeks; 
therefore  they  are  only  capable  of  measuring  progenitor  and  not  stem  cell  function. 
Clonogenic  assays  detect  more  mature  progenitors  and  are  normally  specific  for  a 
particular  lineage  depending  on  the  growth  factors  included.  The  cells  used  to 
establish  these  assays  in  semi-solid  medium  may  be  un-manipulated  bone 
marrow,  peripheral  blood  mononuclear  cells  or  cells  generated  from  assays  of 
more  primitive  stem  cells  such  as  LTC-IC,  discussed  in  more  detail  below.  CFU- 
GM,  CFU-G,  CFU-M,  and  BFU-e  are  commonly  used  to  demonstrate  the  potential 
to  differentiate  down  a  particular  pathway  and  colonies  containing  multiple  cell 
types  are  generally  regarded  as  indicative  of  multipotency.  It  is  accepted  that 
combinations  of  growth  factors  are  needed  to  induce  stem  cell  differentiation 
(some  of  which  can  only  act  in  synergy)  and  this  in  turn  produces  a  variety  of  cell 
types  in  clonogenic  assays. 
The  first  haemopoietic  stem  cell  assay  was  the  CFU-S  assay  described  by  Till  and 
McCulloch  (Till  JE  and  McCulloch  EA.  1961).  This  assay  measured  in  vivo  stem 
cell  proliferation  and  differentiation  based  on  the  observation  that  transplanted 
stem  cells  form  colonies  on  the  spleen  of  a  lethally  irradiated  host  within  two 
weeks  of  transplantation,  and  that  the  number  of  colonies  is  directly  proportional  to 
the  number  of  input  cells.  The  cells  contained  in  these  visible  colonies  have  the 
capacity  to  form  colonies  in  a  secondary  transplant  demonstrating  self-renewal 
capability.  The  CFU-S  colonies  visible  at  day  8  contain  mostly  differentiated  cells 
with  day  12  colonies  containing  more  multilineage  cells,  which  is  a  reflection  of  the 
differentiation  status  of  the  initiating  cells.  However,  both  of  these  belong  to  the 
STRC  class  of  stem  cells;  accordingly,  the  terminology  pre-CFU-S  has  been  used 
to  refer  to  LTRCs. 
To  detect  more  primitive  cells  in  vitro,  cultures  that  include  a  supportive  stroma  are 
required.  To  proliferate  in  culture  LTRC  need  to  have  stromal  contact  that  mimics 
the  bone  marrow  microenvironment.  The  first  stromal  assay  was  developed  by 
Dexter  (Dexter  TM,  Allen  TD  et  al.  1977)  using  mouse  whole  bone  marrow  that 
was  able  to  generate  mature  progeny  for  several  months.  Ploemacher  and  Brons 
further  refined  the  assay  by  seeding  cells  onto  preformed  stromal  layers  that  had Susan  M  Graham,  2005  Chapter  1,22 
been  irradiated  to  prevent  proliferation  of  indigenous  cells  (Ploemacher  RE  and 
Brons  NC.  1988).  This  technique  allowed  the  development  of  the  cobblestone  area 
forming  cell  assay  (CAFC)  in  which  the  cells  that  form  a  distinctive  cobblestone 
pattern  underneath  the  stromal  layer,  were  subsequently  shown  to  demonstrate  a 
maturity  which  correlated  inversely  with  time,  as  tested  in  secondary  colony 
forming  assays.  Day  28  CAFC  was  shown  to  be  proportional  to  the  expected 
frequency  of  marrow  repopulating  cells  and  day  7  CAFC  to  be  equivalent  to  D-12 
CFU-S  (Ploemacher  RE,  Van  Der  Sluijs  JP  et  al.  1989).  The  sequence  of  events  in 
CAFC,  which  apparently  mirrored  in  vivo  stem  cell  development,  led  to  this  assay 
being  utilised  for  the  measurement  of  drug  and  radiation  sensitivity  of  various  stem 
cell  populations  (Down  JD  and  Ploemacher  RE.  1993) 
Another  similar  assay  is  the  long-term  culture  initiating  cell  (LTC-IC)  assay  but  this 
assay  has  a  different  end-point.  Cells  are  seeded  onto  established  irradiated 
stromal  layers  and  colony  forming  assays  carried  out  at  5  weeks  using  the  non- 
adherent  cells  from  the  cultures.  It  has  been  reported  for  human  cells  that  the 
CAFC  and  LTC-IC  assays  may  give  conflicting  results  in  terms  of  primitive  cell 
numbers.  This  may  be  explained  on  the  basis  of  differences  in  the  stromal  cells 
used.  Whilst  these  assays  give  an  indication  of  the  proliferative  capacity  of  stem 
cells  it  must  be  borne  in  mind  that  they  give  no  indication  of  the  in  vivo  homing 
capability  which  is  crucial  for  HSC  reconstitution. 
The  only  reliable  measure  of  true  stem  cell  potential  is  still  the  in  vivo  repopulation 
assay,  a  xenograft  model  which  allows  human  transplanted  cells  to  analysed.  This 
model  utilises  cells  transplanted  into  a  diabetic  mouse  with  severe  combined 
immunodeficiency  disease  (NOD/SCID)  mice.  These  mice  were  produced  by 
crossing  SCID  (T  and  B  cell  defects)  and  NOD  mice  (partially  deficient  in  NK  cells, 
antigen  presentation  and  macrophage  function).  Interestingly  there  was  no 
requirement  to  supplement  these  mice  with  human  cytokines  if  >500  cells  were 
transplanted  (Bonnet  D,  Bhatia  M  et  al.  1999).  Either  the  mouse  bone  marrow 
stroma  produced  the  required  cytokines  or  the  transplanted  cells  were  able  to 
secrete  them. 
First  described  by  Kamel-Reid  and  Dick  in  1988,  this  xenograft  model  has  been 
extensively  used  to  demonstrate  homing,  proliferation,  differentiation  and  self- 
renewal  of  human  stem  cells,  and  has  opened  the  way  for  more  rational 
investigations  of  human  haemopoietic  stem  cell  behaviour  (Kamel-Reid  S  and  Dick Susan  M  Graham,  2005  Chapter  1,23 
JE.  1988).  Some  mouse  strains  have  been  further  modified  to  produce  human 
cytokines  improving  the  environment  for  transplanted  human  cells.  This  model 
though  one  of  the  most  useful  is  not  without  limitation.  For  example,  there  is  a  bias 
in  the  transplanted  mice  toward  B  cell  development  with  T  cell  production  being 
less  favoured.  Engraftment  can  only  be  monitored  for  a  short  time  period  (around 
6  months  lifespan),  which  is  limiting  for  a  model  of  long-term  human  engraftment. 
Other  xenograft  models  have  been  established,  most  notably  in  sheep  by  Zanjani 
et  al,  however  immune  rejection  necessitated  that  human  HSC  be  introduced  into 
the  developing  foetus  to  induce  immune  tolerance  (Zanjani  ED,  Flake  AW  et  at. 
1994).  This  model  has  allowed  transplanted  human  HSC  to  be  monitored  over 
several  years,  and  in  addition,  no  radiation  or  conditioning  of  the  host  environment 
was  required,  minimising  disruptive  effects  on  the  stem  cell  niche.  However,  there 
are  a  number  of  disadvantages  in  large  animal  models  including  expense, 
handling,  and  long  term  read  out. 
1.1.3  Identification  of  Haemopoietic  Stem  Cells 
Due  to  the  relative  accessibility  of  haemopoietic  stem  cells  they  are  probably  the 
most  extensively  studied  of  all  adult  stem  cell  populations.  The  remarkable 
similarity  between  mouse  and  human  haemopoietic  systems  has  allowed  much  of 
the  investigative  work  aimed  at  defining  markers,  to  be  done  in  the  mouse  and 
subsequently  confirmed  for  human  stem  cells.  However,  the  markers  used  to 
identify  stem  cells  differ  between  the  two,  with  in  vivo  repopulating  capacity  being 
the  ultimate  verification  of  stem  cell  status. 
1.1.3.1  Stem  Cell  Markers 
There  is  no  single  marker  for  haemopoietic  stem  cells;  a  combination  of  surface 
markers  and  lack  of  lineage  specific  markers  expressed  on  more  mature  progeny 
is  commonly  used  to  isolate  stem  cell  populations.  These  populations  have  been 
shown  to  contain  cells  with  the  ability  to  rescue  an  ablated  host,  therefore  by 
inference  they  must  contain  multipotent  stem  cells.  Table  1.1  lists  the  markers 
used  most  commonly  for  isolation  of  both  mouse  and  human  cells.  Fluorescently 
tagged  monoclonal  antibodies  to  these  surface  antigens  allow  cells  to  be  identified 
by  FAGS  and  the  relative  stem  cell  numbers  to  be  calculated.  Using  FAGS  sorting, 
stem  cells  can  be  isolated  from  whole  blood  or  bone  marrow  though,  given  their 
rarity,  for  practical  reasons  a  prior  enrichment  step  is  usually  included. Susan  M  Graham,  2005  Chapter  1,24 
Human  Mouse 
CD34+  Sca-1' 
c-kit+  cKit+ 
Thy-1  bO  Thy-1  tO 
Negative  for:  -  _  CD10  B220 
CD14  CD3,4,8 
CD15  Mac-1 
CD16  Gr-1 
CD19  Ter  116 
CD20 
Table  1-1  Table  of  surface  markers  used  for  identification  of  human  and  mouse 
haemopoietic  stem  cells. 
The  most  common  surface  markers  used  to  isolate  mouse  HSC  are  Lin"  Sca-1  i' 
Thy-1b0  cKIT+.  (Spangrude  GJ,  Heimfeld  S  et  al.  1988)  The  addition  of  IL-7Ra  as  a 
marker  has  allowed  the  discrimination  of  CMP  and  CLP  populations.  The  IL-7Ra+ 
fraction  contains  almost  all  of  the  common  lymphoid  progenitors  giving  rise  to  T,  B 
and  NK  cells,  whereas  the  common  myeloid  progenitor  is  found  almost  exclusively 
in  the  IL-7Ra  fraction  of  the  Lin'  Sca-1+  Thy-1b0  population  (Kondo  M,  Weissman  IL 
et  al.  1997;  Akashi  K,  Traver  D  et  al.  2000).  Murine  cells  also  express  CD34, 
however  experiments  using  transgenic  mice  engineered  using  P1-based  artificial 
chromosomes  (PAC-transgenics  allow  human  gene  and  protein  expression  in 
mouse  cells)  have  shown  that  CD34  is  expressed  differently  in  mice  than  in  human 
stem  cells.  CD34  is  only  expressed  on  human  repopulating  cells  whereas  murine 
CMP  and  CLP  express  both  human  and  murine  CD34.  It  has  been  further 
revealed  that  elements  regulating  the  gene  expression  of  CD34  are  very  different 
in  human  and  mouse  haemopoietic  stem  cells  (Akashi  K,  Traver  D  et  at.  2000; 
Okuno  Y,  Huettner  CS  et  al.  2002;  Okuno  Y,  ). 
Undoubtedly  the  most  important  human  stem  cell  marker  is  CD34,  a 
transmembrane  glycoprotein  expressed  on  the  surface  of  haemopoeitic  stem  and 
progenitor  cells,  which  was  first  discovered  in  a  myeloblastic  leukaemia  cell  line 
(Civin  Cl,  Strauss  CL  et  at.  1984).  The  exact  function  of  the  CD34  molecule  on Susan  M  Graham,  2005  Chapter  1,25 
stem  cells  is  as  yet  undefined;  roles  in  differentiation  and  cytoadhesion  have 
recently  been  suggested  (Krause  DS,  Kapadia  SU  et  al.  1997;  Hidalgo  A,  Weiss 
LA  et  al.  2002).  Although  it's  precise  role  in  haemopoiesis  is  still  under 
investigation,  it's  importance  in  selection  and  purification  of  HSC  for  both 
experimental  purposes  and  for  human  transplantation  is  indisputable. 
CD34  is  expressed  on  -1-4%  of  normal  bone  marrow  nucleated  cells  and  on 
<0.1%  of  the  nucleated  peripheral  blood  cells  under  homeostatic  conditions.  This 
small  fraction  of  the  total  white  blood  cells  contains  almost  all  of  the  cells  with  in 
vivo  repopulating  capacity  as  well  as  the  LTC-IC  and  CFC,  but  does  not  include 
terminally  differentiating  cells  (Saeland  S,  Duvert  V  et  al.  1992),  (Civin  Cl,  Strauss 
CL  et  al.  1990).  Following  depletion  of  cells  expressing  lineage  markers  (Lin)  the 
CD34'  cell  population  is  still  extremely  heterogeneous,  and  in  an  effort  to  identify  a 
more  primitive  stem  cell  population,  CD34  has  been  used  in  combination  with 
other  surface  markers  e.  g.  CD38,  which  is  expressed  on  CD34'  cells  as  they 
become  more  mature.  CD34+CD38-  cells  have  the  capacity  to  rescue 
immunodeficient  mice  following  transplantation,  whereas  the  more  mature 
CD34;  CD38+  cells  can  only  confer  short-term  reconstitution  and  have  no 
secondary  repopulation  potential  (Hogan  CJ,  Shpall  EJ  et  al.  2002). 
There  is  now  a  considerable  body  of  evidence  to  suggest  that  CD34'  stem  cells 
exist  in  both  humans  and  mice  that  also  have  repopulation  capacity  (Osawa  M, 
Hanada  K  et  at.  1996;  Bhatia  M,  Bonnet  D  et  al.  1998).  Sato  et  at  documented  that 
murine  CD34  expression  is  inducible  both  in  vitro  and  in  vivo  and  that  it  is  a 
reversible  process  (Sato  T,  Laver  JH  et  at.  1999),  (Dao  MA,  Arevalo  J  et  at.  2003). 
Recently  it  has  been  demonstrated  that  the  same  is  true  of  human  CD34 
expression  and  that  CD34'Lin'  cells  have  marrow-engrafting  capacity.  Furthermore 
tertiary  transplants  confirmed  that  long-term  engraftment  potential  was 
demonstrable  for  both  CD34+  and  CD34'  cells  (Zanjani  ED,  Almeida-Porada  G  et 
at.  2003).  These  observations  suggest  either  that  expression  of  the  CD34  antigen 
is  not  necessary  for  stem  cell  function  or  that  phenotypically  different  cells  can 
have  similar  functional  capacity. 
Recent  published  work  by  Dooley  et  al  has  shown  that  in  vitro  modulation  of  the 
CD34  antigen  takes  place  and  that  it  is  associated  with  proliferation  status.  These 
experiments  illustrated  that  CD34'  cells  can  regain  CD34  expression  and  that  their 
proliferative  capacity  is  similar  to  CD34+  cells.  This  modulation  was  not  associated Susan  M  Graham,  2005  Chapter  1,26 
with  differentiation.  In  addition,  if  CD34+  cells  remained  undivided  i.  e.  quiescent  in 
culture  for  more  than  2  days,  they  lost  CD34  expression,  which  was  reinstated 
when  these  cells  started  to  proliferate.  All  of  these  findings  illustrate  that  the  Lin' 
CD34+  population  is  intrinsically  heterogeneous  with  respect  to  CD34  expression, 
but  still  retains  repopulation  activity  in  this  primitive  subset  that  can  be  used 
clinically  for  transplantation  (Dooley  DC,  Oppenlander  BK  et  al.  2004). 
Other  possible  markers  for  primitive  stem  cells  include  CD133,  which  is  expressed 
on  a  subset  of  CD34+  cells.  These  cells  include  the  repopulating  cells  and  primitive 
progenitors  excluding  erythroid  progenitors.  However  CD133  is  also  expressed  on 
CD34'  human  cord  blood  HSC  (Yin  AH,  Miraglia  S  et  al.  1997;  Gallacher  L, 
Murdoch  B  et  al.  2000).  It  is  unclear  whether  CD133  provides  any  advantage  over 
CD34  as  a  stem  cell  selection  marker.  Another  recently  identified  marker  for 
human  HSC  is  the  vascular  growth  factor  receptor  2  (KDR).  It  has  been  reported 
that  KDR+  cells  are  Lin-  CD34+CD38'  and  are  highly  enriched  for  SRC  (SCID 
repopulating  cell)  potential,  with  lineage  committed  stem  cells  being  CD34+KDR' 
(Ziegler  BL,  Valtieri  M  et  al  1999).  More  recently,  Danet  et  at  have  identified 
ClqRp,  (the  human  homologue  of  the  mouse  stem  cells  antigen  AA4)  which  is 
expressed  on  both  CD34+  and  on  CD34'  stem  cells  from  human  cord  blood  and 
bone  marrow  as  a  positive  marker  of  BM  repopulating  cells  (Danet  GH,  Luongo  JL 
et  al.  2002).  Interestingly,  these  experiments  also  showed  that  C1gRp  cells  have 
the  capacity  to  develop  into  human  hepatocytes  in  NOD/SCID  mice,  indicative  of 
stem  cell  plasticity  discussed  in  more  detail  below. 
1.1.3.2  Alternative  Ways  to  Identify  HSC 
In  1996  Goodell  et  al  identified  a  new  population  of  mouse  stem  cells  by  staining 
with  Hoechst  33342  and  viewing  the  dual  wavelength  UV  emission  on  a  FACS 
plot.  These  cells  were  designated  side  population  cells  due  to  their  position  on  this 
plot.  These  cells  were  subsequently  shown  to  be  Lin'CD34'  and  to  contain 
repopulation  potential.  The  SP  position  of  these  cells  depended  on  their  ability  to 
efflux  dyes  like  Rhodamine  or  Hoechst  (Goodell  MA,  Brose  K  et  al.  1996)  The 
efflux  of  drugs  and  dyes  such  as  these  has  since  been  attributed  to  the  activity  of 
P-glycoprotein;  an  ATP-binding  cassette  (ABC)  transporter  expressed  on  the  cell 
surface.  When  the  activity  of  this  transporter  pump  is  inhibited  by  verapamil  the 
numbers  of  SP  cells  decrease.  However  P-gp  knockout  mice  contain  SP  cells 
indicating  that  other  ABC  transporters  may  contribute  to  the  SP  phenotype. Susan  M  Graham,  2005  Chapter  1,27 
Human  SP  cells  were  also  shown  to  be  Lin'CD34'  and  highly  enriched  for  LTC-IC 
activity  and  to  express  CD34  following  stromal  cell  culture  (Goodell  MA, 
Rosenzweig  M  et  al.  1997). 
An  additional  method  to  purify  HSC,  which  also  relies  on  a  functional 
characteristic,  involves  the  activity  of  the  cytosolic  enzyme  aldehyde 
dehydrogenase  (ALDH).  Responsible  for  oxidising  aldehydes  to  carboxylic  acids, 
ALDH  is  found  in  high  concentration  in  the  cytoplasm  of  HSC  rendering  them 
resistant  to  the  effects  of  alkylating  agents  such  as  cyclophosphamide.  The 
introduction  of  a  fluorescent  substrate  for  ALDH  allowed  the  identification  of  cells 
with  high  levels  of  enzyme  to  be  distinguished  and  sorted  from  the  rest  of  the  HSC 
population  (Storms  RW,  Trujillo  AP  et  al.  1999).  These  cells  were  found  to  be 
enriched  for  repopulating  cells  when  introduced  into  NOD/SCID  mice  (Hess  DA, 
Meyerrose  TE  et  al.  2004).  Given  that  there  appears  to  be  some  debate  regarding 
the  surface  phenotype  of  HSC,  perhaps  isolation  methods  that  rely  on  biological 
function  rather  than  surface  markers  may  prove  to  be  more  reliable. 
1.1.4  Self  Renewal  of  HSC 
In  clinical  terms,  understanding  the  control  of  stem  cell  self-renewal  has  been  the 
ultimate  goal  for  ex  vivo  stem  cell  expansion.  If  stem  cells  could  be  induced  to  self 
renew  in  culture,  the  implications  for  transplantation  would  be  enormous.  By 
definition  a  stem  cell  is  one  that  can  both  renew  itself  and  differentiate  into  multiple 
lineages.  In  addition,  when  a  malignancy  occurs  in  a  self-renewing  stem  cell  it  can 
perpetuate  the  disease  limiting  the  chances  of  a  cure.  Factors  that  control  self- 
renewal  are  still  largely  unknown,  however  the  recent  availability  of  technology  to 
identify  gene  expression  profiles  in  purified  stem  cell  populations  has  shed  light  on 
possible  candidates.  To  date,  genes  implicated  in  self-renewal  include 
transcription  factors,  genes  involved  in  chromosomal  rearrangements,  cell  cycle 
inhibitors  and  signalling  pathways.  It  is  not  surprising  that  many  of  the  genes 
involved  in  stem  cell  self-renewal  identified  so  far  have  their  origins  in 
developmental  biology.  For  an  embryo  to  survive,  the  early  cells  must  divide  and 
retain  their  stem  cell  characteristics  before  differentiating  into  the  cells  of  various 
organs  in  due  course. Susan  M  Graham,  2005 
1.1.4.1  HOX  genes. 
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HOX  genes  are  highly  conserved  transcription  factors  involved  in  embryogenesis. 
HOXB4  was  first  shown  10  years  ago  to  cause  the  selective  expansion  of  primitive 
progenitors  when  over  expressed  in  HSC  and  to  confer  an  enhanced  repopulation 
advantage  over  non-transduced  cells  assessed  after  several  months.  Despite  the 
expansion  of  primitive  HSC  in  these  repopulation  experiments  the  HSC  pool  size 
did  not  exceed  that  of  non-transduced  HSC  suggesting  that  overexpression  of 
HOXB4  did  not  influence  the  regulation  of  pool  size  (Sauvageau  G, 
Thorsteinsdottir  U  et  al.  1995). 
Further  experiments  with  HOXB4  HSC  expanded  ex  vivo  and  marked  with  GFP 
(green  fluorescent  protein)  have  shown  that  the  expanded  cells  were  functional 
and  able  to  reconstitute  long  term  haemopoiesis  when  transplanted.  Furthermore 
there  was  greater  expansion  in  primitive  HSC  compared  to  more  mature  cell  types. 
Using  a  stromal  cell  line  engineered  to  produce  HOXB4,  Amsellem  et  al  showed 
that  human  LTC-IC  and  SCID  repopulating  cells  were  expanded  in  vitro  by  >20- 
and  2.5-fold  respectively  (compared  to  input  numbers)  and  that  this  expansion  was 
accompanied  by  increased  repopulating  ability  in  vivo  (Amsellem  S,  Pflumio  F  et 
al.  2003).  Thus  it  would  appear  that  primitive  human  stem  cells  could  be  expanded 
in  vitro  in  response  to  HOXB4  and  still  retain  their  stem  cell  phenotype. 
Other  published work  has  shown  a  similar  role  for  HOXC4,  where  over  expression 
in  human  CD34+  cells  induces  in  vitro  expansion  of  both  primitive  and  committed 
progenitors  (Daga  A,  Podesta  M  et  al.  2000).  HOXC4  is  a  paralog  of  HOXB4  and 
the  similar  results  obtained  with  over  expression  experiments  suggest  overlapping 
roles  for  paralogs  in  the  maintenance  of  the  primitive  status  of  HSC.  On  the  other 
hand,  more  recent  studies  have  shown  that  HOXB4  deficient  mice  only  have  a 
minor  proliferation  deficiency  and  sustain  comparatively  normal  haemopoiesis 
(Brun  AC,  Bjornsson  JM  et  al.  2004).  In  vitro,  the  cells  from  these  mice  show 
reduced  proliferation  of  primitive  cells,  which  is  also  observed  following 
transplantation.  Further  analysis  revealed  that  the  lack  of  HOXB4  also  appeared  to 
influence  the  expression  of  other  HOX  genes  as  well  as  some  genes  associated 
with  cell  cycle.  It  was  also  noted  that  these  HOXB4  deficient  mice  had  reduced 
cellularity  in  both  the  bone  marrow  and  spleen,  suggesting  that  although  other 
HOX  genes  compensate  for  the  loss  of  B4  they  do  so  at  a  sub  optimal  level.  There 
is  a  close  association  with  the  development  of  leukaemia  and  many  of  the  HOX Susan  M  Graham,  2005  Chapter  1,29 
genes,  however  HOXA4  (a  paralog  of  HOXB4)  does  not  appear  to  be  associated 
with  the  disease.  If  HOXA4  plays  a  central  role  in  stem  cell  self-renewal,  this  would 
suggest  that  augmentation  of  self-renewal  alone  is  not,  in  itself,  able  to  cause 
leukaemia. 
1.1.4.2  Polycomb-group  Genes 
Recent  studies  have  highlighted  another  candidate  involved  in  haemopoietic  stem 
cell  self-renewal,  the  polycomb-group  (PcG)  gene  Bmi-1.  PcG  genes  play  a  vital 
role  in  embryogenesis,  cell  cycle  regulation  and  lymphopoiesis.  They  are 
responsible  for  maintenance  of  gene  silencing  and  in  so  doing  confer  the  cell's 
functional  identity.  Their  involvement  in  malignant  transformation  has  created  a 
great  deal  of  interest  and  subsequent  investigation.  PcG  proteins  form  complexes 
containing  histone  deacetylase  and  methylase  activity  and  are  involved  in  the 
modification  of  chromatin  structure  and  histone  tails  (reviewed  in  (Orlando  V 
2003). 
Park  et  al  have  demonstrated  that  adult  mouse  and  human  HSC  express  the 
proto-oncogene  Bmi-1  and  that  bone  marrow  transplanted  from  Bmi-1-1"  mice  was 
able  to  initiate  temporary  haemopoiesis  only.  In  addition,  there  was  no  evidence  of 
self-renewal  of  adult  HSC  and  gene  expression  analysis  showed  that  a  range  of 
stem  cell  associated  genes  was  altered  in  the  bone  marrow  of  these  mice  (Park 
IK,  Qian  D  et  al.  2003).  Lessard  et  al  showed  that  Bmi-1  has  a  role  in  the 
regulation  of  proliferative  capacity  in  both  normal  and  leukaemic  stem  cells  and 
that  endogenous  Bmi-1  can  rescue  cells  from  apoptosis,  growth  arrest  and 
differentiation  (Lessard  J  and  Sauvageau  G  2003).  A  further  study  by  Iwama  et  al 
has  confirmed  that  increased  expression  of  Bmi-1  promotes  HSC  self-renewal.  By 
transducing  HSC  with  GFP  or  Bmi-1,  culturing  single  cells  and  separating  the 
daughter  cells  by  micromanipulation,  the  authors  were  able  to  show  that  forced 
expression  of  Bmi-1  promoted  symmetrical  cell  division.  Each  of  the  daughter  cells 
was  shown  to  exhibit  similar  proliferation  potential  in  colony  assays,  and  the 
probability  of  symmetrical  cell  division  was  significantly  higher  in  the  Bmi-1 
transduced  cells  than  in  the  controls  (Iwama  A,  Oguro  H  et  at.  2004).  The 
additional  finding  that  Bmi-1  can  extend  the  lifespan  of  mammary  epithelial  cells  by 
up  regulating  the  telomerase  RT  gene  (hTERT)  could  have  further  implications  for 
HSC  self-renewal  and  malignant  transformation  (Dimri  GP,  Martinez  JL  et  al. 
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1.1.4.3  Notch  Genes 
Notch  receptors  are  critical  to  HSC  regulation  where  they  are  involved  in  stem  cell 
fate  decision  i.  e.  whether  a  cell  self-renews  or  differentiates.  They  are  also 
involved  in  specification  of  T  or  B  lymphocyte  development  from  the  common 
lymphoid  progenitor  cell  (Pui  JC,  Allman  D  et  al.  1999).  Notch  receptor  gene 
knockouts  are  embryonic  or  perinatally  lethal,  demonstrating  the  importance  of 
these  genes  in  development  (Xue  Y,  Gao  X  et  al.  1999),  (Jiang  R,  Lan  Y  et  al. 
1998),  (Hrabe  de  Angelis  M,  McIntyre  J  2nd  et  al.  1997).  There  are  4  Notch 
receptors  that  have  partially  overlapping  functions  and  share  homology  in  structure 
and  in  ligand  binding.  The  ligands  for  Notch  receptors  are  the  transmembrane 
proteins  Jagged  1,  Jagged  2  and  Delta.  Following  binding  the  intracellular  portion 
is  cleaved  and  translocates  to  the  nucleus  where  it  acts  as  a  transcriptional 
activator. 
Varnum-Finney  et  at  have  demonstrated,  using  a  retroviral  vector,  that  constitutive 
expression  of  the  intracellular  domain  of  Notch  leads  to  the  generation  of 
immortalised  cell  lines  from  cytokine  dependant  haemopoietic  cells.  These  cells 
are  capable  of  in  vivo  repopulation  of  both  myeloid  and  lymphoid  lineages 
(Varnum-Finney  B,  Xu  L  et  al.  2000).  In  a  series  of  experiments  using  the  Notch 
ligand  Delta  1  immobilised  on  tissue  culture  plates  in  combination  with  defined 
cytokines,  Varnum-Finney  et  al  demonstrated  a  4-5  log  increase  in  the  number  of 
cells  capable  of  short-term  lympho/myeloid  repopulation  in  NOD/SCID  mice  after 
28  days  in  culture.  The  significant  increases  in  progenitor  cells  observed  in  this 
study  are  in  contrast  to  other  published  work  where  only  modest  increases  in 
primitive  cells  have  been  observed  using  Delta  1  as  a  soluble  factor.  The 
considerable  expansion  seen  here  is  attributed  to  the  immobilised  presentation  of 
the  ligand  in  combination  with  the  cytokine  cocktail  (Varnum-Finney  B,  Brashem- 
Stein  C  et  al.  2003).  These  results  confirm  a  role  for  Notch  in  self-renewal  of  HSC 
and  progenitors. 
More  recent  studies  have  identified  Notch  signalling  as  indispensable  for  the 
maintenance  of  undifferentiated  stem  cells  but  not  for  their  survival  or  cell  cycle 
initiation.  In  transgenic  Notch  reporter  mice,  Notch  signalling  was  identified  in  HSC 
in  vivo,  and  was  down  regulated  as  differentiation  progressed.  In  addition  when 
Notch  signalling  was  inhibited  differentiation  was  hastened.  Furthermore  Writ  (see Susan  M  Graham,  2005  Chapter  1,31 
below)  alone  was  unable  to  maintain  undifferentiated  HSC  when  Notch  signalling 
was  absent  (Duncan  AW,  Rattis  FM  et  at.  2005). 
1.1.4.4  Wnt  Genes 
Wnt-mediated  signalling  is  implicated  in  a  number  of  processes  in  both  vertebrate 
and  invertebrate  development.  Wnt  proteins  have  been  shown  to  regulate 
segment  polarity  in  Drosophila  and  axis  specification  in  Xenopus  as  well  as  limb, 
somite  and  axis  configuration  in  mice.  More  recently,  Wnt  signalling  pathways 
have  been  implicated  in  HSC  self-renewal  and  proliferation. 
There  are  19  Wnt  genes  that  encode  lipid-modified  signalling  proteins  that  serve 
as  ligands  for  the  Frizzled  family  of  receptors  or  the  lipoprotein  receptor-related 
protein  (LRP).  In  the  absence  of  Wnt  signalling,  ß-catenin  is  retained  in  the 
cytoplasm  where  it  becomes  associated  with  a  destruction  complex  containing 
APC,  Axin  and  GSK-3ß.  In  the  presence  of  Wnt  signalling,  GSK-3ß  is  inhibited  by 
Dishevelled  and  is  unable  to  phosphorylate  ß-catenin,  which  results  in  its 
stabilization  and  accumulation  in  the  cytosol.  ß-catenin  then  translocates  to  the 
nucleus  where  it  forms  a  complex  with  the  lymphoid-enhancer-binding  factor 
(LEF)/T-cell  factor  (TCF)  family  of  transcription  factors,  which  in  turn  allows 
induction  of  specific  target  genes  (Reya  T  2003),  (Ikeda  S,  Kishida  S  et  al.  1998; 
Kishida  S,  Yamamoto  H  et  at.  1998). 
Murdoch  et  al  have  demonstrated  that  injection  of  Wnt5A  into  mice  transplanted 
with  human  cord  blood  haemopoietic  cells  increased  the  level  of  reconstitution  and 
output  of  primitive  haemopoietic  cells  in  vivo.  Reya  et  al  provided  further  evidence 
of  Wnt  induced  expansion  of  HSC,  where  active  ß-catenin  (normally  produced  as  a 
consequence  of  Wnt  signalling)  was  constitutively  over  expressed  in  retrovirally- 
transduced  stem  cells  resulting  in  the  proliferation  of  HSC  populations  in  the 
absence  of  differentiation.  It  was  estimated  that  ß-catenin  caused  an  8-80-fold 
increase  in  HSC  number  after  just  1  week  in  culture.  Conversely,  engineered 
expression  of  soluble  Frizzled  receptor  (which  inhibits  Wnt  signalling),  or 
intracellular  expression  of  Axin  (involved  in  ß-catenin  degradation)  caused  a 
reduction  in  the  proliferation  and  survival  of  primitive  HSC  in  vitro.  Interestingly, 
these  experiments  also  revealed  that  Wnt  activation  produced  an  increase  in 
expression  of  HOXB4  and  Notch  1,  previously  associated  with  HSC  self  renewal. 
(Reya  T,  Duncan  AW  et  al.  2003). Susan  M  Graham,  2005  Chapter  1,32 
1.1.4.5  p21  and  p27 
Stem  cells  are  comparatively  quiescent,  entering  cell  cycle  relatively  infrequently 
compared  to  progenitor  cells,  whose  expansion  is  rapid  and  extensive.  Cyclin 
dependant  kinases  (CDK)  and  inhibitors  (CDKI)  control  cell  cycle  progression,  with 
the  CDKIs  serving  as  checkpoints  limiting  progression  through  the  different  cell 
cycle  phases.  There  are  two  families  of  CKIs;  the  CIP/KIP  family  which  includes 
p21c'P'waf  (p21),  p27Kip  (p27),  and  p57K'p2,  and  the  INK4  family  including  p161nk4, 
p151nk4b,  p18i"kac  and  p19I"k4d.  The  two  families  are  distinguished  by  the  CDKs  they 
inhibit;  the  INK4  members  act  on  CDK4  and  CDK6  and  the  CIP/KIP  family  acts  on 
a  number  of  CDKs  but  particularly  on  CDK2.  p27  is  distinct  from  p21  in  its  C 
terminus  and  is  not  a  target  for  p53.  Most  CDKIs  are  regulated  at  the  post- 
transcriptional  level,  however  p27  is  also  subject  to  post-translational  regulation. 
It  has  been  shown  that  the  bone  marrow  of  p21''  mice  contain  increased  numbers 
of  HSC  and  show  increased  HSC  cell  cycling,  however  exhaustion  of  stem  cells 
was  observed  under  conditions  of  stress.  (Cheng  T,  Rodrigues  N  et  al.  2000).  p27 
was  shown  to  have  a  similar  effect,  however  this  was  observed  in  a  more  mature 
progenitor  population.  Recent  studies  by  Yuan  et  al  have  demonstrated  that 
deletion  of  p181nk4c  results  in  vastly  improved  engraftment  of  murine  stem  cells, 
largely  due  to  an  increase  in  self-renewal  divisions  (Yuan  Y,  Shen  H  et  al.  2004). 
These  observations  suggest  that  different  CDKIs  have  diverse  effects  depending 
on  cell  context  and  activation  status. 
1.1.4.6  Others 
Maintenance  of  telomeres  is  critical  to  self-renewal.  Telomeres  are  guanine-rich 
repeat  sequences  at  the  ends  of  chromosomes  that  act  to  preserve  genomic 
stability.  In  the  absence  of  telomerase  (an  RNA/protein  complex  that  extends 
telomeres)  DNA  is  not  fully  replicated  and  as  a  result  progressive  shortening  of  the 
chromosome  ends  occurs.  Progressive  telomere  shortening  leads  to  replicative 
senescence  and  ultimately  to  cell  death.  A  feature  of  many  malignant  cells  is  the 
up-regulation  of  telomerase,  and  thus  escape  from  senescence  and  preservation 
of  division  potential.  Telomerase  is  expressed  in  HSC  with  self-renewal  capacity 
and  declines  as  cells  become  more  differentiated  (Morrison  SJ,  Prowse  KR  et  at. 
1996).  Despite  the  intrinsic  telomerase  activity  in  HSC,  their  telomeres  continue  to 
shorten  with  division  in  vivo.  Accelerated  shortening  of  telomeres  in  transplanted Susan  M  Graham,  2005  Chapter  1,33 
HSC  compared  with  donor  HSC  is  observed  initially,  however  the  differences 
reach  a  level  that  does  not  change  after  around  a  year  post-transplant 
(Brummendorf  TH,  Rufer  N  et  al.  2001).  Serial  transplants  in  mice  are  limited  to  -4 
rounds  suggesting  that  HSC  cannot  self-renew  indefinitely,  however  stresses  on 
transplanted  cells  in  terms  of  homing  and  establishment  of  cell  interactions  within 
the  bone  marrow  niche  may  influence  their  long  term  stability  (Harrison  DE  and 
Astle  CM.  1982). 
Yet  another  candidate  implicated  in  stem  cell  regulation  has  its  origins  in 
embryogenesis;  the  Hedgehog  (Hh)  family  of  proteins  is  involved  in  the 
organisation  and  specification  of  early  mesoderm  and  embryonic  tissues.  The 
group  comprises  Sonic  Hedgehog  (Shh),  Indian  Hedgehog  (Ihh)  and  Desert 
Hedgehog  (Dhh),  and  two  transmembrane  receptors  Patched  (Ptc)  and 
Smoothened  (Smo),  with  Ptc  being  the  primary  receptor.  When  Hh  binds  Smo  the 
subsequent  signalling  events  modulate  expression  of  genes  such  as  Writ 
(described  above)  and  the  bone  morphogenic  protein  (BMP)-4  specific  inhibitor 
Noggin.  BMP-4  is  a  member  of  the  transforming  growth  factor  (TGF-ß)  superfamily 
and  has  been  shown  to  enhance  stem  cell  survival  at  high  concentration  (Bhatia 
M,  Bonnet  D  et  al.  1999).  Shh,  Ptc  and  Smo  gene  expression  has  been  identified 
in  primitive  HSC.  Bhardwaj  et  al  have  shown  that  addition  of  anti-Hh  inhibited  the 
cytokine-induced  proliferation  of  HSC;  in  contrast  treatment  with  Shh  induced 
expansion  of  primitive  human  HSC  in  transplanted  mice.  In  addition  Noggin  was 
able  to  inhibit  the  mitogenic  effect  of  Shh  showing  that  Shh  acts  through  BMP-4 
(Bhardwaj  G,  Murdoch  B  et  al.  2001). 
1.1.5  The  Stem  Cell  Niche 
Central  to  the  behaviour  of  stem  cells  are  the  environmental  influences  to  which 
they  are  subject.  The  bone  marrow  stroma  consists  of  a  variety  of  cell  types 
including  endothelial  cells,  fibroblasts  and  osteoblasts  as  well  as  extra  cellular 
matrix  (ECM)  components,  which  include  collagen,  fibronectin,  laminin  and 
proteoglycans.  The  cell-cell  interactions  between  these  and  HSC  are  mediated 
through  a  variety  of  specific  molecular  targets  within  this  niche,  which  act  to  control 
stem  cell  behaviour.  The  ECM  can  bind  growth  factors  produced  by  stromal  cells 
creating  distinct  "pockets"  that  accumulate  HSC.  The  ECM  can  also  bind  to 
glycoproteins  expressed  on  HSC.  Stromal  cells  are  known  to  secrete  or  present  in 
bound  form  a  variety  of  cytokines  important  for  HSC  survival  and  proliferation. Susan  M  Graham,  2005  Chapter  1,34 
These  include  IL-1,  -6,  -11  and  certain  colony  stimulating  factors  e.  g.  stem  cell 
factor  (SCF),  flt3  ligand  (FL),  tumour  necrosis  factor  a  (TNFa)  and  TGFI  (Sensebe 
L,  Deschaseaux  M  et  al.  1997). 
Adhesive  interactions  also  play  a  critical  role  in  HSC  regulation  by  the  BM 
microenvironment.  Numerous  receptors  on  HSC  are  involved  in  adhesion  to 
stroma,  including  very  late  antigen-4  (VLA-4)  and  VLA-5  receptors  for  fibronectin, 
CD44,  the  receptor  for  hyaluroinc  acid  (a  component  of  the  ECM),  and  a  number 
of  stromal  cell  surface  receptors  such  as  intracellular  adhesion  molecule  (ICAM) 
and  vascular  adhesion  molecule  (VCAM),  a  ligand  for  VLA-4.  In  fact,  blocking 
VCAM  with  monoclonal  antibody  in  vivo  leads  to  an  increase  in  circulating  HSC, 
suggesting  that  these  cells  are  unable  to  efficiently  adhere  to  molecules  within  the 
BM  stroma  (Kikuta  T,  Shimazaki  C  et  al.  2000).  Studies  of  BM  CD34+  cells 
cultured  with  and  without  stroma,  fixed  stromal  layers  or  integrin  binding  FN 
fragments  showed  increased  preservation  of  LTC-IC  and  ELTC-IC  with  or  without 
associated  cell  division  in  the  presence  of  stroma  or  FN  fragments  (Bhatia  R, 
Williams  AD  et  al.  2002),  reinforcing  the  significance  of  stromal  interaction  with 
stem  cell  behaviour. 
More  recently  two  groups  have  identified  a  population  of  osteoblasts  in  the  BM  that 
appear  to  influence  HSC  behaviour.  In  the  study  by  Calvi  et  al,  mice  were 
genetically  altered  to  produce  active  parathyroid  hormone  PTH/PTHrP  receptors 
(PPRs)  controlled  by  an  osteoblast  specific  promoter.  They  were  able  to  show  that 
not  only  was  there  an  increase  in  the  number  of  osteoblasts  in  response  to  PPR 
but  this  was  accompanied  by  a  2-fold  increase  in  HSC  (but  not  progenitor  cells), 
and  that  the  effect  could  be  reproduced  in  normal  mice  by  injection  of  PTH. 
Significantly  these  changes  were  also  associated  with  increased  production  of  the 
Notch  ligand,  Jagged  1  by  osteoblasts  and  increased  Notch  activation  in  vivo,  that 
could  be  negated  by  specific  inhibition  of  Notch  (Calvi  LM,  Adams  GB  et  at.  2003). 
Using  a  different  approach  Zhang  et  al  demonstrated  that  mutant  mice  with  an 
increased  endosteal  bone  surface  and  reduced  BM  cavity  also  show  around  a  2- 
fold  increase  in  HSC.  In  addition,  they  also  show  that  long-term  HSC  are 
preferentially  attached  to  the  N-cadherin+  osteoblasts.  N-cadherin  forms  a  complex 
in  tissue  cell  junctions  and  also  forms  active  signalling  complexes  with  ß-catenin, 
recently  shown  to  play  a  role  in  HSC  self-renewal  (Zhang  J,  Niu  C  et  al.  2003). Susan  M  Graham,  2005 
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1.1.5.1  Stem  Cell  Homing  and  Mobilisation 
As  detailed  in  the  previous  section,  stem  cells  have  an  intimate  relationship  with 
the  BM  microenvironment  and  with  specific  cell  types.  Tracking  transplanted  stem 
cells  stained  with  CFSE  (a  permanent  non-specific  stain)  demonstrated  that  more 
primitive  cells  selectively  migrated  to  the  endosteal  region  whereas  more  mature 
cells  lodged  in  the  central  bone  marrow  region  and  that  this  migration  occurred 
rapidly  within  5-15  hours  post-transplant.  Non-ablated  hosts  were  used  in  this 
study  to  eliminate  the  possible  influence  of  a  damaged  stromal  environment 
(Nilsson  SK,  Johnston  HM  et  al.  2001). 
Central  to  the  success  of  BM  and  peripheral  blood  stem  cell  (PBSC) 
transplantation  is  the  ability  of  stem  cells  to  locate  and  colonise  the  host  stem  cell 
niche.  These  processes  are  likely  to  be  regulated  by  a  combination  of  adhesive 
and  chemokine  receptor-ligand  interactions.  Adhesive  interactions  play  a  central 
role  in  homing  and  in  particular  VLA-4  (discussed  in  detail  previously)  has  been 
shown  to  be  a  crucial  factor.  Preincubation  with  anti-VLA-4  antibody  decreased  the 
engraftment  of  human  CD344'  cells  in  the  BM  of  fetal  sheep,  with  a  corresponding 
increase  in  human  cells  in  the  peripheral  blood  (Zanjani  ED,  Flake  AW  et  al. 
1999).  Also  key  to  the  homing  process  is  the  chemoattractant  interaction  between 
stromal-derived  factor-1  (SDF-1  also  known  as  CXCL12)  and  its  receptor  CXCR4 
expressed  on  stem  cells.  SDF  or  CXCR4  knockouts  have  multiple  lethal  defects 
including  impaired  haemopoiesis  (Nagasawa  T,  Hirota  S  et  al.  1996;  Ma  Q,  Jones 
D  et  al.  1998).  However  CXCR44  fetal  liver  cells  are  capable  of  engraftment  in  the 
BM  of  wild  type  mice  albeit  with  defects  in  retention  of  B-lymphoid  and  granulocytic 
lineage  precursors  in  the  BM  (Ma  Q,  Jones  D  et  al.  1999).  These  results  suggest 
SDF-IICXCR4  interactions  can  act  in  combination  with  other  mediators  of  homing 
and  engraftment.  Nonetheless  SDF-1  has  been  shown  to  be  a  potent 
chemoattractant  for  human  stem  cells  in  vitro  and  addition  of  antibody  to  CXCR4 
abolished  these  effects  (Jo  DY,  Rafii  S  et  al.  2000).  Lack  of  engraftment  in  vivo  by 
treatment  with  anti-CXCR4  and  successful  engraftment  of  CD34+  cells  induced  to Susan  M  Graham,  2005  Chapter  1,36 
express  CXCR4  illustrate  the  importance  of  this  receptor-ligand  interaction  in  HSC 
reconstitution  (Peled  A,  Petit  I  et  al.  1999). 
One  of  the  most  important  aspects  of  stem  cell  transplantation  is  the  movement  of 
repopulating  cells  out  of  the  BM  niche  and  into  the  circulation  termed  mobilisation. 
Stem  cell  mobilisation  can  be  stimulated  by  administration  of  cytotoxic  drugs  such 
as  cyclophosphamide,  hydroxyurea  or  5-fluorouracil  and  by  certain  cytokines 
including  G-CSF,  GM-CSF,  IL-11,  IL-3,  IL-8  FIt3L  etc  or  by  a  combination  of  both 
cytotoxic  drugs  and  cytokines.  By  far  the  most  commonly  used  regimen  utilises  G- 
CSF.  Although  the  kinetics  of  mobilisation  are  relatively  slow  (peak  at  5-6  days), 
the  benefits  include  minimal  toxicity  and  relative  ease  of  administration  (IV 
injection,  dose  based  on  weight).  Not  surprisingly,  many  of  the  factors  involved  in 
BM  homing  also  play  a  part  in  mobilisation.  For  example,  in  mice  treated  with 
cyclophosphamide/G-CSF,  expression  of  VLA-2  and  VLA-4  is  reduced  on 
mobilised  peripheral  blood  HSC.  Also,  treatment  with  anti-VLA-4  antibodies 
induces  mobilisation  of  CFC  and  long-term  repopulating  cells  (Craddock  CF, 
Nakamoto  B  et  al.  1997). 
More  recent  data  have  described  the  cleavage  of  the  N-teminus  of  CXCR4  on 
HSC  in  the  BM  and  on  those  mobilised  into  the  circulation  in  response  to  GCSF. 
This  leads  to  a  reduction  in  the  chemoattractant  interactions  of  CXCR4  and  SDF- 
1,  which  was  further  shown  to  involve  a  decrease  in  SDF-1  concentration  in  the 
BM,  accompanied  by  an  increase  in  proteases  able  to  cleave  SDF-1  (Levesque 
JP,  Hendy  J  et  at.  2003).  Petit  et  al  have  further  shown  G-CSF  stimulated 
mobilisation  by  reducing  SDF-1  in  the  BM,  and  that  the  gradual  reduction  was  due 
to  degradation  by  neutrophil  elastase.  Reduction  in  SDF-1  was  associated  with 
increased  mobilisation,  which  was  reduced  by  inhibition  of  neutrophil  elastase. 
(Petit  I,  Szyper-Kravitz  M  et  al.  2002).  A  recent  report  from  Broxmeyer  et  at  has 
demonstrated  that  in  vivo  (mouse  and  human),  treatment  with  a  CXCR4 
antagonist  can  produce  mobilisation  of  HSC  and  can  act  in  synergy  with  G-CSF  to 
increase  stem  cell  mobilisation.  They  also  showed  that  the  mobilised  cells  were 
primitive  HSC  able  to  repopulate  a  secondary  host  (Broxmeyer  HE,  Orschell  CM  et 
at.  2005). 
One  of  the  notable  aspects  of  cytokine-induced  mobilisation  is  that  most  of  the 
circulating  HSC  are  quiescent  (in  GO  or  G1  phases  of  the  cell  cycle),  however  it 
was  not  known  if  quiescent  cells  were  preferentially  released  into  the  circulation  or Susan  M  Graham,  2005  Chapter  1,37 
if  the  cells  had  divided  prior  to  release  (Ponchio  L,  Conneally  E  et  al.  1995; 
Donahue  RE,  Kirby  MR  et  al.  1996;  Uchida  N,  He  D  et  al.  1997).  In  an  interesting 
study  by  Wright  et  al,  mice  were  treated  with  cyclophosphamide/G-CSF  and  BrdU 
(which  is  incorporated  into  dividing  cells)  and  assessed  for  the  presence  of  divided 
and  undivided  stem  cells.  The  results  indicated  that  almost  all  of  the  LT-HSC  had 
entered  cell  cycle  prior  to  release  from  the  BM  and  that  cells  enter  the  blood  in  the 
post  mitotic  M  phase  of  the  cell  cycle  (Wright  DE,  Cheshier  SH  et  al.  2001).  It  is 
known  that  the  proportion  of  cycling  cells  in  the  BM  is  greater  than  in  mobilised 
peripheral  blood,  which  could  be  explained  by  these  findings. 
1.1.6  Stem  Cell  Plasticity 
No  discussion  on  stem  cells  would  be  complete  without  some  mention  of  plasticity 
or  the  apparent  ability  of  stem  cells  to  develop  alternative  fates.  The  demonstration 
of  fate  switching  in  B-lineage  cells  from  Pax-5-deficient  mice  to  different 
haemopoietic  cell  types  has  indicated  that  plasticity  may  be  a  genuine  feature 
(Rolink  AG,  Nutt  SL  et  al.  1999).  Kondo  et  al  have  also  demonstrated  that  the  fate 
of  common  lymphoid  progenitors  could  be  redirected  to  the  myeloid  lineage  by 
stimulation  through  IL-2  receptor,  suggesting  that  the  fate  of  individual  cells  can  be 
influenced  by  cytokine  stimulation  (Kondo  M,  Scherer  DC  et  al.  2000).  A  body  of 
evidence  existed  that  HSC  could  switch  to  a  non-haemopoietic  fate,  particularly  at 
the  site  of  injury  for  example  to  muscle  or  heart  or  following  transplantation. 
However,  more  recent  studies  have  cast  doubt  on  the  interpretation  of  these 
results.  Studies  using  parabiotic  mice  (surgically  joined  to  develop  a  common 
circulatory  system)  and  GFP/GFP"  cells  showed  that  haemopoietic  but  not  non- 
haemopoietic  chimerism  existed  suggesting  that  "transdifferentiation"  was  rare  if  at 
all  possible  (Wagers  AJ,  Sherwood  RI  et  al.  2002),  reviewed  in  (Wagers  AJ  and  IL. 
2004).  It  has  also  been  noted  that  cell  fusion  may  have  been  misinterpreted  as 
plasticity  when  high  levels  of  cell  fusion  were  found  in  liver  cells  following  HSC 
transplantation  in  mice  (Vassilopoulos  G,  Wang  PR  et  al.  2003). 
1.2  Chronic  Myeloid  Leukaemia 
Chronic  myeloid  leukaemia  (CML)  is  a  stem  cell  disease  originating  in  a  pluripotent 
haemopoietic  cell  that  acquires  a  defined  chromosomal  abnormality.  CML  was  first 
identified  clinically  in  the  mid  1800s  when  three  physicians  independently Susan  M  Graham,  2005  Chapter  1,38 
described  patients  with  massive  splenomegaly  and  lethal  leukocytosis  not 
associated  with  documented  conditions  (Virchow  R  1845;  Bennett  JH  1845; 
Craigie  D  1845).  A  major  breakthrough  was  the  pioneering  discovery  of  the 
Philadelphia  chromosome  (Ph)  by  Nowell  and  Hungerford  in  1960.  They  noticed 
that  in  all  CML  samples  there  was  an  abnormally  small  chromosome  22  not 
observed  in  other  leukaemias  (Nowell  PC  and  Hungerford  DA  1960).  This  was  the 
first  chromosomal  abnormality  to  be  linked  to  a  human  cancer.  It  took  a  further  13 
years  to  elucidate  that  the  Ph  chromosome  was  the  result  of  a  translocation 
between  the  long  arms  of  chromosomes  9  and  22  (Rowley  JD  1973).  In  1984 
Groffen  et  at  showed  that  the  translocation  event  involved  the  ABL  proto-oncogene 
on  chromosome  9  and  a  new  "break  point  cluster"  gene  (BCR)  on  chromosome  22 
(Groffen  J,  Stephenson  JR  et  at.  1984).  It  was  confirmed  some  time  later  that  in 
fact  the  translocation  was  reciprocal  also  producing  ABL-BCR  (Melo  JV,  Gordon 
DE  et  al.  1993). 
1.2.1  Clinical  Features  of  CML 
CML  accounts  for  -15-20%  of  all  leukaemias  with  an  incidence  of  1  in  100,000  of 
the  general  population.  It  can  occur  at  any  age,  however  incidence  increases  with 
age  and  the  median  age  at  diagnosis  is  around  60.  There  are  no  predisposing 
factors  to  the  development  of  CML,  though  survivors  of  the  atomic  bombs  in  Japan 
showed  an  increased  incidence  4-10yrs  following  radiation  exposures  from 
explosions.  It  has  also  been  suggested  that  the  proximity  of  BCR  and  ABL  genes 
in  haemopoietic  cells  during  interphase  is  related  to  cell  cycle  and  differentiation, 
with  a  closer  than  predicted  position  observed  for  BCR  and  ABL  in  more  primitive 
cells.  This  could  facilitate  the  opportunity  for  chromosome  rearrangement  in  some 
cells  which  may  be  enhanced  by  their  cell  cycle  position  (Neves  H,  Ramos  C  et  al. 
1999). 
There  are  typically  3  distinct  phases  of  disease:  chronic  phase  (CP),  which  lasts 
-4-6  years,  accelerated  phase  (AP),  which  lasts  up  to  1  year  and  blast  crisis  (BC), 
which  lasts  around  3-6  months.  CP  is  characterised  by  the  accumulation  of 
excessive  numbers  of  mature  and  functional  blood  cells  produced  from  a 
transformed  pluripotent  stem  cell  (Fialkow  PJ,  Jacobson  RJ  et  al.  1977).  There  is  a 
marked  expansion  of  myeloid  lineage  cells  at  the  expense  of  erythroid  cells.  AP 
lasts  upto  lyr  and  is  characterised  by  an  increase  in  more  primitive  cells 
proportional  to  mature  cells.  Disease  progression  is inevitable  and  results  in  a  fatal Susan  M  Graham,  2005  Chapter  1,39 
BC,  which  resembles  an  acute  leukaemia,  and  may  happen  suddenly  without  an 
intervening  AP.  An  accumulation  of  more  immature  cell  types  and  increased 
resistance  to  therapy  in  BC  leads  to  mortality  in  -3-6  months  (Thijsen  S, 
Schuurhuis  G  et  al.  1999).  Around  30%  of  these  acute  leukaemias  are  acute 
lymphoblastic  leukaemia  (ALL)  and  the  rest  are  acute  myeloid  leukaemia  (AML)  or 
acute  undifferentiated  leukaemia  (AUL).  As  yet  the  mechanism  of  progression 
from  CP  to  BC  is  undefined  but  additional  genetic  events  have  been  associated 
with  development  of  BC.  These  include  trisomy  8,  loss  of  p53  function,  alterations 
in  the  retinoblastoma  gene,  p16  gene  rearrangements,  amplification  of  the  c-Myc 
gene  and  alterations  in  RAS  signalling  (Ahuja  HG,  Jat  PS  et  al.  1991;  Feinstein  E, 
Cimino  G  et  al.  1991;  Sill  H,  Goldman  JM  et  al.  1995;  Jennings  BA  and  Mills  KI. 
1998;  Voss  J,  Posern  G  et  al.  2000). 
1.2.1.1  Treatment  Options 
Historically  the  main  aim  of  treatment  for  CML  was  to  reduce  the  excessive 
numbers  of  circulating  white  blood  cells.  This  was  achieved  using  various  cytotoxic 
drugs,  which  prolonged  life  for  -3-5yrs  following  diagnosis  of  CP.  Treatment  with 
a-interferon  (IFN)  prolonged  survival  by  a  further  12  months  compared  to  cytotoxic 
drug  treatment  and  in  a  small  percentage  of  cases  (6-20%)  induced  a  complete 
cytogenetic  remission  (Silver  RT,  Woolf  SH  et  al.  1999).  However,  BCR-ABL 
transcripts  could  still  be  detected  in  patients  in  cytogenetic  remission  using 
sensitive  RT-PCR  techniques.  IFN  is  also  relatively  toxic  and  can  result  in  severe 
side  effects,  in  addition  some  patients  either  cannot  tolerate  the  drug  or  their 
leukaemia  does  not  respond  to  it.  The  only  curative  therapy  for  CML  is  an 
allogeneic  BM  transplant.  However,  many  patients  are  outwith  the  transplant  age 
limit  of  <55yrs.  In  addition,  only  around  one  third  of  patients  have  a  suitable  donor. 
In  effect  this  means  that  the  majority  of  patients  have  chemotherapy  as  their  only 
treatment  option.  The  quest  to  find  more  effective  drugs  lead  to  the  development 
of  targeted  therapy  for  CML  in  the  form  of  ST1571  (or  Glivec),  which  will  be 
discussed  in  more  detail  later.  Figure  1.2  shows  time  lines  of  therapeutic  and 
scientific  landmarks  for  CML  relevant  to  the  following  discussion. Susan  M  Graham,  2005  Chapter  1,40 
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Figure  1-2  Time  lines  of  scientific  observation  and  treatment  options  for  CML. Susan  M  Graham,  2005 
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It  is  generally  perceived  that  CML  develops  when  a  pluripotent  stem  cell  acquires 
the  Ph"  chromosome  with  the  BCR-ABL  fusion  gene.  Fialkow  et  al  demonstrated 
that  CML  was  a  clonal  disease  by  examining  X-linked  polymorphic  genetic  loci  in 
female  CML  patients  in  chronic  phase  and  identifying  the  same  genetic  markers  in 
different  cell  types  (Fialkow  PJ,  Jacobson  RJ  et  al.  1977).  CML  stem  cells  are 
morphologically  indistinguishable  from  normal  stem  cells.  The  demonstration  by 
FISH  and  cytogenetics  that  Ph+  cells  were  found  in  granulocyte,  erythroid, 
megakaryocyte  and  B  and  T  precursors  confirmed  that  the  genetic  lesion  arose  in 
a  pluripotent  stem  cell.  More  recently,  evidence  of  the  presence  of  Ph''  endothelial 
cells  in  CML  BM  has  indicated  that  an  earlier  stem  cell  with  endothelial  and 
haemopoietic  potential  may  be  the  CML  initiating  cell  (Gunsilius  E,  Duba  HC  et  al. 
2000). 
CML  progenitors  are  able  to  generate  LTC-IC  similar  to  normal  stem  cells; 
experiments  culturing  CML  BM  showed  that  normal  haemopoietic  progenitors 
coexisted  alongside  their  leukaemic  counterparts.  Interestingly,  on  further  long- 
term  culture,  the  leukaemic  progenitors  rapidly  disappeared  whereas  the  normal 
progenitors  could  be  detected  for  2-3  months  (Coulombel  L,  Kalousek  DK  et  at. 
1983).  A  similar  observation  was  made  by  Udomsakdi  et  al  using  CML  peripheral 
blood  or  BM.  This  study  also  showed  that  the  number  of  LTC-IC  in  CML  BM  was 
significantly  decreased  compared  to  normal  BM,  and  that  CML  LTC-IC  in  the 
peripheral  blood  were  significantly  increased  to  >10  times  that  of  normal 
(Udomsakdi  C,  Eaves  CJ  et  al.  1992).  These  data  suggest  that  CML  progenitors 
have  limited  capacity  for  self-renewal,  and  exhibit  an  increased  tendency  towards 
maturation.  This  may  seem  at  odds  with  the  idea  of  CML  as  a  stem  cell  disease 
with  uncontrolled  proliferation.  However,  emerging  evidence  is  of  a  complex  series 
of  interactions,  with  the  suggestion  that  bcr-abl  may  exert  effects  on  cell  behaviour 
that  vary  with  maturation,  cell  cycle  and  microenvironment.  It  has  been 
demonstrated  previously,  that  whereas  normal  and  CML  mature  cells  have  similar 
responses  and  proliferation  patterns  to  cytokines,  more  primitive  progenitors 
display  altered  responses  (Reviewed  in  (Clarkson  B  and  Strife  A  1993;  Clarkson 
B,  Strife  A  et  at.  2003).  Strife  et  at  have  also  demonstrated  that  primitive  CML  cells 
display  an  increased  sensitivity  to  single  cytokines  and  that  this  may  allow 
accelerated  maturation,  and  thereby  facilitate  an  accumulation  of  committed Susan  M  Graham,  2005  Chapter  1,42 
progenitors.  In  support  of  this  theory  Buckle  et  at  have  shown  that  CML  primitive 
progenitors  comprise  a  lower  proportion  of  the  stem  cell  compartment  compared  to 
normal  primitive  progenitors  and  that  there  was  an  increased  proportion  of  more 
mature  cells  in  CML  (Buckle  AM,  Mottram  R  et  at.  2000).  Ultimately,  leukaemic 
stem  and  progenitor  cells  replace  normal  haemopoeisis  and  disease  progression 
is  associated  with  an  accumulation  of  more  primitive  CML  cells  in  the  circulation. 
It  has  been  documented  that  CML  stem  and  progenitor  cells  display  altered 
adhesive  interactions  with  BM  stroma,  and  this  could  account  for  the  increased 
number  of  progenitor  cells  in  the  circulation  (Verfaillie  CM,  McCarthy  JB  et  al. 
1992).  CML  cells,  like  normal  cells,  express  integrins,  however  CML  cells  exhibit 
significantly  decreased  adhesion  to  fibronectin  (Verfaillie,  McCarthy  et  al.  1992). 
Recent  work  by  this  group  has  demonstrated  that  binding  of  integrins  in  normal 
cells  causes  up  regulation  of  the  proliferation  inhibitor  p27kip,  preventing  cell  cycle 
entry  (Jiang  Y,  Prosper  F  et  al.  2000).  Further  studies  by  the  same  group  have 
revealed  that  although  CML  cells  bind  integrins,  binding  does  not  inhibit  cell  cycle 
progression.  They  also  found  that  in  contrast  to  normal  cells,  p27  kip  is  found  mostly 
in  the  cytoplasm  where  it  is  unable  to  bind  CDK2  and  inhibit  proliferation  (Jiang  Y, 
Zhao  RC  et  al.  2000).  In  addition  Bhatia  et  al  have  recently  demonstrated  that  ß1 
integrin-fibronectin  interaction  preserved  normal  primitive  progenitors  by 
decreasing  proliferation,  and  enhanced  preservation  of  dividing  primitive 
progenitors,  possibly  by  preventing  differentiation.  In  contrast,  CML  cells  showed 
abnormal  ß1  integrin-mediated  adhesion  and  impaired  signalling  following  contact 
with  FN  or  stroma  (Bhatia  R,  Williams  AD  et  al.  2002).  It  has  also  been 
demonstrated  that  the  effects  of  impaired  integrin  function  are  bcr-abI  associated 
since  they  can  be  reversed  by  inhibition  of  bcr-abl  or  induced  in  normal  cells  by 
expression  of  the  BCR-ABL  gene  (Bhatia  R  and  Verfaillie  CM  1998;  Zhao  R,  Fan 
E  et  al.  1999).  Other  studies  have  shown  that  both  BM  and  PB  CML  CD34+  cells 
display  lower  migration  responses  to  SDF-1  compared  with  normal  CD34+  cells 
and  that  this  was  not  a  result  of  receptor  (CXCR4)  down-regulation  (Durig  J, 
Rosenthal  C  et  al.  2000).  More  recently,  it  has  been  shown  that  CML 
CD34''CXCR4+  cells  show  lower  migratory  responses  to  SDF-1  than  normal 
CD34+CXCR4+  cells  from  the  same  patient  (Peled  A,  Hardan  I  et  al.  2002).  These 
data  indicate  that  altered  adhesive  interactions  almost  certainly  play  a  role  in 
mobilisation  of  CML  progenitors  into  the  circulation  and  possibly  affect  retention  of 
leukaemic  stem  and  progenitor  cells  in  the  BM. Susan  M  Graham,  2005  Chapter  1,43 
1.2.2.1  Stem  Cell  Kinetics 
The  molecular  basis  for  the  proliferative  advantage  of  CML  cells  is  not  fully 
clarified.  There  is  continuing  debate  regarding  the  importance  of  apoptosis  in  the 
CML  phenotype.  Some  studies  have  shown  that  CML  cells  have  an  innate 
resistance  to  apoptosis  and  suggest  that  could  account  for  the  expansion  of  the 
leukaemic  clone  (Bedi  A,  Zehnbauer  B  et  at.  1994).  Conversely,  in  studies  using 
serum  deprivation,  X-rays  or  glucocorticoids  to  induce  apoptosis,  Amos  et  al  found 
no  difference  in  survival  of  normal  and  CML  myeloid  progenitors  or  in  more  mature 
colony-forming  cells  (Amos  TAS,  Lewis  JL  et  at.  1995).  A  more  recent  study  has 
shown  that  non-dividing  CML  progenitor  cells  are  more  resistant  to  drug  induced 
apoptosis,  which  may  have  implications  for  treatment  (see  discussion  chapter  7) 
(Holtz  MS,  Forman  SJ  et  at.  2005). 
Differences  in  cell  cycle  position  between  normal  and  CML  CD34+  cells  have  been 
observed.  Traycoff  et  at  have  demonstrated  that  there  are  fewer  BM  CML  stem 
cells  in  the  GO/G1  cell  cycle  phases  compared  to  normal  CD34+  cells.  They  also 
observed  that  upon  stimulation  with  cytokines,  CML  cells  exit  GO/G1  more  rapidly, 
suggesting  CML  cells  exhibit  greater  cell  cycle  activation.  Furthermore,  in  the 
absence  of  cytokine  stimulation,  CML  cells  were  able  to  enter  cell  cycle,  unlike 
normal  stem  cells  (Traycoff  CM,  Halstead  B  et  at.  1998).  Experiments  using 
exposure  to  tritiated  thymidine  have  shown  that  a  higher  proportion  of  CML  LTC-IC 
and  CFC  are  in  S-phase  of  the  cell  cycle,  with  most  being  killed  following 
exposure.  In  the  case  of  normal  LTC-IC,  only  around  5%  were  killed  in  this  suicide 
assay,  indicating  that  normal  LTC-IC  are  largely  quiescent  (Ponchio  L  and  Eaves 
CJ  1995).  In  a  further  study  by  Bhatia  et  al  using  staining  techniques  to  evaluate 
division  history,  these  authors  show  that  most  CML  LTC-IC  were  generated  from 
CD34+  cells  that  had  previously  undergone  division,  whereas  normal  LTC-IC 
originated  from  undivided  stem  cells  (Bhatia  R,  Munthe  HA  et  al.  2000).  It  has 
been  demonstrated  that,  unexpectedly,  a  population  of  quiescent  CML  stem  cells 
exists  in  CP.  Holyoake  et  al  have  isolated  GO  and  G1/S/G2/M  cells  from  CML 
patients  by  FAGS  and  shown  that,  when  transplanted  into  NOD/SCID  mice  that 
are  also  ß-microglobulin',  some  quiescent  CML  cells  can  exit  GO  and  effect 
engraftment  (Holyoake  T,  Jiang  X  et  at.  1999).  The  finding  that  a  quiescent  stem 
cell  population  existed  in  CML  has  raised  the  question  of  how  to  target  therapy, 
when  historically,  cytotoxic  drug  treatment  was  aimed  at  eliminating  the  cycling Susan  M  Graham,  2005  Chapter  1,44 
population.  This  very  important  issue  will  be  addressed  in  the  experimental  and 
discussion  chapters  as  a  central  theme  in  this  work. 
1.2.3  The  Molecular  Biology  of  CML 
The  majority  of  CML  cases  are  associated  with  the  presence  of  the  Ph 
chromosome,  the  result  of  the  reciprocal  translocation  between  chromosomes  9 
and  22.  The  molecular  consequence  of  this  translocation  is  to  place  the  ABL  gene 
in  close  proximity  to  the  BCR  gene,  creating  the  BCR-ABL  fusion  gene.  The 
properties  of  the  individual  genes  and  the  fusion  gene  are  discussed  below. 
1.2.3.1  c-ABL 
The  ABL  gene  on  chromosome  9  is  the  human  homologue  of  a  gene  formerly 
recognized  in  a  murine  oncogenic  virus,  the  Ableson  murine  leukaemia  virus  (A- 
MuLV).  The  ABL  gene  family  encodes  highly  conserved  intracellular  non-receptor 
tyrosine  kinases  with  similar  features  to  the  SRC  family  of  kinases  (Laneuville  P 
1995).  c-ABL  is  universally  expressed  with  2  isoforms,  la  and  1b,  which  result 
from  alternative  splicing  of  the  first  exon.  Several  functional  domains  on  c-ABL 
have  been  identified  including  3  SRC  homology  domains  (SH1-SH3),  positioned 
near  the  NH2  terminus.  The  SH1  domain  contains  the  tyrosine  kinase  function 
whereas  the  other  two  SH  domains  are  involved  in  interactions  with  other  proteins. 
Nuclear  localisation  signals,  actin-binding  and  DNA-binding  motifs  are  located 
closer  to  the  COOH  end.  Until  recently  the  mechanism  of  c-abl  control  of  was 
speculated  to  involve  a  cellular  inhibitor.  However,  a  series  of  experiments  by  Pluk 
et  al  have  demonstrated  that  in  fact  c-abI  is  controlled  by  autoinhibition  and  the 
elements  involved  in  control  are  absent  in  bcr-abl.  By  testing  the  kinase  activity  of 
mutant  forms  of  the  protein,  they  identified  80  residues  at  the  N-terminal  that  bind 
intramolecularly  and  are  critical  for  regulation  of  c-abl.  These  residues  are 
encoded  by  the  first  exon  of  ABL,  which  is  always  absent  in  fusion  proteins  formed 
with  BCR  (Pluk  H,  Dorey  K  et  al.  2002). 
The  function  of  c-ABL  is  not  completely  understood  but  conservation  and 
expression  in  different  species  suggest  developmental  importance.  In  addition, 
ABL  knockouts  display  a  number  of  developmental  abnormalities  such  as 
abnormal  eyes,  runtedness,  and  defective  spermatogenesis  (Schwartzberg  PL, 
Stall  AM  et  al.  1991).  c-abl  protein  is  located  in  both  the  cytoplasm,  where  it  co- Susan  M  Graham,  2005  Chapter  1,45 
localises  with  F-actin,  and  in  the  nucleus,  where  it  is  bound  to  chromatin.  abl 
proteins  associated  with  transformation  are  exclusively  cytoplasmic  where  they  are 
bound  to  F-actin.  Roles  for  c-abl  in  cell  cycle  regulation,  integrin  signalling  and 
stress  response  have  been  suggested.  (Reviewed  in  (Van  Etten  RA.  1999). 
1.2.3.2  BCR 
The  BCR  gene  on  chromosome  22  has  23  exons  and  produces  a  160kd  protein, 
which  is  also  ubiquitously  expressed.  It  contains  several  structural  motifs  including 
GTPase  activity  for  Rac,  a  small  GTPase  of  the  Ras  superfamily.  BCR  can  also  be 
phosphorylated  on  several  tyrosine  residues,  particularly  177,  which  binds  the 
adaptor  molecule  Grb-2,  involved  in  the  Ras  pathway.  The  function  of  BCR  as  yet 
remains  undetermined,  and  given  that  BCR  knockout  mice  are  viable,  argues  for 
at  least  a  degree  of  redundancy  in  function  (Voncken  JW,  van  Schaick  H  et  al. 
1995).  Interestingly,  recent  data  has  suggested  a  possible  role  for  bcr  in  the 
regulation  of  c-abl.  Work  by  Ling  et  al  has  shown  that  BCR  overexpression  inhibits 
cytoplasmic  c-abl  and  that  sequestration  of  bcr  releases  c-abl  from  the  complex 
with  bcr,  which  in  turn,  leads  to  oncogenic  transformation  as  a  result  of  c-abl 
activation  (Ling  X,  Ma  G  et  al.  2003).  These  data  indicate  that  autoinhibition  of  c- 
abl  as  described  above  may  not  be  the  only  mechanism  of  c-abl  regulation. 
1.2.3.3  BCR-ABL 
The  breakpoint  on  the  ABL  gene  can  occur  over  a  relatively  large  area  (>300bp)  of 
the  5  end,  most  commonly  between  exons  Ia  and  1b,  although  breakpoints  either 
side  of  these  exons  have  been  observed  (Melo  J  1996).  The  mRNA  product 
invariably  lacks  exon  1a  even  if  the  breakpoint  is  anterior  of  this  exon,  probably  as 
a  result  of  mRNA  splicing.  In  contrast,  the  breakpoints  in  BCR  occur  over  a  large 
variable  region  of  >5kb,  which  spans  exons  12-16  and  is  described  as  the  major 
breakpoint  cluster  region  or  M-bcr.  Alternative  splicing  within  this  region,  generates 
two  fusion  transcripts  containing  either  b2a2  or  b3a2  junctions.  Both  mRNAs 
produce  a  210kd  oncoprotein  commonly  labelled  p210BCR.  ABL..  As  well  as  the  M-bcr 
there  are  two  other  breakpoint  regions  named  m-BCR  (minor  breakpoint  cluster 
region)  and  p-BCR.  Breakpoints  in  these  regions  produce  p190  and  p230 
oncogenic  bcr-abl  proteins  respectively.  p190  is  associated  with  Ph*  ALL  (acute 
lymphocytic  leukaemia)  and  only  rarely  with  CML,  and  p230  with  rare  Ph'  chronic 
neutrophilic  leukaemia.  Breakpoints  in  other  regions  associated  with  ALL  and  CML Susan  M  Graham,  2005  Chapter  1,46 
have  been  identified  in  rare  cases.  For  the  classic  b2a2  and  b3a2  junctions  in  CML 
there  appears  to  be  no  correlation  between  breakpoint  and  prognosis  or  time  to 
disease  progression  (de  Braekeleer  M  1987;  Rozman  C,  Urbano-Ispizua  A  et  at. 
1995).  Figure  1.3  details  the  position  of  the  breakpoints  and  the  resultant  fusion 
products. 
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Figure  1-3  BCR  and  ABL  breakpoints  and  fusion  products. 
The  presence  of  the  BCR-ABL  transcript  is  not  in  itself  sufficient  to  cause  disease. 
Using  sensitive  RT-PCR,  BCR-ABL  mRNA  transcripts  were  detected  in  a  very 
small  number  of  white  blood  cells  in  healthy  individuals.  Many  of  the  transcripts 
were  found  to  encode  non-functional  proteins,  however  transcripts  encoding 
functional  bcr-abl  protein  were  identified  (Bose  S,  Deininger  M  et  al.  1998).  The 
potential  to  develop  CML  disease  may  depend  on  the  cell  type  in  which  the 
translocation  arises  and/or  the  microenvironmental  stimuli  encountered  by  the  cell. 
It  is  possible  some  cells  that  acquire  the  translocation  are  eliminated  by  the 
immune  system,  or  that  these  cells  have  limited  division/differentiation  potential, 
and  are  therefore  are  unable  to  sustain  disease. Susan  M  Graham,  2005  Chapter  1,47 
1.2.3.4  Oncogenic  Activity  of  BCR-ABL 
Following  the  identification  of  the  Ph  chromosome  and  its  translocation  partners, 
investigations  into  the  mechanism  of  transformation  gained  momentum.  The 
association  between  ABL  and  transformation  had  previously  been  established  by 
studies  of  the  Ableson  leukaemia  virus  (A-MuLV),  which  had  been  shown  to  cause 
transformation  of  NIH  3T3  cells  and  lymphoid  cells  in  vitro  (Rosenberg  N, 
Baltimore  D  et  al.  1975;  Scher  CD  and  Siegler  R  1975).  In  a  series  of  elegant 
experiments  using  antibodies  to  various  parts  of  the  protein,  it  was  established  that 
the  transforming  ability  of  the  A-MuLV  was  associated  with  a  chimeric  protein 
GAG-ABL.  The  GAG  sequences  were  of  viral  origin  and  the  ABL  sequences  of 
cellular  origin,  and  both  proteins  were  associated  with  transformation  (Witte  ON, 
Rosenberg  N  et  al.  1979;  Witte  ON,  Rosenberg  NE  et  al.  1979).  The  observation 
by  Collett  and  Erikson  that  the  protein  kinase  activity  of  the  Rous  Sarcoma  Virus 
(RSV)  was  associated  with  its  transforming  ability,  lead  to  the  question  of  whether 
other  oncoproteins  possessed  similar  enzymatic  activity  (Collett  MS  and  Erikson 
RL  1978).  The  finding  that  GAG-abl  had  kinase  activity,  and  that  variants  of  the  A- 
MuLV  with  no  kinase  activity  did  not  possess  transforming  capability,  confirmed 
the  importance  of  this  enzymatic  activity  in  transformation  (Witte  ON,  Goff  S  et  al. 
1980).  Further  studies  showed  that  the  protein  kinase  activity  specifically 
phosphorylated  tyrosine  residues,  and  subsequently,  that  abnormal  tyrosine 
kinase  activity  was  associated  with  a  number  of  malignancies  (Hunter  T  and 
Sefton  BM  1980). 
The  demonstration  that  the  ABL  gene  mapped  to  chromosome  9  and  that  it  was 
involved  in  the  translocation  that  generated  the  Ph  chromosome,  lead  to  the 
identification  of  abl  as  part  of  the  protein  product  of  BCR-ABL  (Bartram  CR,  De 
Klein  A  et  al.  1983).  These  findings  were  confirmed  in  cell  lines  expressing  BCR- 
ABL  and  in  cell  lysates  of  primary  CML  cells  (Konopka  JB,  Watanabe  SM  et  al. 
1985).  Antisera  generated  from  Gag-Abl  studies,  discussed  previously,  was  used 
to  show  that  p210BCR-ABL  had  comparable  tyrosine  kinase  activity  to  Gag-Abl  and 
that  a  mutation  in  the  protein  that  inactivated  the  kinase  activity  impaired  its 
transforming  ability.  These  observations  confirmed  the  necessity  of  the  abl 
tyrosine  kinase  in  malignant  transformation  (Konopka  JB,  Watanabe  SM  et  al. 
1984;  Pendergast  AM,  Gishizky  ML  et  al.  1993). Susan  M  Graham,  2005  Chapter  1,48 
One  of  the  most  significant  differences  between  c-abl  and  bcr-abl  proteins  is  their 
location  within  the  cell.  bcr-abl  is  found  exclusively  in  the  cytoplasm  despite  it 
containing  three  nuclear  localization  signals  (NLS)  and  a  nuclear  export  sequence 
(NES)  (McWhirter  JR  and  Wang  JY  1993;  Wen  ST,  Jackson  PK  et  al.  1996).  In 
contrast  c-abI  shuttles  between  the  nucleus  and  cytoplasm,  and  exerts  a 
proapoptotic  effect  in  its  nuclear  form  (Taagepera  S,  McDonald  D  et  al.  1998).  It 
has  been  documented  that  bcr-abl  exerts  an  antiapoptotic  effect  (discussed  more 
fully  below)  and  elegant  experiments  by  Vigneri  and  Wang  have  shown  that  this 
can  be  reversed  to  a  proapoptotic  effect.  Inhibiting  the  tyrosine  kinase  activity  of 
bcr-abl  with  STI  (see  below)  caused  bcr-abI  to  enter  the  nucleus  and  the  addition 
of  Leptomycin  B  (blocks  nuclear  export)  trapped  it  there.  Removal  of  STI  and 
subsequent  reactivation  of  the  bcr-abl  tyrosine  kinase  then  induced  an  apoptotic 
cell  death  (Vigneri  P  and  Wang  JY.  2001). 
1.2.3.5  Model  Systems  To  Study  BCR-ABL  Effects 
Daley  et  al  demonstrated  that  BCR-ABL  was  the  genetic  element  responsible  for 
CML  by  infecting  murine  BM  with  retrovirus  encoding  p210BCR-Asp  and  using  these 
cells  to  transplant  irradiated  animals.  The  result  was  a  range  of  malignancies 
including  a  myeloproliferative  syndrome  that  closely  resembled  CP  CIVIL  The 
leukaemic  cells  were  shown  to  express  viral  BCR-ABL  and  it  was  possible  to 
transplant  the  disease  into  secondary  recipients,  confirming  the  target  cell  for 
leukaemic  transformation  was  a  HSC  (Daley  GQ,  Van  Etten  RA  et  at.  1990). 
Attempts  to  develop  a  BCR-ABL  transgenic  model  of  CML  have  proved  extremely 
difficult  largely  due  to  embryonic  lethality  (Heisterkamp  N,  Jenster  G  et  at.  1991). 
Some  of  these  problems  were  partially  overcome  using  conditional  promoters  such 
as  tetracycline  (Huettner  CS,  Zhang  P  et  at.  2000).  A  further  problem  was  that 
these  mice  seldom  developed  myeloid  leukaemia  and  acute  lymphoid  leukaemias 
were  much  more  common,  which  did  not  resemble  CML-like  disease  (Heisterkamp 
N,  Jenster  G  et  al.  1990).  A  new  transgenic  model  has  been  developed  recently 
using  targeted  BCR-ABL  expression  in  murine  stem  and  progenitor  cells,  which 
produces  a  biphasic  disease  in  mice,  with  many  of  the  characteristics  of  human 
CML  (Koschmieder  S,  Gottgens  B  et  at.  2005).  However  this  model  has  yet  to  be 
fully  tested  in  other  experimental  systems.  Recent  advances  in  transduction  and 
transplantation  efficiency  have  been  able  to  generate  more  robust  murine  models 
of  CML  disease,  however  death  in  experimental  animals  from  complications  not 
associated  with  the  human  disease,  continues  to  be  a  problem  (Pear  WS,  Miller Susan  M  Graham,  2005  Chapter  1,49 
JP  et  al.  1998;  Zhang  X  and  Ren  R  1998).  Models  like  these  still  represent 
important  tools  for  studying  BCR-ABL  induced  leukaemogenesis. 
Established  cell  lines  offer  greater  flexibility  in  terms  of  time  frame  and 
convenience  but  it  is  difficult  to  faithfully  represent  a  chronic  disease  that 
progresses  to  an  acute  disease  in  vitro.  Many  studies  employ  BCR-ABL-positive 
cell  lines  such  as  K562,  produced  in  1975  by  Lozzio  and  Lozzio  from  blast  crisis 
CML  (Lozzio  CB  and  Lozzio  1975).  Whilst  a  useful  model,  it  does  not  mirror  CP 
CML,  possessing  multiple  copies  of  BCR-ABL  and  being  derived  from  the  more 
acute  BC  phase.  In  addition,  cells  that  have  undergone  multiple  passages  in 
culture  are  likely  to  have  acquired  other  mutations.  This  may  affect  their  responses 
to  different  conditions;  therefore  caution  is  warranted  when  extrapolating  data  to  in 
vivo  CML.  Furthermore,  many  studies  employ  BCR-ABL  inducible  on/off  or 
overexpression  systems  to  compare  cell  behaviour.  However,  it  must  be 
appreciated  that  in  CML  where  BCR-ABL  is  constitutively  activated  this  may  not 
represent  a  true  picture,  i.  e.  the  cellular  effect  of  suddenly  turning  on  BCR-ABL 
may  be  very  different  to  one  of  long-term  continuous  exposure. 
Studies  using  primary  cells  from  CML  patients  and  comparable  material  from 
normal  individuals  are  likely  to  yield  the  most  relevant  information.  One  of  the  most 
difficult  factors  is  the  inherent  patient-to-patient  variability  observed  in  CP  CML, 
which  can  result  in  less  robust  statistics.  The  selection  of  defined  cell  populations 
such  as  CD34+  cells  may  help  to  reduce  some  of  the  variability.  As  discussed 
earlier,  the  contribution  of  co-existing  normal  cells  in  CML  has  to  be  eliminated 
from  experimental  data  to  ensure  comparison  of  the  relevant  cell  populations. 
1.2.3.6  BCR-ABL  Interactions 
The  documented  cellular  processes  and  pathways  influenced  by  bcr-abI  are 
continuously  increasing.  A  comprehensive  review  of  all  of  the  candidates  is  out 
with  the  scope  of  this  discussion,  however  some  of  the  most  interesting,  at  least 
from  a  clinical  standpoint,  are  worthy  of  mention.  (Reviewed  in  (Melo  JV  and 
Deininger  MW.  2004).  The  functional  domains/motifs  on  the  bcr-abl  oncoprotein 
facilitate  interactions  with  a  number  of  other  cellular  proteins.  Interactions  with 
mitogens,  cytoskeletal  components,  anti-apoptotic  proteins,  cell  cycle  proteins, 
cytokines  and  adaptor  proteins  have  been  reported. Susan  M  Graham,  2005  Chapter  1,50 
The  interaction  of  bcr-abt  with  members  of  the  RAS  pathway  has  been 
documented.  Protein-protein  interactions  combine  bcr-abl  with  members  of  the 
RAS-MAPkinase  signalling  complex  including  Grb2,  SHC  and  Crkl  (Puil  L,  Liu  J  et 
al.  1994;  Goga  A,  McLaughlin  J  et  al.  1995;  Senechal  K,  Halpern  J  et  al.  1996).  It 
has  been  shown  that  bcr-abl,  through  autophosphorylation  of  tyrosine  177  in  the 
bcr  component,  stabilizes  RAS  in  its  active  conformation,  leading  to  constitutive 
activation.  In  contrast,  inactivation  of  RAS  by  inhibitors  significantly  suppresses  the 
cellular  transformation  by  bcr-abI  (Peters  DG,  Hoover  RR  et  al.  2001).  To  become 
activated,  RAS  proteins  undergo  posttranslational  modification,  the  first  of  which  is 
farnesylation  of  their  C-terminus  catalysed  by  famesyl  transferases.  Studies  using 
farnesyl  transferase  inhibitors  (FTI)  have  shown  that  bcr-abl  induced 
leukaemogenesis  can  be  inhibited  by  FTIs,  and  these  compounds  have  now 
reached  clinical  trial  (Reichert  A,  Heisterkamp  N  et  al.  2001).  Indications  are  that 
activation  of  the  RAS  pathway  is  critical  to  bcr-abl  induced  leukaemogenesis. 
The  JAK/STAT  pathway  involves  three  families  of  genes,  JAK  (Janus  tyrosine 
kinases),  STAT  (signal  transducers  and  activators  of  transcription)  and  SOCS 
(suppressor  of  cytokine  signalling).  The  JAK/STAT  pathway  is  involved  in 
transduction  of  signals  from  cytokine  receptors  to  the  nucleus,  where  stimulation  of 
JAKs  produces  STAT  transcription  factor  activity.  In  bcr-abt  transformed  cell  lines 
a  demonstrable  activation  of  STAT5  and  to  a  lesser  extent  STATs  1  and  3  have 
been  observed  (Ilaria  RL  Jr  and  Van  Ellen  R  1996).  It  has  also  been  demonstrated 
that  STAT  5  induces  the  expression  of  the  antiapoptotic  protein  Bcl-xl  and  through 
this  mechanism  may  promote  survival  of  malignant  cells  (Horita  M,  Andreu  EJ  et 
al.  2000).  CML  patient  cells  and  bcr-abl;  cells  exhibit  similar  biological 
characteristics  to  IL-3  stimulated  cells  or  those  with  engineered  IL-3 
overexpression.  It  has  been  further  demonstrated  in  CML  CD34+  cells  that 
increased  STAT5  phosphorylation  is  a  consequence  of  bcr-abl  induced  IL-3 
stimulation  and  that  IL-3  is  in  fact  produced  through  an  autocrine  mechanism  in 
BCR-ABL+  cells  (Jiang  X,  Lopez  A  et  al.  1999). 
P13  kinase  activity  has  been  shown  to  be  a  requirement  for  transformation  of  bcr- 
abi  expressing  cells  (Skorski  T,  Bellacosa  A  et  al.  1997).  bcr-abl  complexes  with 
P13K  and  adaptor  molecules  which  activate  P13K,  and  requires  the  intact  SH2 
domain  on  bcr-abl.  This  in  turn  activates  the  downstream  effector  Akt  kinase  in 
bcr-abl-positive  cells.  A  kinase  deficient  Akt  mutant  was  unable  to  effect 
transformation  of  murine  cells  in  vitro  and  suppressed  leukaemia  in  SCID  mice Susan  M  Graham,  2005  Chapter  1,51 
(Skorski  T,  Bellacosa  A  et  al.  1997).  However,  more  recent  data  has  suggested 
there  may  be  a  degree  of  redundancy  in  both  the  STAT5  and  Ras  signalling 
pathways  in  bcr-abl  transformed  cells  (Hoover  RR,  Gerlach  MJ  et  al.  2001). 
Although  as  mentioned  previously  RAS  inhibitors  can  suppress  transformation  by 
bcr-abl,  it  is  clear  from  the  apparently  conflicting  evidence  that  bcr-abI  and  its 
associated  tyrosine  kinase  activity  exert  a  myriad  of  effects  on  downstream 
pathways  that  have  a  range  of  consequences  for  cell  behaviour.  The  model 
systems  and  cell  populations  used  in  various  studies  may  yield  different  results, 
and  this  must  be  considered  when  comparing  data.  BCR-ABL  expression  has 
been  shown  to  influence  different  pathways  depending  on  a  variety  of  factors 
including  cell  type,  cell  cycle  status,  maturation  status  and  cell  context. 
1.2.4  The  Development  of  an  Inhibitor  of  BCR-ABL 
It  had  been  demonstrated  that  it  was  possible  to  design  a  Tyrosine 
Phosphorylation  Inhibitor  (tyrphostin)  with  specificity  for  a  particular  tyrosine  kinase 
(Yaish  P,  Gazit  A  et  al.  1988).  AG490  was  the  first  synthetic  tyrosine  kinase 
inhibitor  to  reduce  leukaemic  cell  proliferation  in  vitro  and  in  vivo  with  no  effect  on 
normal  cells  (Meydan  N,  Grunberger  T  et  al.  1996).  Scientists  at  Ciba-Geigy  (now 
Novartis)  began  high  throughput  screening  of  a  range  of  small  molecule  inhibitors 
and  identified  a  platelet  derived  growth  factor  receptor  inhibitor  (PDGF-R),  CGP 
53716.  Unexpectedly  this  compound  was  also  shown  to  inhibit  Gag-abl  tyrosine 
kinase  activity.  Following  some  minor  modifications  to  its  structure  CGP57148B 
(STI1571)  was  generated  and  shown  to  selectively  inhibit  the  tyrosine  kinases  of 
PDGF-R,  KIT,  ABL,  and  ARG  (Reviewed  in  (Traxler  P,  Bold  G  et  al.  2001). 
1.2.4.1  Development  of  ST1571/Glivec 
ST1571  (STI  now  known  as  Glivec  or  Imatinib  Mesylate)  is  a  small  molecule 
inhibitor  that  competes  for  the  ATP  binding  site  of  the  tyrosine  kinase  of  bcr-abl, 
rendering  it  unable  to  phosphorylate  downstream  targets.  However,  more  recent 
data  have  suggested  that  direct  competition  for  the  ATP  binding  site  may  not  be 
the  exact  mode  of  action.  Elucidation  of  the  crystal  structure  of  the  abi  catalytic 
domain  and  comparison  of  the  binding  of  STI  and  another  closely  associated 
molecule  (PD17355),  has  shown  that  STI  only  occupies  part  of  the  binding  pocket 
of  abl  and  may  act  by  stabilising  bcr-abl  in  its  inactive  conformation  such  that  it  is Susan  M  Graham,  2005  Chapter  1,52 
unable  to  bind  ATP  (Nagar  B,  Bornmann  WG  et  al.  2002).  (See  1.2.4.3  on  STI 
resistance). 
In  vitro,  STI  was  shown  to  be  effective  at  micromolar  concentrations.  A  number  of 
bcr-abl+  cell  lines  were  tested  and  an  IC50  (50%  inhibitory  concentration)  in  the 
range  0.1  -  0.5pM  was  established  for  inhibition  of  kinase  activity.  Similar  IC50 
values  were  calculated  for  the  inhibition  of  proliferation  of  bcr-abl+  cells  with  little 
effect  on  bcr-abl'  cells.  Cells  isolated  from  CML  patients  also  showed  selective 
inhibition  of  progenitor  colony  formation,  and  proliferation  in  liquid  culture. 
Eradication  of  human  BCR  ABL+  cells  injected  into  nude  mice  confirmed  the 
efficacy  of  STI  in  vivo  (Le  Coutre  P,  Mologni  L  et  al.  1999).  In  addition,  normal 
haemopoiesis  was  shown  to  be  relatively  unaffected  at  concentrations  of  up  to 
1pM  STI  (Druker  BJ,  Tamura  S  et  al.  1996;  Deininger  MW,  Goldman  JM  et  al. 
1997).  These  promising  results  prompted  the  commencement  of  clinical  trials  in 
the  USA. 
1.2.4.2  Clinical  Studies  with  ST1571 
STI  reached  the  clinic  in  1998  and  was  the  first  drug  specifically  targeted  to 
counteract  the  effects  of  a  cellular  oncoprotein.  Initially  only  patients  who  had 
failed  interferon-a  (IFN)  in  CP  were  approved  for  the  trial.  The  toxicity  was 
comparatively  low  level  and  the  drug  was  well  tolerated.  In  this  first  trial  53  out  of 
54  patients  achieved  a  complete  haematological  response  (CHR)  at  doses  of 
300mg  and,  at  this  level  or  above,  31%  of  patients  achieved  a  cytogenetic 
response,  which  was  complete  in  13%  of  cases.  Pharmacokinetic  data  revealed 
that  at  300mg/day,  the  level  in  the  plasma  was  equivalent  to  1  NM,  shown  to  be 
effective  in  the  in  vitro  studies.  On  the  basis  of  these  results  the  study  was 
expanded  to  include  patients  in  BC  phase  of  the  disease.  However,  most  of  these 
patients  relapsed  within  a  few  months  of  therapy  indicating  that  the  drug  was  much 
less  effective  in  BC.  Phase  II  and  III  trials  followed,  including  patients  at  diagnosis, 
at  all  stages  of  disease  and  with  combinations  of  conventional  drugs  versus  STI. 
Overall  the  STI  treated  patients  showed  improved  survival  and,  due  to  its  lack  of 
toxicity,  better  quality  of  life  (Kantarjian  HM,  O'Brien  S  et  al.  2003).  Although  these 
results  lead  to  confidence  that  an  effective  treatment  for  CML  at  least  in  CP  had 
been  found,  there  were  certain  observations  that  were  cause  for  concern.  One  of 
the  most  significant  was  that  in  patients  who  achieved  a  completed  cytogenetic 
response,  detectable  BCR-ABL  transcripts  were  shown  in  samples  analysed  by Susan  M  Graham,  2005  Chapter  1,53 
sensitive  RT-PCR,  indicating  that  molecular  remissions  were  rare  (Hughes  TP, 
Kaeda  J  et  al.  2003).  It  has  also  been  shown,  in  work  included  in  this  thesis,  that 
quiescent  BCR-ABL+  stem  cells  are  resistant  to  the  effects  of  STI  in  vitro  and  have 
the  potential  to  cause  relapse  (Graham  SM,  Jorgensen  HG  et  al.  2002).  These 
observations  have  increased  doubts  over  the  durability  of  responses  to  STI 
therapy. 
1.2.4.3  Resistance  to  STI 
The  less  favourable  responses  of  CML  patients  in  AP  and  BC  to  STI  therapy, 
together  with  the  existence  of  low  level  BCR-ABL  transcripts  in  treated  patients  in 
CP,  prompted  investigations  into  the  possible  mechanisms  of  resistance.  It  is  clear 
from  the  clinical  data  that  resistance  may  be  acquired  i.  e.  patients  respond  initially 
and  then  fail  therapy,  or  resistance  may  be  inherent  i.  e.  little  or  no  response  is 
observed.  The  mechanism  of  resistance  may  be  associated  with  disease  status 
and  progression,  and  may  be  different  for  both. 
As  early  as  1997,  Deininger  et  al  had  found  that  small  numbers  of  Ph+  colonies 
could  be  grown  in  the  presence  of  1pM  STI  (Deininger  MW,  Goldman  JM  et  at. 
1997).  Le  Coutre  et  al  demonstrated  that  a  BCR-ABL+  cell  line,  LAMA84,  could  be 
induced  to  develop  resistance  to  STI  by  culturing  cells  with  increasing 
concentrations  of  STI  over  a  period  of  time.  They  also  showed  that  resistant  cells 
contained  a  higher  level  of  bcr-abt  expression  and  phosphorylation,  and  that  this 
was  associated  with  gene  amplification  (Le  Coutre  P,  Tassi  E  et  at.  2000).  The 
observation  that  removal  of  STI  from  cultures  could  restore  sensitivity  to  the  drug 
in  cell  lines,  indicated  that  two  populations  of  cells  coexisted  i.  e.  a  sensitive  and  an 
insensitive  one  each  prevailing  under  the  correct  conditions  (Tipping  AJ,  Mahon 
FX  et  at.  2001).  These  results  raise  the  possibility  that  patients  who  have  become 
resistant  may  regain  sensitivity  by  brief  withdrawal  of  the  drug.  It  is  not  clear  what 
implications  these  observations  may  have  in  the  therapeutic  context. 
Drug  resistance  is  most  commonly  associated  with  reactivation  of  bcr-abl  signal 
transduction  and  recent  data  have  indicated  that  the  most  frequent  mechanisms  of 
resistance  to  STI  are  point  mutations  in  the  kinase  domain  of  bcr-abl  or  gene 
amplification  at  the  transcript  or  genomic  level  (Gorre  ME,  Mohammed  M  et  al. 
2001).  Mutations  in  the  kinase  domain  may  interfere  with  STI  binding  or  may 
change  the  conformation  of  the  protein  such  that  drug  binding  is  reduced. Susan  M  Graham,  2005  Chapter  1,54 
Investigations  have  shown  that  there  is  a  range  of  sensitivities  to  STI  associated 
with  particular  mutations  (Corbin  AS,  Buchdunger  E  et  al.  2002).  Recent  work  by 
Bhatia's  group  has  shown  that  kinase  mutations  can  be  detected  in  CD34+  stem 
cells  from  patients  in  CCR  on  STI  therapy,  raising  the  possibility  that  therapy  itself 
may  lead  to  a  selective  advantage  for  the  mutant  clone  and  subsequent  relapse 
(Chu  S,  Xu  H  et  at.  2005).  The  finding  that  point  mutations  could  be  found  in 
patients  prior  to  STI  therapy  argues  for  a  pre-existing  mutant  clone  that  gains 
prevalence  as  its  sensitive  neighbours  are  eliminated  (Shah  NP,  Nicoll  JM  et  al. 
2002). 
Other  possible  mechanisms  for  resistance  to  STI  therapy  include  overexpression 
of  the  MORI  gene,  which  encodes  the  P-glycoprotein  pump,  and  was  shown  to 
inhibit  the  entry  of  STI  into  K562/DOX  cells  (resistant  to  doxirubicin  by  MDR1 
expression).  Retroviral  transfection  of  BCR-ABL+  cells  with  MDR1  reduced  their 
sensitivity  to  STI,  which  could  be  restored  by  inhibition  of  Pgp  with  verapamil 
(Mahon  FX,  Belloc  F  et  al.  2003).  Using  C14-radiolabelled  STI  it  has  been  shown 
recently  that  both  uptake  (by  hOCT1)  and  efflux  (by  MDRI)  are  active  transport 
processes  that  can  be  inhibited  by  verapamil.  Both  transporters  were  expressed  in 
primary  CML  cells  and  in  cell  lines.  This  observation  may  mean  that  resistance  is  a 
result  of  disparity  in  expression  between  the  two  transporters  (Thomas  J,  Wang  L 
et  al.  2004).  Another  recent  report  has  documented  the  first  cellular  effect  of  Pgp 
modulation  in  the  treatment  of  a  Ph*  ALL  patient  with  STI  (Illmer  T,  Schaich  M  et 
al.  2004).  In  contrast,  other  studies  have  shown  overexpression  of  MDRI  in  BCR- 
ABL+  K562  cells  did  not  protect  them  from  the  effects  of  STI  (Ferrao  PT,  Frost  MJ 
et  al.  2003).  The  importance  of  MDR1  in  clinical  resistance  to  STI  has  yet  to  be 
established. 
To  try  to  overcome  the  problems  of  STI  resistance  other  approaches  in  the 
treatment  of  CML  include,  dose  escalation  of  STI,  other  bcr-abl  inhibitors, 
combinations  of  other  cytotoxic  drugs  and  STI  and  inhibitors  of  downstream 
targets  of  bcr-abl.  Undoubtedly,  STI  has  had  a  major  impact  on  both  the  clinical 
management  of  CML  and  on  the  laboratory  investigations  into  this  fascinating 
disease.  Whether  resistance  to  STI  is  a  feature  that  has  to  be  overcome  with 
additional  therapy  or  whether  there  are  (quiescent)  cells  that  are  genuinely  able  to 
evade  therapy,  will  be  elucidated  in  time  to  come. Susan  M  Graham,  2005  Chapter  1,55 
1.3  Microarrays 
Recent  technological  advances  together  with  the  success  of  the  Human  Genome 
Project  have  given  researchers  the  tools  to  investigate  gene  expression  on  a 
genomic  scale.  The  data  generated  from  numerous  studies  have  changed  the 
focus  of  research  in  many  areas,  not  least  cancer.  A  complete  review  of  the 
technology  is  outwith  the  scope  of  this  discussion,  which  will  focus  on  the  areas 
most  relevant  to  this  study. 
1.3.1  Types  of  Arrays 
The  most  common  formats  for  microarrays  are  cDNA  arrays  and  oligonucleotide 
arrays: 
1.  cDNA  arrays  use  gene  sequences,  which  are  normally  PCR  products  derived 
from  cDNAs  that  are  robotically  spotted  onto  either  glass  slides  or  nylon 
membranes.  Labelled  single  stranded  cDNA  is  produced  from  RNA  samples  using 
reverse  transcriptase  and  hybridised  to  the  array,  in  a  typically  competitive 
reaction.  The  two  samples  to  be  compared  are  labelled  with  different  dyes,  most 
commonly  Cy3  and  Cy5,  and  the  arrays  are  then  scanned  at  two  different 
wavelengths  to  detect  the  relative  transcript  levels  for  each  sample.  The  main 
advantages  of  this  type  of  array  are,  a)  they  can  be  generated  in  house,  b)  they 
can  be  customised  to  suit  samples  and  investigation,  and  c)  they  are  relatively 
inexpensive.  However,  the  main  disadvantages  are  that  managing  large  cDNA 
libraries  is  an  onerous  task  and  even  the  best  labs  are  prone  to  errors.  The 
reproducibility  in  array  manufacture  is  variable  and  the  format  is  limited  to  a 
smaller  density  of  spots,  largely  due  to  limitations  in  the  robotics.  A  further 
drawback  of  this  type  of  array  is  the  possible  failure  to  detect  closely  related  genes 
if  there  is  a  large  degree  of  sequence  homology. 
2.  Oligonucleotide  arrays  such  as  Affymetrix  GeneChip®  arrays  are  the  gold 
standard  in  array  technology  and  are  made  by  synthesising  oligonucleotides  on 
the  chip  by  a  process  known  as  photolithography.  There  are  11-16  probe  pairs  or 
sets  for  each  gene  and  hybridisation  is  non-competitive.  A  pair  consists  of  a 
perfectly  matched  sequence  of  25  oligos  and  partner  containing  a  single  mismatch 
base  at  position  13.  Biotin  tagged  RNA  produced  by  in  vitro  transcription  is  applied 
to  the  chips  and  the  signals  obtained  from  the  perfect  match  and  mismatch  probes Susan  M  Graham,  2005  Chapter  1,56 
compared.  The  use  of  multiple  short  sequences  allows  splice  variants  and 
sequences  of  up  to  90%  homology  to  be  identified.  The  probe  mismatch  strategy 
helps  to  minimise  non-specific  and  background  signals.  In  addition,  Affymetrix 
chips  contain  a  number  of  probe  sets  with  known  expression  levels,  which  serve 
as  internal  controls  for  signal  and  background  normalisation.  This  method  of 
manufacture  means  that  at  least  12,000  genes  can  be  represented  per  chip  and 
the  sample  can  be  recovered  following  the  first  hybridisation  and  applied  to 
another  chip.  There  are  a  number  of  disadvantages  of  this  system,  1)  it  requires 
specialist  equipment  and  expertise  to  operate  it,  2)  it  is  very  expensive  especially  if 
multiple  samples  are  to  be  included,  and  3)  the  expense  of  custom  chips  makes 
this  impractical  for  even  small  experiments. 
3.  Recently,  oligonucleotide  arrays  using  60-mer  sequences  (or  longer)  have 
become  available.  This  format  offers  an  increased  level  of  sensitivity  over  the  early 
oligonucleotide  arrays  together  with  the  option  of  custom  gene  sets  at  a 
reasonable  cost.  One  of  the  main  advantages  is  that  these  arrays  do  not  require 
expensive  equipment  to  process  the  slides  and,  due  to  advances  in  spotting 
technology,  now  offer  a  high  level  of  reproducibility.  Comparisons  of 
oligonucleotide  and  Affymetrix  array  formats  have  shown  good  correlation  of 
expression  values  for  comparable  samples  (Barczak  A,  Rodriguez  MW  et  al. 
2003). 
Samples  for  application  to  microarrays  can  be  from  any  source  providing  there  are 
enough  cells  from  which  to  extract  intact  RNA.  Often  clinical  samples  especially 
from  solid  tumours  or  biopsies  yield  very  small  amounts  of  material.  It  is  possible 
to  amplify  the  RNA  prior  to  application  to  the  arrays.  Linear  amplification  is  based 
on  reverse  transcription  with  primers  containing  a  bacteriophage  RNA  polymerase 
promoter  sequence  and  cDNA  is  amplified  by  in  vitro  reverse  transcription  using 
the  appropriate  bacteriophage  RNA  polymerase  (Baugh  LR,  Hill  AA  et  al.  2001). 
The  results  are  reproducible  and  allow  as  little  as  1-50ng  of  total  RNA  to  be  used 
as  starting  material,  equivalent  to  100-5000  cells.  Recent  data  has  validated  this 
amplification  protocol  for  small  amounts  of  starting  material,  showing  that  similar 
differential  gene  expression  profiles  were  generated  from  both  amplified  and  non- 
amplified  RNA  (Patel  OV,  Suchyta  SP  et  al.  2005). Susan  M  Graham,  2005 
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Microarray  experiments  by  their  nature  generate  vast  amounts  of  data.  The  task  of 
analysing  this  data  to  produce  meaningful  results  is  complex  and  time  consuming, 
requiring  input  from  specialist  bioinformatians.  Initially  the  image  data  from  the 
array  scans  has  to  be  normalised  to  subtract  background  noise  and  non-specific 
signals.  In  the  case  of  Affymetrix  Genechips  the  controls  are  internal  to  the  chips 
giving  more  robust  data.  The  next  level  of  analysis  is  aimed  at  identifying  relevant 
changes  in  gene  expression,  usually  comparing  one  sample  with  a  control  sample. 
Specialist  array  programs  are  employed  at  this  stage  to  deal  with  complexity  and 
quantity  of  data.  One  such  program  is  GeneSpring®  (Silicon  Genetics,  USA)  and 
was  the  one  used  for  the  initial  analysis  in  this  work.  Normalised  data  from  the 
array  chips  are  imported  into  the  program,  which  allows  the  data  to  be 
manipulated  in  various  ways.  The  first  step  is  typically  to  look  at  the  fold  change 
either  up  or  down  between  samples.  This  gives  an  indication  of  the  number  of 
genes  that  are  changed  between  experimental  groups.  Utilising  the  numerous 
analysis  tools  in  the  program  allows  generation  of  gene  lists  with  defined 
parameters  i.  e.  fold  change  set  at  2,3,  etc  or  overlapping  genes  in  data  sets  using 
Venn  diagrams.  Further  data  analysis  to  determine  statistical  significance  is 
required  to  confirm  results.  Clustering  analysis  identifies  gene  groups  that  are 
changed  between  samples  and  more  sophisticated  analysis  can  generate  a 
genetic  "fingerprint"  for  a  particular  condition  or  disease,  which  could  be  used  to 
predict  outcome  or  identify  suitable  treatment  (Reviewed  in  (King  HC  and  Sinha 
AA.  2001). 
1.3.3  Confirmation  of  Microarray  Results 
Due  to  the  way  in  which  large  amounts  of  data  are  generated  in  microarray 
experiments,  confirmation  by  independent  analysis  is  required.  Separate  samples 
other  than  the  ones  used  for  the  arrays  increases  the  validation  of  results. 
Normally  another  experimental  platform  is  used  to  corroborate  array  data.  This  is 
commonly  quantitative  real  time  PCR  such  as  Taq-man  (Applied  Biosciences)  or 
Light  Cycler  (Roche),  which  can  measure  relative  expression  levels  in  matched 
samples.  Ultimately,  the  most  relevant  biological  validation  is  variation  in  cellular 
protein  levels,  although  for  technical  reasons  this  may  not  always  be  possible.  It 
must  be  appreciated  that  although  microarrays  are  a  powerful  tool  they  only  give  a Susan  M  Graham,  2005  Chapter  1,58 
snapshot  of  the  transcription  levels  in  a  cell  in  that  time  frame.  Moreover,  they  do 
not  discriminate  post-translational  or  post-transcriptional  modifications,  which  may 
be  just  as  relevant  to  the  cell's  biological  state. 
1.3.4  Microarrays  and  Stem  Cell  Biology 
Microarrays  have  been  used  in  a  number  of  studies  in  an  effort  to  unlock  the 
genetic  program  of  stem  cells.  However,  numerous  investigations  have  failed  to 
yield  consistent  gene  sets.  This  is  perhaps  not  surprising  given  the  variations  in 
studies  between  cell  populations,  selection  methods,  array  formats,  and 
bioinformatics.  A  vast  amount  of  data  has  been  generated,  however  much  of  it  is 
not  directly  comparable  due  to  the  variations  listed  above.  The  ability  to  examine 
the  gene  expression  profile  of  HSC  has  led  to  a  variety  of  microarray  studies  in  the 
search  for  a  "molecular  signature"  that  could  be  used  to  define  these  rare  cells, 
and  thus  separate  them  from  the  general  population.  Phillips  et  at  have  reported  a 
microarray  study  of  murine  HSC,  which  identified  gene  differences  between 
primitive  and  more  differentiated  stem  cells.  The  analysis  recognised  thousands  of 
known  and  unknown  genes  as  differentially  expressed  between  the  cell  types, 
which  were  used  to  construct  a  stem  cell  database  (Phillips  RL,  Ernst  RE  et  al. 
2000).  The  results  illustrate  the  problems  inherent  in  these  types  of  experiments 
i.  e.  vast  amounts  of  data  are  generated  and  it  is  difficult  to  identify  the  most 
important  gene  expression  differences.  Even  in  studies  where  similar  methodology 
has  been  used,  microarray  results  can  generate  different  gene  sets.  This  was 
illustrated  recently  when  two  independent  groups  used  gene  profiling  to  try  to 
identify  a  molecular  signature  of  "sternness".  Both  groups  examined  the 
expression  profile  of  mouse  embryonic,  neural  and  haemopoietic  stem  cells,  and 
produced  a  list  of  genes  associated  with  a  common  stem  cell  profile.  However, 
analysis  of  both  data  sets  by  an  independent  group  revealed  that  there  was  very 
little  overlap  in  the  gene  sets  identified,  in  fact  only  6  genes  were  common  to  both 
gene  sets.  These  data  emphasise  the  importance  of  strictly  defined  cell 
populations  and  caution  in  interpretation  of  analysis  (Ivanova  NB,  Dimos  JT  et  at. 
2002;  Ramalho-Santos  M,  Yoon  S  et  at.  2002;  Evsikov  AV  and  D.  2003). 
The  problems  highlighted  can  be  minimised  to  some  degree  by  using  very  defined 
cell  populations,  such  as  sorted  cells,  although  this  inevitably  means  small 
amounts  of  starting  material.  Other  microarray  studies  have  confirmed  the 
importance  of  recognised  gene  differences  and  subsequently,  increased  the Susan  M  Graham,  2005  Chapter  1,59 
significance  of  these  observations.  In  a  recent  report,  Steidl  et  al  compared  the 
expression  profiles  of  BM  and  circulating  CD34+  cells  and  confirmed  the  increased 
cycling  status  of  BM  CD34+  cells  compared  with  G-CSF  mobilised  PB  CD34+  cells 
(Steidl  U,  Kronenwett  R  et  al.  2002).  It  is  clear  that  this  technology  has  facilitated 
our  understanding  of  some  important  pathways  and  interactions,  and  has  become 
an  important  tool  in  stem  cell  research. 
1.3.5  Clinical  Impact  of  Microarrays 
One  of  the  first  applications  of  successful  gene  profiling,  in  the  context  of 
leukaemia,  was  used  to  distinguish  acute  lymphoblastic  leukaemia  (ALL)  and 
acute  myeloblastic  leukaemia  (AML).  Although  the  two  diseases  were 
distinguishable  through  the  application  of  various  specialist  criteria,  there  was  no 
single  test  that  was  sufficient  to  separate  them.  Treatment  for  each  disease  is 
markedly  different  and  critical  to  success.  Although  both  diseases  will  respond  to 
the  corresponding  treatment  regime,  lower  cure  rates  and  unnecessary  toxicities 
are  observed.  Golub  et  al  used  the  two  diseases  as  a  test  case  to  measure  the 
success  of  a  gene  profiling  strategy  for  disease  classification.  They  were  able  to 
define  a  class  predictor  (50  genes)  for  the  AML/ALL  distinction  and  further 
determined  that  it  could  have  been  automatically  discovered  without  prior 
knowledge  of  the  biology  (Golub  TR,  Slonim  DK  et  al.  1999). 
More  recently,  gene  profiling  identified  a  newly  classified  leukaemia  distinct  from 
ALL  or  AML.  A  subset  of  human  leukaemia  with  a  particularly  poor  prognosis  was 
known  to  possess  a  chromosomal  translocation  involving  the  mixed-lineage 
leukaemia  gene  (MLL).  The  morphology  of  the  disease  is  lymphoblastic  leading  to 
its  classification  as  ALL.  However,  unlike  classic  childhood  ALL,  relapses  post 
chemotherapy  were  common  and  the  cells  exhibited  distinct  immunophenotypic 
differences  from  ALL,  including  lack  of  early  lymphocyte  antigen  and  the  tendency 
to  express  myeloid  antigens.  The  gene  expression  profiles  showed  that  ALLs  with 
the  MLL  rearrangement  displayed  a  uniform  and  distinct  pattern  distinguishing 
them  from  conventional  ALL  and  AML  (Armstrong  SA,  Staunton  JE  et  at.  2002). 
There  are  many  more  studies  that  have  successfully  employed  microarray 
technology  to  clinical  advantage.  The  possibility  of  routine  diagnosis  by  gene 
profiling  is  a  little  way  off,  however  there  is  no  doubt  that  this  technology 
represents  a  major  step  forward  in  clinical  investigation  and  in  targeted  therapy. Susan  M  Graham,  2005 
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Quiescent  HSC  remain  relatively  uncharacterised.  The  existence  of  quiescent 
leukaemic  stem  cells  in  CML  and  their  potential  for  disease  persistence,  presented 
an  attractive  target  for  investigation.  The  initial  experiments  were  aimed  at 
developing  the  methodology  to  select  these  rare  stem  cells  from  the  rest  of  the 
HSC  population.  A  FAGS  sorting  strategy  was  developed  to  isolate  pure 
populations  of  quiescent  and  cycling  stem  cells  from  both  normal  individuals  and 
CML  patients. 
Further  FACS  sorting  methodology  was  utilised  to  investigate  the  differences 
between  normal  and  CML  HSC  in  vitro  in  the  presence  and  absence  of  growth 
factors.  Additional  experiments  were  aimed  at  examining  the  effects  of  a 
specifically  targeted  therapy,  ST1571,  on  CML  stem  cells  in  vitro.  Finally,  FACS 
sorting  methodology  was  used  to  isolate  populations  of  normal  and  CIVIL  HSC  in 
different  phases  of  the  cell  cycle,  in  an  effort  to  identify  the  transcriptional  profile  of 
normal  and  CML  quiescent and  cycling  cells  by  microarrays  . 61 
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2.1  Materials 
2.1.1  Tissue  Culture  Supplies 
Baxter  Healthcare  Gammagard  human  i.  v.  immune 
Northampton,  UK  globulin 
Sterile  water 
Isolex  stem  cell  selection  kit 
Becton  Dickinson  Hypodermic  needles 
Plymouth,  UK  Luer  lock  syringes 
Falcon  tubes 
Bibby-Sterilin  Suspension  culture  dishes  35mm 
Staffordshire,  UK 
Chugai  Pharma,  rHU  G-CSF 
London  UK 
Costar,  Cell  scrapers 
Cambridge,  MA,  USA 
Corning,  24  well  tissue  culture  plates 
Bucks,  UK 
Gibco  BRL,  2-mercaptoethanol 
Paisley,  UK 
Millipore,  Millex-OR  single  use  filter  (0.2pm) 
Watford,  UK 
Nalge  Nunc  International,  50ml  Tissue  culture  flasks 
Roskilde,  Denmark  Cryotubes 
Novartis,  ST1571 
Surrey,  UK 
Roche  Products  Ltd  Recombinant  human  Dnase 
Welwyn  Garden  City,  UK  (Pulmozyme®) 
Scottish  Blood  Transfusion  Service,  20%  Human  serum  albumin  (HSA) 
Glasgow,  UK  4%  Human  serum  albumin  (ALBA) 
Human  immunoglobulin 
Sigma  Aldrich,  Acetic  acid 
Dorset,  UK  Ammonium  chloride 
Dimethyl  sulphoxide 
Dulbecco's  phosphate  buffered  saline 
(w/o  Ca2+  and  Mgt+)  (PBS) 
Foetal  calf  serum  (FCS) 
Glutamine 
Low  density  lipoprotein 
Iscove's  modified  Dulbecco's  medium 
(IMDM) 
Methanol 
Penicillin/streptomycin 
Potassium  chloride 
Tri-sodium  citrate Susan  M  Graham,  2005  Chapter  2,62 
Trypan  blue  solution  (0.4%) 
Isopropyl  alcohol 
Pol  -L-I  sine 
Stem  Cell  Technologies,  BIT  (serum  substitute) 
British  Columbia,  Canada  rHU  FLT3L 
rHU  IL-3 
rHU  IL-6 
rHU  Stem  cell  factor  (SCF) 
Methocult 
Stem  cell  mix  +  erythropoeitin 
Progenitor  enrichment  cocktail 
Biotinylated  anti-CD15 
StemSep  columns 
Sterilin  Ltd  90mm  petri  dishes 
Hounslow,  UK  30mm  triple  vent  dishes 
15ml  centrifuge  tubes 
PES  filter  system  (0.2pm) 
50ml  centrifuge  tubes 
5ml  sterile  disposable  pipettes 
10mi  sterile  disposable  pipettes 
25ml  sterile  disposable  pipettes_ 
Tayside  Pharmaceuticals,  Magnesium  chloride 
Dundee,  UK 
Vysis-Abbott,  FISH  Dual  fusion  probe  (bcr/abl) 
Maidenhead,  UK 
2.1.2  FACS  Reagents 
Becton  Dickinson,  Oxford  Human  anti-CD34  FITC  antibody 
UK  Human  anti-CD34  PE  antibody 
Human  anti-CD38  PE  antibody 
IgG  FITC  isotype  control 
IgG  PE  isotype  control 
Mid  range  FL1  rainbow  alignment 
particles 
Calibrite  FITC/PE  beads 
FAGS  flow 
FACS  safe 
FACS  rinse 
Cambridge  Biosciences,  CFSE 
London,  UK  UV  alignment  beads 
Hoechst  33342 
Sigma  Aldrich,  Propidium  iodide 
Dorset,  UK  ronin  Y Susan  M  Graham,  2005 
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Abgene,  ReddyMix  PCR  Master  Mix  50µI 
Surrey,  UK  reaction  tubes 
Ambion,  DNA-free  Kit 
Texas,  USA 
Beatson  Laboratory  Stock,  DH5a  E.  Coli 
Glasgow,  UK 
Invitrogen,  Superscript  II  kit 
Paisley,  UK  TRlzol  reagent 
TOPO  TA  kit 
MWG,  PCR  Primers 
London,  UK 
Qiagen,  QlAquick  PCR  Purification  Kit 
West  Sussex,  UK  QlAquick  Nucleotide  Removal  Kit 
QlAquick  Gel  Extraction  Kit 
QlAprep  Miniprep  Kit 
Rneasy  Mini  Kit 
Sigma  Aldrich,  Ampicillin 
Poole,  UK  Chloroform 
Dimethyl  formamide  (DMF) 
Isopropyl  alcohol 
Trizol  reagent 
X-gal 
Ethidium  bromide 
Hyperladder  IV  100-1000b 
2.1.4  Primers  for  RT-PCR 
Actin:  forward:  TCC  ATC  ATG  AAG  TGT  GAC  GT 
reverse:  TAC  TCC  TGC  TTG  CTG  ATC  CAC 
CD34:  forward:  CTG  CTA  CCA  CGG  AGA  CTT  CTA  CAC  AAG  G 
reverse:  ATG  GCA  CTC  GGA  GCA  GAA  GAT  GAT 
MCMS;  forward:  GCA  GAG  GCG  CTT  CAA  GGA  GTT  CC 
reverse:  ATG  TTG  GTG  AGG  GTG  TTG  CGC CAG 
PCNA:  forward:  TCA  ACG  AGG  CCT  GCT  GGG  ATA  TTA  G 
reverse:  TGG  CTG  AGA  TCT  CGG  CAT  ATA  CGT  G Susan  M  Graham,  2005  Chapter  2,64 
ABL:  forward:  TTCAGCGGCCAGTAGCATCTGACTT 
reverse:  GGTACCAGGGTGTTTCTCCAGACTG 
BCR-ABL:  forward:  CAGGGTGCACAGCCGCAACGGCAA 
reverse:  GTCCAGCGAGAAGGTTTTCCTfGGA 
2.2  Media  and  Solutions 
2.2.1  Tissue  Culture  Media 
2.2.1.1  Serum  Free  Media 
77.8m1  IMDM 
20m1  BIT  (serum  substitute) 
Im(  L-Glutamine  (200mM) 
1  ml  Penicillin  (5000u)/Streptomycin  (5mg/ml) 
200p12-Mercaptoethanol  (200mM  stock) 
40pg/mI  Low  density  Lipoprotein 
2.2.1.2  Growth  Factor  Cocktail  for  Serum  Free  Media 
IL-3  20ng/mI 
IL-6  20ng/ml 
h-SCF  lOOng/m( 
FLT-3L  IOOng/ml Susan  M  Graham,  2005  Chapter  2,65 
G-CSF  20ng/mi 
2.2.1.3  IMDM  2%  FCS 
98m1  Iscove's  modified  Dulbecco's  medium 
2m1  Foetal  calf  serum 
2.2.2  Tissue  Culture  Solutions 
2.2.2.1  PBS  2%  FCS  (PBS/2%) 
98ml  Dulbecco's  modified  phosphate  buffered  saline  w/o  Ca  +  and 
2m1  Foetal  Calf  Serum 
2.2.2.2  PBS  20%  FCS  (PBS/20%) 
80ml  Dulbecco's  modified  phosphate  buffered  saline  w/o  Ca  +  and 
20m1  Foetal  Calf  Serum 
2.2.2.3  PBS+ 
327ml  Dulbecco's  modified  phosphate  buffered  saline  w/o 
0.5m1  magnesium  chloride 
and 
2.5m1 Susan  M  Graham,  2005 
2.2.2.4  PBS++ 
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500ml  Dulbecco's  modified  phosphate  buffered  saline  w/o  Ca  and  M 
75m1  Tri-sodium  citrate 
25ml  Human  serum  albumin 
l  ml  Magnesium  chloride 
5m1 
2.2.2.5  ALBA  20%  DMSO 
80ml  Human  serum  albumin 
20m1  dimethylsulphoxide 
2.2.3  Molecular  Biology  Solutions 
2.2.3.1  TAE  Buffer 
40mM  Tris-acetate 
1mM  EDTA 
Reagents  were  dissolved  in  distilled  water  and  pH  adjusted  to  8.3  with  glacial 
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2.2.4  Bacterial  Culture  Reagents 
2.2.4.1  SOC  Medium 
2%  (w/v)  bactotryptone 
0.5%  (w/v)  yeast  extract 
10mM  NaCl 
2.5mM  KCI 
20mM  MgCI2 
20mM  MgSO4 
20mM  glucose 
2.2.4.2  Luria-Bertani  (LB)  Broth  and  Agar  Plates 
lg  tryptone 
15g  yeast  extract 
lOg  NaCI2 
950m1  deionised  water 
15g  Agar  (FOR  PLATES) 
All  the  ingredients,  except  the  agar  were  added,  and  the  pH  adjusted  to  7  using 
NaOH.  The  final  volume  was  increased  to  1  litre  and  the  solution  autoclaved 
before  use.  To  make  bacterial  culture  plates,  agar  was  added  at  15gf  to  the  LB Susan  M  Graham,  2005  Chapter  2,68 
broth  and  autoclaved,  before  the  addition  of  50pg/ml  ampicillin.  Approximately 
1  Oml  of  the  solution  was  poured  into  90mm  petri  dishes  to  solidify. 
2.2.4.3  X-Gal  Stock  Solution  40  mg/ml 
400mg  x-gal 
10mi  dimethylformamide 
X-gal  was  dissolved  in  dimethylformamide  and  stored  as  a  stock  solution  at  -20°C 
protected  from  light.  Before  addition  to  the  agar  plates,  the  plates  were  warmed  to 
37°C  and  40pl  of  the  stock  solution  added  to  each  plate  and  spread  evenly  with  a 
sterile  spreader.  The  plates  were  dried  for  15  minutes  and  protected  from  light,  for 
use  within  24  hours  after  the  addition  of  x-gal. 
2.3  Methods 
2.3.1  General  Cell  Culture 
2.3.1.1  Cell  Counts 
Cell  counts  were  performed  on  a  Beckman  Coulter  T660  analyser,  which  required 
120µI  of  sample.  For  counting  small  cell  numbers  or  for  cell  viability  counts,  a 
haemocytometer  counting  chamber  was  used. 
2.3.1.2  Cryopreservation  of  Cells 
Sorted  or  selected  cells  were  stored  frozen  in  liquid  nitrogen  where  appropriate  for 
further  use.  For  cryopreservation,  a  cell  suspension  was  made  not  exceeding 
1x107  cells/ml  in  appropriate  medium  to  which  was  added  an  equal  volume  of 
ALBA  +  20%  DMSO,  to  give  a  final  concentration  of  10%  DMSO.  The  cryotubes 
were  placed  in  a  freezing  container  (Mr  Frosty)  that  included  isopropyl  alcohol  and 
placed  in  a  --80°C  freezer  overnight.  This  allowed  a  controlled  reduction  in 
temperature  of  approximately  1°C/minute.  before  placing  into  long-term  liquid Susan  M  Graham,  2005  Chapter  2,69 
nitrogen  storage.  For  some  CD34+  selected  CML  and  normal  samples  used,  this 
was  performed  by  either  Dr  Michael  Alcom  or  Mrs  Linda  Richmond. 
2.3.1.3  Recovery  of  Frozen  Samples 
To  recover  the  maximum  number  of  viable  cells  from  cryopreservation  it  was 
necessary  to  exercise  extreme  care  when  thawing  patient  samples,  particularly 
CML  samples.  On  removal  from  liquid  nitrogen,  the  vials  were  immediately  thawed 
in  a  370  C  water  bath  until  all  of  the  ice  crystals  had  disappeared.  The  cells  were 
transferred  to  a  sterile  15ml  centrifuge  tube  on  ice  and  10ml  of  ALBA  was  added 
drop-wise  over  a  15-20  minute  period.  The  tubes  were  centrifuged  at  400g  for  10 
minutes.  The  cells  were  washed  twice  by  adding  10ml  of  PBS/2%  and  centrifuging 
as  before.  After  discarding  the  final  wash  supernatant,  the  cells  were  resuspended 
in  appropriate  medium,  counted  and  assessed  for  viability. 
2.3.1.4  Assessment  of  Viability 
Routinely  viability  was  determined  using  the  trypan  blue  exclusion  method.  The 
cell  suspension  was  diluted  to  an  appropriate  number  and  trypan  blue  solution 
added  at  a  ratio  of  1:  4  trypan  blue  to  cells.  The  cell  suspension  was  placed  in  a 
haemocytometer  counting  chamber  and  at  least  200  cells  were  counted  under  a 
light  microscope  at  40x  magnification.  The  blue  stained  cells  were  scored  as  dead 
and  the  unstained  cells  as  live.  The  percentage  of  viable  cells  was  calculated  by 
dividing  the  number  of  viable  cells  by  the  total  cell  count  x100. 
2.3.1.5  Red  cell  Lysis  by  Ammonium  Chloride 
For  most  experimental  purposes  it  was  necessary  remove  red  cell  contamination 
from  leukapheresis  products.  This  was  achieved  by  lysis  of  the  red  cells  with 
ammonium  chloride  solution  0.083%w/v  in  distilled  water,  added  at  a  1:  10  cell 
suspension  to  NH4CI  and  incubated  in  a  37°C  water  bath  for  10  minutes.  The  cells 
were  recovered  by  centrifugation  at  400g  for  10  minutes  followed  by  a  further 
wash  in  PBS/2%.  If  red  cell  lysis  was  incomplete  the  above  procedure  was 
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2.3.1.6  Removal  of  Red  Cells  by  Density  Gradient  Centrifugation 
An  alternative  method  for  effectively  removing  red  cells  from  samples  used 
lymphoprep,  a  density  gradient  medium.  The  cell  samples  were  diluted  in  PBS2% 
to  give  a  working  cell  concentration  of  less  than  5x107/ml.  6-10mis  of  cell 
suspension  was  carefully  layered  over  4ml  of  lymphoprep  avoiding  mixing  the  two 
phases.  The  tubes  were  centrifuged  at  800g  for  20  minutes  during  which  the  red 
cells  moved  through  the  lymphoprep  to  the  bottom  of  the  tube  and  the 
mononuclear  cells  remained  at  the  interface.  Following  recovery  from  the 
interface,  the  cells  were  washed  twice  in  PBS2%. 
2.3.1.7  Removal  of  Platelets 
When  using  leukapheresis  products  it  was  necessary  to  remove  contaminating 
platelets  before  commencing  cell  separation.  This  was  done  by  centrifuging  the 
sample  in  50ml  tubes  at  200g  for  10  minutes  and  stopping  the  rotor  without  the 
brake  activated.  The  supernatant  was  removed  by  aspiration  and  the  above  step 
repeated  with  the  addition  of  PBS++  (section  2.2.2.4)  to  each  tube.  The 
supernatant  was  discarded  and  the  cell  pellet  resuspended  in  appropriate  medium. 
2.3.1.8  Committed  Progenitor  Assay 
As  a  measure  of  functionality,  cells  were  cultured  in  semi-solid  medium  in  the 
presence  of  stimulatory  cytokines  in  CFU-GM/CFU-BFUE  assays.  Methocult,  a 
commercial  ready-  made  methylcelluose,  was  supplemented  with  stem  cell  mix  + 
erythropoietin  (custom  cocktail  from  Stem  Cell  Technologies).  2.3ml  of 
supplemented  methocult  was  aliquoted  into  falcon  tubes  and  stored  at  -20°C  until 
required.  After  thawing  the  tubes,  the  cell  suspension  was  added  in  a  final  volume 
of  0.2ml  in  IMDM/2%FCS  to  each  tube  and  shaken  vigorously  to  mix.  Iml  of  the 
suspension  was  placed  in  each  of  two  35mm  suspension  culture  dishes.  The 
dishes  were  placed  in  a  90mm  petri  dish  together  with  a  dish  of  sterile  water  to 
prevent  drying,  and  incubated  for  12  days  at  37°C  in  a  humidified  incubator  in  5% 
CO2.  The  plates  were  counted  on  day  12  and  GM  colonies  scored  as  having  >40 
cells,  and  each  erythroid  burst  scored  as  a  single  colony.  Duplicate  dishes  for 
each  of  the  cultures  were  scored  and  the  counts  averaged. Susan  M  Graham,  2005  Chapter  2,71 
2.3.2  Stem  Cell  Selection 
2.3.2.1  Primary  Human  Cells 
All  CML  cell  samples  used  were  leukapheresis  products  from  patients  who  were 
undergoing  this  procedure  as  part  of  their  clinical  management  to  reduce 
peripheral  white  cell  counts.  Normal  cells  were  obtained  from  allogeneic  donors 
mobilised  with  rhG-CSF  collected  by  leukapheresis.  Informed  consent  was 
obtained  from  all  patients  and  donors  prior  to  the  procedure,  and  only  material 
surplus  to  clinical  requirement  was  available  for  research  purposes.  All  consents 
were  in  accordance  with  ethical  approval  from  the  Local  Research  Ethics 
Committee. 
2.3.2.2  Negative  Stem  Cell  Selection 
Stem  cells  are  a  relatively  rare  proportion  of  mobilised  peripheral  blood  products 
and  therefore  need  to  be  selected  from  the  whole  population.  This  can  be  done  in 
two  ways,  either  by  labelling  and  selecting  the  population  of  interest  i.  e.  positive 
selection  (see  below)  or  by  removing  most  of  the  other  cells  leaving  the  stem  cell 
fraction  i.  e.  negative  selection.  The  resultant  product  for  each  type  of  selection  is 
intrinsically  different  although  both  contain  stem  cells.  For  some  applications  such 
as  microarrays  it  was  essential  that  the  samples  to  be  compared  had  been 
selected  in  the  same  way. 
Putative  stem  cells  were  selected  from  CML  patient  samples,  using  Stem-Sep 
negative  selection  according  to  the  manufacturer's  instructions.  All  dilutions  and 
column  washes  were  done  in  PBS++.  Briefly,  the  cell  suspension  at  a 
concentration  of  2-8  x107cells/ml  in  PBS++  (after  removal  of  red  cells)  was 
incubated  with  an  antibody  cocktail  containing  CD2,  CD3,  CD14,  CD16,  CD19, 
CD24,  CD56,  CD66b  and  Glycophorin  A  for  15  minutes  at  room  temperature  (RT) 
on  a  roller  mixer.  Then  60pl  of  magnetic  colloid/ml  of  cells  was  added  for  a  further 
15  minutes  at  RT  on  a  roller  mixer.  The  number  of  columns  required  was 
dependent  on  the  total  cell  number.  The  maximum  number  of  cells  was  1  x108- 
1.5x109  per  column.  Four  columns  could  be  run  simultaneously  and  the  whole  run 
was  repeated  if  all  of  the  cells  could  not  be  accommodated  in  a  single  run. 
Columns  were  primed  with  PBS  only  and  washed  with  PBS++  before  being  slotted 
into  the  magnet  prior  to  addition  of  the  cell  suspension.  The  eluted  cells  were Susan  M  Graham,  2005  Chapter  2,72 
collected  in  three  column  volumes  of  PBS++  and  centrifuged  at  400g  for  10 
minutes,  before  resuspension,  counting  and  FACS  (detailed  in  chapter  3).  The 
selected  cell  numbers  were  adjusted  to  -1x107/ml  for  cryopreservation  in  ALBA 
+10%DMSO. 
2.3.2.3  Positive  Stem  Cell  Selection 
For  CD34-positive  selections,  the  cells  were  labelled  with  an  anti-CD34  antibody, 
which  was  subsequently  bound  to  a  magnetic  bead  and  used  to  isolate  the  CD34+ 
cells  with  a  magnetic  column.  For  this  procedure,  stem  cells  were  enriched  using 
the  Isolex®  kit  and  IsolexN  50  automated  system.  This  was  essentially  a  clinical 
processing  kit  scaled  down  for  smaller  cell  numbers  and  which  used  a  smaller 
processing  machine,  the  Isolex  50  (procedure  detailed  in  chapter  3).  Briefly, 
following  removal  of  the  platelets  as  described,  the  cells  were  resuspended  in 
30ml  PBS++  to  a  concentration  of  1-5x101/ml  and  5ml  human  immunoglobulin  (Hu 
Ig)  added  for  15  minutes  at  RT  with  mixing.  Anti-CD34  antibody  (0.5pg/NI)  was 
added  at  I  NI/1  x106  cells  and  incubated  at  RT  with  mixing,  for  30  minutes.  The  cells 
were  loaded  onto  the  column  and  the  automated  procedure  for  washing  and 
release  of  target  cells  was  followed  using  the  Isolex  50  apparatus.  The  cells  were 
collected  at  the  end  according  to  the  instructions  and  FACS  analysis  performed  to 
establish  the  purity  and  recovery  of  the  CD34+  cells.  Some  of  the  samples  used  in 
the  CFSE  experiments  (chapter  5)  were  processed  by  Dr  Michael  Alcorn  or  Mrs 
Linda  Richmond. 
2.3.3  FACS  and  Cell  Sorting 
2.3.3.1  FACS  Sorter  Alignment  and  Set-up 
The  machine  used  was  a  Becton  Dickinson  FACS  Vantage  incorporating  an 
enterprise  argon  laser  for  excitation  at  488nm  and  using  a  beam  splitter  to  give 
excitation  at  340nm  in  the  ultra  violet  range.  The  laser  required  to  be  aligned 
before  each  use.  If  the  UV  was  to  be  used  it  had  to  be  aligned  separately.  The 
optical  alignment  was  done  using  mid-range  FL1  Rainbow  beads  for  the  primary 
laser  and  UV  beads  for  ultra  violet  beam.  The  integrity  of  the  alignment  was 
checked  using  histogram  plots  with  markers  indicating  the  CV  (coefficient  of 
variation)  values  for  each  parameter.  The  percentage  CV  range  for  forward  scatter 
and  FLI  was  2-4%,  and  for  UV  in  FL4  was  1-3%  on  linear  scales.  The Susan  M  Graham,  2005  Chapter  2,73 
parameters  for  sorting  were  defined  by  choosing  the  sort  mode.  There  were  4 
options  with  varying  purities  and  counter  accuracies  depending  on  the  desired  cell 
population.  The  differences  in  sort  modes  defined  how  the  machine  dealt  with 
aborted  events  and  were  operator  controlled.  The  gating  strategies  used  for 
sorting  defined  cell  populations  are  detailed  in  the  relevant  results  chapters.  Once 
the  gating  was  set  the  sample  differential  was  adjusted  to  allow  a  total  event  rate 
of  3000/sec,  which  was  the  maximum  this  particular  sorter  could  deal  whilst 
maintaining  acceptable  cell  recoveries.  The  most  critical  parameter  for  sort  purity 
was  the  drop  delay  setting,  which  was  adjusted  according  to  the  parameters 
described  in  the  manual,  and  constantly  monitored  throughout  the  experiment. 
Following  laser  alignment,  activation  of  the  drop  drive  caused  the  stream 
containing  the  cells  to  be  broken  into  droplets  and  depending  on  the  settings,  the 
drops  were  charged  positively  or  negatively  and  sorted  left  or  right  into  the 
collection  tubes  containing  PBS/2%.  Digital  counters  allowed  the  number  of 
threshold,  left,  right  and  aborted  events  to  be  monitored.  The  proportion  of  cells  in 
each  parameter  gave  constant  indication  of  the  sorting  process  and  allowed 
inspection  of  the  sorting  procedure. 
2.3.3.2  Antibody  Staining 
All  antibodies  were  titrated  to  determine  the  appropriate  concentration  for  use.  The 
concentrations  used  were  the  minimum  amount  of  antibody  that  gave  reliable 
staining  and  good  separation  of  cell  populations.  As  well  as  reducing  the  cost, 
lower  intensity  of  antibody  facilitated  compensation  in  multi-parameter  FAGS 
experiments.  For  standard  antibody  staining  a  reaction  mix  of  200pl  PBS  2%,  cells 
and  antibody  was  used.  Controls  consisted  of  the  same  reaction  volume  with 
matched  isotype  and  fluorescent  label.  i.  e.  if  anti  CD34-FITC  antibody  was  used 
and  it  was  an  IgG1  antibody  the  control  tube  contained  IgG1-FITC.  Isotype 
controls  were  included  for  all  antibody  staining. 
2.3.3.3  CFSE  Staining 
The  cells  to  be  stained  were  recovered  from  liquid  nitrogen  as  described.  After 
resuspension  in  PBS2%,  2x106  cells  were  removed  for  unstained  controls.  The 
remainder  of  the  cells  were  incubated  in  1  pM  CFSE  for  exactly  10  minutes  at 
37°C.  10x  volume  of  ice  cold  PBS  20%  was  added  to  stop  the  reaction  and  the 
cells  centrifuged  at  400g  for  10  minutes.  The  supernatant  was  removed  and  the Susan  M  Graham,  2005  Chapter  2,74 
cells  washed  in  PBS2%.  The  stained  cells  and  the  unstained  control  cells  were 
then  cultured  overnight  in  serum  free  medium  with  or  without  the  addition  of  a  five 
growth  factor  cocktail  as  described  to  allow  excess  dye  to  leach  out.  The  cells 
were  incubated  overnight  on  90mm  sterile  non  tissue  culture  treated  petri  dishes 
or  in  suspension  flasks  at  a  concentration  of  2x107/ml.  The  following  day  the  cells 
were  recovered  from  the  flasks  or  plates  using  a  cell  scaper,  and  washed  in 
PBS2%.  After  removal  of  a  sample  of  cells  for  FAGS  controls,  the  remaining  cells 
were  stained  with  anti-CD34-PE  antibody  and  incubated  at  RT  for  15  minutes 
before  being  washed  twice  in  PBS2%.  The  second  wash  contained  PI  at  a 
concentration  of  1  pg/ml  in  all  tubes.  These  cells  were  now  ready  for  CFSE  sort  I 
as  described  below. 
2.3.3.4  FACS  For  CFSE  Experiments 
The  unstained/isotype  control  cells  were  run  first  to  check  the  position  of  the 
negative  population,  and  if  necessary  the  detectors  were  adjusted  to  place  the 
negatives  in  the  first  log  decade.  The  viable  gate  was  set  around  the  PI' 
population.  Following  gating  on  the  viable  cells,  the  CD34+  stained  cells  were 
identified  and  a  further  gate  set  around  this  population.  The  cells  stained  with 
CFSE/CD34/Pl  were  then  run  and  the  compensation  adjusted  to  give  the  same 
percentage  of  CD34+  events  as  for  the  CFSE  /CD34+/PI'  sample.  Considerable 
levels  of  compensation  were  required  as  the  CFSE  stain  was  very  bright  and  the 
spectral  overlap  into  other  channels  was  significant.  For  CFSE  sort  1,  the  object 
was  to  obtain  a  homogenously  stained  cell  population,  which  would  allow  the 
resolution  of  the  peaks  of  cell  division  after  3  further  days  in  culture.  Two  narrow 
markers  of  19-21  channels,  with  5  channels  between,  were  set  on  the 
CFSEma"/CD34+/PI'  cell  population  and  sorted  left  and  right.  The  two  populations 
of  sorted  cells  were  kept  separate  for  all  further  experiments.  During  sorting  all 
cells  were  kept  on  ice  and  in  the  dark.  All  the  left-sorted  cells  were  pooled  and 
similarly  all  the  right-sorted  cells  pooled  for  counting  and  subsequent  culture. 
Following  a  further  three  days  in  culture  under  various  conditions,  (as  described  in 
the  relevant  results  chapters),  the  cells  were  sorted  again  (sort  2),  into  divided  and 
undivided  populations.  Gates  were  set  around  the  viable  (PI')  cells  that  were 
CD34+  (PE  Bright).  To  set  gates  for  divided  and  undivided  cells,  the  position  of  the 
undivided  peak  was  identified  using  the  same  cells  (left-  or  right-sorted)  cultured  in 
the  presence  of  100ng/ml  colcemid.  Markers  were  set  on  a  histogram  plot  to  sort Susan  M  Graham,  2005  Chapter  2,75 
the  undivided  population  to  the  left  and  all  of  the  divided  cells  to  the  right.  To 
preserve  cell  viability  and  maximum  fluorescence  in  stained  cells  during  lengthy 
sorting  experiments,  all  cells  were  kept  on  ice  in  the  dark. 
2.3.3.5  Hoechst  and  Pyronin  Staining 
In  order  to  identify  the  GO,  G1  and  S/G2/M  phases  of  the  cell  cycle,  DNA  was 
stained  with  Hoechst  33342  (HST)  and  RNA  was  stained  with  Pyronin  Y  (Py). 
Hoechst  was  used  at  a  final  concentration  of  10pM  and  the  cells  incubated  in  a 
37°C  water  bath  for  90  minutes.  Without  washing,  Pyronin  Y  was  added  at  a  final 
concentration  of  0.5pg/ml  for  45  minutes.  Anti-CD34-FITC  was  then  added  1:  25v/v 
again  without  washing  for  15  minutes  at  RT.  The  cells  were  then  washed  in  PBS 
2%  containing  the  same  concentration  of  HST  and  Py.  A  further  wash  in  the  same 
buffer  was  done  with  the  inclusion  of  PI  at  a  final  concentration  of  1  pg/ml.  At  each 
stage  cells  were  removed  for  FACS  controls.  For  antibody  stains,  a  matched 
isotype  control  was  run  prior  to  the  positive  samples  to  verify  the  position  of  the 
negative population.. 
2.3.3.6  FACS  For  Hoechst  and  Pyronin. 
FACS  was  carried  out  using  the  BD  FAGS  vantage  equipped  with  UV  laser.  The 
position  of  the  positively  stained  cells  was  verified  using  a  combination  of 
unstained,  single  and  multiple  stained  controls.  The  positively  stained  cells  were 
gated  as  follows:  PI"  /  CD43+/  HST'O/PVO  (GO)  and  PI'  /CD34+  /HSTb"9nt  /  pyb"9ht 
(G1/S/G2/M).  The  gating  is  shown  in  detail  in  chapter  3. 
2.3.3.7  FISH  on  sorted  cells 
Approximately  1x103  sorted  cells  were  placed  in  0.2ml  tubes  in  50pl  of  PBS/2% 
and  centrifuged  at  4000rpm  in  a  microfuge  for  5  minutes.  The  supernatant  was 
removed  by  aspiration,  without  disturbing  the  pellet.  The  cell  pellet  was 
resuspended  in  50pl  of  pre-warmed  hypotonic  solution  containing  0.075M 
potassium  hydroxide.  Aliquots  of  20pl  were  placed  in  wells  of  a  poly-L-lysine 
coated  slide  and  incubated  for  20  minutes  at  RT  before  the  hypotonic  solution  was 
removed.  The  cells  were  fixed  by  the  addition  of  20pl  freshly  prepared 
methanol:  acetic  acid  (3:  1)  to  each  well  and  incubated  at  RT  for  5  minutes.  This 
fixation  step  was  repeated  before  air-drying  the  slide  overnight.  The  slides  were Susan  M  Graham,  2005  Chapter  2,76 
stored  at  -20°C  wrapped  in  parafilm  until  FISH  was  performed  using  the  bcr/abI 
Dual  Fusion  probe  according  to  the  manufacturers  instructions.  Interphase  nuclei 
were  evaluated  using  a  Leitz  fluorescence  microscope  with  a  triple-band  pass  filter 
for  DAPI,  Spectrum  Orange  and  Spectrum  Green.  All  FISH  slides  were  processed 
and  read  by  Mrs  Elaine  Allan. 
2.3.4  Molecular  Biology 
2.3.4.1  Primer  Design 
Relevant  primers  were  designed  using  Oligo/Exe  program.  First  the  gene  coding 
sequence  was  identified  by  a  Pubmed  nucleotide  search,  and  the  sequence  used 
to  search  for  appropriate  primers  of  between  20  and  25  base  pairs  (bp)  with  similar 
melting  temperatures  and  no  internal  loops  or  palindromes.  The  forward  primer 
was  typically  around  50bp  into  the  coding  sequence  and  the  reverse  primer  was 
around  300bp  downstream.  All  primers  were  diluted  to  alOpM  stock  and  used  at 
final  concentration  of  0.2pM. 
2.3.4.2  Generation  of  Total  RNA 
Cell  samples  were  spun  down  to  a  pellet  and  most  of  the  supernatant  removed  by 
aspiration.  Up  to  1ml  of  TRlzol®  was  added  depending  on  the  number  of  cells. 
After  vortexing  the  samples  were  frozen  at  -80°C  until  required.  The  RNA 
extraction  was  as  per  the  Trizol  protocol,  briefly  the  samples  were  thawed  at  room 
temperature  and  0.2ml  of  chloroform  added  per  I  ml  of  Trizol  and  shaken  for  15 
seconds.  The  volumes  of  reagents  were  adjusted  if  the  volume  of  Trizol  was  less 
than  1  ml.  The  samples  were  centrifuged  at  10,000rpm  in  a  microfuge  for  15 
minutes  at  2-8°C.  The  colourless  upper  aqueous  phase  (containing  the  RNA)  was 
transferred  to  a  fresh  tube  and  0.5ml  isopropanol/ml  (of  original  Trizol  volume)  was 
added  for  10  minutes  at  RT  and  centrifuged  at  10,000  rpm,  2-8°C  for  10  minutes. 
The  supernatant  was  removed  and  discarded.  The  pellet  was  washed  in  1ml  of 
75%(  v/v)  ethanol  per  ml  of  Trizol  in  original  preparation,  by  vortexing  thoroughly 
and  spinning  at  5000rpm  for  5  minutes  at  2-8°C.  After  discarding  the  supernatant 
the  pellet  was  air  dried  briefly  and  resuspended  in  RNA-free  water.  The  pellets 
were  incubated  at  55-60°C  for  10  minutes  to  ensure  total  dissolution. Susan  M  Graham,  2005 
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Following  the  protocol  for  the  superscript  kit  II,  briefly,  for  each  sample  a  mix  was 
prepared  which  included  5.51I  RNA,  0.5µI  oligo  DT,  3µI  random  hexamers,  1µl 
DNTP  and  incubated  at  65  °C  for  5  minutes  before  being  transferred  to  ice  for  I 
minute.  A  reaction  mix  containing  2µI  of  10x  RT  buffer,  4µI  of  25mM  MgCI2,2µI  of 
0.1  M  DTT,  1  µl  RNAse  Out  was  added  to  each  sample  tube  and  incubated  at  42°C 
for  2  minutes.  1µl  of  Superscript  11  RT  enzyme  or  DPC  water  (-RT  control)  was 
added  to  each  tube  and  incubated  at  42°C  for  50  minutes,  then  at  70°C  for  15 
minutes.  The  tubes  were  transferred  to  ice  and  1µl  of  RnaseH  was  added  to  each 
sample  for  20  minutes  at  37°C.  All  reagents  were  supplied  with  the  kit. 
2.3.4.4  Removal  of  DNA  from  RNA  Samples 
Contaminating  genomic  DNA  was  removed  from  RNA  samples  using  the  DNA-free 
kit  from  Ambion,  briefly  0.1  volume  of  10x  DNase  buffer  1  and  1µl  of  DNase  (2 
units)  were  added  to  a  maximum  of  100µI  of  RNA.  The  samples  were  then 
incubated  for  20  minutes  at  37°C.  After  resuspension,  0.1  volume  of  DNase 
inactivation  reagent  was  added  and  mixed  thoroughly.  Following  2  minutes  at  RT, 
the  samples  were  spun  at  15,000rpm  in  a  microfuge  for  1  minute.  The  supernatant 
containing  the  RNA  was  removed  to  a  clean  tube.  The  resultant  DNA 
contamination  was  typically  <0.1  %. 
2.3.4.5  PCR 
Using  the  Reddymix  tubes  from  Abgene,  1  pl  of  each  primer  at  1  0µM  was  added  to 
the  50µl  tube  together  with  51iI  of  cDNA.  Control  tubes  included  H2O  and  minus  RT 
samples.  The  PCR  machine  was  set  up  to  go  through  35  cycles  with  each  cycle 
consisting  of  92°C  for  2  minutes,  58°C  for  30  seconds  and  72°C  for  1  minute. 
When  35  cycles  were  completed  the  tubes  were  heated  to  72°C  for  10  minutes 
before  being  cooled  to  4°C  until  removed  from  the  machine. 
2.3.4.6  Analysis  of  PCR  Products 
The  PCR  products  were  run  on  electrophoresis  gels  that  allowed  visualization  of 
the  bands.  Briefly,  a  2%  agarose  gel  was  made  using  2g  of  agarose  powder  in 
I00ml  of  TAE  buffer  which  was  melted  in  a  microwave  for  2  minutes  at  full  power. Susan  M  Graham,  2005  Chapter  2,78 
To  this  1.2µI  of  ethidium  bromide  stock  was  added  at  10mg/ml  and  mixed.  The  gel 
was  then  poured  into  a  cast  containing  a  comb  to  create  sample  wells.  This  was 
done  in  a  cold  (4°C)  room  and  left  to  set  for  approximately  15  minutes.  The  sample 
comb  was  then  removed  and  the  gel  placed  in  the  gel  tank  containing  1x  TAE 
buffer  before  the  samples  were  loaded.  15-20µl  of  PCR  product  was  loaded  into 
each  well.  Hyperladder  IV  (100-1000bp)  was  included  as  a  reference.  Gels  were 
run  N  15OmV  constant  voltage.  The  gels  were  viewed  on  a  UV  transilluminator  and 
photographed. 
2.3.4.7  Extraction  of  Gel  Bands 
Whilst  viewing  on  a  transilluminator,  bands  were  cut  from  the  gel  using  a  scalpel, 
minimising  the  amount  of  agarose  extracted  with  each  band.  The  DNA  was  then 
extracted  using  the  Qiagen  QlAquick  gel  extraction  kit  (which  contained  all 
reagents)  and  protocol.  Briefly,  the  gel  slices  were  placed  in  Eppendorf  tubes  and 
weighed.  3x  volume  of  buffer  QG  was  added and  the  tubes  placed  in  a  50°C  water 
bath  for  10  minutes  to  melt  the  agarose.  After  adding  one  gel  volume  of 
isopropanol,  the  samples  were  applied  to  QlAquick  spin  columns  and  centrifuged 
for  1  minute  in  a  microfuge  at  full  speed.  The  eluate  was  discarded  and  the 
columns  washed  with  750pl  of  buffer  PE.  The  DNA  was  eluted  in  50pl  of  distilled 
water. 
2.3.4.8  Cloning  of  DNA  Fragments  with  TOPO  TA® 
The  PCR  products  were  ligated  into  pCR®  2.1-TOPO®  using  the  TOPO®TA  kit 
from  Invitrogen.  According  to  the  manufacturer's  instructions  0.5-4p1  of  PCR 
product  was  added  to  I  pl  of  salt  solution  and  1  pl  of  TOPO®  and  the  reaction  mix 
made  up  to  6p1  with  sterile  water.  The  tube  was  mixed  gently  and  incubated  at  RT 
for  5  minutes.  The  reaction  was  placed  on  ice  for  between  5  and  30  minutes.  2p1  of 
this  mix  was  added  to  I  vial  of  One  Shot  chemically  competent  DH5a  E.  coli,  which 
were  then  heat-shocked  at  42°C  for  30  seconds  and  immediately  transferred  to 
ice.  250pL  of  SOC  medium  at  RT  was  added  to  each  tube  and  incubated  at  37°C 
for  1  hour  in  a  shaker  at  200rpm.  LB  agar  plates  were  prepared  by  adding  1.5% 
agar  to  prepared  LB  medium  and  autoclaving  before  pouring  into  90mm  petri 
dishes.  When  the  agar  had  cooled  and  solidified,  40pl  of  x-gal  at  a  concentration 
of  40mg/ml  in  dimethylformamide  (DMF)  was  added  to  the  surface  of  each  plate, 
spread  with  a  sterile  spreader  and  dried  for  15  minutes. Susan  M  Graham,  2005 
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Following  incubation  at  37°C,  10-50pl  from  each  transformation  was  spread  evenly 
on  an  LB  agar  plate  prepared  (as  detailed  2.2.4.2)  and  incubated  overnight  at 
37°C.  White  colonies  containing  insert  were  picked  from  the  plate  and  cultured 
overnight  at  37°C  in  LB  medium  containing  50pg  /  ml  ampicillin. 
2.3.4.10  Isolation  of  Plasmid  DNA 
DNA  was  isolated  from  plasmid  preparations  using  the  QIAPprep  miniprep  kit 
which  is  based  on  the  alkaline  lysis  of  bacterial  cells,  adsorption  of  DNA  onto  silica 
in  the  presence  of  high  salt,  followed  by  elution  in  low  salt  buffer.  Only  DNA  is 
adsorbed  on  to  the  membrane  all  RNA,  cellular  protein  and  metabolites  are  found 
in  the  flow  through.  Briefly,  the  bacterial  cells  were  pelleted  and  the  supernatant 
removed  by  aspiration  before  the  addition  of  250pl  of  buffer  P1  (containing  RNase 
A).  The  solution  was  transferred  to  Eppendorf  tubes  and  250pl  of  buffer  P2  added 
with  gentle  mixing.  350pl  of  buffer  N3  was  added  and  the  tubes  mixed  by 
inversion.  The  tubes  were  centrifuged  for  10  minutes  at  15000rpm  in  a  microfuge. 
The  supernatants  were  applied  to  QlAprep  spin  columns  in  a  2ml  collection  tube 
and  centrifuged  for  30-60  seconds  and  the  flow  through  discarded.  The  columns 
were  washed  by  adding  750pl  of  buffer  PE  and  centrifuging  for  30-60  seconds  and 
discarding  the  flow  through.  The  columns  were  centrifuged  for  a  further  1minute  to 
remove  residual  wash  buffer.  The  DNA  was  eluted  by  the  addition  of  50NI  of 
distilled  water,  letting  it  stand  for  1  minute  and  centrifuging  for  1  minute  at 
15000rpm. 
2.3.4.11  Verification  of  DNA  Sequence 
The  amount  of  DNA  from  each  extracted  band  was  measured  using  a 
spectrophotometer.  A  known  amount  was  processed  through  the  ABI  sequencer 
by  Mrs  Christine  Lang  and  the  results  recorded.  The  sequences  were  compared 
with  the  gene  coding  sequences  and  the  primer:  gene  specificity  verified. 
2.3.4.12  Sample  Preparation  For  Microarrays 
Cells  positively  selected  for  CD34  were  recovered  from  liquid  nitrogen  as 
described  and  sorted  for  GO  and  dividing  (G1/S/G2IM)  cells  according  to  the Susan  M  Graham,  2005  Chapter  2,80 
protocol  described  for  HST  and  Py.  Cells  sorted  on  the  same  parameter  were 
pooled  following  sorting,  centrifuged  and  placed  in  Eppendorf  tubes,  where  most 
of  the  PBS2%  was  removed  by  aspiration.  Trizol  was  added  and  the  volume 
adjusted  depending  on  the  number  of  sorted  cells.  The  amount  of  Trizol  added 
was:  1  ml  per  106-107  cells,  0.5ml  per  105-106  cells  and  0.2ml  per  104-105  cells. 
The  tubes  were  vortexed  and  placed  immediately  in  the  -80°C  freezer  until  all  of 
the  samples  had  been  acquired.  Generation  of  total  RNA  was  as  described  and  it 
was  crucial  for  the  microarray  study  that  all  samples  were  processed  at  the  same 
time  to  reduce  the  possibility  of  disparity  in  preparation. 
2.3.5  Statistics 
Statistical  analysis  was  performed  by  either  the  student's  t-test  or  the  wilcoxon- 
signed  rank  test. 81 
Chapter  3  Results  I-  Identification  and  Isolation  of 
Stem  Cells  in  Different  Phases  of  the  Cell  Cycle 
3.1  Introduction 
Chronic  myeloid  leukaemia  is  a  stem  cell  disease,  which  is  characterised  by 
excessive  numbers  of  circulating  intermediate  progenitors  and  mature 
granulocytes  (Eaves  CJ  and  Eaves  AC  1987).  Stem  cells  are  intrinsically  resistant 
to  damage  by  either  cytotoxic  drugs  or  radiation,  and  diseases  that  originate  in  a 
stem  cell  are  difficult  to  eradicate.  CML  has  three  distinct  phases  of  progression, 
an  initial  chronic  phase,  during  which  large  numbers  of  relatively  mature 
granulocytes  exist  with  a  typical  time  scale  of  4-6  years  (see  figure  3.1),  is  followed 
by  the  onset  of  accelerated  phase,  which  can  last  up  to  1  year,  and  culminates  in 
blast  crisis,  where  the  numbers  of  immature  white  cells  increase  proportionately  to 
mature  cell  types  (Sawyers  CL  1999).  At  this  stage  the  disease  becomes  much 
more  resistant  to  therapy  and  almost  certainly  involves  further  acquired  mutations. 
Patient  mortality  is  100%  within  3-6  months  of  onset  of  blast  crisis  if  untreated 
(Spiers  ASD  1977). 
Variable  duration 
Chronic  Phase 
4-6  years 
Accelerated  Phase 
<1  year 
Blast  Crisis 
3-6  months 
Mature>immature  Immature>mature 
Figure  3-1  A  schematic  diagram  of  the  progression  of  CML  disease. Susan  M  Graham,  2005  Chapter  3,82 
If  an  appropriate  therapy  could  be  found  for  the  treatment  of  CML  in  chronic 
phase,  progression  to  fatal  blast  crisis  could  be  arrested.  Since  chronic  phase 
offers  the  best  opportunity  for  successful  therapy,  the  work  described  in  this  thesis 
focuses  exclusively  on  this  stage  of  the  disease.  In  an  effort  to  identify  possible 
targets,  which  could  be  exploited  for  therapeutic  purposes,  some  of  the  properties 
of  normal  and  CML  stem  cells  in  vitro  have  been  investigated. 
Normal  stem  cells  are  known  to  be  largely  quiescent,  residing  in  the  GO  phase  of 
the  cell  cycle,  where  they  can  be  recruited  into  division  in  response  to  appropriate 
stimuli  (Bradford  GB,  Williams  B  et  al.  1997),  (Ponchio  L,  Conneally  E  et  at.  1995). 
This  has  been  demonstrated  by  introducing  quiescent  cells  into  NOD/SCID  mice, 
where  some  cells  can  exit  GO  and  repopulate  the  haemopoietic  system  of  the 
mouse.  It  was  an  unexpected  finding  that  alongside  the  actively  cycling  malignant 
population  in  the  chronic  phase  of  CML,  there  also  coexisted  a  quiescent  stem  cell 
fraction.  These  cells  were  primitive,  expressing  the  stem  cell  marker  CD34  and 
were  part  of  the  leukaemic  clone,  as  verified  by  FISH  (fluorescence  in-situ 
hybridisation)  and  RT-PCR  (Holyoake  T,  Jiang  X  et  al.  1999).  It  has  been 
established  that  cells  expressing  CD34,  but  lacking  lineage  markers,  are  primitive 
and  able  to  generate  progeny  of  different  phenotypes.  However,  there  is  also 
some  evidence  that  an  earlier  stem  cell  exits  which  does  not  express  CD34  or 
lineage  markers  and  is  able  to  repopulate  the  haemopoietic  system  of  a 
myeloablated  host  (Bhatia  M,  Bonnet  D  et  al.  1997).  CD34'  cells  have  been  used 
successfully  for  clinical  transplantation  and  the  presence  of  this  marker  is  currently 
used  as  an  indicator  of  stem  cell  dose  for  peripheral  blood  stem  cell 
transplantation.  For  the  experiments  presented  in  this  thesis  identification  of 
CD34+  cells  was  used  as  an  indicator  of  stem  cell  status. 
In  order  to  compare  the  properties  of  normal  and  CML  stem  cells,  it  was  necessary 
to  separate  them  from  the  rest  of  the  circulating  blood  cells,  prior  to  subsequent 
experimentation.  Using  CD34  as  a  stem  cell  marker  the  cells  were  enriched  by 
either  positive  or  negative  stem  cell  selection.  The  following  describes  the 
selection  process  in  detail  with  representative  numbers  and  FACS  plots  for  each 
system  and  for  normal  and  CML  cells.  All  of  the  CML  cells  used  in  this  study  were 
collected  from  patients  in  chronic  phase  at  diagnosis  and  before  treatment. Susan  M  Graham,  2005 
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Stem  cells  represent  a  very  rare  fraction  of  the  circulating  progenitors,  around 
0.1  %,  and  in  order  to  study  these  cells,  it  was  necessary  to  significantly  enrich  the 
stem  cell  fraction,  before  FAGS  sorting  specific  cell  sub-populations.  This  was 
achieved  by  either  positive  or  negative  stem  cell  selection.  The  starting  cell 
population  was  collected  from  CML  patients  during  leukapheresis,  which  is 
primarily  performed  to  reduce  excessive  numbers  of  circulating  white  blood  cells, 
or  to  store  autologous  material  for  future  treatment.  The  procedure  was  performed 
using  a  dedicated  leukapheresis  machine,  which  allows  red  blood  cells  and 
plasma  to  be  returned  to  the  patient,  after  removal  of  a  large  number  of  the  white 
cells.  Leukapheresis  products  that  are  surplus  to  clinical  requirement  can  be  used 
for  research  with  appropriate  patient  consent.  Within  the  CML  patient  group,  there 
was  a  large  variation  in  the  starting  CD34+  percentage  from  0.3-50%,  the  median 
being  approximately  3%,  characteristic  of  a  stem  cell  disease  (Richmond  U, 
Alcorn  MJ  et  al.  2002). 
For  normal  stem  cell  collections,  donors  receive  G-CSF  (granulocyte  stimulating 
factor)  for  4-6  days  before  collection  to  boost  the  number  of  circulating  progenitors. 
There  can  be  large  differences  in  the  effectiveness  of  G-CSF  mobilisation,  leading 
to  differences  in  both  the  percentage  of  CD34+  cells  in  the  starting  fraction,  from 
0.3-1.7%,  and  in  total  white  cell  numbers  harvested.  The  dose  required  by  the 
patient  for  a  stem  cell  transplant  at  this  institution  was  calculated  as  6x106  CD34" 
cells/kg  and,  with  consent,  a  proportion  of  the  remainder  could  be  used  for 
research  purposes.  The  leukapheresis  machine  settings  were  operator  controlled 
and  the  purity  of  the  stem  cell  collections  obtained,  influenced  by  the  settings.  For 
this  reason,  and  because  of  differences  in  effectiveness  of  mobilisation,  there 
could  be  a  significant  variation  in  the  starting  CD34'  number,  and  subsequent 
recovery  of  stem  cells  following  selection. 
The  stem  cell  populations  derived  from  positive  or  negative  selections  are 
intrinsically  different.  There  is  some  evidence  that  a  more  primitive  cell  than  a 
CD34  expressing  cell  exists  within  the  stem  cell  compartment  that  can  in  turn 
generate  CD344*  cells  (Goodell  MA,  Rosenzweig  M  et  at.  1997).  A  negative 
selection  would  retain  these  cells  since  they  would  also  lack  lineage  markers.  A 
positive  selection  would  exclude  these  cells  since  it  only  targets  cells  expressing Susan  M  Graham,  2005  Chapter  3,84 
the  CD34  marker.  The  method  of  choice  was  dependant  on  the  final  experiments 
to  be  performed.  Throughout  the  studies  presented  in  this  thesis,  it  was  necessary 
to  freeze  cells  following  stem  cell  enrichment.  Both  types  of  selection  involved  a 
considerable  time  input  and  further  cell  sorting  required  at  least  12  hours,  including 
staining  and  cell  culture  post-sort. 
3.2.1  Positive  stem  cell  selection 
In  a  positive  selection,  the  cells  of  interest  are  removed  from  the  rest  of  the 
population  by  labelling  with  antibody,  magnetic  beads  and  selecting  using  a 
magnetic  column.  For  the  positive  selections  described  here  the  Isolex®  50  system 
was  used.  This  was  a  commercial  method  used  for  clinical  stem  cell  selections, 
which  was  scaled  down  using  a  smaller  magnetic  column  for  research  samples,  as 
the  number  of  total  cells/column  was  critical  to  cell  recovery  and  purity. 
The  cells  were  labelled  with  a  mouse  anti-human  monoclonal  antibody  against  the 
CD34  antigen,  and  further  labelled  with  a  sheep  anti-mouse  antibody  bound  to  a 
magnetic  bead.  The  cells  were  then  passed  through  a  magnetic  column  such  that 
the  unlabelled  cells  were  eluted  first  before  a  stem  cell  releasing  agent  was  added 
in  order  to  detach  the  bound  cells.  The  releasing  agent  contained  a  nano-peptide 
(PR34®)  with  a  similar  sequence  to  the  CD34  antigen,  which  competed  for  binding 
of  the  active  site,  and  due  to  the  excess  of  nano-peptide,  the  antigen-bound  cells 
were  released  from  the  magnetic  column. 
3.2.2  Example  of  a  CML  and  a  Normal  Positive  Cell  Selection 
A  diagram  of  the  labelling  and  selection  procedure  is  shown  in  figure  3.2.  Stem 
cells  were  released  with  the  CD34  antigen  intact  and  available  for  further  labelling. 
The  selected  cells  were  assessed  by  flow  cytometry  for  CD34  purity  and  plots  of 
the  pre-column  and  post-column  samples  for  both  normal  and  CML  are  shown  in 
figure  3.3. Susan  M  Graham,  2005 
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Figure  3-2  Isolex  CD34  stem  cell  selection  method. 
Cells  are  labelled  and  selected  as  described  in  the  text. 
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Using  side  scatter  (SSC)  to  discriminate  cells  on  the  basis  of  their  granularity 
(lower  granularity  indicates  less  differentiation)  and  including  a  marker  for  CD34, 
the  more  primitive  cells  can  be  identified.  Figure  3.3  shows  that  the  proportion  of 
CD34  positive  cells  has  increased  in  the  CML  sample  from  31.8-98%,  and  in  the 
normal  sample  from  1.59-83%.  The  cells  were  a99%  viable  post  selection  for  both 
normal  and  CML  examples  and  these  were  representative  for  most  selections.  The 
final  percentage  of  CD34  positive  cells  obtained  using  this  method  varied  between 
53-98%  for  both  CML  and  normal,  with  recoveries  ranging  from  36-71  %  in  normal 
samples  and  69-98%  for  CML  samples.  The  quality  of  the  starting  population  both 
in  terms  of  total  cell  number  and  percentage  of  CD34+  cells  influenced  the 
efficiency  of  the  selection. 
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Figure  3-3  FACS  plots  of  normal  and  CML  positive  stem  cell  selections. 
The  plots  show  CD34  versus  SSC,  the  gated  populations  shown  are  low  in 
SSC  and  high  in  CD34  expression.  The  regions  indicate  the  percentage  of 
CD34'  cells  pre-  and  post-selection  for  both  normal  and  CML  samples. 
The  plots  in  figure  3.3  illustrate  there  is  little  qualitative  difference  in  post-selection 
samples  between  normal  and  CML.  The  number  of  CD34+  cells  recovered  and  the 
final  purity  of  the  sample  (as  shown  in  table  3.1)  were  dependent  on  the  starting 
cell  population  and  not  on  the  disease  status  of  the  patient. Susan  M  Graham,  2005 
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selection  number 
CD34  cell  CD34  CD34  cells 
cells  number  cells  cells  recovered 
Isolex 
positive  1.2X1010  1.53  1.8x108  85  62  1.12x108 
Selection 
Stem-Sep 
negative  1.75x1010  0.64  1.12x108  60.2  82  9.2x107 
selection 
CML 
Starting S  Starting  Starting 
+ 
Final  %  Rec  Total 
+  Type  of  cell 
%  of  CD34  %  of  CD34 
selection  number 
CD34+  cell  CD34  CD34  cells 
cells  number  cells  cells  recovered 
Isolex 
positive  7.3x109  4.72  3.4x108  94  53  1.84x108 
Selection 
Stem-Sep 
negative  4.5x109  5.6  2.5x108  77.5  47  1.17x108 
selection 
Table  3-1  Table  of  selection  numbers  for  normal  and  CML  representative  examples. 
The  numbers  are  shown  for  both  Isolex  positive  and  StemSep  negative 
selections  described  in  the  text. 
Table  3.1  shows  an  example  of  the  cell  numbers  obtained  from  positive  stem  cell 
selections  for  normal  and  CML  representative  samples.  The  total  cell  starting 
number  in  the  normal  example  was  1.2x1010  and  the  total  number  of  CD34 
positive  cells  available  was  1.8x108,  based  on  the  CD34  starting  percentage  of 
1.53%.  The  selection  produced  a  cell  population  which  was  85%  CD34;  and  62% 
of  the  available  CD34  cells  were  recovered  from  the  column  giving  a  total  of 
1.12x108  cells,  which  were  then  frozen  in  liquid  nitrogen  in  aliquots  of  20x106/vial. 
In  the  CML  example,  the  stem  cell  selection  produced  an  increase  in  CD34+ 
percentage  of  4.72  to  94%  with  a  recovery  of  53%  of  the  available  CD34+  cells, 
(which  were  a  total  of  3.44x108)  giving  a  final  number  of  1.84x108  selected  stem 
cells,  which  were  frozen  in  liquid  nitrogen  at  20x106/vial.  As  the  selection  system 
used  was  a  unique  scaled  down  clinical  system  there  were  no  published  numbers 
using  this  method,  however  the  recoveries  and  enrichments  were  within  the  limits Susan  M  Graham,  2005  Chapter  3,88 
published  for  the  full  clinical  system,  using  the  same  antibody  cocktail  and 
methodology  but  a  different  magnetic  column  (Farley  TJ,  Ahmed  T  et  al.  1997). 
3.2.3  Negative  Stem  Cell  Selection 
In  negative  stem  cell  selections,  cells  expressing  lineage  markers  were  labelled 
with  a  panel  of  mouse  anti-human  antibodies  including  CD2,  CD3,  CD14,  CD16, 
CD19,  CD24,  CD56,  CD66b,  and  glycophorin  A,  then  further  labelled  with  a  sheep 
anti-mouse  antibody  bound  to  magnetic  colloid.  The  unbound  stem  cells  were 
eluted  from  the  column  separating  them  from  the  bound  cells,  which  remained 
attached.  Table  3.2  shows  the  antibodies  contained  in  the  progenitor  enrichment 
cocktail  and  their  relevant  target  cells. 
Antibody  Target  cell 
CD2  T  cells,  NK  cells 
CD3  T  cells, 
CD14  Monocyte/macrophage 
CD15  (CML)  Granulocytes/basophils 
CD16  NK  cells,  granulocytes 
CD19  B  cells 
CD24  B  cells 
CD56  NK  cells, 
CD66b  Granulocytes 
Glycophorin  A  Erythroid  cells 
Table  3-2  Table  of  antibodies  in  the  StemSep  progenitor  enrichment  cocktail. 
A  schematic  outline  of  the  selection  procedure  is  shown  in  figure  3.4.  The  method 
was  modified  when  CML  cells  were  processed  by  the  addition  of  biotinylated  anti- 
CD15  to  the  cells  before  the  addition  of  the  other  antibodies  described  and  anti- 
biotin  included  with  the  magnetic  colloid.  This  step  facilitated  the  removal  of  the 
excessive  number  of  granulocytes  characteristic  of  this  stage  of  CML  disease.  The 
cells  were  then  passed  through  a  magnetic  column  where  the  unlabelled  cells 
were  eluted  and  the  labelled  lineage+  cells  remained  attached  to  the  column.  The 
CD34+  purity  and  recovery  of  the  selected  cells  was  assessed  by  flow  cytometry, 
in  the  same  way  as  the  positively  selected  cells  i.  e.  by  calculating  the  percentage 
of  CD34  strongly  positive  cells  that  were  also  low  in  side  scatter  before  and  after 
selection. Susan  M  Graham,  2005 
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Figure  3-4  Diagrammatic  representation  of  StemSep  negative  selection. 
Chapter  3,89 
3.2.4  Example  of  a  Normal  and  a  CML  Negative  Selection 
y 
In  the  normal  example  shown  in  figure  3.5  the  number  of  CD34  positive  cells  has 
increased  from  1.23  to  76.2%  and  in  the  CML  sample  the  percentage  of  CD34 
positive  cells  has  increased  from  5.9  to  86%.  Since  this  population  also  contains 
cells  that  do  not  express  lineage  markers  or  CD34  it  would  not  be  expected  that 
the  percentage  of  CD34+  cells  would  be  as  high  as  in  the  positive  selection.  In 
practice,  negative selections  produced  a  lower  percentage  of  CD34+  cells,  typically 
from  40-88%,  compared  to  53-98%  for  positive  selections.  The  FACS  plots  in 
figure  3.5  show  that,  as  in  the  case  of  the  positively  selected  cells,  there  was  little 
difference  between  the  normal  and  CML  samples  in  terms  of  stem  cell  purity.  The 
addition  of  anti-CD15  in  the  CML  sample  maximised  the  purity  of  the  CD34+  cells 
in  the  selected  fraction  by  removing  the  large  excess  of  granulocytes  typical  of 
CML  in  chronic  phase. Susan  M  Graham,  2005 
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Figure  3-5  FACS  plots  of  normal  and  CML  StemSep  negative  selections. 
The  regions  show  the  percentage  of  CD34+  cells  pre-  and  post-selection  for  a 
representative  normal  and  CML  sample. 
In  the  negatively  selected  normal  example  in  table  3.1,  a  starting  cell  number  of 
1.75x1010,  with  a  starting  CD34  percentage  of  0.64,  giving  1.12x108  available 
CD34  cells,  yielded  9.2x107  CD34+  cells.  The  yield  from  the  column  was  82%.  In 
the  CML  example,  from  2.5x108  available  CD34+  cells,  1.17x108  were  recovered, 
indicating  a  recovery  of  47%.  Comparing  these  examples  of  positive  and  negative 
selection  for  normal  cells,  the  negatively  selected  example  has  a  better  recovery  of 
stem  cells  82%  compared  to  62%  in  the  positive  selection.  However  in  the  CML 
examples,  there  was  little  difference  in  recovery  between  positive  and  negative 
selection  53-47%.  A  possible  explanation  for  the  CML  examples  was  that  all  of  the 
stem  cells  were  not  labelled  in  the  positive  selection,  or  that  they  were  not 
completely  released  from  the  column.  Due  to  the  nature  of  the  processing  in  both 
situations  involving  multiple  wash  steps,  antibody  labelling,  columns  and  sample- 
to-sample  variation,  there  were  differences  in  the  final  recovered  cell  numbers. 
Also,  there  were  insufficient  amounts  of  any  sample  to  enable  direct  comparison  of 
selection  methods  with  the  same  sample.  For  all  of  the  samples,  the  recoveries 
and  yields  were  within  the  limits  suggested  by  the  manufacturers.  The  rationale  for 
doing  the  stem  cell  selections  was  to  enrich  for  primitive  progenitors  to  facilitate 
isolation  of  rare  quiescent  stem  cells.  Given  that  CML  is  a  disease  that  originates 
in  a  pluripotent  stem  cell  and  that  normal  stem  cells  are  largely  quiescent,  the 
overall  aim  was  to  compare  the  characteristics  of  normal  and  CML  stem  cells,  in 
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relation  to  their  cell  cycle  position.  To  do  this,  a  method  of  isolating  quiescent  and 
cycling,  viable  stem  cells  was  required. 
3.3  Hoechst  and  Pyronin  Y  staining 
There  are  a  number  of  fluorescent  stains  available,  which  allow  discrimination  of 
the  different  phases  of  the  cell  cycle,  however  few  allow  the  isolation  of  viable 
cells.  The  choice  of  staining  protocol  is  also  limited  by  the  excitation  and  emission 
spectral  capacity  of  the  sorting  instrument,  in  this  case  the  FACS  Vantage  cell 
sorter.  For  these  reasons  the  choice  of  stain  was  Hoechst  33342  (HST)  for 
staining  DNA  and  Pyronin  Y  (Py)  for  staining  RNA,  which  allowed  discrimination  of 
the  cell  cycle  compartments.  By  combining  these  stains  with  anti-CD34-FITC  as  a 
stem  cell  marker  and  propidium  iodide  (PI)  for  exclusion  of  dead  cells,  it  was 
possible  to  sort  viable  quiescent  and  cycling  stem  cells. 
HST  is  a  DNA  selective,  UV  excited,  blue  fluorescent  bisbenzimidazole  dye 
originally  synthesized  by  Loewe  (Loewe  H  and  Urbanietz  J  1974)  as  an  anti- 
protozoal  drug  for  Hoechst  and  was  first  used  in  flow  cytometry  in  1974  by  Latt 
(Latt  SA  1974).  HST  dyes  bind  to  sequences  of  three  A-T  base  pairs  in  DNA, 
binding  to  the  minor  groove  of  the  DNA  helix,  rather  than  by  intercalation.  Their 
affinity  for  DNA  is  sufficiently  strong  that  they  will  displace  bound  molecules  of 
intercalating  dyes  (Loontiens  FG,  Regenfuss  P  et  al.  1990).  Binding  of  dyes  like 
HST  has  been  shown  to  exhibit  a  certain  level  of  toxicity  (Durand  RE  and  Olive  PL 
1982),  which  is  relative  to  cell  type.  For  this  reason  it  was  necessary  to  confirm 
that  the  staining  process  did  not  adversely  affect  the  viability  or  functional  capacity 
of  the  cells. 
Py  is  a  homologue  of  acridine  orange  (AO)  which  has  been  used  for  the 
assessment  of  cell  cycle  for  a  number  of  years.  Py  diffuses  into  the  cell  and  allows 
staining  of  RNA  whilst  permitting  the  cells  to  remain  viable,  unlike  AO,  which 
requires  fixing  and  permeabilisation  of  the  cells.  Py  binds  to  RNA  with  a 
preference  for  G-C  rich  regions  and  although  DNA  staining  by  Py  has  been 
documented  in  some  cases,  it  is  not  likely  to  confuse  DNA/RNA  based  sorting 
using  this  protocol  as  pre-incubation  with  the  HST  stain  blocks  access  of  Py  to 
binding  sites  on  DNA  (Ladd  AC,  Pyatt  R  et  al.  1997). Susan  M  Graham,  2005  Chapter  3,92 
Due  to  the  variability  of  DNA  and  RNA  staining  it  was  necessary  to  determine  the 
concentration  of  the  combined  stains,  which  would  allow  discrimination  of  the  cell 
populations  by  FACS,  whilst  preserving  cell  viability.  This  was  done  by  staining 
cells  with  different  concentrations  of  each  stain  and  measuring,  staining  efficiency, 
viability  and  colony  forming  capability.  The  availability  of  stem  cell  enriched  patient 
samples  was  very  limited,  however  it  was  important  to  use  representative 
examples  of  experimental  cells,  to  ensure  comparable  results.  The  number  of  cells 
required  to  set  up  the  initial  experiments  limited  the  replicates  to  one  normal  and 
one  CML. 
3.3.1  Comparison  of  Colony  Forming  Capacity  Following 
Hoechst  and  Pyronin  Y  Staining 
Plating  cells  in  a  clonogenic  assay  gives  a  measure  of  the  colony  forming  capacity, 
which  in  turn  gives  an  indication  of  functionality.  The  objective  was  to  determine  if 
the  combination  of  stains  required  to  produce  good  FACS  profiles  had  a 
deleterious  effect  on  the  capacity  of  the  cells  to  divide  and  form  colonies.  The  cells 
used  were  CD34+  selected  cells,  either  CML  or  normal,  recovered  from  frozen  and 
incubated  overnight  in  a5  growth  factor  cocktail  containing  IL-3,  IL-6,  FLT3L, 
hSCF  and  G-CSF  to  allow  recovery  from  frozen.  If  the  cells  were  used  immediately 
following  recovery  from  cryopreservation,  cells  dying  as  a  result  of  thawing  could 
interfere  with  the  data  relating  to  toxicity  of  the  dyes.  By  incubating  overnight  in  a 
growth  factor  rich  cocktail,  recovery  of  viable  cells  was  maximised.  The  following 
day  the  cells  were  removed  from  petri  dishes  or  flasks,  washed  in  PBS/2%  and 
stained  with  HST  at  concentrations  of  0  to  10pM  alone  or  in  combination  with  Py  at 
concentrations  of  0  to  1  pg/mi.  Similar  concentrations  of  these  dyes  in  combination 
had  been  used  previously,  though  it  was  necessary  to  establish  optimal 
concentrations  of  both  dyes  using  our  FACS  sorter.  This  allowed  assessment  of 
the  minimum  laser  power  setting  required  to  produce  acceptable  FACS  profiles,  as 
it  has  been  previously  reported  that  increased  laser  power  could  be  lethal  to  some 
cells  (Shapiro  HM  1981). 
The  clonogenic  assay  input  cell  counts  were  adjusted  for  viability  and  for  the 
percentage  of  CD34  positive  cells  so  that  the  same  number  of  viable  stem  cells 
was  used  to  initiate  each  culture.  1x104  viable  CD34  positive  cells  were  plated  in 
duplicate  in  methylcellulose  containing  a  cocktail  of  cytokines  designed  to Susan  M  Graham,  2005  Chapter  3,93 
stimulate  both  myeloid  and  erythroid  colony  growth.  The  GM  colonies  (1  colony= 
>40  cells)  and  BFU-e  (single  bursts)  were  counted  after  incubation  at  37°C  in  a 
humidified  incubator  for  12  days.  Counts  were  an  average  of  two  plates.  The 
results  are  shown  in  table  3.3. 
NnPMAI 
Hoechst  Pyronin  Y  %  Viable  GM  BFUe  TOTAL 
0  0  38.6  158  407  565 
5  0.5  40.7  89  335  424 
5  1  43.3  43  79  122 
10  0.5  43.6  62  382  450 
10  1  40.8  56  160  216 
10  0  38.5  49  404  453 
0  0.5  45.3  211  348  559 
CML 
Hoechst  Pyronin  Y  %  Viable  GM  BFUe  TOTAL 
0  0  35.9  190  339  529 
5  0.5  40.1  106  177  283 
5  1  42.8  108  337  445 
10  0.5  39.5  56  512  568 
10  1  35.8  58  283  341 
10  0  39.1  105  351  456 
0  0.5  42.8  190  287  477 
Table  3-3  Table  of  colony  counts  for  normal  and  CML  cells  stained  with  various 
concentrations  of  HST  and  Py. 
The  cells  were  stained  with  the  dyes  as  Indicated  In  the  table  and  plated  In 
colony  assays  as  described  In  the  text.  The  colonies  were  counted  at  day  12 
and  GM  scored  as  >40  cells  and  BFU-e  as  single  bursts.  The  cell  viabilities 
were  assessed  by  PI  exclusion  by  FACS  following  staining,  and  before  plating 
In  colony  assays. 
Table  3.3  shows  the  percentage  of  total  viable  cells  together  with  the  GM,  BFU-e 
and  total  colony  counts  (GM  +  BFU-e)  for  unstained  and  combinations  of  dyes  at 
various  concentrations.  Results  for  both  a  normal  and  CML  sample  are  shown. 
The  total  cell  viabilities  were  determined  by  FACS  following  incubation  of  the  cells 
with  PI  after  staining  with  HST  and  Py  as  indicated  in  table  3.3.  All  combinations  of 
stains  were  run  on  the  FAGS  sorter  to  establish  the  success  of  the  staining 
procedure.  This  indicated  that  the  HST  stain  was  the  least  consistent  especially  at 
low  concentrations.  Increasing  the  incubation  time  with  HST  from  45to  90  minutes 
before  the  addition  of  Py,  improved  the  reliability  of  staining. 
The  results  in  table  3.3  indicate  that  compared  to  unstained  cells,  for  both  normal 
and  CML,  the  staining  had  some  effect  on  the  total  colony  count.  For  normal  cells, 
in  most  cases,  the  number  of  CFU-GM  was  reduced  except  in  the  Py  only  culture Susan  M  Graham,  2005  Chapter  3,94 
where  the  number  of  CFU-GM  colonies  exceeded  the  control.  The  largest 
reduction  in  total  colony  count  was  seen  in  the  5pM  HST/1  pg/ml  Py  combination  in 
the  normal  sample,  where  the  total  colony  count  was  reduced  from  565  to  122. 
The  10pM  HST/1  pg/ml  Py  would  have  been  expected  to  show  a  greater  reduction 
in  colonies  but  only  reduced  the  counts  from  565  to  216.  For  CML  cells,  the  large 
reduction  in  total  colony  count,  identified  in  the  normal  sample  with  5pM 
HST/1  pg/ml  Py,  was  not  observed,  however  there  was  a  similar  level  of  reduction 
in  CFU-GM  numbers  from  190  to  108.  Although  there  was  a  reduction  in  overall 
colony  count,  it  was  only  from  529  to  445,  most  of  which  was  attributed  to  the 
reduction  in  CFU-GM. 
Comparing  the  colony  counts  for  the  single  stains,  the  numbers  indicate  that  HST 
appears  to  affect  the  CFU-GM  count  preferentially.  AT  10pM,  HST  alone  reduces 
the  CFU-GM  count  from  158  to  49  for  the  normal,  and  from  190  to  105  for  the 
CML,  whereas  the  BFU-e  count  remains  at  the  same  level.  In  contrast,  Py  appears 
to  exert  a  greater  effect  on  the  BFU-e  count.  At  0.5pgIml  the  BFU-e  count  was 
reduced  in  the  normal  from  407  to  348  and  in  the  CML  from  339  to  287,  while  the 
GM  count  remained  the  same  for  the  CML,  and  increased  in  the  normal  from  158 
to  211.  This  phenomenon  is  worthy  of  further  investigation  but  was  outwith  the 
scope  of  this  project. 
The  results  in  table  3.3  also  demonstrate  that  in  the  normal  sample,  increasing  the 
Py  concentration  to  1  pg/ml  in  combination  with  either  5  or  I  OpM  HST  reduced  the 
total  number  of  colony  counts  to  a  level  below  any  of  the  other  combinations  that 
used  0  or  5pg/m  Py.  In  the  CML  example,  the  5pmHST/  0.5pg/ml  Py  combination 
appears  to  have  a  reduced  overall  count  compared  to  both  unstained  and  other 
combinations.  This  may  be  experimental  error  and  these  results  represent  one 
example  of  each  combination,  as  availability  of  material  limited  replication  of  these 
experiments.  The  total  population  viability  appears  to  be  higher  in  the  stained 
samples  than  in  the  unstained  control.  The  lack  of  replicates  in  these  experiments 
due  to  limitations  in  sample  availability  meant  it  was  not  possible  to  achieve 
statistical  significance.  However,  the  data  gave  an  indication  of  the  toxicity  of  the 
dyes  and  enabled  examination  of  the  FACS  profiles. 
Following  inspection  of  the  FACS  profiles  of  stained  cells,  the  combination  of 
IOpM  HST/0.5pg/ml  Py  gave  the  most  acceptable  and  reliable  staining  using  our 
sorter  set-up.  Having  demonstrated  that  this  combination  did  not  appreciably  affect Susan  M  Graham,  2005  Chapter  3,95 
the  viability  and  clonogenicity,  at  least  in  terms  of  the  total  colony  counts,  this  was 
the  combination  used  in  all  subsequent  experiments.  In  addition,  similar 
concentrations  of  these  dyes  have  been  used  previously  to  isolate  stem  cells, 
which  retain  full  functional  capacity,  as  demonstrated  by  their  ability  to  reconstitute 
immuno-deficient  mice  (Holyoake  T,  Jiang  X  et  al.  1999). 
Figure  3.6  shows  an  example  of  the  FACS  profile  obtained  using  this  combination 
of  dyes.  By  manipulating  the  amplitude  of  the  detectors  it  was  possible  to  increase 
the  level  of  the  detector  on  the  y-axis  (Py)  to  identify  cells  with  the  lowest  Py 
staining,  which  were  also  HST1°,  as  those  being  in  GO.  Figure  3.6  shows  the 
corresponding  profile  obtained  on  the  histogram  plot  of  HST  (FL4).  This 
demonstrates  the  cell  cycle  distribution,  with  most  of  the  cells  in  the  2n  population, 
which  includes  GO  and  G1  The  4n  population  are  cells  which  have  reached  the 
end  of  the  cell  cycle  and  are  about  to  divide  into  two  cells  and  either  become 
quiescent  by  going  back  into  GO,  or  continue  to  divide  by  moving  into  G1.  The  two 
daughter  cells  may  have  different  fates  depending  on  the  environmental  stimuli 
they  receive. Susan  M  Graham,  2005 
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Figure  3-6  FACS  profiles  of  Hoechst  and  Pyronin  Y  staining. 
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The  dot  plot  shows  CD34+  selected  cells  from  a  normal  sample  stained  with 
10NM  HST  and  0.5pg/ml  Py.  The  cells  have  been  gated  on  the  viable  PI" 
population.  The  histogram  plot  shows  the  HST  profile  for  the  same  cells 
identifying  the  2n  and  4n  populations. 
Overall,  the  combination  of  10pM  HST  and  0.5pg/ml  Py  gave  the  most  reliable  cell 
staining  by  FACS  and  maintained  acceptable  levels  of  cell  viability.  Various 
staining  strategies  were  employed  to  increase  the  reliability  of  the  Hoechst  stain, 
which  could  be  inconsistent.  Increasing  the  HST  incubation  time  from  45  to  90 
minutes  before  the  addition  of  Py  resulted  in  almost  100%  reliable  profiles  for  HST. 
3.3.2  Comparison  of  Total  Cell  and  Stem  Cell  Viability 
Following  Hoechst  and  Pyronin  Y  Staining 
Since  the  availability  of  material  precluded  doing  toxicity  analysis  on  multiple 
samples,  the  viabilities  of  the  total  and  stem  cell  populations  were  recorded  for 
each  subsequent  experiment.  This  allowed  the  monitoring  of  the  effects  of  staining 
with  HST  and  Py  on  a  larger  sample  group.  Comparing  a  number  of  samples  both 
normal  and  CML  cells  stained  with  10NM  HST  and  0.5pg/ml  Py,  indicated  that Susan  M  Graham,  2005  Chapter  3,97 
neither  the  total  cell,  nor  the  stem  cell  viability  was  significantly  affected  by  the 
staining  procedure.  Table  3.4  shows  normal  and  CML  samples  stained  with  10pM 
HST  and  0.5pg/mI  Py  in  combination,  compared  to  unstained  cells.  The 
concentrations  selected  had  been  used  previously  for  isolation  of  cells  in  various 
phases  of  the  cell  cycle  (Gothot  A,  Pyatt  R  et  at.  1997).  The  results  in  table  3.4 
show  the  mean  total  cell  viability  in  the  normal  unstained  cells  was  46%  compared 
to  47%  for  the  mean  HST  and  Py  stained  cells.  The  mean  stem  cell  viability  was 
82%  for  the  unstained  cells  compared  to  87%  for  the  stained  stem  cells.  For  the 
CML  samples  the  mean  total  cell  unstained  viability  was  61  %  compared  to  62%  for 
the  stained  cells.  The  mean  stem  cell  viability  was  92%  for  unstained  compared  to 
94%  for  stained  stem  cells.  These  results  show  that  staining  with  this  combination 
of  HST  and  Py  did  not  significantly  affect  the  total  cell  or  the  stem  cell  viability  in 
either  the  normal  or  CML  samples. Susan  M  Graham,  2005  Chapter  3,98 
%  Viable  of  Total  %  Viable  of  CD34+ 
Unst  HST!  Py  Unst  HSTIPy 
I  Normal1  48  44  83  78 
2  Normal2  46  49  82  95 
3  Normal3  44  48  81  89 
MEAN  46  47  82  87 
4  CML  1  74  72  91  93 
5  CML  2  63  69  94  95 
6  CML  3  58  57  77  83 
7  CML  4  44  51  96  99 
8  CML  5  48  41  99  99 
9  CML  6  56  67  90  91 
10  CML  7  81  78  97  98 
MEAN  61  62  92  94 
Table  3-4  Comparison  of  total  cell  and  stem  cell  viabilities  following  staining  with 
Hoechst  and  Pyronin  Y. 
Following  recovery  from  cryopreservation  and  an  overnight  Incubation  In 
media  with  5  growth  factors,  the  cells  were  stained  with  10NM  HST  and 
0.5pg,  ml  Py.  The  total  cell  and  stem  cell  viabilities  were  assessed  by  FACS 
following  additional  staining  with  anti-CD34-FITC  and  Pl. 
For  both  CML  and  normal  samples,  the  unstained  stem  cell  viability  (77-99%)  was 
considerably  higher  than  the  unstained  total  cell  viability  (44-81%),  suggesting  that 
stem  cells  were  less  susceptible  to  damage  by  cryopreservation. 
It  had  been  documented  previously  that  exposing  cells  to  increasing  laser  power 
rendered  them  non-viable.  Historically,  during  the  development  of  staining 
protocols,  exposure  to  laser  power  of  100mV  was  common.  This  was  not  a 
problem  until  researchers  wanted  to  obtain  viable  sorted  cells  for  further 
experimentation.  Studies  revealed  that  acceptable  FAGS  profiles  could  be 
obtained  using  much  lower  settings  and  that  cells  could  survive  sorting  on  this 
basis  (Shapiro  HM  1981).  For  the  experiments  in  this  thesis,  the  laser  power  level 
for  excitation  of  Hoechst  was  set  at  the  minimum  of  30mV  using  UV  beads  and 
verified  with  stained  cells. Susan  M  Graham,  2005  Chapter  3,99 
3.3.3  Sorting  Using  Hoechst  and  Pyronin  Y 
To  obtain  populations  of  viable  stem  cells  in  different  phases  of  the  cell  cycle  it 
was  necessary  to  use  the  HST  and  Py  fluorescent  stains  described,  which  allowed 
discrimination  of  cell  populations  whilst  maintaining  viability,  functional  capacity 
and  proliferative  potential.  Cells  in  the  GO  phase  of  the  cell  cycle  were  HSTb/Pybo, 
cells  in  the  G1  phase  were  HST  '°/Py+  and  those  in  the  S/G2/M  phase  were 
HSTb"9ht/Py+.  By  combining  these  two  stains  with  a  stem  cell  marker  (CD34)  and 
PI  as  a  viable  marker,  it  was  possible  to  obtain  pure  populations  of  viable  stem 
cells  in  three  phases  of  the  cell  cycle.  However,  the  sorter  was  only  capable  of 
collecting  two  populations  of  cells  simultaneously,  which  meant  the  third 
population  was  resigned  to  waste.  For  this  reason  most  sorts  were  set  up  to  collect 
two  parameters  only,  GO  and  dividing.  Figure  3.7  shows  the  gating  strategy  used 
to  sort  the  different  fractions  of  the  cell  cycle.  The  HST  and  Py  plot  was  gated  on 
the  viable,  CD34+  cells. Susan  M  Graham,  2005 
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Figure  3-7  FACS  gating  strategy  for  isolation  of  viable  quiescent  and  cycling  stem  cells. 
Following  overnight  incubation  in  growth  factor  supplemented  media,  the 
cells  were  stained  with  HST,  Py,  CD34  and  PI.  A  viable  gate  was  set  around  the 
PI'  cells  (RI)  and  a  further  gate  set  around  the  CD34'  cells  (R2).  This 
combination  of  gates  was  used  to  set  further  gates  on  the  GO  (R3)  and  cycling 
cells  (R4). 
3.3.4  Assessment  of  Success  of  Cell  Cycle  Stage  Sub- 
Selection 
It  was  not  feasible  to  re-run  sorted  cells  on  the  FACS  to  assess  sort  purity  as  the 
cells  were  collected  in  sheath  fluid  and  would  have  effluxed  the  HST  and  Py  dyes. 
Since  the  purity  of  the  sort  was  operator  controlled,  it  was  necessary  to  verify  the 
correct  cell  populations  had  been  sorted.  This  was  achieved  by  analysing  the  gene 
expression  of  sorted  cells  by  PCR  for  genes  specific  to  cell  cycle  position.  For  this 
experiment  an  additional  gate  was  used  to  isolate  the  G1  population.  It  was  not 
possible  to  commit  any  more  than  one  CML  sample  to  processing  for  PCR  for Susan  M  Graham,  2005  Chapter  3,101 
verification  of  sort  purity,  as  cell  numbers  were  prohibitive.  Nor  was  it  possible  to 
repeat  the  PCR  with  a  normal  sample  as  these  were  in  very  limited  supply. 
The  cells  were  sorted  into  viable,  CD34+,  GO,  G1  and  S/G2/M  fractions  for  PCR. 
Figure  3.8  shows  the  results  of  PCR  with  primers  for  Actin  (control),  CD34,  PCNA 
and  MCM5.  Primers  for  the  genes  of  interest  were  designed  as  described  in  the 
methods.  Figure  3.9  illustrates  that  all  samples  showed  a  band  for  actin  and  for 
CD34.  Although  MCM5  is  typically  associated  with  proliferating  cells,  it  was 
present  in  all  of  the  sorted  cells  (discussed  below).  The  band  for  proliferating  cell 
nuclear  antigen  (PCNA),  known  to  be  synthesised  in  S  phase,  was  clearly  absent 
in  GO  and  G1  and  present  in  S/G2/M.  All  of  the  bands  were  excised  from  the  gel 
and  processed  for  sequencing  at  the  Beatson  Laboratories.  The  results  of 
sequencing  verified  that  the  primers  were  specific  for  the  genes  indicated. 
This  is  strong  evidence  that  the  sorting  strategy  has  indeed  separated  the  relevant 
populations.  Interestingly,  the  cells  used  were  malignant  (CML)  cells  and 
aberrations  in  MCM5  expression  have  been  documented  in  cancer  cells  compared 
their  normal  counterparts  (Going  JJ,  Keith  WN  et  al.  2002).  PCR  on  normal  cells 
would  have  verified  this  observation,  however  as  stated  previously  limited  sample 
availability  precluded  these  experiments  being  done.  The  results  presented  in 
chapter  6  of  this  thesis  may  explain  this  observation. Susan  M  Graham,  2005 
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Figure  3-8  PCR  of  sorted  cells. 
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The  cells  were  sorted  into  GO,  GI,  and  S/G2/M  phases  of  the  cell  cycle  as 
described  in  the  text.  PCR  was  performed  with  primers  specific  for  the  genes 
indicated. 
3.3.5  Comparison  of  Relative  Percentage  of  Cells  in  Different 
Cell  Cycle  Positions  for  Normal  and  CML  Stem  cells 
It  was  noted  during  the  course  of  staining  and  sorting  for  quiescent  cells,  that  there 
were  differences  in  the  proportion  of  cells  in  the  GO  and  G1  phases  of  cell  cycle 
between  normal  and  CML  samples.  In  particular  the  number  of  GO  cells  sorted  for 
the  CML  samples  was  always  lower  than  for  normal  samples. Susan  M  Graham,  2005 
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Figure  3-9  FACS  plots  showing  the  proportion  of  cells  in  GO  and  G1  for  normal  and  CML. 
The  plots  are  gated  on  the  viable  CD34`  cells  as  described  in  the  text.  The 
percentages  are  the  mean  for  all  samples,  n=3  for  the  normals  and  n=9  for  the 
CML  samples. 
A  number  of  normal  and  CML  samples  were  compared  to  investigate  this 
observation.  Following  an  overnight  incubation  in  a5  growth  factor  cocktail,  to 
enable  recovery  from  cryopreservation,  the  cells  were  removed  from  plates  or 
flasks  and  washed  in  PBS2%  before  staining  with  HST  and  Py  as  described 
previously.  Gates  were  set  around  the  viable  CD34+  cells  and  the  percentage  of 
cells  in  GO  and  G1  compared.  The  numbers  represent  the  mean  of  9  CML 
samples  and  3  normal  samples.  The  number  of  quiescent  cells  i.  e.  those  in  GO 
was  significantly  lower  in  the  CML  sample  than  in  the  normal  sample,  1.9% 
compared  to  3.8%  (p=0.04).  The  difference  in  the  percentage  of  cells  in  the  G1 
gate,  70%  in  the  normal  compared  to  50%  in  CML,  was  also  significant  (p=0.04). 
These  observations  suggest  that  CML  cells  exhibit  greater  cell  cycle  activation 
than  normal  cells,  or  that  the  CML  cells  are  'primed'  to  go  into  division.  The 
observation  that  a  greater  proportion  of  CML  cells  were  in  the  G1  phase  of  the  cell 
cycle  compared  to  normal  does  not  necessarily  mean  that  they  were  cycling  at  a 
greater  rate.  These  data  give  no  information  on  the  time  taken  to  complete  the  cell 
cycle,  merely  that  there  are  fewer  CML  cells  in  GO  and  G1  compared  to  normal. 
Other  studies  have  also  documented  that  for  CML  CD34+  cells,  a  greater  number 
are  in  the  S/G2/M  phase  of  the  cell  cycle  compared  with  normal  CD34+  peripheral 
blood  stem  cells.  In  addition,  others  have  shown  that  CML  cells  do  not  cycle  at  a Susan  M  Graham,  2005  Chapter  3,104 
faster  rate  than  normal  cells,  and  that  this  does  not  explain  the  increase  in  cell 
numbers  observed  for  CML  in  chronic  phase  (Buckle  AM,  Mottram  R  et  al.  2000). 
3.3.6  Summary 
The  work  described  in  this  chapter  documents  the  identification  and  isolation  of 
quiescent  haemopoietic  stem  cells  from  normal  and  CML  patient  samples.  The 
success  of  the  sorting  strategy  was  confirmed  by  PCR  analysis  of  the  sorted  cells. 
It  was  noted  that  for  CML,  the  proportion  of  cells  in  the  S/G2/M  phase  of  the  cell 
cycle  was  greater  than  for  the  normal  samples,  suggesting  they  display  an 
increased  cell  cycle  activation  compared  to  normal  cells.  The  following  chapter 
describes  experiments  aimed  at  assessing  the  behaviour  of  CML  quiescent  stem 
cells  in  culture  compared  to  normal  cells,  in  an  effort  to  gain  a  clearer 
understanding  of  the  properties  of  CML  stem  cells. 105 
Chapter  4  Results  2-  Comparison  of  Normal  and 
CML  Stem  Cell  Division  Characteristics  In-Vitro 
4.1  Introduction 
Previous  work  by  Buckle  et  al  (Buckle  AM,  Mottram  R  et  at.  2000)  has  shown  that 
CML  cells  do  not  divide  at  a  greater  rate  than  normal  cells.  In  contrast,  Kramer  et 
at  (Kramer  A,  Loffler  H  et  at.  2001)  have  shown  that  CML  CD34+  cells  display 
greater  cell  cycle  activation  than  their  normal  counterparts  with  many  more  cells  in 
S/G2/M.  It  remained  a  possibility  that  differences  in  the  pattern  of  cell  division 
within  the  stem  cell  population  could  shed  some  light  on  the  abnormal  cell 
behaviour  exhibited  by  malignant  cells.  Having  previously  identified  quiescent 
stem  cells  in  both  normal  and  CML  samples,  the  aim  of  the  work  presented  in  this 
chapter  was  to  further  characterise  the  dynamics  of  the  cell  population  by  tracking 
the  pattern  of  cell  division  in  normal  and  CML  stem  cells  under  different  conditions. 
It  was  also  proposed  that  this  approach  could  be  used  to  monitor  the  division 
history  of  the  cells  in  conjunction  with  their  viability  and  stem  cell  status  using 
CD34  expression  as  a  stem  cell  marker. 
4.2  CFSE  for  High  Resolution  Tracking  of  Cell  Division 
In  order  to  follow  the  pattern  of  cell  division  in  culture,  it  was  necessary  to  devise  a 
strategy  that  would  allow  discrimination  of  the  number  of  cell  divisions  together 
with  stem  cell  status  in  each  division.  Monitoring  viability  of  the  cells  as  they 
progressed  through  each  division  was  necessary  in  order  to  obtain  information  on 
the  proliferative  status  of  the  culture.  A  method  of  specifically  tracking  cell  division 
in  lymphocytes  was  developed  by  Lyons  et  al  in  1994  (Lyons  AB  and  Parish  CR 
1994)  using  the  fluorescent  stain  CFSE  (carboxyfluorescein  diacetate  succinimidyl 
ester).  CFSE  is  a  non-polar  molecule  that  passively  enters  cells  where  it  is 
converted  to  a  reactive  dye  by  non-specific  esterases.  The  amine-reactive 
coupling  of  CFSE  to  cellular  proteins  results  in  stable  long-term  intracellular 
retention.  Thus,  when  the  cell  divides  each  daughter  cell  will  have  exactly  half  of 
the  fluorescence  of  the  parent  cell.  The  effect  is  permanent,  fluorescent, 
intracellular  staining  that  can  be  used  to  track  cell  division  over  a  period  of  time.  Li 
et  at  (Li  X,  Dancausse  H  et  at.  2003)  have  shown,  using  mixtures  of  stained Susan  M  Graham,  2005  Chapter  4,106 
human  and  unstained  rat  cells  in  co-culture,  that  no  dye  leaks  from  stained  cells 
and  the  fluorescence  intensity  of  the  undivided  cells  remains  constant.  These 
observations  confirm  the  integrity  of  this  technique  for  identification  of  undivided 
cells.  Previous  protocols  have  used  a  5pM  concentration  of  USE,  which  was 
highly  fluorescent,  allowing  the  cells  to  be  monitored  over  a  period  of  time.  The 
disadvantage  of  such  a  high  concentration  of  CFSE  is  that  it  makes  compensation 
with  other  fluorescent  dyes  very  difficult,  and  as  monitoring  of  stem  cell  status  and 
viability  were  an  integral  part  of  this  study  certain  modifications  to  the  protocol 
were  necessary.  Reducing  the  concentration  of  CFSE  to  1  pM  gave  adequate  cell 
staining  but  allowed  FACS  compensation  with  other  dyes,  for  example  CD34-PE. 
As  the  cells  of  particular  interest  in  this  study  were  the  undivided  ones  i.  e.  the  most 
brightly  CFSE  stained,  it  was  important  that  compensation  could  be  achieved  at 
the  highest  concentration  of  USE  When  utilised  with  a  sorting  strategy  to 
enhance  resolution  (described  in  detail  in  4.4),  the  peaks  of  cell  division  could  be 
clearly  distinguished.  By  combining  CFSE  with  cell  surface  markers  such  as 
CD34,  this  strategy  could  yield  data  unobtainable  in  any  other  way.  It  should  be 
emphasised  that  the  undivided  cells  identified  by  CFSE  staining  are  not 
necessarily  quiescent  as  recognised  by  HST  and  Py  staining  in  the  previous 
chapter,  since  their  cell  cycle  position  cannot  be  identified  using  this  labelling 
technique. 
4.3  The  Effect  of  CFSE  Staining  on  Cell  Viability 
Although  higher  concentrations  of  CFSE  than  the  one  proposed  had  been  used 
previously  with  no  deleterious  effect  on  cell  viability  (Li  X,  Dancausse  H  et  al. 
2003),  it  was  essential  to  establish  that,  in  this  system,  cell  viability  was  not 
adversely  affected  by  the  staining  protocol.  To  this  end  stem  cell  enriched 
samples,  from  either  normal  donors  or  CML  patients,  were  recovered  from  frozen 
and  stained  with  1pM  CFSE  for  10minutes,  before  washing  in  PBS/2%  and 
incubating  in  culture  medium  containing  a5  growth  factor  cocktail  as  described  in 
the  methods.  Following  an  overnight  incubation,  to  allow  excess  stain  to  leach  out, 
cells  were  recovered  from  petri  dishes  and  further  stained  with  PI  as  an  indicator 
of  viability.  The  total  cell  viability  was  measured  by  gating  on  the  PI"  population.  if 
the  samples  used  in  the  experiments  were  >94%  (94-98.6%)  CD34`,  it  was  not 
normally  a  requirement  to  set  a  CD34}  gate  for  the  first  sort,  as  all  of  the  CD34+ 
cells  were  within  the  viable  gate  following  overnight  incubation.  The  cells  which Susan  M  Graham,  2005  Chapter  4,107 
failed  to  recover  from  cryopreservation,  tended  to  be  the  CD34-  cells.  An  example 
of  the  staining  and  gating  strategy  is  shown  in  figure  4.1.  The  FACS  plots  show  the 
viable  PI-  cells  in  (A)  gated  in  R1,  which  were  further  gated  on  the  CD34+  cells  in 
R2  shown  in  (B).  The  histogram  in  (C)  illustrates  both  the  unstained  and  CFSE+ 
cells  gated  on  R1  and  R2,  thus  Pl-/CD34+.  The  histogram  plot  in  (C)  also  shows 
the  markers  L  (left)  and  R  (right),  representing  the  left  and  right  sorting  gates  used 
in  CFSE  sort  1. 
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Figure  4-1  FACS  gating  strategy  for  first  CFSE  sort. 
FACS  plots  showing  the  gating  strategy  used  in  the  first  CFSE  sort.  The  viable 
PI'  cells  are  shown  in  RI  (A).  The  CD34+  cells,  which  are  already  gated  on  the 
viable  cell  population,  are  contained  in  R2  (B).  The  histogram  plots  shown  in 
(C)  indicate  the  position  of  the  unstained"  control  cells  and  the  CFSE  positively 
stained  cells.  The  markers  labelled  L  (left)  and  R  (right)  show  the  sorting  gates 
used  to  obtain  CFSE  +  homogenously  stained  cell  populations.  If  the 
percentage  of  CD34+  cells  was  less  than  95%,  a  combination  of  both  R1  and  R2 
were  used. 
The  stained  and  unstained  populations  shown  on  the  histogram  plot  were  gated  on 
the  viable  (PI")  cells.  Table  4.1  shows  the  total  cell  viabilities  from  both  normal  and 
CML  cells  stained  with  CFSE,  following  an  overnight  incubation  in  5  growth  factor 
medium.  Comparing  10  unstained  and  stained  CML  samples  there  was  very  little 
difference  between  them,  with  7  out  of  10  showing  a  slight  increase  following 
CFSE  staining.  The  differences  in  viability  were  not  statistically  significant  (p=0.3). Susan  M  Graham,  2005  Chapter  4,108 
The  small  differences  in  the  stained  cells  were  most  likely  due  to  the  washing 
steps  following  staining,  which  removed  some  of  the  dead  cells. 
Unstained  CFSE 
%Viabie  %Viable 
CML  54.5  59.4 
CML  59.5  53.4 
CML  75.6  75.4 
CML  62.2  65.9 
CML  58.8  63.6 
CML  58.3  58.8 
CML  67.5  71.1 
CML  73.5  77.3 
CML  48.7  52.7 
CML  64.6  63.5 
Normal  65.9  60.7 
Normal  50.6  47.5 
Table  4-1  Viability  of  CFSE  stained  cells. 
Following  recovery  from  cryopreservation,  the  cells  were  stained  with  1pM 
CFSE.  An  aliquot  of  unstained  cells  was  reserved  as  a  FACS  control.  The  total 
cell  viabilities  were  measured  by  staining  with  PI  after  16hours  In  culture  with 
growth  factors. 
A  graphic  representation  of  this  data  is  shown  in  figure  4.2.  For  the  2  normal 
samples  there  was  a  slight  decrease  in  the  stained  cell  viability,  however  there 
were  only  two  samples  in  this  group  due  to  the  limited  availability  of  material, 
therefore  statistics  were  not  possible. Susan  M  Graham,  2005 
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Figure  4-2  Graph  of  CFSE  viabilities  for  normal  and  CML. 
Viabilities  of  CFSE  stained  and  unstained  cells,  for  both  normal  and  CML 
samples.  The  percentages  were  calculated  by  FACS  on  the  basis  of  PI 
exclusion. 
If  the  cells  were  placed  in  culture  at  this  stage  and  allowed  to  proliferate  cell 
divisions  could  be  identified,  but  due  to  overlap  of  the  CFSE  peaks  shown  in  figure 
4.3,  it  was  difficult  to  determine  where  one  division  began  and  ended.  This  made 
calculation  of  the  numbers  of  cells  in  each  division  unfeasible,  and  it  was  not 
possible  to  set  sorting  gates  on  cell  peaks  in  this  instance.  It  was  therefore 
necessary  to  develop  a  sorting  strategy  to  enhance  the  resolution  of  the  peaks  of 
cell  division,  allowing  more  data  to  be  obtained  from  these  experiments. Susan  M  Graham,  2005 
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Figure  4-3  FACS  histogram  showing  unresolved  peaks  of  cell  division. 
Histogram  plot  of  unsorted  CFSE  stained  cells  after  3  days  in  culture  with 
growth  factors.  The  histogram  is  gated  on  the  viable  CD34'  cells  with  markers 
showing  the  position  of  the  peaks  and  their  values.  Each  peak  has  exactly  half 
the  fluorescence  of  the  previous  peak,  however  lack  of  resolution  makes 
identification  of  the  exact  position  of  each  peak  difficult. 
4.4  Identification  of  the  Undivided  Cells 
As  the  main  focus  of  the  experiments  contained  in  this  work  was  the  quiescent, 
undivided  cells,  it  was  important  to  be  able  to  accurately  identify  the  position  of  the 
undivided  cell  peak.  Since  the  number  of  undivided cells  could  be  so  small  that  the 
first  peak  of  division  could  be  misinterpreted  as  undivided  cells,  accurate 
measurement  was  crucial.  In  order  to  precisely  position  the  undivided  peak  it  was 
essential  to  use  the  same  cell  population  as  the  experimental  one  i.  e.  one  left- 
sorted  and  one  right-sorted  (sort  1),  to  ensure  the  level  of  fluorescence  was 
equivalent.  A  small  number  (typically  5x104)  of  the  left  and  right-sorted  cells  were 
incubated  in  the  presence  of  0.4pg/ml  colcemid,  a  known  inhibitor  of  cell  cycle 
progression  (Taylor  E  1965).  Figure  4.4  shows  a  representative  example  of  CFSE 
sorted  normal  cells  cultured  for  3  days  and  gated  on  the  viable  CD34+  cells  This 
histogram  plot  illustrates  the  resolved  peaks  of  cell  division  obtained  following  the 
first  CFSE  sort.  The  peaks  of  cell  division  are  overlaid  with  the  colcemid  control 
from  the  same  cell  population.  This  clearly  demonstrates  the  position  of  the 
undivided  cells  and  allows  a  further  markers  to  be  set.  Colcemid  controls  were 
included  for  each  cell  population  (left  and  right-sorted)  for  every  experiment. Susan  M  Graham,  2005 
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Figure  4-4  Histogram  of  cell  division  peaks  and  colcemid  control. 
Chapter  4,111 
An  example  of  the  peaks  of  cell  division  obtained  after  3  days  in  culture, 
following  CFSE  staining  and  sort  1.  The  histogram  is  gated  on  the  viable 
CD34`  cells.  The  peak  shown  in  green  represents  sorted  cells  Incubated  in  the 
presence  of  0.4pg/ml  colcemid  to  prevent  further  cell  division.  The  colcemid 
control  allows  accurate  identification  of  the  undivided  cell  population. 
4.5  Sorting  Strategy  to  Allow  High  Resolution  Tracking 
of  Cell  Division 
In  order  to  gain  the  maximum  amount  of  information  from  these  experiments  it  was 
necessary  to  devise  a  method  which  would  allow  calculation  of  the  numbers  of 
cells  in  each  division  together  with  their  stem  cell  status.  As  can  be  seen  in  figure 
4.5  when  cells  were  stained  with  CFSE  a  relatively  broad  spectrum  of  staining  was 
observed  and  as  detailed  in  section  4.3,  further  culture  of  these  cells  gave 
indistinguishable  peaks  of  cell  division.  By  reducing  the  width  of  the  peak  i.  e.  by 
sorting  a  homogenously  CFSE-stained  population  of  cells,  the  subsequent  peaks 
of  cell  division  were  enhanced.  To  achieve  this,  two  very  narrow  channels  (19-22 
channel  widths)  were  sorted  left  and  right,  and  kept  separate  throughout 
subsequent  culture.  The  channel  widths  were  set  by  the  operator  using  the  FACS 
sorter  software.  Figure  4.5  shows  the  resultant  peaks  when  the  sorted  cells  were 
re-analysed;  the  figures  in  the  table  represent  the  channel  widths  for  each  marker. Susan  M  Graham,  2005 
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Figure  4-5  Histogram  showing  analysis  of  sorted  cells  from  first  CFSE  sort. 
A  histogram  plot  showing  the  widths  of  fluorescence  peaks  of  unsorted  and 
sorted  cells  as  defined  by  the  marker  bounds.  The  unsorted  cells  are  the  solid 
blue  peak  and  the  left  and  right-sorted  peaks  are  green  and  pink  respectively. 
The  marker  bounds  indicate  the  fluorescent  channel  limits  in  each  peak. 
The  total  width  of  the  peak  for  unsorted  cells  was  186  channels,  marker  (Ml).  M2 
(sorted  left)  and  M3  (sorted  right)  were  48  and  49  channels  respectively.  Although 
the  markers  for  sorting  were  set  around  20  channels,  in  practice  the  resultant 
sorted  channel  widths  were  wider.  This  was  due  to  the  mechanics  of  sorting  and 
the  settings  applied.  The  total  width  of  the  two  sorted  peaks  (M4)  was  65 
channels,  which  is  considerably  less  than  the  starting  width  of  186  channels.  If  the 
channel  widths  were  set  beyond  the  limits  described,  the  resolution  in  the  peaks  of 
cell  division  was  not  observed.  In  terms  of  recovered  cell  numbers,  the  2-sorted 
peaks  amounted  to  approximately  40%  of  the  available  viable  stem  cells.  To 
obtain  enough  sorted  cells  for  further  culture  it  was  necessary  to  sort  around  3- 
4x107  cells  in  total.  Taking  the  cell  viabilities  into  account  the  number  of  sorted 
cells  recovered  was  4.5-7.8x106  in  total  for  both  peaks. Susan  M  Graham,  2005  Chapter  4,113 
Having  successfully  achieved  the  desired  resolution  in  the  peaks  of  cell  division, 
this  technology  was  utilised  to  investigate  the  proliferative  potential  of  normal  and 
CML  GO  cells.  Figure  4.6  shows  examples  of  CML  and  normal  cells  first  sorted 
into  a  homogenously  stained  population  as  described  above  and  then  placed  in 
culture  for  3  days.  The  cells  were  then  stained  with  anti-CD34-PE  and  Pl.  The 
CFSE  histogram  was  gated  on  the  CD34+/Pl"  cells.  The  FAGS  histograms  show 
that  the  cells  from  both  normal  and  CML  samples  have  divided  up  to  5  times  and 
that  the  individual  peaks  of  cell  division  were  clearly  visible.  Each  histogram  shown 
represents  the  left  sorted  cells;  the  right-sorted  cells  were  also  set  up  in  culture  for 
each  experiment  providing  a  duplicate.  All  of  the  numbers  generated  from  these 
experiments  were  a  mean  of  the  left  and  right  sorts.  M1  represents  the  undivided 
cells  as  established  with  the  colcemid  control  cells,  and  M2-M6  the  peaks  of  cell 
division.  The  small  numbers  of  cells  to  the  right  of  the  undivided  cells  in  the  normal 
example  were  probably  doublets,  however  without  access  to  doublet  discriminator 
software  it  was  not  possible  to  confirm  this. 
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Figure  4-6  CFSE  histograms  showing  resolution  of  peaks  of  cell  division  for  normal  and 
CML  cells. 
Histogram  plots  showing  the  peaks  of  cell  division  obtained  following  sort  1 
and  3  days  in  culture  with  growth  factors  for  a  normal  and  CML  sample.  The 
histograms  are  gated  on  the  PI'CD34+  cells.  The  markers  show  the  position  of 
each  peak  including  the  undivided  cells  (MI)  identified  by  the  colcemid 
control. 
The  precise  identification  of  the  division  history  in  a  population  of  cultured  cells 
provides  data  unavailable  otherwise.  If  the  number  of  cells  used  to  establish  the Susan  M  Graham,  2005  Chapter  4,114 
culture  is  known,  as  well  as  the  number  of  cells  recovered  at  the  end  point,  it  is 
possible  to  calculate  the  proportion  of  input  cells  recovered  in  each  peak  of  cell 
division.  In  combination  with  a  stem  cell  marker  such  as  CD34  it  is  also  possible  to 
gain  information  on  the  stem  cell  status  in  each  division  under  different  conditions. 
For  both  normal  and  CML  examples,  shown  in  figure  4.6,  a  population  of  cells  in 
MI  i.  e.  undivided,  is  clearly  visible.  This  indicates  there  is  a  degree  of 
heterogeneity  in  the  starting  population  with  some  of  the  cells  "primed"  to  go  into 
division  under  appropriate  stimuli.  Also  in  both  examples,  there  are  cells  that  have 
undergone  different  numbers  of  divisions  (M2-M5)  suggesting  that  there  may  be 
cells  responding  differently  to  the  growth  factor  conditions  in  the  culture  or  to 
products  secreted  by  other  cells.  For  both  normal  and  CML,  most  of  the  cells 
appear  to  be  in  M3,  M4  and  M5,  which  show  the  largest  peaks.  The  cells  in  both 
cultures  have  divided  up  to  5  times  suggesting  a  division  time  of  around  12  hours. 
It  is  interesting  that  the  number  of  cell  divisions  is  similar  for  both  normal  and  CML, 
indicating  that  the  CML  cells  are  not  dividing  at  a  greater  rate  than  the  normal 
ones  in  this  culture  system.  This  observation  is  consistent  with  the  findings  of 
Buckle  et  al  (Buckle  AM,  Mottram  R  et  al.  2000)  who  observed  little  difference  in 
cell  cycle  characteristics  between  normal  and  CML  CD34  selected  cells.  It  has 
been  suggested  that  increased  resistance  to  apoptosis,  rather  than  faster  cell 
division,  allows  accumulation  of  excessive  CML  cell  numbers  in  the  circulation 
(Bedi  A,  Zehnbauer  B  et  al.  1994). 
4.6  Comparison  of  the  Pattern  of  Cell  Division  in  the 
Presence  and  Absence  of  Growth  Factors  for  Normal 
and  CML  Stem  Cells 
It  is  well  documented  in  many  cancers  that  malignant  cells  have  the  capacity  to 
proliferate  in  the  absence  of  exogenous  growth  factors  (Rodeck  U,  et  at.  1993). 
The  development  of  a  method  for  tracking  cell  division  in  stem  cells  allowed 
comparison  of  the  properties  of  normal  and  CML  cells  in  vitro.  CD34  selected 
cells,  from  both  normal  and  CML  samples,  were  recovered  from  frozen,  stained 
with  1  pm  CFSE  and  incubated  overnight  in  the  presence  or  absence  of  a5  growth 
factor  cocktail  containing  IL-3,  IL-6,  G-CSF,  hSCF  and  FIt3-L  as  described  in  the 
methods.  The  following  day  the  cells  were  stained  with  anti-CD34-PE  and  PI 
before  sorting  into  two  narrow  channels  as  described  above.  Cells  were  then Susan  M  Graham,  2005  Chapter  4,115 
incubated,  again  in  the  presence  or  absence  growth  factors,  for  a  further  3  days. 
1-5x104  cells  from  each  of  the  sorted  populations  were  incubated  in  the  presence 
of  0.4pg/ml  colcemid  as  described.  After  the  May  culture  period,  the  cells  were 
stained  with  anti-CD34-PE  and  PI  and  sorted  (sort  2)  into  divided  and  undivided 
populations.  Figure  4.7  shows  normal  cells  (as  in  fig  4.6)  in  the  presence  and 
absence  of  added  growth  factors. 
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Figure  4-7  CFSE  histogram  plots  of  normal  cells  with  and  without  growth  factors. 
Histogram  plots  of  normal  CFSE  stained,  sorted  cells,  following  3  days  in 
culture  in  the  presence  or  absence  of  growth  factors.  The  histograms  are 
gated  on  the  PI"CD34+  cells. 
The  histogram,  which  is  gated  on  the  viable  stem  cells,  shows  that  in  the  presence 
of  growth  factors,  normal  stem  cells  were  able  to  undergo  up  to  5  divisions  in  the 
3-day  time  period.  However,  in  the  absence  of  growth  factors,  normal  cells  were 
unable  to  divide  and  only  a  small  undivided  peak,  representing  the  remaining 
viable  stem  cells  was  observed. Susan  M  Graham,  2005 
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Figure  4-8  CFSE  histogram  plots  of  CML  cells  with  and  without  growth  factors. 
Histogram  plots  showing  CML  cells  CFSE  stained  and  sorted  followed  by  3 
days  in  culture  in  the  presence  and  absence  of  growth  factors.  The  green 
overlaid  peak  shows  the  position  of  the  colcemid  control  i.  e.  the  undivided 
cells. 
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Figure  4-9  Graph  of  the  percentage  of  cells  in  each  peak  for  CML  cells  with  and  without 
growth  factor 
Graphic  representation  of  the  percentage  of  CML  cells  in  each  peak  in  the 
presence  and  absence  of  growth  factors,  as  shown  in  figure  4.8. 
In  the  CML  example  shown  in  figure  4.8,  the  stem  cells  have  divided  a  comparable 
number  of  times  in  the  presence  of  growth  factors  as  the  normal  cells,  and  with 
similar  kinetics.  In  contrast,  in  the  absence  of  growth  factors,  the  CML  cells  have 
been  able  to  divide  up  to  3  times  as  shown  by  the  markers  M2-M4,  demonstrating 
growth  factor  independence.  However,  the  percentage  of  cells  in  M1  is  higher  in 
the  absence  than  in  the  presence  of  growth  factors  as  shown  in  figure  4.9, 
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suggesting  that  without  added  growth  factors  some  of  the  cells  either  fail  to  enter 
cell  division  or  there  is  a  delay  while  autocrine  growth  factor  production  is 
established.  A  further  possibility  is  that  the  stem  cell  population  is  heterogeneous 
and  that  some  of  the  cells  are  not  capable  of  growth  factor  independent 
expansion.  Nevertheless,  the  cell  divisions  observed  in  the  absence  of  growth 
factors  demonstrate  that  a  number  of  CML  stem  cells  exhibit  growth  factor 
independence. 
Another  question  that  arises  as  a  result  of  these  observations,  is  why,  in  the 
presence  of  growth  factors,  the  cell  divisions  are  asynchronous.  In  other  words,  if 
the  stringent  sorting  strategy  has  produced  a  generally  homogenous  population, 
why  are  the  cell  cycles  not  synchronous?  There  are  cells  that  have  divided  only 
once,  while  others  have  divided  a  number  of  times.  Apart  from  the  possibility  that 
the  cell  population  exhibits  a  significant  degree  of  heterogeneity,  another 
explanation  may  be  that  as  the  cells  divide  they  respond  to  growth  factor  stimuli  in 
a  variety  of  ways.  The  implication  being,  that  the  population  is  becoming  more 
heterogeneous  with  every  division.  For  instance,  all  of  the  cells  in  M2  must  have 
come  from  M1  so  if  some  of  the  cells  have  gone  through  one  division  which  has 
produced  two  different  daughter  cells  i.  e.  one  stem  cell  copy  and  one 
differentiating  cell,  these  cells  may  be  responsible  for  the  further  divisions 
observed.  This  may  have  further  consequences  if,  for  example,  some  of  the  cells 
are  producing  growth  factors/inhibitors/chemokines  etc  which  influence  the 
behaviour  of  residual  cells. 
4.7  The  effect  of  Withdrawal  of  Growth  Factors  on 
Proliferation  of  CML  Stem  Cells 
The  ability  of  CML  stem  cells  to  proliferate  in  the  absence  of  exogenous  growth 
factors  could  have  implications  for  disease  progression.  If  cells  are  able  to  thrive 
outwith  the  stem  cell  niche,  and  proliferate  autonomously,  then  the  capacity  for 
maintenance  of  disease  is  escalated.  In  an  effort  to  gain  some  understanding  of 
the  CML  cells  capability  for  proliferation,  the  culture  period  was  extended  to  12 
days.  It  was  possible  that  prior  to  culture  in  conditions  of  growth  factor  starvation, 
the  cells  had  gained  mitotic  signals  from  previous  in  vivo  stimuli.  By  culturing  cells 
for  a  longer  time  period  and  monitoring  the  behaviour  of  cells  that  had  arisen Susan  M  Graham,  2005  Chapter  4,118 
within  the  culture,  a  clearer  picture  of  the  extended  proliferative  capacity  of  the 
cells  could  be  ascertained. 
Fold  amplification 
(mean) 
+GF 
Da  3  18.2±7 
Da  6  107±41 
Day  12  233  ±  47 
-GF 
Da  3  7.6±4 
Da  6  6±4 
Day  12  32±19 
Table  4-2  Table  of  mean  fold  amplification  for  CML  cells  with  and  without  growth  factors. 
The  table  shows  the  mean  fold  amplification  of  CML  cells  cultured  in  the 
presence  and  absence  of  growth  factors  over  a  period  of  12  days.  The  fold 
amplification  was  calculated  as  the  total  viable  cell  output  proportionate  to  the 
input  cell  number.  The  figures  represent  the  mean  of  5  CML  samples  :t  SEM. 
While  the  CML  stem  cells  were  able  to  divide  up  to  4  times  in  the  absence  of 
growth  factors  in  the  3  day  time  period,  there  was  a  reduction  in  the  overall 
recovery  of  viable  cells.  It  remained  a  possibility  that  the  assay,  at  3  days,  was 
selecting  cells  able  to  proliferate  without  growth  factor  stimulation,  but  unable  to 
sustain  the  culture  beyond  this  time  period.  To  address  these  issues  the  cells  were 
cultured  for  12  days,  with  viability  and  cell  recovery  assessed  on  days  3,6,  and 
12,  in  the  presence  and  absence  of  growth  factors.  Table  4.2  shows  that  in  the 
presence  of  growth  factors  the  mean  total  viable  cell  number  increased  by  18.2-, 
107-,  and  233-fold  on  days  3,6,  and  12  respectively  (p=0.06  between  days  3  and 
6,  p=0.05  between  days  6  and  12).  In  the  absence  of  supplementary  growth 
factors  the  mean  total  viable  cell  number  increased  by  7.6-,  6-,  and  32-fold  on 
days  3,6,  and  12.  The  figures  in  this  table  represent  the  mean  of  5  CML  samples 
±  SEM  based  on  an  input  number  of  5x104  cells  per  assay  in  Iml  medium.  The 
figures  did  not  achieve  statistical  significance  in  the  absence  of  growth  factors; 
p=0.2  between  days  3  and  6,  and  p=0.16  between  days  6  and  12,  however  there 
was  considerable  variation  between  patient  samples,  which  is  a  consistent  feature 
of  CML.  The  slight  fall  in  fold  amplification  on  day  6  could  be  due  to  the  death  of 
cells  that  although  Ph'  may  not  be  fully  growth  factor  independent.  There  may  be 
a  lag  period  as  the  cells  adjust  to  growth  factor  starvation  either  by  producing 
autocrine  growth  factors  or  by  circumventing  the  processes  that  require 
exogenous  stimuli.  By  day  12  the  fold  amplification  had  increased  to  32, 
demonstrating  that  growth  factor  independence  is  a  typical  characteristic  of  CML Susan  M  Graham,  2005  Chapter  4,119 
stem  cells  and  is in  accordance  with  other  published  results  (Pierce  A,  Spooncer  E 
et  al.  2002)  (Witte  0N  2001). 
4.8  Expression  of  CD34  in  CML  Cells  in  the  Presence 
and  Absence  of  Growth  Factors 
Having  observed  significant  differences  in  the  proliferation  of  stem  cells  from  CML 
patients  in  the  presence  and  absence  of  growth  factors,  the  level  of  CD34 
expression  was  examined  in  these  cultures.  Clearly  the  stem  cell  status  may  well 
impact  on  their  ability  to  maintain  disease  and  is  an  important  consideration  for 
possible  eradication  of  CML. 
A  detectable  difference  in  CD34  expression  was  observed  in  the  presence  and 
absence  of  growth  factors  for  the  CML  samples.  Figure  4.10  illustrates,  in  this 
representative  example,  in  the  absence of  growth  factors,  cells  that  divided  up  to  4 
times  retained  high  levels  of  CD34  expression,  compared  to  cells  undergoing 
division  in  the  presence  of  growth  factors.  The  difference  in  CD34  expression 
between  the  two  sets  of  conditions  was  highly  significant  by  division  3  (p=.  009). 
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Figure  4-10  FACS  plots  of  CFSE  versus  CD34  expression  for  CML  cells  with  and  without 
growth  factors. 
The  plots  are  gated  on  the  viable  cells  following  3  days  in  culture  in  the 
presence  and  absence  of  growth  factors,  after  the  first  CFSE  sort  to  enhance 
resolution  of  the  peaks  of  cell  division.  The  cells  were  stained  with  anti- 
CD34PE  and  Pl  and  analysed  by  FACS. Susan  M  Graham,  2005 
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Figure  4-11.  Graph  of  CD34+  percentage  versus  peaks  of  cell  division  in  the  presence  and 
absence  of  growth  factors. 
The  graph  shows  the  percentage  of  CML  viable  CD34`  cells  as  a  function  of 
cell  division.  The  cells  were  cultured  for  3  days  in  the  presence  and  absence  of 
growth  factors  following  the  first  CFSE  sort,  before  being  stained  with  anti- 
CD34PE  and  PI  and  assessed  by  FACS. 
The  graph  in  figure  4.11  shows  the  percentage  of  cells  that  remained  CD34+  for 
divisions  0-4,  for  CML  cells  cultured  in  the  presence  and  in  the  absence  of  added 
growth  factors.  In  the  presence  of  growth  factors  the  percentage  of  CD34+  cells 
has  fallen  from  90  to  42%,  whereas  in  the  absence  of  growth  factors  the  CD34+ 
percentage  was  75  after  the  same  4  divisions.  This  shows  that  the  proportion  of 
cells  that  retained  CD34  expression  was  greater  in  the  absence,  than  in  the 
presence  of  growth  factors.  A  possible  explanation  was  that  as  cells  differentiated 
and  lost  CD34  expression  they  disappeared  from  the  culture,  possibly  due  to  cell 
death.  Another  reason  may  be  that  in  the  absence  of  added  growth  factors,  cells 
preferentially  undergo  self-renewal  divisions  with  retention  of  a  primitive 
phenotype.  It  has  been  previously  demonstrated  by  Jiang  et  al  (Jiang  X,  Lopez  A 
et  al.  1999)  that  in  primitive  cells  autocrine  production  of  IL-3  fell  as  cells 
differentiated  from  CD34+CD45RA/71-,  through  the  intermediate 
CD34+CD45RA/71+,  to  the  more  mature  CD34-  cells.  Under  the  culture  conditions 
described  here,  survival  may  perhaps  depend  on  the  retention  of  a  primitive 
phenotype  and  possibly  on  autocrine  production  of  growth  factors. 
4.9  Demonstration  of  Leukaemic  Status  in  the  Undivided 
cells 
It  was  important  to  establish  that  the  cells  that  survived  in  the  undivided  fraction 
were  in  fact  Ieukaemic  cells.  It  was  a  possibility  that  these  cells  could  have  been  a 
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deeply  quiescent  normal  population  (known  to  co-exist  in  CML)  that  had  failed  to 
go  into  division.  When  normal  cells  were  cultured  in  the  absence  of  growth  factors 
a  very  small  number  of  viable  stem  cells  was  observed  (see  section  4.6)  and  it 
was  essential  to  exclude  this  possibility  in  the  case  of  the  CML  samples,  since  if 
these  cells  were  normal  stem  cells,  they  represented  no  risk  to  the  well  being  of 
the  patient. 
Cells  from  the  undivided  peak  (identified  by  colcemid  controls),  cultured  in  the 
presence  and  absence  of  growth  factors,  were  sorted  and  fixed  for  FISH.  Figure 
4.12  shows  a  representative  example  of  the  cells  stained  with  the  D-FISH  probe 
for  BCR-ABL  and  ABL-BCR.  The  detection  of  double  signal  i.  e.  recombinant 
genes  established  the  presence  of  leukaemic  cells,  which  were  greater  than  95% 
of  the  total  sorted  cells.  The  FISH  picture  is  the  D-FISH  probe,  which  labels  BCR, 
and  ABL,  red  and  green  respectively.  Two  yellow  fusion  signals  are  observed  on 
BCR-ABL  and  ABL-BCR.  The  double  fusion  signal  reduces  the  chances  of  a  false 
positive  often  observed  when  the  chromosomes  are  in  particularly  close  proximity. 
A  positive  is  recorded  only  when  two  fusion  signals  are  detected  with  both  a  red 
and  green  signal. 
Figure  4-12  FISH  analysis  of  undivided  cells. 
The  cells  have  been  cultured  in  the  absence  of  growth  factors  for  3  days, 
before  being  sorted  into  divided  and  undivided  populations  and  fixed  for  FISH. 
4.10  Discussion 
In  conclusion,  these  experiments  have  confirmed  that  CML  stem  cells  are  clearly 
different  from  normal  stem  cells  in  their  response  to  withdrawal  of  growth  factors  in 
this  culture  system.  The  ability  of  CML  stem  cells  to  divide  in  the  absence  of Susan  M  Graham,  2005  Chapter  4,122 
exogenous  growth  factors  is  a  feature  of  malignant  cells  that  is  not  observed  for 
normal  cells.  Although  all  of  the  CML  samples  had  FISH  performed  prior  to 
commencement  of  the  experiments,  it  still  remained  a  possibility  that  a  very  small 
number  of  normal  stem  cells  were  present  in  the  CML  population.  The 
demonstration  that  normal  stem  cells  were  unable  to  divide  in  the  absence  of 
growth  factors  indicated  that  any  cell  division  in  growth  factor  deficient  media  was 
due  to  CML  cell  proliferation.  It  was  possible  that  undivided  cells  in  the  CML 
population  contained  some  normal  cells,  however  sorting  the  undivided  population 
and  performing  FISH  confirmed  that  these  cells  were  almost  completely  Ph  4*  within 
the  limits  of  detection.  Therefore,  proliferation  in  the  absence  of  growth  factors 
could  be  used  as  an  indication  of  leukaemic  cell  division  as  opposed  to  normal  cell 
division,  not  observed  under  these  conditions. 123 
Chapter  5  Results  3-  The  Effect  of  ST1571  on  the 
Pattern  of  Cell  Division  in  Normal  and  CML  Stem 
Cells 
5.1  Introduction 
The  molecular  event  that  gives  rise  to  the  disease  of  chronic  myeloid  leukaemia  is 
a  reciprocal  translocation  between  chromosomes  9  and  22  (Rowley  JD  1973).  The 
resultant  product  is  a  shortened  chromosome  22,  known  as  the  Philadelphia 
chromosome,  which  in  turn  gives  rise  to  the  BCR-ABL  oncogene  (Shtivelman  E, 
Lifshitz  B  et  at.  1985).  The  fusion  gene  product  is  a  p210  oncoprotein  containing  a 
constitutively  activated  tyrosine  kinase  (TK)  that  is  responsible  for  the  CML 
phenotype  (Ben-Neriah  Y,  Daley  GQ  et  at.  1986)  (Lugo  TG,  Pendergast  AM  et  at. 
1990).  The  TK  activity  of  normal  c-ABL  is  tightly  regulated  and  shuttles  between 
the  nucleus  and  cytoplasm,  whereas  BCR-ABL  is  exclusively  cytoplasmic.  It  is  the 
deregulated  TK  activity  of  bcr-abl,  together  with  the  cytoplasmic  location,  that  are 
considered  to  be  the  defining  elements  in  the  CML  phenotype  (Lugo  TG, 
Pendergast  AM  et  at.  1990).  The  bcr-abl  TK  phosphorylates  a  number  of  cellular 
proteins,  that  in  turn  impact  on  a  myriad  of  downstream  targets  involved  in  many 
cellular  processes,  including  cell  growth,  stromal  interaction  and  apoptosis  (Salgia 
R,  Li  JL  et  al.  1997;  Deininger  M,  Vieira  S  et  at.  2000)  (Gordon  MY,  Dowding  CR 
et  al.  1987).  With  a  defined  molecular  target,  it  was  feasible  to  design  specific 
inhibitors  of  the  bcr-abl  TK  activity,  potentially  abrogating  its  downstream  effects 
with  minimal  consequence  for  normal  cells. 
As  a  result  of  synthesis  and  screening  of  a  large  number  of  small  molecule  TK 
inhibitors,  Signal  Transduction  Inhibitor  571  (ST1571)  was  identified  as  a  potential 
therapeutic  agent  for  CML  (Buchdunger  E,  Zimmermann  J  et  al.  1996).  From 
results  of  clinical  trials,  STI  was  very  effective  in  chronic  phase,  reducing  white  cell 
numbers  to  within  normal  limits  in  a  few  weeks.  With  relatively  few  side  effects  for 
the  patient,  STI  was  well  tolerated  with  none  of  the  debilitating  toxicity  observed 
with  other  forms  of  chemotherapy,  largely  due  to  its  selectivity  for  leukaemic  cells 
(Druker  BJ,  Tamura  S  et  al.  1996).  On  treatment  with  STI,  97%  of  patients 
achieved  a  complete  haematological  response  and  75%  achieved  a  complete 
cytogenetic  response  (Kantarjian  H,  Sawyers  C  et  al.  2002).  However,  the  results Susan  M  Graham,  2005  Chapter  5,124 
in  blast  crisis  were  less  encouraging,  with  only  transient  haematological  responses 
observed,  and  few  molecular  responses  recorded  (Hughes  T,  Kaeda  J  et  al. 
2002).  There  are  now  documented  cases  of  relapse  in  patients  who  achieved  a 
complete  cytogenetic  response  on  STI,  which  indicates  that  the  disease 
progressed  even  in  the  presence  of  the  drug  (Sawyers  CL,  Hochhaus  A  et  al. 
2002).  Using  very  sensitive  Q-PCR  it  has  been  observed  that  patients  achieving 
remissions  with  STI  still  have  detectable  BCR-ABL  transcripts  and  that  few 
patients  have  been  negative  on  treatment  (Hughes  T,  Kaeda  J  et  al.  2002).  These 
observations  lead  to  the  premise  that  a  small  population  of  cells  was  able  to 
survive  exposure  to  the  drug  and  could  possibly  contribute  to  relapse  at  a  later 
date.  It  was  proposed  that  one  source  of  surviving  leukaemic  cells  could  be  the 
quiescent  population,  identified  in  previous  experiments  in  chapter  4.  The  aim  of 
the  next  set  of  experiments  was  to  determine  the  effect  of  STI  on  the  pattern  of  cell 
division  in  CML  stem  cells  and  to  assess  which  cells,  if  any,  survived  exposure  to 
the  drug. 
5.2  Effect  of  Different  Concentrations  of  ST1571  on  the 
Growth  of  CML  Cells  in  Culture 
The  objective  was  to  determine  the  response  of  a  number  of  CML  samples  to 
differing  concentrations  of  STI.  Since  the  clinically effective  and  achievable  dose  of 
STI  in  the  initial  trials  was  1  pM  (Buchdunger  E,  Zimmermann  J  et  al.  1996;  Druker 
BJ,  Tamura  S  et  at.  1996;  Peng  B,  Hayes  M  et  at.  2004),  this  was  the  starting 
concentration  used  in  these  experiments.  CD34  enriched  stem  cells  from  5  CML 
patient  samples  were  recovered  from  cryopreservation  and  cultured  in  the 
presence  and  absence  of  a5  growth  factor  cocktail  as  described  in  the  methods. 
The  no  growth  factor  arm  was  included  as  a  selection  for  leukaemic  cell 
proliferation,  as  normal  cells  were  unable  to  proliferate  under  these  conditions  (as 
shown  in  chapter  4). 
All  of  the  samples  were  from  patients  at  diagnosis  and  before  clinical  intervention, 
and  all  were  >95%  BCR-ABL  positive  by  FISH.  STI  was  added  on  day  0  at 
concentrations  of  0,1,5  and  10pM.  On  days  3,6  and  12  triplicate  wells  for  each 
concentration  were  harvested,  counted  and  assessed  for  viability  by  trypan  blue 
exclusion.  Figure  5.1  shows  graphs  of  viable  cell  numbers  on  days  3,6  and  12  in 
the  presence  and  absence  of  growth  factors,  with  increasing  concentrations  of Susan  M  Graham,  2005  Chapter  5,125 
STI.  In  the  presence  of  growth  factors  (figure  5.1(A)),  the  mean  total  viable  cell 
number  continued  to  increase  over  the  12  day  period  in  the  absence  of  STI. 
However,  in  the  presence  of  1,5,  and  10pM  STI  the  total  viable  cell  number  was 
consistently  lower  than  the  control.  In  the  absence  of  growth  factors  (figure  5.1(B)), 
or  STI  in  parallel  cultures,  the  total  viable  cell  number  was  lower  than  in  the 
presence  of  growth  factors,  but  still  showed  an  increase  over  time.  The  addition  of 
STI  at  concentrations  of  1-10NM  reduced  the  viable  cell  number  to  a  greater  extent 
when  no  exogenous  growth  factors  were  present.  In  these  cultures,  the  decrease 
in  cell  proliferation  as  a  result  of  growth  factor  starvation  and  cell  kill  by  STI  were 
indistinguishable  but  the  cumulative  effect  was  a  reduction  in  viable  cell  recovery. 
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Figure  5-1  Graphs  of  viable  cell  number  with  concentration  of  STI  over  time. 
The  cells  were  cultured  in  the  presence  and  absence  of  growth  factors,  with 
differing  concentrations  of  STI.  5x104  cells  in  Iml  of  media  were  used  to 
establish  the  cultures  and  the  viable  cell  number  assessed  by  typan  blue 
exclusion  on  days  3,6,  and  12  as  described  in  the  text. Susan  M  Graham,  2005  Chapter  5,126 
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Fold 
amplification 
(mean) 
% 
Recovery 
(mean) 
+GF 
Day  3  18±7  11  t4  62  7±3  39  10±8  55 
Da  6  107±40  38±17  36  25±12  23  15±5  14 
Day  12  233±54  204±74  87  172±68  74  95  ±43  41 
-GF 
Day  3  7.6±4  1.8±0.6  24  1.4±0.7  18  1.611  21 
Day  6  6±4  1±0.3  17  0.6  ±  0.3  10  0.4  ±  0.2  7 
Day  12  32±19  2±1.4  6  1±0.6  3  0.8±0.3  2.5 
Table  5-1  Table  of  fold  amplification  and  viable  cell  recovery±GF  and  i  STI. 
The  figures  are  the  mean  of  5  CML  samples  ±SEM. 
Table  5.1  shows  the  fold  amplification  for  the  same  cultures  ±STI  and  ±growth 
factors  on  days  3,6,  and  12.  For  each  culture  5x104  cells  were  added  to  1  ml  of 
media  in  24  well  plates  and  each  well  set  up  in  triplicate.  On  days  3,6,  and  12  the 
wells  were  harvested  and  viable  cell  recovery  assessed  by  trypan  blue  exclusion. 
The  fold  amplification  was  calculated  as  the  viable  cell  output  proportional  to  the 
input  number.  The  results  in  table  5.1  represent  the  mean  of  5  CML  patient 
samples  ±  SEM.  The  data  shows  that  in  the  presence  of  growth  factors,  the  mean 
total  viable  cell  number  increased  by  18-,  107-,  and  233-fold  on  days  3,6,  and  12 
respectively  (as  detailed  previously  in  chapter  4,  section  4.7).  The  addition  of  1,5, 
and  10pM  STI  reduced  the  total  amplification  to  11-,  7-,  and  10-fold  by  day  3.  By 
day  6  the  total  cell  amplification  was  38-,  25-,  and  15-fold  and  by  day  12  it  had 
reached  204-,  172-,  and  95-fold.  In  order  to  assess  the  effect  of  STI,  the  viable  cell 
recovery  was  calculated  as  a  percentage  of  the  no  drug  control.  The  maximum 
effect  of  STI  was  observed  on  day  6  when  the  overall  recovery  of  viable  cells  was 
reduced  to  36%,  23%,  and  14%  of  control  for  1,5,  and  10pM  STI  respectively. 
However,  by  day  12  the  viable  cell  recoveries  had  improved  to  87%  and  74%  of 
the  control  for  I  and  5pM  STI.  (p=0.048).  For  10pM  STI,  although  the  viable  cell 
recovery  had  improved  from  14  to  41  %  this  did  not  achieve  statistical  significance. 
In  the  absence  of  growth  factors  and  STI  the  mean  total  viable  cell  number 
increased  by  7.6-,  6-,  and  32-fold  on  days  3,6,  and  12  respectively  (as  detailed 
previously  in  chapter  4  section  4.7).  In  the  presence  of  1,5,  and  I  OpM  STI  the  fold 
amplification  of  viable  cells  was  reduced  to  1.8-,  1.4-,  and  1.6-fold  by  day  3,  to  1-, 
0.6-,  and  0.4-fold  by  day  6,  and  to  2-,  1-,  and  0.8-fold  on  day  12.  The  maximum Susan  M  Graham,  2005  Chapter  5,127 
effect  of  STI  was  observed  on  day  12  when  the  overall  viable  cell  recoveries  were 
6%,  3%,  and  2.5%  for  1,5,  and  1  0pM  STI  respectively. 
In  the  presence  of  growth  factors  the  mean  viable  cell  recovery  decreased 
between  days  3  and  6  in  the  presence  of  1,5,  and  10pM  STI  but  increased 
between  days  6  and  12  suggesting  that  a  subset  of  Ph+  cells  were  insensitive  to 
STI  at  greater  than  clinically  achievable  concentrations.  Figure  5.2  shows  graphic 
representations  of  the  recoveries  of  viable  cells  for  each  STI  concentration 
±growth  factors.  As  stated  above,  the  recovery  of  viable  cells  in  the  presence  of 
growth  factors  and  STI  at  each  concentration  showed  a  decline  on  day  6  and  an 
increase  between  days  6  and  12.  In  the  absence  of  growth  factors,  although  the 
fold  amplification  increased  between  days  6  and  12  for  each  concentration,  as 
shown  in  table  5.1,  the  recovery  of  viable  cells  continued  to  decrease  over  this 
time  period.  The  data  generated  in  these  experiments  suggested  that  a  small 
population  of  cells  were  able  to  survive  exposure  to  STI,  at  10pM.  It  was  proposed 
that  the  CFSE  assay  described  in  the  previous  chapter  could  be  used  to  identify 
which  cells  were  able  tolerate  exposure  to  the  drug  and  would  generate  further 
information  on  the  stem  cell  status. 
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Figure  5-2  Graphs  of  cell  recovery  (growth  factors  and  tSTI. 
The  cells  were  cultured  for  12  days  as  described  in  the  text.  The  viable  cell 
number  was  assessed  on  days  3,6,  and  12  by  trypan  blue  exclusion.  The 
viable  cell  recovery  was  calculated  as  a  proportion  of  the  input  cell  number 
5x104)  in  1ml  of  media  ±GF.  The  results  are  the  mean  of  5  CML  samples. 
5.3  The  Effect  of  ST1571  on  the  Pattern  of  Cell  Division 
in  Normal  and  CML  Stem  Cells 
As  demonstrated  in  the  previous  chapters,  quiescent  stem  cells  could  be  identified 
in  all  CML  samples;  it  was  consequently  hypothesised  that  these  cells  may  be  the Susan  M  Graham,  2005  Chapter  5,128 
ones  that  survive  exposure  to  STI.  Figure  5.3  shows  a  schematic  outline  of  the 
experimental  strategy  used  here,  and  illustrates  that  following  the  first  sort  to 
enhance  resolution  of  the  peaks  of  cell  division  (detailed  in  chapter  4,  section  4.5), 
the  sorted  cells  were  incubated  in  serum  free  medium  with  or  without  a5  growth 
factor  cocktail  for  a  further  3  days.  Although  previous  experiments  had  shown  that 
normal  cells  failed  to  proliferate  in  the  absence  of  growth  factors,  the  introduction 
of  STI  into  the  culture  may  have  influenced  this;  therefore  control  cells  were 
treated  in  the  same  way  as  experimental  ones.  The  cells  were  incubated  in  the 
presence  or  absence  of  10µM  STI,  cultured  for  3  days  and  further  sorted  into 
divided  and  undivided  fractions.  As  10pM  had  been  the  most  effective 
concentration  of  STI  in  reducing  the  recovery  of  viable  cells  this  was  the 
concentration  used  for  the  rest  of  the  experiments,  although  this  was  not  clinically 
achievable.  The  three-day  time  point  was  chosen,  as  the  effect  of  STI  could  be 
observed  within  this  time  frame.  Figure  5.4  illustrates  the  sorting  and  gating 
strategy  used  for  these  experiments.  For  both  sorts  the  cells  were  first  gated  on 
the  viable  (PI")  population  and  on  the  CD34+  population,  before  setting  the  markers 
for  sorting. Susan  M  Graham,  2005  Chapter  5,129 
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Figure  5-3  Schematic  outline  of  the  CFSE  sorting  and  experimental  strategy. 
Following  recovery  from  cryopreservation,  the  cells  were  stained  with  1pM 
CFSE  and  cultured  overnight  ±  growth  factors.  The  cells  were  then  sorted  (sort 
1)  to  obtain  homogeneously  stained  CFSE'  populations  before  being  cultured 
for  3  days  ±  GF  and  ±  STI.  After  3  days  the  cells  were  further  sorted  (sort  2) 
into  undivided  (UD)  and  divided  (DIV)  cell  populations  identified  by  the 
colcemid  control  cells  as  described  previously. Susan  M  Graham,  2005 
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Figure  5-4  Gating  strategies  for  CFSE  sorts  1  and  2. 
Sort  2 
colcemid 
control 
The  cells  were  first  gated  on  the  PI"  cells  and  then  on  the  CD34'  population. 
For  sort  1,  two  markers  (L  and  R)  of  -20  channels  were  set  on  the  CFSE'  cells 
to  obtain  homogeneously  stained  populations.  Sort  2  was  done  after  the  cells 
had  been  in  culture  for  a  further  3  days.  The  colcemid  control  identifies  the 
position  of  the  undivided  cells,  and  allows  the  markers  to  be  set  for  sort  2. 
Figure  5.5  shows  normal  cells  in  the  presence  and  absence  of  10pM  STI,  and 
±growth  factors.  The  histograms  are  gated  on  the  viable  (PI-)  and  CD34+  cells; 
therefore  the  peaks  of  cell  division  represent  the  viable,  CD34+  cells  in  each 
culture.  As  previously  shown  in  chapter  4  section  4.6,  in  the  presence  of 
exogenous  growth  factors,  stem  cells  have  undergone  up  to  5  divisions  with  a 
small,  undivided  peak  observed.  The  addition  of  STI  did  not  affect  the  cell  cycle 
kinetics  or  the  recovery  of  viable  stem  cells.  The  cells  were  able  to  undergo  a 
similar  number  of  divisions  in  the  presence  of  STI  as  in  the  absence.  This  was  not 
surprising,  as  STI  had  previously  been  shown  to  have  little  effect  on  the 
proliferation  of  normal  stem  cells  at  this  concentration.  It  has  however,  been 
documented  that  at  concentrations  of  >10µM  STI,  inhibition  of  proliferation  in 
normal  cells  is  observed,  possibly  due  to  the  inhibition  of  other  tyrosine  kinases 
(Deininger  MW,  Goldman  JM  et  al.  1997). 
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Figure  5-5  Normal  CFSE  stained  and  sorted  cells  ±GF  and  tSTI  on  day  3. 
The  plots  were  gated  on  the  PI",  CD34'  population.  Normal  cells  were 
unaffected  by  the  addition  of  STI  to  the  culture  with  GF.  In  the  absence  of  GF 
there  were  no  cell  divisions  and  only  a  small  number  of  undivided  cells 
remained  viable 
In  contrast  to  the  normal  example  for  CML  1  shown  in  figure  5.6,  the  addition  of 
STI  to  the  culture  eliminated  all  of  the  dividing  cells  both  in  the  presence  and 
absence  of  growth  factors.  In  both  instances,  a  small,  undivided  peak  was 
observed  representing  viable  stem  cells  that  had  survived  exposure  to  the  drug. Susan  M  Graham,  2005 
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Figure  5-6  CML  I  CFSE  stained  and  sorted  cells  ±GF  and  ±STI  on  day  3. 
All  plots  were  gated  on  the  PI",  CD34*  population.  STI  has  killed  all  of  the 
dividing  cells  both  In  the  presence  and  absence  of  growth  factors.  A  small, 
undivided  peak  is  observed  ±GF  following  drug  treatment. 
The  CML  undivided  cells  were  sorted  and  processed  for  FISH  and  RT-PCR. 
Representative  examples  are  shown  in  figure  5.7,  which  demonstrated  that  these 
cells  were  part  of  the  leukaemic  clone.  The  FISH  picture  shows  the  dual  fusion 
signal,  which  gives  two  yellow  signals  when  BCR-ABL  and  ABL-BCR  are  detected. 
The  red  and  green  signals  are  the  single  BCR  and  ABL  genes.  The  PCR  picture 
illustrates  the  presence  of  BCR-ABL  transcripts  in  the  sorted  undivided  cells  from 
cultures  ±  growth  factors  following  treatment  with  STI.  It  was  important  to  exclude 
the  possibility  that  these  cells  were  a  very  small  number  of  normal  cells  that  had 
been  unaffected  by  STI  exposure.  The  previous  observation  that  CML  cells  exhibit 
growth  factor  independence  (chapter  4)  is  also  evident  in  this  example,  which 
shows  4  peaks  of  cell  division  in  the  absence  of  added  growth  factors. Susan  M  Graham,  2005  Chapter  5,133 
Figure  5-7  FISH  and  PCR  on  sorted  undivided  cells  on  day  3. 
Following  sorting  on  day  3  as  described  in  the  text,  the  cells  were  fixed  for 
FISH  using  the  dual  fusion  signal  probe.  PCR  was  done  (by  H  Jorgensen) 
using  primers  for  BCR-ABL  and  cABL. 
This  response  to  STI  treatment  was  not  observed  for  all  CML  patients.  Figure  5.8 
illustrates  another  CML  patient  whose  stem  cells  were  less  sensitive  to  the  drug  in 
this  assay.  In  the  presence  of  growth  factors  and  10pM  STI,  a  number  of  cells 
have  been  able  to  undergo  up  to  4  divisions.  In  conditions  of  growth  factor 
starvation,  and  10pM  STI,  some  of  the  cells  have  still  been  able  to  undergo  1 
division.  The  relative  difference  between  the  divisions  ±  growth  factors  may  be 
attributable  to  the  decline  in  cell  proliferation  at  this  early  time  point;  as  observed 
when  the  cells  were  cultured  for  12  days  in  the  absence  of  growth  factors,  detailed 
in  the  previous  chapter.  (Chapter  4,  section  4.7).  The  differences  in  patient 
responses  to  STI  exposure  seen  here  may  reflect  a  range  of  sensitivities  to  the 
drug,  analogous  to  observations  of  in  vivo  responses. 
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Figure  5-8  CML  2  CFSE  stained  and  sorted  cells  ±GF  and  iSTI. 
The  histograms  were  gated  on  the  PI',  CD34;  cells.  The  peaks  of  cell  division 
with  GF  and  STI  are  indicated  showing  that  the  cells  have  been  able  to  divide 
up  to  4  times  in  the  presence  of  10pM  STI.  In  the  absence  of  GF  with  STI,  some 
cells  have  been  able  to  undergo  I  cell  division. 
Although  STI  is  targeted  to  BCR-ABL;  cells,  published  reports  have  suggested 
that  inherent  resistance  occurs,  possibly  due  to  over-expression  of  BCR-ABL  or  to 
mutations  in  the  ATP  binding  site  on  the  tyrosine  kinase.  In  all  patient  samples 
used  in  this  study,  a  quiescent  population  was  identified  following  STI  exposure 
(n=5),  and  in  all  cases  these  cells  were  CD34+  and  BCR-ABL+  by  FISH.  The  CD34 
status  of  the  cultures  was  recorded  routinely  and  this  allowed  access  to  data  on 
the  expression  of  this  stem  cell  marker  under  a  range  of  conditions.  As  CIVIL  is  a 
stem  cell  disease  with  the  capability  for  production  of  excessive  cell  numbers,  the 
expression  of  a  stem  cell  marker  could  serve  as  an  indication  of  the  replicative 
potential  of  the  malignant  cells. 
5.4  The  Effect  of  STI  Exposure  on  the  Expression  of 
CD34  in  CML 
It  was  important  to  illustrate  what  happened  to  the  stem  cell  status  in  the  treated 
cultures.  For  example  STI  may  have  induced  differentiation  including  loss  of  CD34 
and  have  exerted  its  effects  in  this  way.  It  was  also  important  to  assess  the 
proliferation  potential  of  any  cells,  which  survived  exposure  to  the  drug.  If  the Susan  M  Graham,  2005  Chapter  5,135 
surviving  cells  were  more  mature  then  the  risk  of  disease  relapse  may  have  been 
reduced,  as  these  cells  would  be  naturally  exhausted  through  differentiation. 
Information  on  the  stem  cells  status  as  a  function  of  division  could  be  gained  by 
visualising  CFSE  (i.  e.  division)  versus  CD34  expression  on  a  dot  plot.  The  cells 
were  first  gated  on  Pl"  viable  cells,  and  cell  division,  identified  by  CFSE  staining, 
with  CD34  expression  visualised  on  a  dot  plot.  Figure  5.9  shows,  for  this  STI- 
sensitive  example  also  shown  in  figure  5.6,  that  the  cells  remaining  following  STI 
exposure  were  all  CD34+.  The  dotted  line  indicates  the  position  of  the  undivided 
cells,  identified  by  the  colcemid  control.  As  shown  previously  in  chapter  4,  section 
4.8,  growth  factor  starvation  lead  to  increased  retention  of  the  CD34+  phenotype 
with  cell  division.  The  addition  of  STI  to  the  cultures  containing  growth  factors 
eliminated  all  of  the  dividing  cells  and  all  of  the  remaining  viable  cells  were  CD34+. 
In  the  second  less  sensitive  example,  shown  in  figure  5.10,  where  STI  has  not 
eliminated  the  dividing  cells,  the  expression  of  CD34  remained  high.  This  would 
suggest  that  the  most  primitive  cells  show  increased  resistance  to  the  effects  of 
the  drug.  Given  that  more  primitive  stem  cells  have  the  capacity  for  greater 
expansion,  this  could  potentially  lead  to  disease  relapse. 
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Figure  5-9  CD34  expression  with  cell  division. 
The  plots  are  gated  on  the  PI'  cells  and  show  cell  divisions  (CFSE)  versus 
CD34  expression.  This  is  the  same  sample  shown  in  figure  5.6  (CML  1).  The 
dotted  line  represents  the  position  of  the  undivided  cells. Susan  M  Graham,  2005 
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Figure  5-10  CD34  expression  versus  cell  division  for  CIVIL  2. 
The  plots  were  gated  on  the  P1'  cells  and  show  CD34  expression  after  3  days  in 
culture  ±  GF  and  ±  STI.  The  events  to  the  right  of  the  dotted  line  are  undivided 
cells,  identified  by  the  colcemid  control  as  described  in  the  text. 
To  give  an  indication  of  the  cells  recovered  in  each  cell  division,  the  total  number 
of  viable  cells  in  each  culture,  as  well  as  the  number  of  viable  CD34+  cells  was 
calculated  as  a  percentage  of  the  input  number  (corrected  for  the  number  of 
divisions).  Figure  5.11  shows  the  gating  strategy  used  to  generate  the  CD34 
percentages  used  for  these  calculations.  The  cells  were  first  gated  on  the  viable 
population,  then  visualised  on  a  dot-plot  showing  cell  division  (CFSE)  and  CD34 
expression.  Good  resolution  of  the  cell  divisions  (achieved  by  the  first  CFSE  sort) 
allowed  markers  to  be  set  for  measurement  of  CD34  percentages  in  each  division. 
Table  5.2  shows  the  total  cell  i.  e.  CD34+  and  CD34"  (A),  and  CD34+  only  (B) 
recoveries  for  each  division  ±  growth  factors  and  ±  STI  at  10pM  (n=4).  The  figures 
illustrate  that  in  the  presence  of  growth  factors,  the  mean  total  cell  recovery  was 
91%  compared  to  56%  following  the  addition  of  STI.  In  the  absence  of  growth 
factors,  the  total  cell  recovery  was  47%  compared  with  22%  on  addition  of  10NM 
STI.  Considering  the  recoveries  in  each  individual  peak,  17%  recovery  was 
observed  in  M1  (undivided  cells)  with  growth  factors  alone.  Cell  recovery  in  the 
presence  of  STI  was  16%,  which  was  not  significantly  different.  It  would  appear 
that  STI  did  not  affect  the  recovery  of  viable  cells  until  division  3,  where  the 
recovery  decreased  from  28%  with  growth  factors  alone  to  1.6%  with  the  addition 
of  STI.  In  the  absence  of  growth  factors,  the  percentage  of  cells  in  the  undivided 
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peak  (Ml)  was  14%  compared  to  11  %  with  the  addition  of  STI.  However,  in  this 
culture  the  effect  of  STI  was  observed  in  M2  where  the  recovery  of  viable  cells  fell 
from  21  %  to  9%,  suggesting  that  as  soon  as  the  cells  entered  cell  cycle  they  were 
killed  by  STI,  or  that  STI  was  preventing  them  from  entering  cell  cycle.  As  would 
perhaps  be  expected,  the  overall  recovery  in  the  presence  of  STI  was  markedly 
lower,  22%  versus  47%,  with  the  effect  again  observed  as  soon  as  the  cells 
entered  cell  division.  If  the  calculations  were  done  using  the  viable  CD34+  cells  as 
opposed  to  the  total  viable  cells,  the  results  were  almost  exactly  the  same  for  each 
of  the  4  experimental  arms  (table  5.2  (B)) 
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Figure  5-11  FACS  plot  of  cell  division  (CFSE)  with  CD34  expression. 
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The  cells  were  cultured  for  3  days  in  the  presence  of  GF,  after  initial  sorting  of 
CFSE  stained  cells  as  described  in  the  text.  Cells  were  then  stained  with  anti- 
CD34-PE  and  gates  set  for  each  division  to  calculate  the  percentage  of  CD34+ 
and  CD34'  cells  in  each  division.  This  plot  was  gated  on  the  PI'  population.  R3 
and  R14  represent  the  undivided  cells  identified  by  the  colcemid  control. Susan  M  Graham,  2005 
(A)  Total  cell  recovery 
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Conditions 
Recovery 
in  M1 
(mean  %) 
Recovery  in 
M2 
(mean  %) 
Recovery  in 
M3 
(mean  %) 
Recovery  in 
M4 
(mean  %) 
Recovery 
in  M5 
mean  % 
Total 
recovery 
(mean 
+GF  17  13  26  28  6  91 
+GF  +  STI  16  15  23  1.6  0.9  56 
-GF  14  21  10  1.4  -  47 
-GF+STI  11  9  2  0.2  -  22 
(B)  Recovery  of  CD34+  cells 
Conditions 
Recovery 
in  M1 
(mean  %) 
Recovery  in 
M2 
(mean  %) 
Recovery  in 
M3 
(mean  %) 
Recovery  in 
M4 
(mean  %) 
Recovery 
in  M5 
(mean  %) 
Total 
recovery 
(mean 
+GF  11  13  28  28  6  85 
+GF  +  STI  15  16  23  1.6  0.9  55 
-GF  13  25  11  1.4  -  51 
-GF+STI  11  10  2  0.2  -  24 
Table  5-2  Table  of  total  cell  and  CD34+  cell  recoveries  in  each  peak  of  cell  division. 
Numbers  are  the  mean  (n=4)  percentage  recovery  for  the  number  of  cells  in 
each  division  peak,  (corrected  for  the  number  of  divisions)  as  a  fraction  of  the 
input  cell  numbers. 
If  the  premise  is  that  quiescent  undivided  cells  in  CML  are  the  most  difficult  to 
eradicate,  then  any  treatment  which  exerts  an  anti-proliferative  effect,  may 
potentially  allow  harbouring  of  quiescent  leukaemic  stem  cells.  These  cells  would 
have  the  capacity  to  cause  relapse  at  a  later  date,  as  a  consequence  of  their  high 
proliferative  potential.  The  total  cell  and  CD34+  cell  recovery  in  table  5.2  showed 
little  difference  in  the  mean  recoveries  of  cells  in  M1  (undivided),  with  and  without 
STI.  However,  anti-proliferative  effects  of  STI  treatment  could  be  demonstrated  in 
one  particularly  sensitive  CML  sample.  This  sample  is  shown  in  figure  5.6  where 
the  cell  divisions  and  CD34  status  were  identified  (as  discussed  in  section  5.4).  If 
the  number  of  cells  recovered  in  the  undivided  peak,  (as  a  proportion  of  the  input 
number)  was  calculated,  with  growth  factors  alone,  the  recovery  in  M1  was  3.2%:  t 
0.4%  and  in  the  presence  of  STI  was  15.6%.  ±  1.4%  (p=0.014).  This  demonstrated 
that  STI  was  exerting  an  anti-proliferative  effect,  as  the  cells  had  backed  up  in  the 
undivided  peak,  i.  e.  the  recovery  of  undivided  cells  had  increased  in  the  presence 
of  the  drug.  It  remained  a  possibility  that  the  cells  identified  in  the  undivided  peak 
were  early  apoptotic  cells,  however  due  to  limitations  in  this  assay  it  was  not 
possible  to  confirm  this.  Further  work  by  our  group  (not  shown  in  this  thesis),  has 
established  that  the  undivided  cells,  which  survive  STI  exposure,  have  the 
capacity  to  proliferate  upon  removal  of  the  drug  and  therefore  retain  the  potential 
to  cause  disease  relapse  (Jorgensen  HG,  Allan  EK  et  al.  2005). Susan  M  Graham,  2005  Chapter  5,139 
Holtz  et  at  (Holtz  MS,  Slovak  ML  et  at.  2002)  have  demonstrated  that  STI 
selectively  inhibits  the  proliferation  of  primitive  CML  progenitors  and  more  recently 
Bhatia  et  at  (Bhatia  R,  Holtz  M  et  at.  2003)  have  shown  that  malignant  progenitors 
persist  in  patients  treated  with  STI.  Studies  within  our  group  have  shown  that  the 
anti-proliferative  effect  of  STI  can  be  enhanced  or  reduced  by  the  introduction  of 
other  drugs  in  combination  with  STI  in  vitro  (Jorgensen  HG,  Allan  EK  et  at.  2005). 
Holtz  et  at  have  also  demonstrated  that  haemopoietic  progenitor  cells  persist  in 
CML  patients  treated  with  STI  who  are  in  complete  cytogenetic  remission,  and 
confirmed  that  BCR-ABL  mRNA  levels  in  the  progenitor  cells  were  higher  than  in 
the  more  mature  MNC  (Holtz  MS,  Forman  SJ  et  at.  2005).  However,  it  is  still  too 
early  to  assess  whether  these  cells  can  ultimately  contribute  to  relapse  in  patients 
treated  with  STI  therapy. 
5.5  Summary 
In  summary,  the  experiments  presented  in  this  chapter  were  aimed  at  assessing 
the  sensitivity  of  a  number  of  CML  patient  stem  cells  to  differing  doses  of  STI. 
These  results  established  a  range  of  sensitivities  to  the  drug  with  one  particular 
example,  which  was  very  susceptible.  Having  established  test  doses  and  a  time 
frame  for  the  protocol,  further  work  investigated  the  pattern  of  cell  division  in  the 
presence  of  the  drug,  together  with  the  effects  on  the  stem  cell  status.  It  was 
confirmed  that  some  cells  from  every  patient  sample  survived  exposure  to  the  drug 
at  greater  than  clinically  achievable  doses.  It  was  also  established  that  these  cells 
were  part  of  the  leukaemic  clone  by  FISH,  and  expressed  the  stem  cell  marker 
CD34.  It  was  further  determined  that  the  surviving  cells  were  the  undivided, 
quiescent  cells  and  that  STI  exerted  anti-proliferative  activity  (shown  in  one 
example)  by  causing  the  number  of  undivided  cells  to  increase  in  the  presence  of 
the  drug.  Taken  together  it  would  seem  likely  that  STI  is  not  going  to  cure  CIVIL  as 
a  single  therapy.  However,  in  combination  with  other  agents  aimed  at  inducing 
quiescent  cells  into  cycle,  or  by  increasing  their  susceptibility  to  other  agents,  a 
more  effective  treatment  may  be  feasible.  In  an  effort  to  identify  potential 
therapeutic  targets,  an  investigation  of  the  gene  expression  profile  of  normal  and 
CML  quiescent  cells  compared  to  cycling  cells  was  undertaken,  and  the  following 
chapter  describes  the  preliminary  analysis. 140 
Chapter  6  Results  4-A  Comparison  of  the  Gene 
Expression  Profile  of  Normal  and  CML  Quiescent 
and  Dividing  Stem  Cells. 
6.1  Introduction 
Advances  in  the  treatment  of  chronic  myeloid  leukaemic  saw  the  first  molecularly 
targeted  therapy  for  a  human  cancer  reach  the  clinic.  STI571  (STI)  was  rationally 
designed  to  inhibit  the  constitutively  active  tyrosine  kinase  of  the  BCR-ABL 
oncoprotein.  This  in  turn,  is  responsible  for  BCR-ABL-induced  transformation  in 
primitive  haemopoietic  stem  cells  typical  of  CML  disease.  Initial  clinical  trials  with 
STI  showed  remarkable  results  particularly  in  chronic  phase,  with  almost  all 
patients  achieving  a  haematologic  response  and  many  achieving  major  or 
complete  cytogenetic  responses.  However,  molecular  remissions  were  rare  and 
detectable  levels  of  BCR-ABL  transcripts  were  noted  in  patients  achieving  a 
complete  cytogenetic  response,  with  cases  of  disease  relapse  whilst  on  therapy 
documented.  It  was  clear  that  some  cells  were  resistant  to  the  effects  of  STI  and 
able  to  repopulate  the  haemopoietic  system  post-treatment. 
The  results  presented  in  the  previous  chapter  identified  a  quiescent  population  of 
primitive  stem  cells  that  survived  exposure  to  STI  at  concentrations  in  excess  of 
those  used  clinically.  Other  reports  have  also  documented  progenitor  cells  that 
remain  viable  in  vitro  and  in  vivo  following  exposure  to  STI  (Holtz  MS,  Slovak  ML 
et  al.  2002;  Hughes  TP,  Kaeda  J  et  al.  2003).  In  an  effort  to  characterise  the 
quiescent  cells  compared  to  cycling  cells  in  both  normal  and  CML,  a  microarray 
approach  was  used.  Gene  expression  profiling  had  been  used  successfully  in 
other  studies  of  leukaemia,  identifying  a  previously  unrecognised  class  of  mixed 
lineage  leukaemia  (MLL)  (Armstrong  SA,  Staunton  JE  et  al.  2002).  It  was 
anticipated  that  a  microarray  approach  would  yield  important  information  not  only 
concerning  leukaemic  cells,  but  also  regarding  normal  haemopoietic  stem  cell 
biology.  It  was  hoped  that  differences  in  the  expression  profiles  would  yield  targets 
valuable  for  CML  therapy  alone,  or  perhaps  in  combination  with  other  known 
cytotoxic  agents.  Quiescent  cells  were  identified  and  sorted  using  the  protocols 
described  in  chapter  3,  then  processed  for  RNA.  The  RNA  was  converted  to Susan  M  Graham,  2005  Chapter  6,141 
biotinylated  cRNA,  applied  to  Affymetrix  U133A  gene  chips  and  the  results 
analysed  by  two  different  methods. 
6.2  Sorting  to  Isolate  Quiescent  and  Cycling  Stem  Cell 
Fractions 
It  was  of  critical  importance  that  the  cell  populations  used  for  microarray  studies 
were  subject  to  consistent  conditions,  as  any  deviation  in  the  protocol  may  have 
induced  changes  in  gene  expression  related  to  procedure.  The  Hoechst  (HST)  and 
Pyronin  (Py)  sorting  strategy  (as  described  in  chapter  3,  section  3.1.3)  was  used  to 
generate  quiescent  cells  in  GO  and  cycling  cells  in  G1/S/G2/M  from  previously 
CD34  selected  samples  A  representative  CML  sample  is  shown  in  figure  6.1.  The 
plots  illustrate  the  cells  were  first  gated  on  the  PI-  viable  cells  and  then  on  the 
CD34+  population.  The  gates  on  the  HST/Py  plot  are  set  for  sorting  GO 
(HST1OPyIO)  and  cycling  cells  in  G1/S/G2/M.  This  protocol  was  previously  verified 
for  sorting  of  cell  cycle  phases  in  chapter  3  section  3.14. 
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Figure  6-1  Sorting  gates  for  isolation  of  GO  and  dividing  cells. 
The  cells  were  incubated  overnight  In  growth  factor  medium  to  enable 
recovery  from  cryopreservation.  The  following  day  the  cells  were  stained  with 
Pi,  anti-CD34FITC,  HST  and  Py.  The  sorting  gates  were  set  firstly  on  the  viable 
Pl'  cells  (RI),  then  on  the  CD34+  cells  (R2).  Further  gates  were  set  on  the  GO 
(R3)  and  dividing  cells  (R4). Susan  M  Graham,  2005  Chapter  6,142 
To  maintain  consistency  (essential  for  arrays),  all  of  the  samples  were  positively 
selected  using  the  Isolex  method  described  in  section  3.2.1  of  chapter  3.  In  total  5 
CML  samples  and  3  normal  samples  were  sorted  and  processed  for  RNA  as 
described  in  materials  and  methods  section  2.3.4.12.  Unfortunately,  one  of  the 
normal  GO  samples  failed  to  produce  enough  RNA  for  the  microarray  experiment, 
which  meant  that  the  normal  GO  set  had  only  2  samples;  the  corresponding  normal 
divided  cell  sample  was  included. 
6.3  Generation  of  RNA  for  Application  to  Arrays 
The  total  number  of  sorted  cells  together  with  the  amount  of  RNA  obtained  form 
each  sample  is  shown  in  table  6.1.  The  cell  numbers  were  from  the  sorter  counts 
and  in  an  effort  to  conserve  cells  no  further  counting  was  done.  As  shown  in  the 
table,  the  amount  of  RNA  obtained  varied  considerably  from  0.07pg  to  45pg  and 
did  not  appear  to  correlate  well  with  starting  cell  number  although  this  could  be 
due  in  part,  to  the  reduced  accuracy  of  the  sorter  counts.  The  level  of  the  least 
amount  of  RNA  necessitated  that  an  amplification  protocol  be  employed  in  order  to 
generate  data  on  every  sample. 
Sample  Number  of  cells  x106 
Total  amount  of 
RNA  pg 
CML  1  GO  0.4  0.07 
CML  1  Div  11  17 
CML2GO  0.5  0.16 
CML  2  DIV  8  45 
CML  3  GO  0.4  0.38 
CML  3  DIV  11  37 
CML  4  GO  0.05  0.07 
CML  4  DIV  0.5  0.80 
CML5GO  0.4  0.09 
CML  5  DIV  10  10.2 
NORM  1  GO  0.8  0.34 
NORM  1  DIV  6  15 
NORM2GO  1  0.84 
NORM  2  DIV  10  3.3 
NORM  3  DIV  8  14 
Table  6-1  Table  of  sorted  cell  numbers  and  total  RNA. 
Normal  and  CML  cells  were  sorted  to  produce  quiescent  GO  and  cycling 
S/G21M  cell  populations.  The  cells  were  Immediately  placed  Into  Trizol  and 
stored  at  -80°C.  When  all  of  the  samples  had  been  sorted,  RNA  was  extracted 
in  a  single  batch.  The  concentrations  of  RNA  were  measured  at  the  microarray 
facility  using  the  Nanodrop  machine. Susan  M  Graham,  2005  Chapter  6,143 
lt  was  crucial  that  all  of  the  samples  were  treated  similarly,  to  enable  comparison 
of  the  expression  profiles.  Although  the  samples  were  sorted  on  different  days,  the 
RNA  processing  was  done  in  a  single  batch  using  the  same  reagents.  The  RNA 
samples  were  then  handed  over  to  the  Sir  Henry  Wellcome  Functional  Genomics 
(SHWFG)  facility  at  the  University  of  Glasgow,  where  the  remaining  procedures 
were  carried  out.  These  included;  measurement  and  quality  assessment  of  RNA, 
generation  of  cDNA,  amplification  of  RNA,  labelling  of  cRNA,  application  to 
Affymetrix  gene  chips  UI33A,  generation  of  results  and  analysis  of  data.  Analysis 
included  normalization  of  the  data,  production  of  gene  lists  and  clustering  analysis. 
Additional  analysis  of  the  data  was  done  by  myself  using  the  GeneSpring®(Silicon 
Genetics)  program. 
The  Affymetrix  microarray  methodology  was  chosen  as  the  internal  controls  and 
reproducibility  were  robust  and  the  system  had  been  used  in  numerous  previous 
studies.  This  study  used  the  HU-133A  GeneChip  which  contains  22,000  probes 
representing  12,600  well  substantiated  genes.  The  sequences  were  selected  from 
GenBank®,  dbEST,  and  RefSeq  and  sequence  clusters  created  from  UniGene 
database  (build  133,  April  2001)  and  refined  by  comparison  with  other  public 
databases.  It  was  decided  at  this  early  stage  that  only  validated  gene  sequences 
would  be  used  which  incorporated  a  limited  number  of  expressed  sequence  tags 
(EST),  most  of  which  are  contained  in  the  HU-133B  chip.  Affymetrix  GeneChips 
contain  reference  standards  for  both  gene  expression  and  target  intensity,  which 
enable  scaling  and  normalization  of  the  data.  Sets  of  genes  known  to  be 
expressed  in  a  diverse  range  of  human  tissues  are  included  on  the  chip.  This 
technology  allows  data  from  different  experiments  to  be  compared  quantitatively. 
6.4  Production  of  Gene  Lists 
Normalization  of  the  data  and  generation  of  gene  lists  was  done  by  the  SHWFG 
facility  at  the  University  of  Glasgow  where  the  microarray  experiments  were 
carried  out.  Normalization  was  done  using  the  robust  multichip  average  (RMA),  a 
published,  validated  method  of  normalization  specific  to  Affymetrix  GeneChip 
technology  (Irizarry  RA,  Hobbs  B  et  al.  2003). 
Lists  of  differentially  expressed  genes  for  the  desired  comparisons  were  produced 
using  Rank  Products  (RP);  a  recently  published  method  which  sorts  all  genes 
according  to  their  expression  changes  and  provides  statistical  confidence  levels Susan  M  Graham,  2005  Chapter  6,144 
which  are  particularly  applicable  to  small  and  noisy  data  sets  (Breitling  R, 
Armengaud  P  et  al.  2004).  A  more  sophisticated  level  of  analysis  was  done  using 
an  innovative  method  for  identification  of  functional  gene  classes  known  as 
Iterative  Group  Analysis  (iGA).  This  method  generates  a  biological  summary  of  the 
physiological  processes  altered  in  a  particular  experiment  and  provides  powerful 
statistical  confidence  measures  (Breitling  R,  Amtmann  A  et  al.  2004).  These 
results  will  be  discussed  in  detail  later. 
6.5  Analysis  of  Data  Using  GeneSpring® 
Conducted  by  myself,  the  gene  lists  imported  into  the  GeneSpring  (Silicon 
Genetics)  program  were  normalized  data  produced  by  SHWFG  using  RP  as 
detailed  above. 
The  results  were  generated  on  the  basis  of  defined  comparisons.  The  sample 
groups  of  most  interest  were:  1.  CML  GO  versus  CML  dividing,  2.  Normal  GO 
versus  Normal  dividing,  3.  CML  GO  versus  Normal  GO,  4.  CML  dividing  versus 
Normal  dividing.  Lists  of  genes  were  collated  and  ranked  in  order  of  fold  change 
with  an  indication  of  false  discovery  rate  (FDR)  i.  e.  a  conservative  estimate  of  the 
expected  percentage  of  false  positives.  For  practical  purposes  an  arbitrary  cut-off 
of  5%  was  used,  in  the  initial  assessment  of  the  data.  As  this  was  a  relatively  small 
sample  group  the  FDR  was  quite  high  for  many  of  the  genes  in  the  comparisons. 
Comparisons  Regulated  Number  of  Genes 
CML  GO  Vs  CML  DIV  UP  1088 
CML  GO  Vs  CML  DIV  DOWN  614 
Norm  GO  Vs  Norm  DIV  UP  448 
Norm  GO  Vs  Norm  DIV  DOWN  1676 
CML  GO  Vs  Norm  GO  UP  1793 
CML  GO  Vs  Norm  GO  DOWN  208 
CML  DIV  Vs  Norm  DIV  UP  743 
CML  DIV  Vs  Norm  DIV  DOWN  139 
Table  6-2  Table  of  the  number  of  genes  changed  for  each  comparison. 
The  results  represented  in  the  table  are  the  numbers  of  genes  changed  either 
up  or  down,  as  Identified  by  RP  analysis,  for  each  comparison. 
Table  6.2  shows  the  number  of  consistently  differentiated  genes  up-  and  down- 
regulated  for  each  comparison.  This  illustrates  that  hundreds  of  genes  were 
changed  between  the  groups,  which  were  accompanied  by  large  differences  in 
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groups,  which  made  identification  of  the  most  relevant  genes  more  difficult.  As  with 
all  global  expression  arrays  the  analysis  yields  very  large  amounts  of  data  and  to 
facilitate  identification  of  the  most  significant  genes,  clustering  analysis  is  required. 
The  data  was  subsequently  re-analysed  using  the  GeneSpring®  program. 
Normalized  raw  data  from  Affymetrix  gene  chips  was  imported  into  the  program, 
which  allowed  the  data  to  be  manipulated  such  that  genes  could  be  grouped 
according  to  fold  change.  Analysis  of  the  data  using  scatter  plots  generated 
groups  of  genes  with  >3,  >4  and  >5  fold  changes.  Table  6.3  shows  the  number  of 
genes  changed  either  increased  or  decreased,  for  each  comparison. 
Comparison  >3-Fold  >4-Fold  >5-Fold 
CML  GO  Vs  CML  DIV  37  21  10 
Norm  GO  Vs  Norm  DIV  188  92  47 
CML  GO  Vs  Norm  GO  168  85  49 
CML  DIV  Vs  Norm  DIV  49  27  8 
Table  6-3  Table  of  the  numbers  of  changed  genes  with  fold  change. 
The  genes  changed  and  the  level  of  fold  change  was  generated  by  GeneSpring 
analysis  of  RP  lists  imported  into  the  program. 
The  greatest  number  of  genes  changed  >3-fold  (188)  was  in  the  Normal  GO  versus 
Normal  dividing  group  and  the  least  number  >3-fold  changed  (37)  was  in  the  CML 
GO  versus  CML  dividing.  There  was  a  large  number  of  genes  >3-fold  changed 
between  CML  GO  and  Normal  GO  (168)  suggesting  that  the  normal  GO  cells  were 
very  different  in  their  gene  expression,  from  either  their  dividing  counterparts  or 
CML  GO  cells.  Figure  6.2  shows  a  mathematical  model  of  the  relative  distance  in 
terms  of  gene  expression  between  the  samples.  The  Euclidean  distance  diagram 
represents  the  data  (>3-fold  change)  plotted  on  a  relative  scale.  Euclidean 
distance  is  plotted  using  the  formula:  distance  (x,  y)  =  sqrt(  SUM(xi  -  yi)2  )%Z 
(where  the  sum  is  over  all  points  i),  which  calculates  the  geometric  distance  in  the 
multidimensional  space.  It  gives  an  indication  of  how  close  the  groups  are  in  terms 
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Figure  6-2  Euclidean  distance  diagram  of  gene  differences  >3-fold  changed. 
The  model  was  created  using  the  genes  >3-fold  changed,  up  or  down,  between 
the  groups  to  give  an  Indication  of  how  close  each  group  was  In  gene 
expression.  The  height  scale  is  arbitrary  and  Indicates  the  relative  distance 
between  the  groups. 
The  diagram  in  figure  6.2  shows  that  CML  and  normal  dividing  cells  are  closest  in 
gene  expression  and  that  normal  GO  cells  show  the  least  homogeneity  with  the 
other  sample  groups,  since  they  are  separated  by  the  greatest  distance.  The 
diagram  also  illustrates  that  CML  GO  cells  are  closer  in  gene  expression  to  normal 
and  CML  dividing  cells  than  to  Normal  GO  cells. 
6.6  Analysis  of  Gene  Expression  in  Normal  GO  Versus 
Normal  Dividing  Cells 
One  of  the  particular  areas  of  interest  in  terms  of  gene  expression  was  the 
difference  between  Normal  GO  and  Normal  dividing  cells.  The  gene  expression  of 
such  specific  populations  of  normal  stem  cells  has  not  been  previously 
investigated.  It  has  been  shown  that  most  mobilised  primitive  stem  cells  are  out  of 
cycle  i.  e.  in  GO,  and  it  was  anticipated  that  this  data  set  would  shed  some  light  on 
the  gene  expression  profile  of  quiescent  stem  cells  compared  to  cycling  cells 
(Uchida  N,  He  D  et  al.  1997). 
Given  that  the  cells  were  sorted  on  the  basis  of  cell  cycle  position,  the  change  in 
expression  of  cell  cycle  genes  was  examined.  Table  6.4  shows  a  list  of  cell  cycle 
genes  and  their  fold  change  between  Normal  GO  and  Normal  dividing  cells.  The Susan  M  Graham,  2005  Chapter  6,147 
list  shows  significant  up-regulation  of  many  cell  cycle  associated  genes  in  dividing 
cells,  which  would  be  expected  if  the  cells  were  accurately  sorted  into  their  cell 
cycle  compartments.  This  was  a  further  confirmation  of  the  success  of  the  sorting 
strategy  using  HST  and  Py  for  identification  of  cell  cycle  position.  In  addition,  the 
dividing  cells  also  showed  up  regulation  of  genes  associated  with  transcription  and 
translation,  which  would  be  anticipated  in  cells  exhibiting  greater  cellular  activity. 
Gene  Fold  up-regulation 
CDC2  8 
CDC20  6 
CCNB2  5 
CCN1  3.5 
CDC25  3.5 
MCM2  4 
MCM5  3 
CHEKI  4 
CDC6  5 
CDKN3  4 
Table  6-4  Table  of  cell  cycle  genes  up-regulated  in  normal  cycling  cells. 
The  table  shows  a  selection  of  gene  up-regulated  in  normal  dividing  versus 
quiescent  cells.  An  indication  of  the  fold  change  for  each  gene  is  also  shown. 
Curiously,  the  greatest  fold  change  in  Normal  GO  versus  Normal  dividing  cells  was 
seen  in  a  set  of  chemokine  genes,  specifically  the  ligands,  not  the  receptors,  which 
were  between  5  and  10  fold  up-regulated  in  the  quiescent  cells.  The  significance 
of  this  observation  is  not  immediately  obvious  and  no  other  published  work  on 
haematopoietic  stem  cells  has  suggested  a  role  for  these  chemokines  in 
maintenance  of  quiescence.  These  data  will  be  discussed  in  more  detail  later. 
6.7  Analysis  of  Gene  Expression  in  CML  GO  Versus  CML 
Dividing  Cells 
As  the  analysis  of  cell  cycle  genes  in  normal  cells  had  shown  good  differential 
expression  between  GO  and  dividing  cells  it  was  anticipated  that  the  same  would 
hold  true  for  the  CML  cells,  since  these  had  been  sorted  in  the  same  way. 
However,  similar  differences  in  cell  cycle  associated  gene  expression  were  not 
observed  in  the  CML  samples.  There  appeared  to  be  significant  up-regulation  of 
cell  cycle  genes  in  the  CML  sorted  quiescent  cells  compared  to  normal  GO,  such 
that  these  more  closely  resembled  dividing  cells.  One  possible  explanation  may  be 
that  the  sorted  population  of  cells  was  heterogeneous  and  contained  cycling  cells Susan  M  Graham,  2005  Chapter  6,148 
in  the  quiescent  fraction.  However,  on  the  basis  of  the  normal  data,  the  sorting 
strategy  would  appear  to  be  robust.  Another  potential  explanation  could  be  that  the 
CML  cells  were  more  efficient  in  dye  efflux  by  ABCG2  transporters,  known  to  efflux 
Hoechst.  This  would  place  some  cells  in  the  GO  gate  when  in  fact  they  were 
cycling  cells.  Increased  expression  of  the  ABCG2  transporter  in  stem  cells  has 
been  identified  in  primitive  haemopoietic  cells,  specifically  in  side  population  (SP) 
cells  (Scharenberg  CW,  Harkey  MA  et  al.  2002).  ABCG2  is  responsible  for 
Hoechst  efflux,  which  places  the  SP  cells  in  a  particular  position  on  a  FAGS  plot 
where  dual  fluorescence  of  Hoechst  is  analysed.  However,  the  data  generated  in 
this  microarray  experiment  does  not  show  significant  up  regulation  of  ABCG2  in 
the  CML  GO  versus  CML  dividing  cells  or  indeed  between  the  CML  and  normal 
cells.  If  expression  of  ABC  transporter  genes  in  CML  cells  were  a  factor  in 
determining  their  position  on  the  Hoechst  and  Pyronin  FAGS  plot,  it  would  be 
expected  to  show  some  differential  expression  between  CML  and  Normal  cells. 
However,  it  was  possible  that  the  set  level  of  3  fold  differential  expression  was  too 
high  to  detect  changes  in  ABCG2  transporter  activity.  The  only  way  to  exclude  the 
possibility  of  the  influence  of  ABCG2  would  be  to  sort  the  cells  using  a  different 
FAGS  staining  strategy  and  examine  the  expression  of  cell  cycle  genes.  The  fact 
remains  that  quiescent  CML  stem  cells  behave  differently  from  CML  cycling  cells 
as  demonstrated  in  chapter  5,  where  these  cells  were  shown  to  survive  exposure 
to  STI.  Such  distinct  differences  in  cell  behaviour  would  not  be  expected  if  the  cell 
cycle  position  identified  as  GO  was  an  artefact  of  the  staining  and  sorting  strategy. 
Although  expression  of  cell  cycle  genes  in  the  GO  CML  cells  has  cast  some  doubt 
on  the  integrity  of  the  sorting  procedure,  a  similar  up-regulation  of  the  same  group 
of  chemokine  genes  observed  in  the  Normal  GO  cells  was  also  observed  for  the 
CML  GO  cells.  This  would  suggest  that  these  populations  of  cells  share  at  least 
some  similar  characteristics.  Figure  6.3  shows  a  Venn  diagram  of  the  comparisons 
of  Normal  GO  versus  Normal  dividing  and  CML  GO  versus  CML  dividing  cells. Susan  M  Graham,  2005 
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Figure  6-3  Venn  diagrams  of  differential  gene  expression  between  all  comparisons. 
The  Venn  diagrams  were  created  in  GeneSpring  by  selecting  all  genes  >3-,  >4- 
and  >5-fold,  changed  between  the  groups  as  illustrated.  Genes  common  to 
both  groups  for  >4-fold  and  >5-fold  are  shown  in  the  boxes. 
Figure  6.3  illustrates  that  of  genes  showing  >3-fold  change,  188  genes  were 
differentially  expressed  in  Normal GO  versus  Normal dividing  cells,  37  genes  were 
expressed  in  CML  GO  versus  CML  dividing  and  that  19  genes  were  commonly 
expressed  in  both  Normal  and  CML  GO  versus  dividing  cells.  When  the  level  of 
change  is  set  at  >4-fold,  9  genes  were  common  to  both  groups.  Significantly,  7  of 
the  9  genes  encode  chemokines.  If  a  similar  comparison  is  done  with  the  fold 
change  set  at  >5,  as  shown  in  figure  6.4,47  genes  were  changed  in  Normal  GO 
versus  dividing,  10  genes  were  changed  in  CML  GO  versus  dividing,  and  4  genes 
were  common  to  both  comparisons.  The  4  common  genes,  >5-fold  up-regulated  in 
the  GO  cells  were  all  chemokine  genes,  and  this  was  a  surprising  finding.  The 
particular  chemokines  identified  have  not  been  previously  associated  with  stem 
cell  quiescence.  This  may  be  an  important  observation,  as  the  level  of  up 
regulation  (5-10-fold)  in  quiescent  cells,  is  significant  compared  to  cycling  cells. 
Also,  although  genes  encoding  the  ligands  were  up  regulated,  there  was  no  up- 
regulation  of  the  corresponding  receptors  as  shown  in  table  6.5,  suggesting  that 
this  was  not  an  autocrine  mechanism.  The  involvement  of  these  particular 
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chemokines  in  quiescent  stem  cells  has  not  been  documented  and  as  such 
represents  a  novel  observation,  which  merits  further  investigation. 
Receptor  Present  Comments 
CXCR1  +  Norm  vs  CML 
CXCR2  - 
CXCR3  + 
CXCR4  +  3-fold  in  Norm  GO 
CXCR5  - 
CCR1  - 
CCR2A  - 
CCR4  + 
CCR5  + 
CCR6  - 
CCR7  - 
CCR8  - 
CCR10  - 
CCRL1  +  lNorm  vs  CML 
Table  6-5  Table  of  gene  expression  of  chemokine  receptors. 
The  table  shows  the  presence  or  not  of  signals  on  the  arrays  for  chemokine 
receptor  genes.  The  levels  of  expression  between  the  groups  were  similar 
unless  otherwise  indicated. 
6.8  Iterative  group  analysis  (iGA)  to  Identify  Functional 
Gene  Classes  for  Each  Comparison 
Iterative  group  analysis  (iGA)  is  based  on  the  premise  that  combined  expression 
change  of  some  or  all  members  of  a  functional  group  is  physiologically  relevant. 
iGA  uses  statistics  to  identify  functional  gene  classes  that  are  significantly 
changed  in  an  experiment,  and  at  the  same  time  determines  which  of  the  class 
members  are  most  likely  to  be  differentially  expressed.  iGA  does  not  depend  on 
fixed  lists  of  differentially  changed  genes  but  instead  uses  an  iterative  procedure  to 
determine  the  optimal  threshold  for  each  functional  class.  By  concentrating  on 
gene  groups  rather  than  single  genes  it  is  feasible  to  establish  statistical 
significance  even  in  the  absence  of  experimental  replication,  as  the  group 
members  serve  as  internal  replicates.  This  is  a  powerful  tool  that  enhances  the 
sensitivity  of  gene  detection  especially  in  small  data  sets  such  as  this  one.  A 
further  advantage  of  this  technique  for  the  analysis  of  microarray  experiments  is 
that  it  allows  comparison  of  data  from  different  platforms  or  analytical  techniques 
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Using  the  iGA  method,  the  data  from  these  experiments  was  further  analysed  to 
identify  clusters  of  significantly  changed  genes.  The  list  of  genes  and  their 
functional  class  assignments  is  contained  in  Appendix  1.  These  results  also 
identify  the  greatest  changes  in  gene  expression  as  being  between  the  Normal  GO 
cells  and  their  dividing  counterparts,  with  some  20  gene  groups  significantly 
changed.  Interestingly,  most  of  the  changed  groups  in  the  dividing  cell  up- 
regulated  cohort  are  related  to  cell  cycle.  The  differential  expression  of  cell  cycle 
genes  strongly  suggests  that  the  sorting  strategy  has  indeed  isolated  quiescent, 
GO  cells  from  cycling  ones. 
Analysis  of  up-regulated  genes  in  the  Normal  GO  samples  shows  significant 
expression  of  chemokine  genes  identifying  not  only  the  ones  found  in  the 
GeneSpring  analysis,  but  a  further  5  genes  in  this  functional  class.  In  addition,  the 
gene  groups  are  ranked  in  order  of  significance  with  chemokine  genes  at  the  top 
of  the  list.  This  analysis  corroborates  the  GeneSpring  data,  and  increases  the 
significance  of  this  observation.  The  relevance  of  this  finding  will  be  studied  in 
further  experiments,  as  no  previously  published  work  has  established  a  role  for 
these  chemokines  in  stem  cell  quiescence. 
In  the  CML  GO  versus  cycling  cells,  the  consistent  up  regulation  of  genes 
associated  with  initiation  of  cell  cycle  observed  in  the  normal  samples,  was  not 
detected  in  this  clustering  analysis.  However,  there  was  significant  up  regulation  of 
genes  associated  with  the  mitotic  phase  of  the  cell  cycle  and  of  those  associated 
with  spindle  formation  and  chromosome  assembly.  This  suggests  that  there  were 
considerable  differences  in  gene  expression  between  the  two  CML  cell 
populations.  However,  it  would  appear  that  cells  identified  as  quiescent  CML  cells 
are  not  truly  quiescent  in  the  same  way  as  normal  cells  are.  The  GO  CML  cells 
appear  to  have  little  differential  expression  of  genes  associated  with  early  cell 
cycle  events,  but  have  increased  expression  of  genes  involved  in  the  later  mitotic 
phase.  This  would  support  the  findings  documented  in  chapter  3  of  this  thesis, 
which  identified  a  significant  increase  in  the  proportion  of  cells  in  the  S/G2/M 
phase  of  the  cell  cycle,  for  CML  samples  compared  to  normal.  The  CML  GO  cells 
were  clearly  very  different  from  normal  GO  cells;  however,  the  same  up-regulation 
of  chemokine  genes  was  observed  in  the  CML  quiescent  cells  as  in  the  normal 
ones,  albeit  at  a  slightly  lower  level.  It  is  possible  that  the  genes  associated  with 
expression  of  chemokines  are  a  quiescent  stem  cell  feature  and  the  aberrant  cell 
cycle  gene  expression  is  a  consequence  of  malignancy. Susan  M  Graham,  2005 
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In  conclusion,  the  microarray  study  has  confirmed  that  for  normal  cells,  significant 
up-regulation  of  cell  cycle  genes  was  observed  in  sorted  cycling  compared  to 
quiescent  cells.  For  CML  samples  this  differential  cell  cycle  gene  expression  was 
not  observed,  suggesting  that  quiescent  CML  cells  display  altered  expression  of 
some  cell  cycle  associated  genes.  Gene  expression  profiling  also  identified  an 
unexpected  cohort  of  chemokine  genes  5-10-fold  up-regulated  in  quiescent  stem 
cells  from  both  normal  and  CML  samples. 153 
Chapter  7  Discussion 
7.1  Introduction 
The  aim  of  the  work  presented  in  this  thesis  was  to  isolate  and  characterise 
quiescent  haemopoietic  stem  cells  (HSC)  from  CML  and  normal  patients.  These 
isolated  stem  cell  populations  were  used  to  determine  if  cell  cycle  position  affected 
their  sensitivity  to  a  specifically  targeted  treatment,  STI.  These  cell  populations 
were  further  utilised  in  a  microarray  study  in  an  effort  to  identify  genotypic 
differences  between  quiescent  and  cycling  stem  cells,  and  between  normal  and 
CML  stem  cells. 
7.2  Identification  and  Isolation  of  Stem  Cells  in  Different 
Phases  of  the  Cell  Cycle 
HSC  comprise  a  very  small  proportion  of  the  circulating  progenitors,  typically 
around  0.1%  in  normal  individuals.  Although  there  are  no  definitive  markers  for 
human  stem  cells,  CD34  is  the  most  commonly  used.  This  sialomucin  molecule  is 
expressed  on  the  surface  of  cells  capable  of  rescuing  a  myeloablated  host,  and 
therefore  possessing  the  capacity  to  generate  every  cell  of  the  haemopoietic 
system.  In  practice,  stem  cell  populations  enriched  by  selection  with  this  marker, 
have  been  used  clinically  for  transplantation  for  a  number  of  years.  All  samples  in 
this  study  were  enriched  for  CD34+  cells  by  either  positive  or  negative  selection, 
prior  to  sorting  by  flow  cytometry.  The  different  CD34  selection  methods  generate 
subtly  different  populations  of  stem  cells.  Positive  selection  separates  cells  bearing 
the  CD34  antigen  from  the  whole  population.  Negative  selection  uses  a  cocktail  of 
antibodies  to  a  variety  of  lineage  markers,  which  allows  removal  of  these  cells 
leaving  the  immature  CD34+  cells,  which  express  no  lineage  markers.  Generally 
the  percentage  of  CD34+  cells  is lower  for  the  negative  selection.  If  CD34'Lin"  cells 
(possibly  more  immature  than  CD34+Lin)  are  present  in  the  population,  they  will 
be  retained  by  a  negative selection  but  lost  in  a  positive  selection.  However,  all  of 
the  FACS  sorting  experiments  described  in  this  thesis  included  gating  on  the 
CD34+  population,  which  in  effect  excludes  any  CD34"Lin  cells. 
Stem  cells  are  generally  accepted  to  be  predominantly  quiescent  and  enter  cell 
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potentially  damaging  influences,  and  reduces  the  incidence  of  genetic  mutation 
associated  with  DNA  replication.  It  is  possible  that  quiescence  is  a  factor  in  the 
maintenance  of  malignant  stem  cell  disease  and  the  experiments  described  in  this 
thesis  were  aimed  at  addressing  the  importance  of  a  quiescent  phenotype  in 
leukaemic  survival  following  cytotoxic  therapy,  and  the  possible  implications  for 
disease  persistence. 
Previous  work  by  Holyoake  et  at  had  demonstrated  that  a  quiescent  stem  cell 
population  existed  in  CP  CML  and  that  these  cells  could  be  isolated  by  FACS 
sorting  (Holyoake  T,  Jiang  X  et  at.  1999).  Intracellular  staining  of  DNA  by  Hoechst 
(HST)  and  RNA  by  Pyronin  Y  (Py)  is  the  most  commonly  used  method  of  isolating 
viable  cells  in  different  phases  of  the  cell  cycle.  Most  other  dyes  used  in  flow 
cytometry  for  discrimination  of  cell  cycle  phases  (e.  g.  propidium  iodide)  are  not 
able  to  distinguish  the  GO  and  G1  phases.  In  addition,  most  stains  require  the  cells 
to  be  fixed  and  therefore  non  viable.  Furthermore,  HST  and  Py  can  be  combined 
with  additional  stains,  as  described  below,  which  allow  more  specific  cell 
populations  to  be  isolated. 
Using  the  HST  and  Py  staining  method,  GO  and  dividing  populations  were 
identified  (shown  in  figure  3.6).  In  addition,  setting  gates  around  the  viable  (PI) 
CD34''  cells  allowed  GO  and  cycling  stem  cells  to  be  sorted  separately  (figure  3.7). 
Success  of  the  sorting  strategy  was  confirmed  by  PCR  analysis  of  the  CML  sorted 
cells  showing  the  presence  of  PCNA  (synthesised  in  S-phase)  in  the  cycling  cells, 
which  was  absent  in  the  GO  and  G1  cells.  Interestingly,  another  cell  cycle 
associated  gene  MCM5,  which  is  synthesised  when  cells  enter  G1,  was  also 
observed  in  the  GO  cells.  However,  other  studies  have  documented  aberrant 
expression  of  MCM5  in  malignant  cells  of  the  oesophagus,  which  may  be  related 
to  disruption  in  cell  cycle  control  in  cancer  cells  (Going  JJ,  Keith  WN  et  al.  2002). 
Unfortunately,  due  to  limitations  in  the  availability  of  material,  it  was  not  possible  to 
repeat  the  PCR  confirmation  experiments  with  a  normal  sample.  These  preliminary 
results  showed  we  could  successfully  isolate  viable,  quiescent  and  cycling,  stem 
cell  populations. 
One  of  the  first  observations  following  HST  and  Py  staining,  was  that  the 
proportion  of  cells  in  GO  was  lower  in  the  CML  samples.  There  was  also  a 
significant  difference  in  the  proportion  of  cells  in  G1,70.9%  in  normal  compared  to 
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samples  compared  to  normal,  suggesting  that  there  were  fewer  quiescent  stem 
cells  in  CIVIL  Given  that  all  cells  were  stained  following  24hrs  in  culture  after 
recovery  from  cryopreservation,  it  would  appear  that  the  CIVIL  cells  displayed  an 
increased  cell  cycle  activation,  with  fewer  cells  in  GO/GI  than  in  the  normal 
samples.  Kramer  et  al  have  made  similar  observations  for  CD34"  cells  in  both  BM 
and  PB  from  newly  diagnosed  CIVIL  patients.  They  noted  the  proportion  of  cycling 
progenitor  cells  was  higher  in  CIVIL  PB  and  BM  compared  to  matched  samples 
from  BCR-ABL'  myeloproliferative  disease,  and  concluded  that  BCR-ABL'  CD34+ 
cells  display  an  increased  cell  cycle  activation  (Kramer  A,  Loffler  H  et  al.  2001). 
Although  the  results  presented  here,  and  those  of  Kramer  et  al,  indicate  that  a 
greater  proportion  of  the  CIVIL  cells  are  in  the  S/G2/M  phase  of  the  cell  cycle,  it 
does  not  imply  that  these  cells  are  cycling  more  rapidly.  Rather  it  suggests  CIVIL 
cells  are  more  likely  to  enter  cell  division,  but  does  not  give  information  on  the  time 
taken  to  complete  the  cell  cycle.  Furthermore,  data  on  the  division  history  of  CIVIL 
and  normal  stem  cells  detailed  in  chapter  4,  indicates  that  both  populations 
undergo  a  similar  number  of  divisions  following  3  days  in  culture  with  growth 
factors,  after  the  same  initial  24  hours  recovery  from  cyropreservation.  Moreover, 
Buckle  et  al  have  also  demonstrated  that  CIVIL  stem  cells  do  not  exhibit  increased 
cell  cycling  compared  to  normal  stem  cells  (Buckle  AM,  Mottram  R  et  al.  2000) 
These  observations  suggest  similar  cell  cycle  kinetics  for  CIVIL  and  normal  CD34+ 
stem  cells,  at  least  in  vitro. 
7.3  Comparison  of  Division  History  and  Stem  Cell  Status 
in  Normal  and  CML  Cells 
The  experiments  described  in  chapter  4  investigated  some  of  the  characteristics  of 
CML  stem  cells  compared  to  normal  stem  cells  in  vitro.  Culturing  cells  in  the 
absence  of  exogenous  growth  factors  identified  distinct  differences  between 
normal  and  CML  stem  cells.  To  gain  some  understanding  of  the  behaviour  of  stem 
cells  under  varying  conditions,  a  method  of  tracking  cell  division  and  'stem  cell 
status  was  devised.  By  staining  cells  with  a  permanent,  non-toxic  cytoplasmic  dye 
(CFSE)  and  developing  a  sorting  strategy  to  enhance  the  resolution  of  cell  division 
peaks,  it  was  possible  to  precisely  track  the  pattern  of  cell  division.  In  addition,  it 
was  possible  to  calculate  with  some  accuracy,  stem  cell  amplifications  together 
with  the  proportions  of  cells  recovered  in  each  peak  of  division  relative  to  the 
number  of  input  cells.  When  sorted  CD34+  cells  were  cultured  in  the  presence  and Susan  M  Graham,  2005  Chapter  7,156 
absence  of  a5  growth  factor  cocktail  containing  IL-3,  IL-6,  SCF,  GCSF  and  FIt3L, 
there  were  distinct  differences  between  normal  and  CML  cells.  In  the  presence  of 
growth  factors,  both  normal  and  CML  cells  have  undergone  up  to  5  divisions  in  3 
days.  However,  in  the  absence  of  growth  factors,  normal  cells  were  unable  to 
divide  and  only  a  very  small  proportion  remained  viable  and  undivided.  It  is 
possible  that  these  cells  represent  a  deeply  quiescent  population  resistant  to  the 
detrimental  effects  of  growth  factor  starvation,  or  that  they  are  early  apoptotic  cells 
still  able  to  exclude  Pl.  Unfortunately,  it  was  not  possible  using  this  FACS  staining 
strategy  to  confirm  either  status. 
In  contrast,  in  the  absence  of  growth  factors,  CML  cells  were  able  to  divide  up  to  3 
times,  demonstrating  their  growth  factor  independence.  This  is  in  accordance  with 
other  published  data,  which  was  recently  convincingly  substantiated  when  CD34' 
normal  cord  blood  (CB)  cells  infected  with  retrovirus  encoding  p210BCR-ABL, 
displayed  a  growth  factor  independent  phenotype  (Chalandon  Y,  Jiang  X  et  al. 
2004).  The  mechanism  of  growth  factor  independence  in  CML  cells  is  not  clearly 
defined.  It  has  previously  been  shown  that  in  primitive  CML  cells  growth  factor 
autonomous  proliferation  was  associated  with  autocrine  production  of  IL-3  and 
GCSF  (Jiang  X,  Lopez  A  et  al.  1999).  In  other  studies,  we  have  further 
demonstrated  that  whereas  quiescent  CML  CD34+  cells  have  no  detectable  IL-3 
transcripts,  following  culture  in  the  absence  of  growth  factors  these  cells 
spontaneously  up  regulate  IL-3  expression  as  they  enter  cell  cycle  (Holyoake  T, 
Jiang  X  et  al.  2001).  Further  experiments  by  Jiang  et  al  demonstrated  the  rapid 
acquisition  of  autocrine  IL-3  production  by  BCR-ABL  transduced  primitive  murine 
BM  cells,  which  was  associated  with  immediate  growth  factor  independence  (Jiang 
X,  Ng  E  et  at.  2002).  Chalandon  et  al  also  found  that  in  p210BCRABL  retrovirally 
transduced  cells,  growth  factor  independent  proliferation  was  associated  with 
autocrine  production,  not  only  of  IL-3,  but  also  of  GCSF  and  erythropoietin.  This 
evidence  strongly  suggests  that  bcr-abI  confers  a  growth  factor  independent 
phenotype  in  association  with  autocrine  growth  factor  production.  Furthermore, 
proliferation  in  the  absence  of  growth  factors  can  be  considered  selective  for  Ph+ 
cells,  as  normal  cells  fail  to  divide  under  these  conditions. 
Experimental  analysis  of  CD34  status  together  with  cell  division  showed  CML  cells 
preferentially  maintained  expression  of  CD34  following  growth  factor  withdrawal.  In 
the  presence  of  added  growth  factors  the  percentage  of  CD34'  cells  declined  with 
division,  however,  in  the  absence  of  growth  factors,  the  cells  retained  significant Susan  M  Graham,  2005  Chapter  7,157 
levels  of  CD34  expression.  This  suggests  that  in  the  absence  of  exogenous 
growth  factors,  the  cells  that  are  able  to  survive  and  divide  are  the  most  primitive 
i.  e.  expressing  the  CD34  stem  cell  marker,  and  that  they  maintain  this  status  with 
division. 
Interestingly,  both  in  the  presence  and  absence  of  growth  factors,  a  small  number 
of  undivided  cells  were  observed  in  all  CML  samples,  which  displayed  a  high  level 
of  CD34  expression.  It  remained  a  possibility  that  these  cells  represented  a  small 
number  of  primitive  normal  cells,  analogous  to  the  in  vivo  population  known  to 
coexist  alongside  Ph"'  cells.  Sorting  divided  and  undivided  populations  allowed 
FISH  analysis,  which  showed  that  all  of  the  undivided  cells  were  in  fact  BCR-ABL;, 
confirming  their  leukaemic  status.  This  data  verified  that,  even  when  exposed  to  a 
potent  growth  factor  cocktail,  a  number  of  CML  stem  cells  remained  undivided. 
This  methodology  does  not  allow  assessment  of  cell  cycle  status,  only  division 
history.  It  is  likely  that  the  undivided  cells  were  indeed  quiescent,  having  failed  to 
enter  cell  division  after  3  days  in  the  presence  of  growth  factors,  however  it  was 
not  possible  to  confirm  this  using  this  experimental  strategy. 
7.4  The  Effect  of  STI571  on  Cell  Division  in  Normal  and 
CML  Stem  Cells 
The  central  role  of  bcr-abl  in  leukaemic  transformation  presented  an  attractive 
target  for  drug  therapy.  A  small  molecule  inhibitor,  STI,  was  found  to  inhibit  the 
constitutive  tyrosine  kinase  activity  of  bcr-abl+  cells  both  in  vitro  and  in  vivo. 
However,  in  vitro  studies  with  STI  had  revealed  that  some  Ph+  cells  were  able  to 
survive  exposure  to  the  drug  (Deininger  MW,  Goldman  JM  et  al.  1997).  Clinical 
observations  suggest  that  all  BCR-ABL+  cells  are  not  eliminated  by  STI  treatment, 
and  the  potential  for  relapse  exists  in  the  majority  of  treated  patients.  One  of  the 
mechanisms  of  resistance  to  STI  is  the  development  of  mutations  in  the  kinase 
domain  of  bcr-abl,  which  inhibit  STI  binding  and  can  be  detected  prior  to  treatment. 
It  is  possible  that  this  could  explain  the  differences  in  sensitivities  to  STI 
documented  in  the  work  presented  in  chapter  5  of  this  thesis,  however  only 
mutation  analysis  could  confirm  this. 
There  are  other  proposed  mechanisms  to  explain  the  resistance  of  CML  cells  to 
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transporter,  Pgp,  can  reduce  intracellular  concentrations  of  STI,  leading  to  less 
effective  inhibition  of  the  tyrosine  kinase  activity  (Illmer  T,  Schaich  M  et  al.  2004). 
Mahon  et  at  have  also  demonstrated  that  Pgp  activity  may  be  responsible  for 
resistance  to  STI  in  cell  lines,  however  it  has  not  been  conclusively  established  if 
overexpression  of  this  transporter  is  a  clinical  feature  of  CML  disease  (Mahon  FX, 
Belloc  F  et  al.  2003).  Conversely,  others  have  shown  that  overexpression  of  Pgp, 
at  least  in  BCR-ABL'  cell  lines,  does  not  confer  resistance  to  STI  in  vitro  (Ferrao 
PT,  Frost  MJ  et  al.  2003).  The  evidence  so  far  has  not  confirmed  if  drug  efflux  is  a 
significant  factor  in  STI  resistance. 
Gene  amplification  and  overexpression  of  BCR-ABL  have  also  been  described  in 
STI  resistant  cells,  and  it  is  generally  accepted  that  reactivation  of  the  bcr-abl 
tyrosine  kinase  is  required  to  induce  a  malignant  phenotype.  However  these 
mechanisms  remain  controversial  in  the  clinical  setting.  Although  gene 
amplification  has  been  described  in  some  patients,  whether  this  results  in 
increased  bcr-abl  protein  has  not  been  established  (Gorre  ME,  Mohammed  M  et 
al.  2001). 
It  was  possible  that  a  quiescent  phenotype  could  allow  stem  cells  to  escape  the 
effects  of  cytotoxic  therapy.  In  an  effort  to  identify  which  CML  cells  (if  any)  could 
survive  exposure  to  STI,  the  previous  experimental  strategy  to  identify  division 
history  and  stem  cell  status  was  utilised.  CML  and  normal  CD34'  cells  were 
stained  with  CFSE  and  cultured  in  the  presence  or  absence  of  STI,  with  a 
relatively  short  time  frame  (3days)  to  exclude  the  possibility  of  outgrowth  of 
resistant  mutant  clones.  Cultures  of  CML  cells  in  the  absence  of  growth  factors 
were  included  in  an  effort  to  focus  on  leukaemic  cell  proliferation  without  the 
potential  contribution  of  normal  cells,  unable  to  divide  under  these  conditions. 
Preliminary  experiments  were  aimed  at  establishing  a  test  concentration  of  STI  in 
excess  of  clinical  doses,  to  determine  if  any  CML  cells  were  able  to  survive  at 
greater  than  clinically  achievable  doses.  Pharmacokinetic  studies  demonstrated 
that  at  the  prescribed  dose  of  300mg/day,  a  peak  plasma  concentration  of  I  pM 
was  achieved  in  the  patient.  IOpM  STI  was  selected  for  all  subsequent  studies  as 
this  represented  10x  the  clinically  achievable  dose  at  the  time  of  the  experiments. 
More  recently,  in  vivo  doses  have  been  escalated  to  600-800mg/day,  giving  peak 
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The  experiments  described  in  chapter  5  demonstrated  that  some  CML  stem  cells 
could  survive  when  cultured  in  the  presence  of  10pM  STI,  which  had  little  effect  on 
normal  stem  cell  proliferation  in  this  system.  Effects  of  higher  concentrations  of 
STI  (>lOpM)  on  normal  cells  have  been  observed,  possibly  due  to  inhibition  of  c- 
kit  or  other  tyrosine  kinases.  Holtz  et  al  have  documented  that  whereas  some 
effect  of  STI  on  normal  CFC  is  observed  at  5pM,  it  does  not  affect  more  primitive 
LTC-IC  (Holtz  MS,  Slovak  ML  et  al.  2002).  It  is  worth  mentioning  that  many  of  the 
early  investigations  into  the  effectiveness  of  STI  as  an  agent  that  inhibited  the 
proliferation  of  Ph*  cells  examined  its  effects  on  very  heterogeneous  cell 
populations  or  in  cell  lines.  Work  in  this  thesis  focused  specifically  on  the  stem  cell 
fraction,  and  the  importance  of  this  defined  population  will  become  evident  as  this 
discussion  develops. 
Tracking  the  pattern  of  cell  division  by  staining  and  sorting  stem  cell  populations 
+/-  STI  revealed  that  in  all  CML  samples,  a  population  of  undivided  cells  was  able 
to  survive  exposure  to  STI  at  greater  than  clinically  achievable  doses.  It  was  also 
evident  that  a  range  of  sensitivities  to  STI  existed  among  CML  patients.  In  a 
particularly  sensitive  example  all  of  the  dividing  cells,  +/-  growth  factors  were  killed 
by  STI.  In  less  sensitive  patients  a  number  of  cells  were  able  to  divide  +/-growth 
factors  and  also  in  the  presence  of  10pM  STI.  A  possible  explanation  for  this 
heterologous  response  of  patient  cells  may  be  that  some  patients  harbour  a  small 
number  of  cells  with  a  mutation,  which  renders  them  insensitive  to  STI  treatment. 
Such  mutations  in  either  the  ATP  binding  pocket  or  in  other  parts  of  the  protein 
that  confer  conformational  changes  have  been  documented  in  cases  of  resistance. 
There  is  now  evidence  that  these  mutations  exist  in  a  small  number  of  cells  even 
before  treatment,  and  that  elimination  of  the  STI-sensitive  cells  reveals  their 
presence  (Roche-Lestienne  C,  Lai  JL  et  al.  2003).  More  recent  evidence  suggests 
that  kinase  domain  mutations  exist  in  around  22%  of  STI-naive  CML  patients. 
However,  their  existence  does  not  correlate  directly  with  resistance  to  STI  therapy. 
The  authors  concluded  that  additional  factors  were  required  to  induce  a  fully 
resistant  phenotype  (Willis  S,  Lange  T  et  al.  2005). 
These  data  support  the  theory  that  innate  or  acquired  resistance  to  STI  is  not  the 
only  explanation  for  disease  persistence.  Indeed,  data  presented  in  chapter  5  of 
this  work  offers  an  alternative  explanation  for  the  minimal  residual  disease 
observed  in  STI  treated  patients,  namely,  that  it  is  the  quiescent  cells  that  are  able 
to  evade  therapy.  In  support  of  this,  it  has  recently  been  demonstrated  that  non- Susan  M  Graham,  2005  Chapter  7,160 
proliferating  CD34`  BCR-ABL+  cells  are  resistant  to  the  effects  of  apoptosis 
inducing  stimuli  including  STI,  and  that  only  dividing  cells  display  sensitivity  to  the 
effects  of  these  agents  (Holtz  MS,  Forman  SJ  et  al.  2005).  If  quiescent  cells  can 
re-enter  cell  cycle  then  the  potential  for  relapse  exists  and  represents  a  genuine 
clinical  problem.  It  is  still  too  early  to  assess  whether  the  remissions  due  to  STI 
therapy  will  be  durable.  Evidence  from  patients  who  had  to  stop  the  drug  due  to 
complications,  suggests  that  relapse  from  disease  reactivation  is  a  distinct 
possibility. 
Observations  in  the  experiments  described  in  this  thesis  may  have  implications  in 
the  therapeutic  context.  If  quiescence  or  a  non-dividing  state  allows  cells  to 
escape  the  effects  of  STI,  then  any  treatment  that  induces  quiescence  has  the 
potential  to  perpetuate  disease.  In  the  experiments  described  in  chapter  5, 
analysis  of  the  most  STI-sensitive  example  revealed  an  increased  recovery  of  cells 
in  the  undivided  peak  as  a  proportion  of  the  input  number,  demonstrating  that  STI 
was  exerting  an  anti-proliferative  effect.  A  similar  observation  was  made  by  Holtz 
et  al.  Using  a  similar  FACS  sorting  strategy,  they  also  found  that  exposure  to  5pM 
STI  increased  the  proportion  (relative  to  the  input  number)  of  primitive  undivided 
cells  (Holtz  MS,  Slovak  ML  et  al.  2002).  In  addition,  they  also  observed  that 
whereas  increased  proliferation  was  inhibited  by  STI,  there  was  no  concomitant 
effect  in  apoptosis,  suggesting  that  STI  was  exerting  a  cytostatic  and  not  a 
cytotoxic  effect. 
These  data  raise  concerns  in  relation  to  the  clinical  effectiveness  of  STI  treatment. 
If  one  of  the  effects  of  STI  therapy  is  to  reduce  the  number  of  committed 
progenitors  but  also  to  induce  the  quiescence  of  primitive  leukaemic  stem  cells, 
then  long-term  patient  survival  may  be  jeopardised.  It  has  already  been 
documented  that  most  patients  who  achieve  a  complete  cytogenetic  response  also 
harbour  detectable  BCR-ABL  transcripts,  and  that  molecular  remissions  are  rare 
(Hughes  TP,  Kaeda  J  et  al.  2003). 
In  separate  studies  not  included  in  this  thesis,  we  have  identified  combinations  of 
STI  with  other  agents  that  reduce  the  quiescent  fraction  in  vitro  following 
treatment.  Evaluation  of  the  effects  of  treatment  on  the  primitive  CD34`  BCR-ABL+ 
population  revealed  that  STI  in  combination  with  lonafamib,  a  famesyl  transferase 
inhibitor,  reduced  the  number  of  undivided  cells  and  inhibited  their  ability  to 
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combinations  (Jorgensen  HG,  Allan  EK  et  al.  2005).  If  leukaemic  stem  cells  are 
able  to  evade  STI  therapy  when  they  are  quiescent,  then  only  combinations  of 
agents  that  induce  cell  cycle  and  target  CML  stem  cells  in  concert  are  likely  to  be 
effective.  Although  there  is  accumulating  evidence  to  suggest  primitive  quiescent 
CML  stem  cells  are  the  most  resistant  to  STI  treatment  in  vitro,  it  is  impossible  to 
say  if  disease  persistence  in  vivo  is  due  to  the  same  cell  population.  Clearly,  in 
vivo  stem  cells  are  subject  to  microenvironmental  stimuli  impossible  to  mimic  in 
vitro. 
7.5  Gene  Expression  Profiling  of  Quiescent  Versus 
Cycling  Normal  and  CML  Cells 
Comprehensive  analysis  of  gene  expression  by  cDNA  microarrays  has  become  an 
important  tool  for  research  in  many  areas.  This  technology  produces  a  snapshot  of 
the  gene  expression  profile  of  a  cell  and  provides  information  on  the  relative  levels 
of  gene  expression  between  different  cells.  Microarrays  have  been  used 
extensively  in  the  search  for  distinctions  between  subsets  of  cells;  indeed  a  recent 
Pubmed  search  on  "microarray"  yielded  over  10,000  references,  a  testament  to 
the  universal  appeal  of  this  relatively  new  methodology.  Analysis  of  microarray 
data  has  moved  on  from  single  gene  differences  to  the  generation  of  "molecular 
signatures"  or  groups  of  genes  consistently  changed  between  samples.  However, 
the  enormous  data  sets  generated  by  these  types  of  analyses  has  emphasised  the 
importance  of  ever  more  defined  cell  populations  in  the  generation  of  meaningful 
data.  Recently,  microarrays  have  been  used  successfully  to  identify  consistent 
gene  differences  between  populations  of  haemopoietic  stem  cells  (Manfredini  R, 
Zini  R  et  al.  2005),  and  to  identify  genes  associated  with  CML  disease  (Nowicki 
MO,  Pawlowski  P  et  al.  2003).  The  potential  to  identify  both  known  and  novel  gene 
differences  using  microarrays,  together  with  the  ability  to  sort  very  specific  cell 
populations  (as  described  in  chapter  3),  was  the  rational  for  the  experiments 
presented  in  chapter  6  of  this  thesis. 
In  an  effort  to  gain  insight  into  the  properties  of  quiescent  stem  cells  such  as 
surface  markers,  receptors,  and  possible  therapeutic  targets,  gene  expression 
profiling  was  carried  out  using  microarray  technology.  Utilising  the  HST  and  Py 
FACS  sorting  strategy  developed  in  chapter  3,  populations  of  viable,  quiescent 
and  cycling  stem  cells  were  isolated  from  normal  and  CML  samples.  Five  CML Susan  M  Graham,  2005  Chapter  7,162 
and  three  normal  samples  were  sorted  and  processed  for  total  RNA.  Affymetrix 
GeneChip®  U133A  arrays  were  used  and  the  processing  carried  out  at  the 
University  of  Glasgow.  Affymetrix  arrays  were  chosen,  currently  the  gold  standard 
in  array  technology,  largely  due  to  their  stringent  internal  controls,  which  minimise 
the  potential  for  false  results.  These  data  were  analysed  by  two  different  methods, 
GeneSpring®  and  IGA  (Iterative  Group  Analysis).  The  first  level  of  analysis  by 
GeneSpring  generated  lists  of  genes  with  fold  change  of  >3-,  >4-  and  >5-fold 
between  comparative  groups.  Due  to  the  large  number  of  genes  changed  between 
samples  in  this  study,  a  minimum  arbitrary  cut-off  of  3-fold  was  used  in  the 
GeneSpring  analysis.  IGA  is  a  recently  published  method  of  analysis  generating 
gene  groups  and  statistical  significance  of  changed  groups,  and  is  particularly 
applicable  to  small  data  sets  such  as  this  (Breitling  R,  Amtmann  A  et  al.  2004). 
The  largest  number  of  genes  changed  in  this  study  was  between  normal  quiescent 
(GO)  and  cycling  cells.  Analysis  showed  that  these  populations  exhibited 
significant  differences  in  their  expression  profiles.  One  of  the  most  interesting  was 
the  extent  of  cell  cycle  associated  genes  that  were  up-regulated  in  normal  cycling 
cells  compared  to  quiescent  cells,  e.  g.  MCM2,4,5,6,  and  7.  CDC2,6,7,  and  20, 
Cyclin  A2  and  E2,  PCNA  and  CDC25.  This  expression  profile  verified  the  sorting 
strategy  for  the  isolation  of  GO  and  cycling  cells.  Interestingly,  examination  of  the 
expression  profile  of  CML  GO  cells  revealed  that  these  cells  were  much  closer  in 
expression  to  both  normal  and  CML  cycling  cells.  Indeed  a  mathematical  model 
(Euclidean  distance)  of  the  differences  in  gene  expression  of  all  genes  (not  just 
cell  cycle  genes)  >3-fold  changed,  demonstrated  that  normal  GO  cells  exhibited 
the  greatest  differences  in  gene  expression  when  compared  to  the  other  three 
groups. 
Further  analysis  revealed  that  the  differential  gene  expression  in  cell  cycle  genes 
observed  for  normal  GO  versus  cycling  cells  was  different  for  CML,  indicating  that 
CML  GO  cells  were  expressing  many  cell  cycle  associated  genes,  notwithstanding 
they  appeared  in  the  GO  sorting  gate.  It  is  possible  that  overexpression  of  the 
Hoechst  efflux  pump  ABCG2  in  CML  cells  could  have  placed  them  in  the  GO  gate. 
Initial  analysis  revealed  a  slight  increase  in  expression  of  ABCG2  of  1.5-fold  in  the 
CML  GO  cells  compared  with  their  cycling  counterparts.  However,  this  was 
associated  with  a  false  discovery  rate  of  11  %,  which  suggests  this  finding  was  not 
universal  for  all  samples,  indicating  it  was  unlikely  to  be  a  significant  factor.  In 
addition,  ABCG2  did  not  appear  as  statistically  significant  in  the  IGA  analysis. Susan  M  Graham,  2005  Chapter  7,163 
These  findings  suggest  that  CML  cells  may  not  be  quiescent  in  the  same  way  that 
normal  GO  cells  are  and  that  they  already  exhibit  activation  of  a  number  of  cell 
cycle  genes.  This  could  explain  the  results  shown  in  chapter  3  which  indicated 
greater  cell  cycle  activation  for  CML  cells  in  culture  compared  to  normal  cells.  It 
may  be  that  CML  GO  cells,  although  they  are  not  actively  dividing,  are  'primed'  to 
go  into  division  in  a  way  that  differs  from  normal  stem  cells. 
IGA  analysis  of  the  genes  up-regulated  in  the  normal  cycling  versus  GO  cells 
identified  genes  associated  with  DNA  replication  initiation  as  the  most  significantly 
changed  gene  group.  In  total,  20  gene  groups  were  identified  as  significantly 
changed  for  these  samples  with  mitosis,  DNA  replication  and  genes  associated 
with  early  cell  cycle  events  identified  as  the  most  important  statistically.  These 
data  again  increased  confidence  in  the  sorting  methodology  for  isolation  of  cells  in 
different  phases  of  the  cell  cycle.  Conversely,  for  the  CML  cycling  versus  GO  cells, 
the  top  changed  group  was  genes  associated  with  mitosis  and  spindle  formation, 
later  cell  cycle  events,  than  for  the  normal  cells.  These  data  confirm  the 
observation  in  chapter  3,  that  in  the  CML  samples,  there  were  significantly  more 
cells  at  the  later  S/G2/M  phase  of  the  cell  cycle  compared  to  normal  cells,  where 
most  were  in  G1.  IGA  analysis  of  genes  up-regulated  in  CML  GO  versus  normal 
GO  again  identified  cell  cycle  genes  as  significantly  changed  between  these 
groups,  indicating  increased  cell  cycle  activation  in  the  CML  GO  cells  compared  to 
normal  GO.  These  results  are  in  accordance  with  the  work  of  other  groups 
identifying  greater  cell  cycle  activation  in  CML  cells  (Kramer  A,  Loffler  H  et  al. 
2001;  Kronenwett  R,  Butterweck  U  et  al.  2005). 
These  observations  suggest  that  strategies  to  induce  CML  quiescent  cells  into 
active  cell  cycle,  thereby  reducing  resistance  to  drug  therapy,  may  be  relatively 
easy  if  they  already  exhibit  activation  of  a  number  of  cell  cycle  genes.  This  would 
result  in  more  effective  bcr-abl+  cell  kill  by  STI.  Anecdotal  evidence  that  this  may 
occur  in  vivo  comes  from  studies  of  patients  on  STI  therapy,  who  undergo 
concurrent  stem  cell  mobilisation  with  GCSF  to  obtain  stem  cells  for  future 
autologous  transplant.  A  recent  study  by  Le  Coutre's  group  has  shown  that 
following  simultaneous  GCSF  mobilisation  and  STI  treatment,  one  patient 
achieved  a  complete  molecular  remission,  rare  in  patients  treated  with  STI  alone, 
and  that  most  stem  cell  harvests  were  free  of  detectable  BCR-ABL  mRNA 
transcripts  (Kreuzer  KA,  Kluhs  C  et  al.  2004).  Another  recent  study  concluded  that 
GCSF  treatment  increased  the  response  to  STI  in  62%  of  patients.  This  also Susan  M  Graham,  2005  Chapter  7,164 
included  patients  with  a  previous  history  of  extended  (median  22  months)  STI 
treatment  without  a  major  cytogenetic  response  (CCR),  notwithstanding  the 
chances  of  patients  achieving  CCR  after  12  months  of  therapy  is  extremely  low. 
They  concluded  that  the  improved  responses  were  due  to  reduced  neutropenia, 
which  allowed  sustained  STI  treatment  (Quintas-Cardama  A,  Kantarjian  H  et  at. 
2004).  It  would  be  difficult  to  reproduce  these  results  in  vitro  if  mobilisation  from 
the  BM  is  preceded  by  induction  of  cell  cycle,  before  reverting  to  a  quiescent  state 
in  the  PB,  as  reported  by  Wright  et  al,  and  this  is  a  factor  in  STI  response  (Wright 
DE,  Cheshier  SH  et  al.  2001). 
Comparison  of  the  significantly  up-regulated  genes  in  normal  GO  versus  cycling 
cells  yielded  a  completely  unexpected  group  of  chemokine  genes  as  the  top 
changed  group.  The  most  significantly  up-regulated  chemokine  genes  in  the 
quiescent  cells  included  CXCL1,2,3,6,8,10,11,13,  and  CCL19.  Interestingly, 
although  the  ligands  were  up-regulated,  the  corresponding  receptors  were  not. 
Many  chemokines  have  been  shown  to  play  a  role  in  both  positive  and  negative 
regulation  of  haemopoiesis.  However,  cellular  context  and  maturity  almost 
certainly  influence  specific  responses  to  individual  and/or  combinations  of 
chemokines.  In  addition,  it  has  been  shown  recently  that  the  effects  of  the 
chemokine  SDF-1  (secreted  by  BM  cells)  can  selectively  reverse  the  inhibitory 
effect  of  a  range  of  myelosuppressive  chemokines  on  haemopoietic  progenitor 
cells  (Broxmeyer  HE,  Cooper  S  et  al.  2005).  This  may  be  one  mechanism  that 
allows  differential  responses  in  a  context  dependant  manner  and  may  represent  a 
further  level  of  proliferative  control  in  stem  cells. 
To  our  knowledge,  the  significance  of  the  up-regulation  in  chemokine  genes 
identified  in  the  microarray  study  in  the  maintenance  of  stem  cell  quiescence  has 
not  been  reported  and  as  such  represents  a  novel  finding.  The  differential 
expression  observed  in  these  samples  could  be  a  consequence  of  GCSF 
mobilisation  prior  to  sample  collection,  and  only  a  comparison  with  matched 
samples  from  resting  BM  would  address  this  question.  Other  microarray  studies 
that  compared  BM  and  MPB  have  not  identified  differences  in  expression  of  any  of 
these  chemokine  genes.  Either  there  are  no  differences  in  expression  of  these 
genes  between  BM  and  MPB,  or  the  subsets  we  have  sorted  represent  such  a 
small  proportion  that  their  differential  expression  is  lost  in  the  milieu. Susan  M  Graham,  2005  Chapter  7,165 
A  possible  explanation  for  these  findings  may  be  that  quiescent  cells  produce 
these  chemoattractant  chemokines  to  recruit  neutrophils,  which  in  turn  increase 
the  local  concentration  of  proteases  and  facilitate  exit  from  the  BM  niche. 
Surprisingly,  CML  GO  cells  also  showed  up-regulation  of  the  same  chemokine 
genes  compared  to  their  cycling  counterparts,  albeit  at  slightly  lower  levels  than 
normal  GO  cells.  CML  patients  have  not  been  exposed  to  GCSF,  and  it  is 
interesting  to  speculate  that  perhaps  this  is  one  mechanism  which  allows  the 
premature  release  of  CML  progenitors  into  the  circulation,  characteristic  of  CML 
disease.  In  support  of  this,  expression  of  CXCR4,  the  receptor  for  SDF-1 
expressed  by  stromal  cells,  was  2.9-fold  lower  in  the  quiescent  CML  cells  than  in 
normal  GO  cells,  suggesting  that  these  cells  display  altered  adhesive  interactions, 
which  again  may  promote  their  release  into  the  circulation.  In  addition,  Cashman 
et  al  documented  that  addition  of  SDF-1  to  normal  long-term  BM  cultures  inhibited 
cell  cycle  entry  of  primitive  quiescent  CFC,  and  the  addition  of  a  CXCR4 
antagonist  prevented  activated  CFC  from  re-entering  a  quiescent  state. 
Interestingly,  this  effect  was  not  observed  for  CML  CFC  and  could  perhaps  be 
explained  by  the  lower  levels  of  CXCR4  expression  observed  in  this  study  for 
quiescent  CML  cells  (Cashman  J,  Clark-Lewis  I  et  al.  2002).  A  recent  microarray 
study  by  Kronenwett  et  al  compared  CD34+  cells  from  CML  BM  and  PB  to  normal 
CD34+  BM  and  GCSF  mobilised  PB.  Although  these  populations  are 
heterogeneous  compared  with  the  sorted  populations  we  have  used,  they  include 
the  subsets  we  have  separated  and  demonstrate  certain  similarities.  For  example, 
these  researchers  also  identified  enhanced  cell  cycle  gene  expression  in  the  CML 
CD34*  cells  compared  to  normal  CD34+  cells.  In  addition  they  also  identified  lower 
expression  of  CXCR4  on  CML  CD34+  cells  compared  to  normal  (Kronenwett  R, 
Butterweck  U  et  al.  2005).  These  findings  increase  our  confidence  in  the  array 
data  and  further  increase  the  significance  of  the  novel  gene  expression  profiles  we 
have  identified.  To  date  there  is  no  published  data  on  such  specifically  isolated 
stem  cell  populations  as  those  used  in  this  study.  Although  sample  numbers  were 
small,  sophisticated  statistical  methods  allowed  us  to  generate  significant  data 
sets,  which  also  identified  genes  observed  in  other  published  gene  lists. 
One  of  the  aims  of  this  work  was  to  identify  possible  CML  targets  that  could  be 
exploited  in  a  therapeutic  context.  Although  the  analysis  so  far  has  not  yielded 
specific  gene  differences  that  are  immediately  obvious  as  targets,  the  data 
analysis  is  not  complete  and  will  be  subject  to  further  investigation. Susan  M  Graham,  2005  Chapter  7,166 
Conclusions  and  Future  Aims 
The  data  presented  in  this  thesis  has  focused  on  isolation  of  specifically  defined 
stem  cell  populations  from  normal  and  CML  patients.  Culture  of  CML  stem  cells 
has  identified  a  population  of  quiescent  cells  resistant  to  a  specific  targeted 
therapy,  analogous  to  an  in  vivo  population  known  to  evade  this  therapy.  The 
development  of  FACS  sorting  strategies  allowed  separation  of  stem  cell 
populations  on  the  basis  of  their  cell  cycle  position  and  enabled  microarray 
analysis  of  these  specific  cell  subsets.  Aberrant  cell  cycle  gene  expression  was 
identified  in  the  CML  GO  cells  compared  to  normal  cells.  Importantly,  a  group  of 
chemokine  genes  was  identified  as  being  up-regulated  in  quiescent  cells  from  both 
normal  and  CML  samples  and  signifies  a  novel  finding  which  may  be  of  major 
consequence  in  the  understanding  of  haemopoietic  stem  cell  biology. 
The  data  generated  by  these  experiments  have  both  answered  and  raised  a 
number  of  questions.  It  is  clear  that  a  quiescent  phenotype,  especially  in  malignant 
cells,  confers  certain  survival  advantages.  It  is  also  apparent  that  some  therapies 
induce  quiescence,  exacerbating  the  problem  of  disease  persistence.  Microarray 
analysis  has  yielded  a  significant  amount  of  data,  which  has  yet  to  be  fully 
analysed.  The  results  presented  in  this  thesis  represent  the  first  round  of  analysis 
and  further  work  will  almost  certainly  identify  other  genes  of  significant  importance. 
The  unexpected  up-regulation  of  a  cohort  of  chemokine  genes  in  quiescent  cells 
deserves  further  investigation.  One  of  the  first  questions  is  whether  this  is  a 
product  of  G-CSF  mobilisation.  This  will  be  addressed  by  examining  gene 
expression  in  sorted,  quiescent  BM  stem  cells,  initially  by  real  time  PCR  and 
possibly  by  microarrays.  Independent  validation  of  the  genes  identified  by 
microarrays  will  be  required  and  this  will  be  done  by  real  time  PCR,  to  enable 
relative  quantitation  of  gene  expression.  The  limited  amount  of  patient  material 
obtained  following  the  stringent  sorting  reduces  the  opportunities  for  further 
experimentation. 
Some  of  these  problems  could  be  resolved  by  repeating  the  experiments  in  an 
animal  model  e.  g.  mouse.  If  microarray  results  for  normal  cells  can  be  reproduced 
in  the  murine  system  it  is  anticipated  that  a  considerable  amount  of  data  regarding 
normal  stem  cell  biology  would  be  obtained.  Furthermore,  these  data  could  be 
used  to  identify  possible  targets  in  CML  quiescent  cells,  which  could  be  exploited Susan  M  Graham,  2005  Chapter  7,167 
to  increase  the  effectiveness  of  cytotoxic  therapies.  We  anticipate  experiments 
essential  to  verify  biological  function  will  be  performed.  For  the  chemokines 
identified,  ELISA  or  protein  analysis  would  confirm  their  presence  in  cultures  of 
quiescent  versus  cycling  cells.  Once  again  the  problem  of  limited  patient  material 
restricts  the  options  for  further  experimentation,  which  could  also  be  resolved  by 
using  an  animal  model.  There  is  no  doubt  that  studies  which  elucidate  stem  cell 
properties  contribute  appreciably  to  our  understanding  of  malignant  stem  cell 
disease. 168 
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Experiment  report 
Software 
This  refers  to  software  that  actually  runs  the  whole  analysis 
automatically.  In  particular  it: 
""  Generates  a  directory  structure  for  a  project  and  its 
experiments 
""  Manages  the  security  of  the  project 
""  Performs  RMA  low-level  analysis 
""  Performs  RP  identification  of  differentially  expressed  genes 
for  a  number  of  between-group  comparisons 
""  Functionally  annotates  the  list  of  RP-identified  top  genes 
""  Performs  iGA  to  find  differentially  expressed  functional 
classes  of  genes  (written  by  Rainer  Breitling). 
""  Presents  the  RP  and  iGA  results  in  form  of  web  pages 
and/or  downloadable  tab-delimited  text  files  suitable  for  reading 
in  Excel. 
The  software  has  been  written  and  implemented  by  Pawel  Herzyk  in 
the  Autumn  2003  -  Spring  2004. 
Project 
Project  refers  to  data  that  belongs  to  a  particular  researcher  or  a  group 
of  researchers.  Each  PI  (principal  investigator)  can  only  have  one 
project  that  can  be  divided  into  many  experiments.  Each  project  has 
associated: 
"  Name  -  this  is  usually  constructed  from  the  PI's  name  e.  g. 
j  ohn_dav  would  be  a  name  of  a  project  owned  by  John  Davis. 
.  Class  -  this  could  be  Microarray  or  Proteomics 
""  Type  -  e.  g.  Affymetrix  or  spotted  depending  on  the 
type  of  microarrays  used 
Experiment 
Each  project  can  be  divided  into  experiments.  Each  experiment 
contains  data  from  a  number  of  replicated  (or  not)  samples 
corresponding  to  different  conditions. 
Array 
This  refers  to  an  identifiable  type  of  array  e.  g.  U133  is  the  Affymetrix 
human  array  HG-U  133. 
Chip 
Some  Affymetrix  arrays  may  consist  of  several  subarrays.  E.  g.  HG- 
U133  array  is in  fact  represented  by  two  arrays  HG-U133A  and  HG- 
U133B.  In  this  case  we  say  that  the  array  has  two  chips  A  and  B.  If  the 
array  has  only  one  chip  it  is  denoted  as  N  (for  none). Susan  M  Graham  2005  Appendix  1.2 
Normalisation 
This  really  is  a  shorthand  for  low-level  analysis.  In  case  of  Affymetrix 
data  this  consists  of 
"  Background  correction 
"  Multichip  normalisation  on  the  probe  level 
"  Summary  of  the  log-normalised  probe  level  data  into  a 
probe-set  level  data 
By  default  we  use  Robust  Multichip  Average  (RMA)  method 
implemented  in  module  Affe  in  the  Bioconductor  microarray  analysis 
software. 
Differential  Expression 
A  method  of  identification  of  differentially  expressed  genes  between 
two  groups  of  replicated  samples.  We  use  the  RankProducts 
method(RP)  developed  in  University  of  Glasgow. 
Differentialy  expressed  gene  classes 
A  method  for  identification  of  functional  gene  classes  that  are 
differentially  expressed  in  a  given  comparison.  We  use  the  Iterative 
Group  Analysis  method  developed  in  the  University  of  Glasgow. 
Baseline 
For  every  comparison  between  two  groups  of  replicated  samples  we 
select  one  of  the  groups  as  a  reference  (baseline).  This  is  usually  done 
upon  suggestion  from  a  researcher  who  owns  the  data. 
Treatment 
This  refers  to  the  group  of  replicated  samples  that  has  not  been 
selected  as  baseline.  The  software  analyses  the  expression  of  a 
treatment  group  with  respect  to  the  baseline. 
Direction 
This  refers  to  the  direction  of  the  differential  expression  of  the 
treatment  with  respect  to  the  baseline: 
""  Positive  -  means  a  list  of  genes  with  significantly  higher 
expression  in  the  treatment  group  than  in  the  baseline  group 
""  Negative  -  means  a  list  of  genes  with  significantly  lower 
expression  in  the  treatment  group  than  in  the  baseline  group 
RPhtml 
Results  of  RP  in  html  format 
RPtext 
Results  of  RP  in  tab-delimited  text  format 
iGAcla 
Results  of  iGA  in  Classic  mode  (html  format).  Look  at  paragraph  Mode 
in  section  iGA  report  for  more  explanations. 
iGArep 
Results  of  iGA  in  Representative  mode  (html  format).  Look  at 
paragraph  Mode  in  section  iGA  report  for  more  explanations. 
RP  report Susan  M  Graham  2005  Appendix  1.3 
Comparison 
This  refers  to  a  comparison  between  two  groups  of  replicated  samples. 
E.  g.:  Samples:  A,  B,  C  vs  samples:  D,  E,  F  means  that  samples 
A,  B,  C  correspond  to  the  treatment  group  and  D,  E,  F  correspond  to  the 
baseline  group. 
Probe-set  ID 
The  Affymetrix  probe-set  identificator 
RPscore 
This  is  a  measure  of  differential  expression  calculated  by  the  RP 
method.  For  every  gene  this  is  calculated  as  a  geometric  mean  of  fold- 
change  ranks  over  the  number  of  all  possible  between-chip 
comparisons  contributing  to  a  given  between-group  comparison. 
FDR 
This  is  a  conservative  estimate  of  False  Discovery  Rate.  If  you  cut  the 
differentially  expressed  gene-list  at  the  particular  position  associated 
with  a  particular  FDR  then  it  shows  the  expected  percentage  of  false 
positives. 
FCrma 
Before  FunAlyse  version  1.4.1  this  is  a  mean  fold-change  over  all 
possible  between-chip  comparisons  contributing  to  a  given  between- 
group  comparison. 
From  FunAlyse  version  1.4.1  onwards  this  is  calculated  as  an  antilog  of 
a  mean  log-fold-change  over  all  possible  between-chip  comparisons 
contributing  to  a  given  between-group  comparison. 
In  both  cases  if  you  have  two  groups  of  three  Affymetrix  chips  the 
FCrma  is  calculated  over  all  nine  comparisons. 
FCnom 
It  has  been  demonstrated  in  the  experiment  where  selected  genes 
were  spiked-in  at  known  concentrations  on  the  HG-U95A  chip  that  the 
fold-changes  calculated  after  RMA  low-level  analysis  are  significantly 
lower  than  the  nominal  fold-changes  calculated  from  the  spiked-in  gene 
concentrations.  The  relation  between  these  two  fold-changes  was 
calculated  by  a  fitting  procedure: 
log2(rma  FC)  =  0.61  x  log2(nominal  FC) 
Consequently,  the  FCnom  corresponds  to  the  mean  nominal  fold- 
change  obtained  from  the  rma  fold-changes  using  the  above  equation 
over  all  possible  between-chip  comparisons  contributing  to  a  given 
between-group  comparison.  Please,  treat  it  with  caution  as  it  is  not 
known  how  universal  the  above  equation  is.  Consult  Figure  6  in  the 
original  paper  Cope  et  al.  2003  (PubMed  abstract  . 
Gene  annotation  database 
This  is  a  database  that  contains  functional  annotation  of  your  genes. 
Every  gene  in  the  reported  list  of  differentially  expressed  genes  has  a 
hyperlink  to  it.  Currently,  we  use  the  following  databases: 
"  Human,  Mouse  and  Rat  -  SOURCE  database 
"  Arabidopsis  -  MIPS  and  TAIR  databases 
Drosophila  -  FlyBase 
Yeast  -  SGD  database Susan  M  Graham  2005  Appendix  1.4 
Gene  symbol 
Common  gene  symbol  used  by  biologists. 
Gene  ID 
Publicly  used  gene  identificator. 
Title 
Short  functional  annotation  of  a  gene.  This  is  very  brief,  you  shouldn't 
rely  on  it  too  much. 
iGA  report 
Mode 
The  iGA  module  in  the  FunAlyse  software  can  work  in  two  modes: 
Classic  -  all  probe-sets  on  the  chip  are  taking  part  in  the  iGA 
calculations.  Representative  -  only  one  probe-set  per  gene  is 
selected.  This  is  to  remove  a  bias  towards  a  particular  groups  in  case 
more  then  one  probe-set  represent  a  gene  contributing  to  this  group.  A 
probe  set  producing  the  best  RPscore  in  a  given  comparison 
(calculated  seperately  for  positive  and  negative  expression)  is  selected 
as  a  representative  for  that  gene.  The  non-redundant  set  of  genes  is 
defined  differently  for  different  organisms.  For  Human,  Mouse  and  Rat 
they  are  defined  using  Unigene  IDs,  for  Arabidopsis  and  Yeast  they  are 
defined  on  the  base  of  gene  IDs  whilst  for  Drosophila  it  is based  on 
gene  symbols. 
Number  of  probe-sets  on  the  chip 
A  number  of  Affymetrix  probe-sets  on  a  given  chip.  In  the  Classic 
mode  some  probe-sets  may  refer  to  the  same  gene. 
Number  of  annotated  probe-sets 
A  number  of  probe-sets  on  a  given  chip  that  have  functional  annotation 
in  the  current  Affymetrix  annotation  file  that  has  been  used  for 
functional  group  construction. 
Number  of  groups 
A  total  number  of  functionally  annotated  gene-groups.  They  are  pre- 
constructed  independently  of  the  microarray  experiment.  Usually  we 
use  GeneOntology  (GO)  annotations  present  in  the  Affymetrix 
annotation  file  but  you  may  advise  us  to  use  other  annotation  sources. 
Number  of  singletons 
A  number  of  functionally  annotated  gene-groups  that  contain  a  single 
gene.  These  are  not  particularly  useful  for  iGA. 
Significance  threshold 
A  threshold  for  P-value  changed.  P-values  lower  than  the  threshold 
are  considered  statistically  significant.  (see  also  P-value  changed) 
File  Name 
A  name  of  the  input  file  that  contains  full  list  of  genes  sorted  by 
RankProducts  score  RPscore  that  is  our  measure  of  gene  differential 
expression. 
Annotations 
This  is  a  name  of  the  Affymetrix  functional  annotation  file  used  for  the 
functional  group  construction. 
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A  list  of  significantly  differentially  expressed  gene-groups. 
Group  Members 
Number  of  probe-sets  that  belong  to  a  particular  group. 
Changed  Members 
Number  of  group  members  that  have  actually  contributed  to  achieving 
a  given  P-value  changed  for  this  group. 
P-value  changed 
This  tells  you  what  is  a  probability  of  a  random  event  that'that  many'  of 
changed  members  out  of  'that  many'  group  members  has  been 
found  'that  high'  on  the  RP  list  of  'that  many'  sorted  genes.  This  is 
calculated  from  the  hyper-geometric  distribution.  Consult  Figure  1  in 
the  original  paper 
P-value 
Going  down  from  the  top  of  the  RP  list,  for  every  encountered  subset  of 
a  particular  gene  group  we  calculate  the  p-value  that  tells  you  how 
probable  a  random  event  is  that  such  subset  was  found  'that  high'  on 
the  RP  list.  This  is  calculated  from  the  hyper-geometric  distribution.  In 
this  context  P-value  changed  is  a  smallest  p-value  over  all  the  above 
subsets.  Consult  Figure  1  in  the  original  paper 
Percent  changed 
This  is  simply  changed  members  over  group  members  times  100. 
Rank 
This  is  rank  of  a  particular  gene  in  the  list  of  differentially  expressed 
genes.  This  list  was  created  from  the  RP  list  by  exclusion  of  genes  that 
are  not  assigned  to  the  functional  gene-groups. Susan  M  Graham  2005  Appendix  1.6 
iGA  report  on  the  differentially  expressed  functional  gene 
classes:  up-regulated  CML  GO  vs  Normal  GO 
General 
Mode  Representative 
12698 
9533 
3991 
1649 
Number  of  genes  on  chip 
Number  of  annotated  genes 
Number  of  groups 
Number  of  singletons 
Significance  threshold 
File  name 
F  2.5e-04 
TCML  GO  Vs  N  GO 
Top  Changed  Groups 
Group  Changed  P-Value  Percent 
Members  Members  Changed  Changed 
5833  -  hemoglobin  complex  935.7e-10  33.33 
------------  --------- 
-  oxygen  transport  935.7e-10  33.3i--  15671 
5344  oxygen  transporter  11  3  1.1  e-09  27.27 
activity 
7067  -  mitosis  74  7.7e-09  [  12.16 
5819  -spindle  11  4 
. 
5e-06  36.36 
79  -  regulation  of  cyclin 
dependent  protein  kinase  34  5  3.0e-06  14.71 
activity 
6260  -  DNA  replication  76  7  9.8e-06  9.21- 
9440  -  cyanate  catabolism  224.4e-05  100.00 
4792  -  thiosulfate  224.4e-05  100.00 
sulfurtransferase  activity 
5638  -  lamin  filament  222.3e-04  100.00 
9113  -  purine  base  biosynthesis  r442.4e-04  100.00 
Changed  group  breakdown: 
P-  Probe-set  Gene 
Group 
value  ID 
Rank  Gene  ID 
Symbol 
Title 
5833- 
hemoglobin  04 
209116  x  at  1  M25079  HBB  hemoglobin,  beta 
complex 
707 
213515  x  at  2  Al133353  j  HBG1  hemoglobin,  gamma  A 
show  the  whose  group 
53e- 
206834  at 
-1 
3  ;  NM  000519 
10 
HBD  hemoglobin,  d delta Susan  M  Graham  2005  Appendix  1.7 
15671  -  oxygen 
transport 
9.4e- 
209116  x  04  at  1  M25079  HBB  hemoglobin,  beta 
7  9e- 
. 07 
2x 
07  at  2  AI133353  HBG1  hemoglobin,  gamma  A 
5 
show  the  whole  group  206834 
10  at  3  NM  000519  HBD  hemoglobin,  delta 
5344  -  oxygen  1_ 
transporter  03 
209116  x 
1 
at  1  M25079  HBB  hemoglobin,  beta 
activity 
1.2e- 
213515  x  06  at  2  Al133353  HBG1  hemoglobin,  gamma  A 
show  the  whole  group 
F1  ý9  -  206834  at  3  !  NM  000519  HBD  hemoglobin,  delta 
7067  -  mitosis 
8.9e- 
1  202870  s  at  12  NM  001255  CDC20 
CDC20  cell  division  cycle  20 
homolog  (S.  cerevisiae) 
1  Oe-  f 
. 02 
202705  at  20  NM  004701  CCNB2  cyclin  B2 
103-  ( 
203213  at  28  AL524035  CDC2  cell 
division 
and  G21to21ýG1 
to  S 
2  Oe- 
04 
219306  at  38  NM  020242  KNSL7  kinesin-like  7 
r-  -- 
3  6e 
SMC2  structural  maintenance 
.  204240  s  at  49  NM  006444  SMC2L1  of  chromosomes  2-like  1  05 
(yeast) 
2.7e- 
203968  s  at  52  NM  001254  CDC6 
CDC6  cell  division  cycle  6 
06  homolog  (S.  cerevisiae) 
1  9e- 
.  204695  at  55  AI343459  CDC25A  cell  division  cycle  25A 
. 
1e  1218662  s  at  57  NM  022346  HCAP-G  chromosome  condensation 
08  protein  G 
BUBI  budding  uninhibited  by 
show  the  whole  group  7  7e- 
209642 
09  at  78  AF043294  BUB1  benzimidazoles  1  homolog 
(yeast) 
5819  -  spindle 
1.4e-1 
202870  s  at  12  NM  001255  CDC20  CDC20  cell  division  cycle  20 
02  homolog  (S.  cerevisiae) 
5.5e-  207828  s 
( 
at  31  NM  005196  CP  centromere  protein  F, 
04  350/400ka  (mitosin) 
3.6e- 
204444  at  59  NM  004523  KIF11  kinesin  family  member  11 
05 
1  5e- 
show  the  whole  group  06 
217879  at  81  AL566824  CDC27  cell  division  cycle  27 
79  -  regulation  of  c  clip-de  endent  kinase 
cyclin  dependent  1.0e-  1209714 
s  at  30  AF213033  CDKN3  inhibitor  3  (CDK2-associated 
protein  kinase  01  dual  specificity  phosphatase) 
activity 
6.4e-  218723  s  at  34  NM  014059  RGC32  response  gene  to  complement 
03  32 
1  8-1  P-203968  s  at  52  NM  001254  CDC6  [  Cfl  A  cell  riivicinn  nvnla  F Susan  M  Graham  2005  Appendix  1.8 
04  homolog  (S.  cerevisiae) 
4 
05 
204695  at  55  A1343459  CDC25A  cell  division  cycle  25A 
show  the  whole  group  3.  Oe 
205394  at  65  I  NM  001274  CHEM 
CHK1  checkpoint  homolog  (S. 
06  pombe) 
660DNA  0  3.2e- 
209773  s  at  i  4  B0001886  RRM2  reductase  tase  M2  ribonucleotide 
replication  2  PoyP  P  e 
6 
203968 
-- 
s  at  52 
, 
NM  001254  CDC6 
_  CDC6  cell  division  cycle  6 
02  homolog  (S.  cerevisiae) 
MCM5  minichromosome 
1.0e- 
201755  at  56  ,  NM  006739  MCM5  maintenance  deficient  5,  cell 
02  division  cycle  46  (S. 
cerevisiae) 
2.5e- 
205909  at  72  NM  002692  POLE2  polymerase  (DNA  directed), 
03  epsilon  2  (p59  subunit) 
[6.3e- 
204127  at  87  B0000149  RFC3  replication  factor  C  (activator 
04  1)  3,38kDa 
8  7e- 
204767  s  at  92  B0000323  FEN1  flap  structure-specific 
05  endonuclease  1 
snow  the  wh  204126  s  at  95  '  NM  003504  CDC45L 
CDC45  cell  division  cycle  45- 
U°  11Ke  ko.  cerevisiae) 
03 
thiosulfate  sulfurtransferase  9440  -  cyanate  te  2.7  e-  209605  at  13  D87292  TST 
(rhodanese) 
4.4e-  1203524 
s  at  64  NM  021126  MPST  mercaptopyruvate 
05  sulfurtransferase 
4792  -  thiosulfate 
sulfurtransferase 
2.7e- 
209605  at  13  D87292  TST  thiosulfate  sulfurtransferase 
activity 
03  (rhodanese) 
4.4e- 
203524  s  at  64  NM  021126  MPST  mercaptopyruvate 
05  sulfurtransferase 
5638  -  lamin  3.8e- 
1203411  s  at  18  NM  005572  LMNA  lamin  A/C 
filament  03 
2.3e- 
203276  at  109  NM  005573,  LMN61  lamin  B1 
04 
phosphoribosylaminoimidazolE 
9113  -  purine  7.8e-  carboxylase, 
base  02  201014  s  at  !  191  NM  006452  PAICS  phosphoribosylaminoimidazolE 
b  biosynthesis  succinocar  oxamide 
synthetase 
7.7e-  214431  at  347  ý 
NM  003875  GMPS  guanine  monphosphate 
03  synthetase 
phosphoribosylglycinamide 
formyltransferase, 
7.3e- 
212378  at  492  NM  000819  j  GART  phosphoribosylglycinamide 
04  synthetase, 
phosphoribosylaminoimidazole 
synthetase 
705  A1457  433 
2  I  phosphoribosyl  pyrophosphate 
s  at  04 
209  120  PPAT 
amidotransferase Susan  M  Graham  2005  Appendix  1.9 
iGA  report  on  the  differentially  expressed  functional  gene 
classes:  up-regulated  Normal  GO  vs  CML  GO 
General  Information 
'_; 
t'n 
'r 
Functional 
Genomics 
Facility  J 
4' 
Top  Changed  Groups 
19884  -  antigen  presentation, 
exogenous  antigen 
19886  -  antigen  processing, 
exogenous  antigen  via  MHC 
class  II 
45012  -  MHC  class  II  receptor 
activity 
8009  -  chemokine  activity 
6935  -  chemotaxis 
9596  -  detection  of  pest, 
pathogen  or  parasite 
Mode  Representative 
Number  of  genes  on  chip  12698 
Number  of  annotated  genes  9530 
Number  of  groups 
F  3988 
Number  of  singletons 
T  1644 
Significance  threshold  2.5e-04 
File  name  I  1N  GO  vs  CML  GO 
Group  r  Changed  P  Value  Percent 
Members  Members  Changed  Changed 
13  5  7.1e-12  38.46 
14  5  1.6e-11  35.71 
14  5  16e-11  35.71 
--  r-  40  ------------  7  -  8.9e-08  [  17.50 
-  --  --  86  --  ------ 7  -  -----  1.  e-5  8.14 
4  2  7.4e-05  50.00 
Changed  group  breakdown: 
Group  P-value 
Probe-set  Rank  Gene  ID 
Gene 
Title 
ID  Symbol 
19884  -  major 
antigen 
presentation,  1.4e-03  209480  at  11  M16276 
HLA-  histocompatibility 
DQB1  complex,  class  II, 
exogenous  DQ  beta  1 
antigen 
major 
2e-06  X212671  s  at  '3  BG397856  HLA-  histocompatibility 
5 
.  DQA1  complex,  class  II, 
DQ  alpha  1 
HLA-  major 
9e-09  213831  at  4  X00452 
DQA2  ///  histocompatibility 
7 
.  HLA-  complex,  class  II, 
DQA1  no  atnha  9  /// Susan  M  Graham  2005  Appendix  1.10 
major 
histocompatibility 
complex,  class  II, 
DQ  alpha  1 
major 
HLA-  histocompatibility 
2.4e-1  1  209728  at  5  B0005312 
DRB4  complex,  class  II, 
DR  beta  4 
major 
show  the  whole  7.1e-12  213537  at  7  Al128225 
HLA-  histocompatibility 
group  DPA1  complex,  class  II, 
DP  alpha  1 
19886- 
antigen 
---- 
major 
processing,  HLA-  histocompatibility 
exogenous 
1.5e-03  209480  at  1  M16276 
DQB1  complex,  class  II, 
antigen  via  DQ  beta  1 
MHC  class  II 
major 
6.0e-06  212671  s  at  3  BG397856 
HLA-  histocompatibility 
DQAI  complex,  class  II, 
DQ  alpha  1 
major 
histocompatibility 
HLA-  complex,  class  II, 
1.  Oe-08  213831  at  4  X00452 
DQA2  ///  !  DQ  alpha  2  /// 
HLA-  major 
DQA1  histocompatibility 
complex,  class  II, 
DQ  alpha  1 
r--  -----  major 
HLA-  histocompatibility 
3.5e-11  209728  at  5  B0005312 
DR64  complex,  class  II, 
DR  beta  4 
major 
show  the  whole  1.6e-11  213537  at  7  A1128225 
HLA-  histocompatibility 
group  DPA1  complex,  class  II, 
1  DP  alpha  1 
--r  major  45012  -  MHC 
class  II  1.5e-03  209480  at  1  M16276 
HLA-  histocompatibility 
receptor 
DQB1  complex,  class  II, 
activity 
DQ  beta  1 
major 
HLA-  histocompatibility 
6.  Oe-06 
r212671 
sat  3  BG397856  DQA1  complex,  class  II, 
DQ  alpha  1 
major 
HLA- 
histocompatibility 
complex,  class  II, 
1.  Oe-08  213831  at  4  X00452 
DHLA  /ll 
DQ  alpha  2  /ll 
DQA1  major 
histocompatibility 
cömnIPx  class  II Susan  M  Graham  2005  Appendix  1.11 
DQ  alpha  1 
major 
3.5e-11  209728  at  5  B0005312  HLA  histocompatibility 
DRB4  complex,  class  II, 
DR  beta  4 
major 
show  the  whole  1.6e-11  213537  at  7  Al128225  HLA-  histocompatibility 
group  DPA1  complex,  class  II, 
DP  alpha  1 
8009 
chemokine  9.2e-02  210163  at  23  AF030514  CXCL11  chemokine  inine  e  (C-X-C 
ligand  11 
activity 
1.5e-02  204533  at  45  NM  001565  CXCL10  chemokine  (C-X-C 
motif)  ligand  10 
9.8e-04  209774  x  at  47  M57731  CXCL2  chemokine  (C-X-C 
motif)  ligand  2 
chemokine  (C-X-C 
1.4e-04  205242  at  64  NM  006419  CXCL13  motif)  ligand  13 
(B-cell 
chemoattractant) 
chemokine  (C-X-C 
motif)  ligand  6 
1.2e-05  206336  at  73  NM  002993  CXCL6  (granulocyte 
chemotactic 
protein  2) 
chemokine  (C-X-C 
motif)  ligand  1 
1.9e-06  204470  at  91  001511  CXCL1  (melanoma  growth 
stimulating  activity, 
alpha) 
show  the  whose  92  NM  002090  CXCL3  chemokine  (C-X-C 
8.9e-08  207850  at 
uot>  motif)  ligand  3 
6935  -  chemokine  (C-X  -C  1.9e-01  210163  at  23  AF030514  CXCL11 
chemotaxis  motif)  ligand  11 
r6.2e-02 
204533  at  45  NM  001565  CXCL10  chemokine  (C-X-C 
motif)  ligand  10 
8.6e-03  1209774  x  at  47  M57731  chemokine  (C-X-C 
CXCL2 
motif)  ligand  2 
chemokine  (C-X-C 
2.6e-03  205242  at  64  NM  006419  CXCL13  motif)  ligand  13 
(B-cell 
chemoattractant) 
chemokine  (C-X-C 
motif)  ligand  6 
4.9e-04  206336  at  73  NM  002993  CXCL6  (granulocyte 
chemotactic 
protein  2) 
chemokine  (C-X-C 
204470  at  91  NM  001  motif)  ligand  1 
1.6e-04  511  CXCL1 
(melanoma  growth 
stimulatinn  antivity Susan  M  Graham  2005  Appendix  1.12 
alpha) 
show  roerwhole  1.8e-05  207850  at  92  I  NM  002090  CXCL3  chemokine  (C-X-C 
motif)  ligand  3 
9596- 
detection  of  major 
pest,  1.4e-02  203932  at  33  NM  002118  HLA-  histocompatibility 
pathogen  or 
DMB  complex,  class  II, 
parasite 
DM  beta 
-  ---i  -ý 
major 
show  the  whole  7  4e-05  217478  s  at  34  X76775  HLA-  histocompatibility 
group  DMA  complex,  class  II, 
i  DM  alpha Susan  M  Graham  2005  Appendix  1.13 
iGA  report  on  the  differentially  expressed  functional  gene 
classes:  up-regulated  CML  Divided  vs  Normal  Divided 
L  J  L  C  b  Jý 
___ 
General  Information 
Mode 
Number  of  genes  on  chip 
Number  of  annotated  genes 
Number  of  groups 
Number  of  singletons 
Significance  threshold 
File  name 
Representative 
12698 
9532 
3990 
1648 
2.5e-04 
TCML  DIV  vs  N  DIV 
Top  Changed  Groups 
Group  Changed  P-Value  Percent 
Members  Members  Changed  Changed 
F 
2.0e-06  36.36  5819  -  spindle  11  F4 
626i--  DNA  topological  17211.4e-04 
28.57 
change  I 
,,  nangeu  group  uredKuuwn- 
Grou  P-value 
Probe-set  Rank  Gene  ID 
SGymbol 
Title  p 
centromere  protein  5819- 
pindle 
4.0e-02  207828  s  at  35 
; 
NM  005196  CENPF  F,  350/400ka 
s  (mitosin) 
1.2e-03  204444  at  46  {NM  004523  KIF11  kmembeam1y 
-  ----  ----  ---  cell  division  cycle  3.8e-05217878  sat  60  A1203880  CDC27 
27 
CDC20  cell 
show  the  whole  2.0e-06  202870  s  at 
I 
87  NM  001255  CDC20 
1  division  cycle  20 
group  I  homolog  (S. 
cerevisiae) 
6-  DNA  265  topoisomerase 
topological  1.3e-02  201292  at  18  AL561834  TOP2A  (DNA)  II  alpha 
change  170kDa 
show  the  whole  topoisomerase 
group  1.4e-04  208900  s  at  25  AW025108  TOP1 
(DNA) Susan  M  Graham  2005  Appendix  1.14 
iGA  report  on  the  differentially  expressed  functional  gene 
classes:  up-regulated  Normal  Divided  vs  CML  Divided 
General  Information 
Mode  Representative 
---  '  Number  of  genes  on  chip  12698 
Functional  Number  of  annotated  genes  9532 
Gnonsics  _-  --- 
Facility  Number  of  groups  3988 
Number  of  singletons  1646 
s"-'  Significance  threshold  2  5e-04 
. 
ý,  ý--=  File  name  TN  DIV  vs  CML  DIV 
Group  Changed  P-Value  Percent  Top  Changed  Groups 
Members 
I 
Members  Changed  Changed 
19884  -  antigen  presentation,  13  7  2.  Oe-12  53.85 
exogenous  antigen 
19886  antigen  processing, 
exogenous  antigen  via  MHC  14  6  2.9e-1  1  42.86 
class  II 
45012  -  MHC  class  II  receptor 
activity 
14  6  2.9e-11  42.86 
8009  -  chemokine  activity  40  8  5.7e-09  20.00 
6935  -  chemotaxis  86  8  6e-06  9.30 
9596  -  detection  of  pest,  4  2  1.9e-04  50  00 
pathogen  or  parasite  . 
Changed  group  breakdown: 
Group  P-value 
Probe-set 
Rank  Gene  ID 
Gene 
ID  Symbol 
h 
400QA 
major 
I  IJU  V-  HLA-  complex,  class  II 
antigen  nnn--)  iii  nn  ni.,  º,  n  ýýý 
presentation,  1.4e-03  213831  at  1  X00452 
exogenous 
HLA- 
antigen 
DQA1 
1.7e-06  209480  at  2  M16276 
qHLA-  B1 
HLA-  7.9e-09  212671  s  at  4  BG397856 
DQA1 
vý.  [  cý1r1iCI  c.  ni 
major 
histocompatibiliý 
complex,  class  II 
DQ  alpha  1 
major 
histocompatibility 
complex,  class  II, 
DO  beta  1 
major 
histocompatibility 
complex,  class  II, 
DQ  alpha  1 Susan  M  Graham  2005  Appendix  1.15 
major 
6.3e-09  209728  at  18  B0005312  HLA-  histocompatibility 
DRB4  complex,  class  II, 
DR  beta  4 
-___---  major 
HLA-  histocompatibility  1.8e-10  211991  s  at  28  M27487 
DPA1  complex,  class  II, 
DP  alpha  1 
major 
HLA- 
1.2e-1  1  208894  at  31  M60334  histocompatibility 
DRA  complex,  class  II, 
DR  alpha 
major 
show  the  whole  2.0e-12  201137  s  at  50  NM  002121 
HLA-  histocompatibility 
group  DPB1  complex,  class  II, 
DP  beta  1 
major 
19886  -  histocompatibility 
antigen  HLA-  complex,  class  II, 
processing,  1.5e-03  213831  at  1  X00452 
DQA2  DQ  alpha  2 
major  exogenous  HLA- 
antigen  via  DQA1  histocompatibility 
MHC  class  II  complex,  class  II, 
DQ  alpha  1 
major 
HLA-  histocompatibility 
2.0e-06  209480  at  2  M16276  DQB1  complex,  class  II, 
DQ  beta  1 
major 
1.0e-08 
1212671 
s  at 
lH  LA 
4  BG397856 
histocompatibility 
DQA1  complex,  class  II, 
DQ  alpha  1 
major 
8.8e-09  209728  at  18  B0005312 
HLA-  histocompatibility 
DRB4  complex,  class  II, 
DR  beta  4 
----f-----.  _----  - 
major 
3.1e-10  211991  s  at  28  M27487 
HLA-  histocompatibility 
DPA1  complex,  class  II, 
DP  alpha  1 
major 
HLA-  histocompatibility 
show  the  whole 
ý 
M60334 
group 
2.9e-1  1  208894  at  31 
DRA  complex,  class  II, 
DR  alpha 
major 
histocompatibility 
45012  -  MHC  HLA-  complex,  class  II, 
class  II  1.5e-03  213831  at  1  X00452 
DQA2  DQ  alpha  2 
receptor  HLA-  major 
activity  DQA1  histocompatibility 
complex,  class  II, 
DQ  alpha  1 
2.  Oe-06  209480  at  2  M16276  HI  A-  mainr Susan  M  Graham  2005  Appendix  1.16 
DQB1  histocompatibility 
complex,  class  II, 
DQ  beta  1 
major 
1.0e-08  1212671  s  at  4  BG397856  HLA-  histocompatibility 
DQA1  complex,  class  II, 
DQ  alpha  1 
ý  _I 
major 
8.8e-09  209728  at  18  B0005312  HLA-  histocompatibility 
DRB4  complex,  class  II, 
DR  beta  4 
major 
HLA-  histocompatibility  3.1e-10  !  211991  s  at  28  M27487 
DPA1  complex,  class  II, 
DP  alpha  1 
major 
show  the  whole  2.9e-11  208894  at  31  M60334 
HLA-  histocompatibility 
group  DRA  complex,  class  II, 
DR  alpha 
8009  [NM 
chemokine  (C-X-C 
chemokine  4.5e-02  204533  at  11  001565  CXCL10 
motif)  ligand  10 
activity 
2.8e-03 
1 
210163  at  19  1  AF030514  r  CXCL11  chemokine  (C  X-C 
motif)  ligand  11 
x  at  35  NM  000584  lL8  r  202859  4.1  e-04  interleukin  8 
rr 
chemokine  (C-X-C 
motif)  ligand  1 
4.5e-05  204470  at  48  I  NM  001511  CXCL1  (melanoma  growth 
stimulating  activity, 
alpha) 
chemokine  (C-X-C  3.6e-06  207850  at  57  NM  002090  CXCL3 
motif)  ligand  3 
chemokine  (C-X-C 
3.1  e-07  i  209774  x  at 
r67 
M57731  CXCL2 
motif)  ligand  2 
chemokine  (C-X-C 
motif)  ligand  6 
4.4e-08  206336  at  83  NM  002993  CXCL6  (granulocyte 
chemotactic 
protein  2) 
show  the  whole  5.7e-09 
r 
210072  a9  8  U88321 
[ 
CCL19  chemokine  (C-C 
group  motif)  ligand  19 
6935-  9.5e-02  204533  at  11  NM  001565  CXCL10  chemokine  (C-X-C 
chemotaxis  motif)  ligand  10 
1.2e-02  210163  at  r 
19  AF030514  CXCL11  chemokine  (C-X-C 
motif)  ligand  11 
3.8e-03  202859  x  at  I  35  NM  000584  IL8  interleukin  8 
chemokine  (C-X-C 
motif)  ligand  1 
8.9e-04  204470  at  48  NM  001511  CXCL1 
(melanoma  growth 
Stimulatinn  artivity Susan  M  Graham  2005  Appendix  1.17 
alpha) 
04  207850  57  !  NM  chemokine  (C-X-C  1.5e-  at  002090  CXCL3 
motif)  ligand  3 
2.9e-05  209774  x  at  67  M57731  CXCL2  chemokine  (C-X-C 
motif)  ligand  2 
chemokine  (C-X-C 
motif)  ligand  6 
9.1e-06  206336  at  83  NM  002993  CXCL6  (granulocyte 
chemotactic 
protein  2) 
show  the  whole  2.6e-06  210072  at  98  U88321  CCL19  chemokine  (C  C 
group  motif)  ligand  19 
9596- 
detection  of 
pest,  2.2e-02  203932  at  52  NM  002118 
HLA- 
major 
histocompatibility 
DMB  complex,  class  II, 
pathogen  or  DM  beta 
parasite 
show  the  whole  9e-04  1  217478  s  at  54  X76775 
HLA- 
major 
histocompatibility 
group  .  DMA  complex,  class  II, 
DM  alpha Susan  M  Graham  2005  Appendix  1.18 
iGA  report  on  the  differentially  expressed  functional  gene 
classes:  up-regulated  Normal  Divided  vs  Normal  GO 
General  Information 
Mode  Representative 
Number  of  penes  on  chip  12698 
------  --------  -----  Number  of  annotated  genes  9532 
Number  of  groups 
F  3990 
Number  of  singletons  I  1648 
Siqnificance  threshold  2.5e-04 
File  name  1N  DIV  vs  N  GO 
Top  Changed  Groups 
Group  Changed  ý'_  P-Value  Percent 
Members  Members  Changed  Changed 
6270  -  DNA  replication  initiation  17  7  1.4e-10  41.1-8-- 
7.067  -  mitosis 
1  74  11  r  1.5e-10  14.86 
6260  -  DNA  replication  76  11  1.7e-10  14.47 
8094  -  DNA-dependent  ATPase 
13 
-  ---- 
6 
-  ----  - 
6.3e-10 
- 
46  15 
activity  . 
79  -  regulation  of  cyclin  I 
dependent  protein  kinase  34  6  1.4e-07  17.65 
activity 
6281  -  DNA  repair  96  _  9  _  P6.  Oe-07  9.38 
5660  -delta-DNA  polymerase  3  3  8.7e-07  -  100  00 
cofactor  complex  . 
3684  -  damaged  DNA  binding  35  6  1.2e-06  r  17.14 
5833  -  hemoglobin  complex  9  3  2.1e-06  33.33 
15671  -  oxygen  transport  9  3  2.1  e-06  33.33 
5344  -  oxygen  transporter  11  3  4.1  e-06  27  27 
activity 
i  . 
4(4ö  -  rioonucieosiue-  2  2  1  le-05  100  00 
diphosphate  reductase  activity  .  . 
7089  -  traversing  start  control  6  3  1  5e-05  50  00 
point  of  mitotic  cell  cycle  j  .  . 
r76 
-  DNA  replication  checkpoint  4  2  2.3e-05  50.00 
776  -  kinetochore  14  3  2.6e-05  21.43- 
5876  -  spindle  microtubule  4  2  4.0e-05  x50.00 
8156  -  negative  regulation  of  4  2  4  6e-05  00  50  DNA  replication  .  . Susan  M  Graham  2005 
6189  -'de  novo'  IMP 
thesis  bi 
3  3 
osyn 
9113  -  purine  base  biosynthesis  4  4 
5762  -  mitochondrial  large 
4  4 
ribosomal  subunit 
166  -  nucleotide  binding  91  6 
Appendix  1.19 
1.8e-04  100.00 
2.2e-04  100.00 
2.2e-04  100.00 
2.4e-04  6.59 
replication 
3.3e-  j 
204126  s  at  19 
I 
NM  003504  CDC45L 
CDC45  cell  division  cycle  45-like 
initiation  1  02  (S.  cerevisiae) 
2.6e- 
MCM2  minichromosome 
03 
202107  s  at  43  NM  004526  MCM2  maintenance  deficient  2,  mitotin 
(S.  cerevisiae) 
MCM4  minichromosome  7.3e- 
222037  at  47  A1859865  MCM4  maintenance  deficient  4  (S. 
05  i 
cerevisiae) 
1  4  ma maintenance  6  MISS 
.  e  201930  at  49  NM  005915  MCM6  ( 
06  i  homolog,  S.  pombe)  (S. 
cerevisiae) 
5  61  AA807529  MCM5 
MCM5  minichromosome 
i  t  08 
216237  s  at  n  ma  enance  deficient  5,  cell 
division  cycle  46  (S.  cerevisiae) 
83  AF279900  MCM7 
MCM7  minichromosome 
i  t 
09 
210983  s  at  ma  n  enance  deficient  7  (S. 
cerevisiae) 
show  the  whole  group 
[14 
,  204510  at  88  NM  003503  CDC7 
CDC7  cell  division  cycle  7  (S. 
10  cerevisiae) 
3.1e 
203213  7067  -  mitosis  at  4  AL524035  CDC2  . 
cell  division  cycle  2,  G1  to  S  and 
G2  t  M  02  o 
1.2e-202870 
s  at  7  NM  001255  CDC20 
CDC20  cell  division  cycle  20 
li  03  homolog  (S.  cerevisiae) 
7.1e-  203968  s  at  11  NM  001254  CDC6  ion  cycle  6  CDC6  cell  division  ll  -ivi 
05  homolog  (S.  cerevisiae) 
4  3e 
.  202705  at  15  NM  004701  CCNB2  cyclin  B2 
06 
0  3.  e-  219306 
06  at  30  NM  020242  KNSL7  kinesin-like  7 
[7e-142 
at  33  AF043294  BU  131  BUB1  budding  uninhibited  by 
07  benzimidazoles  1  homolog  (yeast) 
-  --  1.1  e-  --  ý  - 
7 
---  - 
8  MAD2L1 
MAD2  mitotic  arrest  deficient-like  1 
NM  0023  203362  s 
(  ý08 
at  3  5 
(yeast) 
. 
Oe 
203418 
ý 
at 
-39 
NM  001237  CCNA2  A2  c  10 Susan  M  Graham  2005  Appendix  1.20 
BUB1  budding  uninhibited  by 
1.9e- 
203755  at  41  NM  001211  BUB1B  benzimidazoles  1  homolog  beta 
10 
(yeast) 
1.6e- 
10 
204695  at  42  A1343459  CDC25A  cell  division  cycle  25A 
1.5e-  1218662 
sat  45  NM  022346  HCAP-G  chromosome  condensation  protein 
show  the  whole  group  10  G 
6260  -  DNA  8.0e-  ribonucleotide  reductase  M2 
replication  03 
209773  s  at  1  B0001886  RRM2 
polypeptide 
3.3e- 
203968  s  at  11  NM  001254 
CDC6  cell  division  cycle  6 
03 
CDC6 
homolog  (S.  cerevisiae) 
204126  s  at 
CDC45  cell  division  cycle  45-like 
19  NM  003504  CDC45L 
04  (S.  cerevisiae) 
replication  factor  C  (activator  1)  3,  205 
204127  at  21  B0000149  RFC3 
38kDa 
6.7e-  DNA  re  lication  complex  GINS 
07 
221521  s  at  22  B0003186  Pfs2  pp 
protein  PSF2 
6Ö8 
208955  at  28  AB049113  DUT  dUTP  pyrophosphatase 
3.6e-  Ir 
31  NM  004111 
flap  structure-specific  204768  s  at  09 
FEW 
endonuclease  1 
ribonucleotide  reductase  M1  11  210.2e  32  NM  001033  !  RRM1 
polypeptide 
1.8e- 
MCM2  minichromosome 
10 
202107  s  at  43  NM  004526  MCM2  maintenance  deficient  2,  mitotin 
(S.  cerevisiae) 
1.7e- 
205909  at  I  46  NM  0026921  POLE2  polymerase  (DNA  directed), 
10  epsilon  2  (p59  subunit) 
MCM4  minichromosome 
(  show  the  whole  group 
1.7e- 
222037  at  47  AI859865  MCM4  maintenance  deficient  4  S. 
10 
cerevisiae) 
8094  -  DNA- 
5  7e- 
MCM2  minichromosome 
dependent  02 
202107  s  at  43  NM  004526  MCM2  maintenance  deficient  2,  mitotin 
ATPase  activity  (S.  cerevisiae) 
1.8e  j  47  -1859865  MCM4 
MCM4  minichromosome 
maintenance  deficient  4  (S. 
03 
222037  at 
cerevisiae) 
MCM6  minichromosome 
3.5e 
201930  at  49  NM  005915  MCM6  maintenance  deficient  6  (MISS 
05  j  homolog,  S.  pombe)  (S. 
cerevisiae) 
MCM5  minichromosome 
. 
0e-216237 
s  at  61  AA807529  MCM5  maintenance  deficient  5,  cell 
06  division  cycle  46  (S.  cerevisiae) 
3.  Oe- 
209849  sat  74  AF029669 
IRAD51C 
!  RAD51  homolog  C  (S.  cerevisiae) 
08 
MCM7  minichromosome 
show  the  whole  group 
6.3e3 
s  at  83  AF279900  MCM7  maintenance  deficient  7  (S. 
1" 
ýi  cerevisiae) Susan  M  Graham  2005  Appendix  1.21 
79  -  regulation 
of  cyclin 
dependent  3  9e- 
203968  s  at  11  NM  001254  CDC6 
CDC6  cell  division  cycle  6 
protein  kinase  02  homolog  (S.  cerevisiae) 
activity 
3 
205394  at  23  NM  001274  CHEK1  CHK1  checkpoint  homolog  (S. 
03  pombe) 
1  0e-  cyclin-dependent  kinase  inhibitor  3 
. 04  209714  s  at  26  AF213033  CDKN3  (CDK2-associated  dual  specificity 
phosphatase) 
1Oe- 
05  203418  at  39  NM  001237  CCNA2  cyclin  A2 
3.3e- 
07  204695  at  42  Al343459  CDC25A  cell  division  cycle  25A 
1  4e- 
07 
205034  at  70  NM  004702  CCNE2  cyclin  E2 
6281  DNA  3  7e  205909  at  46  NM  002692  POLE2  polymerase  (DNA  directed), 
repair  01  epsilon  2  (p59  subuni 
1  5e- 
201202  at  69  NM  002592  PCNA  proliferating  cell  nuclear  antigen  01 
3  8e- 
209849  s  at  74  AF029669  RAD51C  RAD51  homolog  C  (S.  cerevisiae)  02 
8  9e- 
03  205733  at  81  NM  000057  BLM  Bloom  syndrome 
1  5e- 
205024  s  at  84  NM  002875  RAD51 
RAD51  homolog  (RecA  homolog, 
03  E.  coli)  (S.  cerevisiae) 
3  2e 
203209  at  92  B0001866  RFC5  replication  factor  C  (activator  1)  5, 
04  -  36.5kDa 
48e  mat  96  B0005264  RPA3  replication  protein  A3,14kDa 
05 
5  5e 
203564  at  97  NM  004629  FANCG 
Fanconi  anemia,  complementation 
06  group  G 
6  0e- 
,  n4'(_`  s  ý!  99  NM  002452  NUDT1  nudix  (nucleoside  diphosphate 
linked  moiety  X)-type  motif  1 
5660  -  delta- 
DNA 
polymoraso 
6  6e 
204127  a  21  B0000149  RFC3  replication  factor  C  (activator  1)  3, 
38kDa 
cofactor 
03 
complex 
1  5e-  201202  at  69  NM  002592  PCNA  proliferating  cell  nuclear  antigen 
04 
8  7e-  replication  factor  C  (activator  1)  5, 
07 
203209  at  92  B0001866  RFC5  36.5kDa 
3684  -  1  le-  flap  structure-specific  damaged  DNA 
01 
2047  at  31  NM  004111  FEN1 
endonuclease  1 
binding 
1  9e-  mutS  homolog  2,  colon  cancer, 
0; 
O(A21  at 
- 
58  U04045  MSH2 
nonpolyposis  type  1  (E.  coli) Susan  M  Graham  2005  Appendix  1.22 
2.5e- 
03 
209849  s  at  74 
ý 
AF029669  !  RAD51  C  RAD51  homolog  C  (S.  cerevisiae) 
1  Ö4 
204531  s  at  77  NM  007295  BRCA1  breast  cancer  1  earl  onset  ,  y 
ý.  2e 
205024  s  at  84  NM  002875  RAD51  RAD51  homolog  (RecA  homolog, 
05  E.  coli)  (S.  cerevisiae) 
show  the  whole  group  06 
203564  at  97  NM  004629  FANCG  Fanconi  anemia,  complementation 
group  G 
.  5833  -  28 
hemoglobin  e-  206834 
03  at  3  NM  000519  HBD  hemoglobin,  delta 
complex 
605  -  213515  x  at  13  Al133353  HBG1  hemoglobin,  gamma  A 
2  -  ,  Iio  :  use  whole  group 
06 
20-9116  x  at  29  M25079  HBB  hemoglobin,  beta 
15671  -oxygen 
transport 
2.8e- 
206834 
03  at  3  NM  000519  HBD  hemoglobin,  delta 
le-  6 
05 
213515  x  at  13  Al133353  HBG1  hemoglobin,  gamma  A 
06 
209116  x  at  29  M25079  HBB  hemoglobin,  beta 
5344  -  oxygen 
_  3 
transporter 
03 
206834  at  3  NM  000519  HBD  hemoglobin,  delta 
activity 
X  1  9  at 
213515 
05 
13  Al133353  HBG1  hemoglobin,  gamma  A 
show  the  whoirý'J".  p 
ý406 
209116  x  at  29  M25079  HBB  hemoglobin,  beta 
4748- 
ribonucleoside-  2.1e-  ribonucleotide  reductase  M2  diphosphate  209773  s  04  at  1  B0001886  RRM2 
polypeptide 
reductase 
activity 
-  ------------  1.1e- 
201477  s  at  32  NM  001033  RRM1  ribonucleotide  reductase  M1 
05 
-----  --  -- 
polypeptide 
7089-  ý 
start  traversing  ll  di  l  i  i  2  G 
control  point  of 
2  5e- 
203213  at  4  AL524035  CDC2  ce  v  s  on  cyc  e  , 
1  to  S  and 
mitotic  cell 
03  G2  to  M 
cycle 
1.8e- 
203968  s  at  11  NM  001254  CDC6 
CDC6  cell  division  cycle  6 
05  homolog  (S.  cerevisiae) 
show  the  whole  group  1.5e-  204510  05  at  88  NM  003503  CDC7  CDC7  cell  division  cycle  7  (S. 
cerevisiae) 
7  -DNA 
i 
4.6e-  203968  t  11 
- 
NM  CDC6  cell  division  cycle  6 
p  replication  s  03  a  001254  CDC6 
homolog  (S.  cerevisiae) 
checkpoint 
show  the  whoEEe  <J  0uP 
205  1204126  s  at  19  NM  003504  CDC45L  CDC45  cell  division  cycle  45-like 
cerevisiae)  S  (  . Susan  M  Graham  2005  Appendix  1.23 
776  -  4.7e 
209642  at  33  AF043294  BUB1 
BUB1  budding  uninhibited  by 
kinetochore  02  benzimidazoles  1  homolog  (yeast) 
103 
203362  s  at  i  37  NM  002358  MAD2L1  MAD2  mitotic  arrest  deficient  like  1 
t  (yeas  ) 
2 
! 
BUB1  budding  uninhibited  by 
show  the  whose  group ý  203755 
05  at  41  NM  001211  BUB1B  1  benzimidazoles  1  homolog  beta 
(yeast) 
5876  -  spindle  53 
218009  s  03  at  14  NM  003981  PRC1  protein  regulator  of  cytokinesis  1 
ýnow  t  1(  whole  qt 
4.  Oe- 
202095  s  05  at  25  NM  001168  BIRC5  baculoviral  IAP  repeat-containing  5 
i  i  (surv  v  n) 
81  56  -  negative 
regulation  of  4.6e- 
203968  s  at  11  NM  001254  CDC6  CDC6  cell  division  cycle  6 
DNA  (  03  homolog  (S.  cerevisiae) 
replication 
4 
show  the  whole  group  5  218-5- 
0  at  27  NM  895  015  GMNN  geminin,  DNA  replication  inhibitor 
6189  -'de  novo' 
phosphoribosylaminoimidazole 
IMP  1  3.3e- 
201014  s  at  107  NM  006452  PAILS  1  carboxylase, 
biosynthesis 
02  1  phosphoribosylaminoimidazole 
succinocarboxamide  synthetase 
phosphoribosylglycinamide 
ý  formyltransferase, 
6.0e- 
212378  at  117  1  NM  000819  GART  phosphoribosylglycinamide 
04  synthetase, 
phosphoribosylaminoimidazole 
synthetase 
1.8e-  phosphoribosylformylglycinamidine 
04 
213302  at  251  AL044326  PFAS  synthase  (FGAR 
amidotransferase) 
9113  -  purine 
phosphoribosylaminoimidazole 
base 
4.4e- 
201014  s  at'  107  NM  006452  PAICS  carboxylase, 
biosynthesis 
02  phosphoribosylaminoimidazole 
succinocarboxamide  synthetase 
phosphoribosylglycinamide 
formyltransferase, 
1.1e-  212378  at  117  '  NM  000819  GART  Phosphoribosylglycinamide 
03  ,  synthetase, 
phosphoribosylaminoimidazole 
synthetase 
2.3e-  214431  at  176  NM  003875  GMPS  guanine  monphosphate 
04  synthetase 
2.2e 
209434  s  at  461  U00238  PPAT  phosphoribosyl  pyrophosphate 
04  amidotransferase 
5762  - 
mitochondrial 
large  ribosomal 
4.1e- 
218049  s  02  at  98  NM  014078  MRPL13  mitochondrial  ribosomal  protein 
L13 
subunit 
1.5e- 
03 
(203931 
s  at  144  NM  002949  MRPL12  mitochondria)  ribosomal  protein 
L12 Susan  M  Graham  2005  Appendix  1.24 
204 
208787  at  196  B0003375  MRPL3  mitochondrial  ribosomal  protein  L3 
2 
. 
2e- 
213897  sat  493  AI832239  MRPL23  mitochondria)  ribosomal  protein 
04 
166- 
nucleotide 
1.  Oe- 
203968  s  at  11  NM  001254  i  CDC6 
! 
CDC6  cell  division  cycle  6 
binding 
01  homolog  (S.  cerevisiae) 
1.1e- 
204033  at  17  NM  004237  TRIP13  thyroid  hormone  receptor 
02  interactor  13 
f  9.9e 
204127  at  21  B0000149  RFC3  replication  factor  C  (activator  1)  3, 
04  38kDa 
_f  1 
MCM4  minichromosome 
03 
222037  at  47  A1859865  MCM4  maintenance  deficient  4  (S. 
cerevisiae) 
1.1e- 
3  AF279900  MCM7 
MCM7  minichromosome 
03 
210983  s  at  8  maintenance  deficient  7  (S. 
cerevisiae) 
show  the  whole  group 
2.4e- 
i  203209  at  92  B0001866  RFC5  replication  factor  C  (activator  1)  5,  or  C 
04  3 
. 
5kDa Susan  M  Graham  2005  Appendix  1.25 
iGA  report  on  the  differentially  expressed  functional  gene 
classes:  up-regulated  Normal  GO  vs  Normal  Divided 
Functional 
4anoinics 
Facility 
General  Information 
Mode  Representative 
Number  of  genes  on  chip  12698 
Number  of  annotated  genes  9529 
Number  of  groups  3990 
Number  of  singletons  1646 
Significance  threshold  2.5e-04 
File  name  IN  GO  vs  ND 
Group  Changed  P-Value  Percent 
Top  Changed  Groups  Members  Members  Changed  Changed 
8009  -  chemokine  activity  40  -1  9  2.4e-10  I  22.50 
6935  -  chemotaxis  86  10  8.7e-09  11.63 
7001  -  chromosome  organization 
and  biogenesis  (sensu  54  7  5.5e-08  12.96 
Eukaryota) 
786  -  nucleosome  42  5  2.8e-07  1  11.90 
5  6334  -  nucleosome  assembly 
T  47  5 
. 
Oe-07  1  10.64 
569  94  -  chromosome  37  4  7.3e-06  ---  10.81 
6928  -  cell  motility  99  7j  5.9e-05  7.07 
8219  -  cell  death  16  3  1.2e-04  18.75 
9596  -  detection  of  pest,  4  4  2.4e-04  100.00 
pathogen  or  parasite 
16126  -  sterol  biosynthesis  3  3  2.4e-04  100.00 
OVuV 
chemokine  1.7e-02  210163  at  4  AF030514  CXCL11  chemokine  (C  X-C 
motif)  ligand  11 
activity 
6e-04  1209774 
x  at  7  10  M57731  CXCL2  chemokine  (C-X-C 
.  motif)  ligand  2 
1.1e-04  204533  at  23  NM  001565  CXCL10  chemokine  (C-X-C 
d  10  li  f  gan  moti  ) 
205242  at  3.2e-06  25  !  NM  006419  CXCL13  chemokine  (C-X-C 
mntifl  linanrl  1  (R- Susan  M  Graham  2005  Appendix  1.26 
-  ----- 
cell 
chemoattractant) 
4.  Oe-07  207850  at  37  NM  002090  CXCL3  I  chemokine  (C-X-C 
motif)  ligand  3 
chemokine  (C-X-C 
motif)  ligand  6 
1.7e-08  206336  at  42  NM  002993  CXCL6  (granulocyte 
chemotactic 
protein  2) 
chemokine  (C-X-C 
motif)  ligand  1 
2.7e-09  204470  at  56  NM  001511  CXCL1  (melanoma  growth 
stimulating  activity, 
alpha) 
1.4e-09  202859-x  at  82  NM  000584  IL8  interleukin  8 
show  the  whole  2.4e-10  210072  at  88  U88321  CCL19  chemokine  (C-C 
group  I  motif)  ligand  19 
chemokine  (C-X-C  6935  -- 
chemotaxis 
3.6e02  210163  at  4  AF030514  CXCL11 
motif)  ligand  11 
3.5e-03209774  x  at  10  M57731  CXCL2  chemokine  (C-X-C 
motif)  ligand  2 
1.1  e-03  204533  at  23 
!; 
NM  001565  chemokine 
motif)  ligand 
(C-X-C  CXCL10 
10 
chemokine  (C-X-C 
6.8e-05  205242  at  25  NM  006419  motif)  ligand  13  (B-  CXCL13 
cell 
chemoattractant) 
---  ------  -----  -  r--  --  -  -----  --  ---  --- 
1.8e-05  207850  at  37  NM  002090  CXCL3  chemokine  (C-X-C 
motif)  ligand  3 
chemokine  (C-X-C 
motif)  ligand  6 
1.8e-06  206336  at  42  1  NM  002993  CXCL6  (granulocyte 
chemotactic 
protein  2) 
chemokine  (C-X-C 
motif)  ligand  1 
6.2e-07  204470  at  56  NM  001511  CXCL1  (melanoma  growth 
stimulating  activity, 
alpha) 
interleukin  8  6.6e-07  1202859  x  at 
r  82  [NM  000584  IL8 
[8.3e 
08  210072  at  88  U88321  CCL19  chemokine  (C-C 
motif)  ligand  19 
v-ral  simian 
show  the  whole 
leukemia  viral 
group 
8.7e-09  214435  x  at  92  NM  005402  RALA 
oncogene  homolog 
A  (ras  related) 
7001  - 
-----------  i 
chromosome 
organization 
1.1e-02  1215071  s  at  j2  AL353759  HIST1  H2AC  histone  1,  H2ac 
and Susan  M  Graham  2005  Appendix  1.27 
biogenesis 
(sensu 
Eukaryota) 
9.4e-05  X202708  s  at 
r3  NM  003528  HIST2H2BE  histone  2,  H2be 
6.  Oe-05  209806  at  14  80000893  HIST1  H2BK  histone  1,  H2bk 
9.0e-06  214290  s  at,  24  A1313324  HIST2H2AA  ,  histone  2,  H2aa 
stone  f  1.0e-06  208886  at  33  B0000145  H1  FO  H1  hi 
m  ember 
p  ily, 
alpha 
thalassemia/mental 
retardation  4.7e-07  208859  s  at  53  A1650257  ATRX 
syndrome  X-linked 
1 
(RAD54  homolog, 
S.  cerevisiae) 
show 
group 
whole  5.5e-08 
x209911 
x  at 
p63  (B0002842 
HIST1H2BD  histone  1,  H2bd 
786  - 
nucleosome 
8.8e-03  215071  s  at  2  AL353759  HIST1H2AC  histone  1,  H2ac 
5.7e-05  202708  s  at  3  NM  003528  HIST2H2BE  histone  2,  H2be 
209806  a1  4  B0000893  HIST1H2BK  r  histone  1,  H2bk  ý-  -  -f  2.8e-05 
[ 
. 
3e-06  1214290 
s  at  24  r  A1313324  HIST2H2AA  histone  2,  H2aa 
tone  family,  show  the  whol? 
f  H1  his  le 
He 
-07  208886  at  33  B0000145  H1FO 
group  I  member  0 
6334  - 
nucleosome  9.8e-03  215071  s  at  2  AL353759  HIST1  H2AC  histone  1,  H2ac 
assembly 
7.1e-05  202708  s  at  3  NM  003528  HIST2H2BE  histone  2,  H2be 
-3.9e-05  209806  at  14  B0000893  HIST1H26K  histone  1,  H2bk 
5.1e-06  1214290  s  at  24  A1313324  HIST2H2AA  '  histone  2,  H2aa 
show  the  whole 
[oe07  H1  histone  family, 
208886  at  33  B0000145  H1  FO 
group  member  0 
5694  -  7.8e-03  215071  s  at  2  AL353759  HIST1  H2AC  histone  1,  H2ac 
chromosome 
4.4e-05  X202708  s  at 
F3  NM  003528  HIST2H26E  histone  2,  H2be 
1.0e-04214290  s  at 
l  24  A1313324  HIST2H2AA  histone  2,  H2aa 
show  the  whole  7.3e-06  208886  at  33  B0000145  H1  FO 
H1  histone  family, 
member  0 
6928  -  cell  chemokine  (C-X-C 
2.1e-01  204533  a 
motility 
23  NM  001565  CXCL10 
motif)  ligand  10 
prostaglandin- 
endoperoxide 
3.6e-02  204748  at  29  NM  000963  PTGS2  synthase  2 
(prostaglandin  G/H 
synthase  and 
cyclooxygenase) 
1.3e-02  transmembrane  4 
209108  at  47  AF053453  TM4SF6 
I  cunPrfamily Susan  M  Graham  2005  Appendix  1.28 
member  6 
1.6e-03  203476  at  49 
[NM 
006670  TPBG 
trophoblast 
glycoprotein 
[1.3e-03  205844  at  1  78  !  NM  004666  VNN1  vanin  1 
2.  Oe-04  1202859  x  at  82  NM  000584  i-  1  IL8  interleukin  8 
Show  the  whose  5.9e-05  201005  at  96  I  NM  001769 
group 
CD9  CD9  antigen  (p24) 
8219  -  cell 
epithelial 
death 
1.0e-02  201324  at  6  NM  001423  EMP1  membrane  protein 
1 
optineurin  2.3e-03  202073  at  43  AV757675  OPTN 
amyloid  beta  (A4) 
show  the  whole  1.2e-04  200602  at  59  'NM  000484  APP  precursor  protein 
group  (protease  nexin-II, 
Alzheimer  disease) 
-  9596- 
detection  of 
pest,  1.8e-01  205101  at  463  NM  000246  MHC2TA 
MHC  class  II 
pathogen  or 
transactivator 
parasite 
major 
1.4e-02  217478  s  at  472  X76775  HLA-DMA 
histocompatibility 
complex,  class  II, 
DM  alpha 
major 
8.5e-04  1  203932  at  525  !  NM  002118  '  HLA-DMB 
2.4e-04  210514  x  at  695  AF226990 
---16126- 
213577  at  150  AA639705  sterol  4.6e-02 
biosynthesis 
2.6e-03  209146  at  273  AV704962 
2.4e-04  211423  s  at  415  D85181 
HLA-G 
histocompatibility 
complex,  class  II, 
DM  beta 
HLA-G 
histocompatibility 
antigen,  class  I,  G 
SALE  squalene 
epoxidase 
SC4MOL  sterol-C4-methyl 
oxidase-like 
sterol-C5- 
desaturase  (ERG3 
SC5DL  delta-5-desaturase 
homolog,  fungal)- 
like Susan  M  Graham  2005  Appendix  1.30 
7.4e-06  203418  at  17  NM  001237  CCNA2  cyclin  A2 
hepatocyte 
5.8e-07  210997  at  22  M77227  HGF  growth  factor 
(hepapoietin  A; 
scatter  factor) 
CDC20  cell 
7.4e-08  202870  s  at  , 
29  NM  001255  CDC20  division  cycle  20 
homolog  (S. 
cerevisiae) 
chromosome 
3.8e-09  218663  at  32  NM  022346  HCAP-G  condensation 
protein  G 
7.3e-10  219306  at  40  :  NM  020242  j  KNSL7  kinesin-like  7 
coronin,  actin 
1.8e-10  209083  at  43  U34690  COROIA  binding  protein, 
1A 
show  the  whole  1  5e-10  202240  at  44  NM  005030  PLK1  polo-like  kinase  1 
g  oup  .  (Drosophila) 
5819  -  spindle  2.6e-02  204444  at  23  NM  004523  KIF1  1 
kinesin  family 
b  11  mem  er 
-_---  -  -  ý  -  I 
---  -  ---  ---  !  CDC20  cell 
8e-04  4  202870  s  at  29  NM  001255  CDC20  division  cycle  20 
.  homolog  (S. 
cerevisiae) 
2.0e-05  1204709  s  at  49  NM  004856  KIF23 
kinesin  family 
b  mem  er  23 
0e-07  3  208079  s  at  54  NM  003158  STK6  serine/threonine 
.  kinase  6 
TPX2, 
microtubule- 
show  the  whole whole  5.7e-09  210052  s  at  65  AF098158  TPX2  associated  g 
protein  homolog 
(Xenopus  laevis) 
5871  -  kinesm  f  kinesin  family 
complex 
2.2e-02  204444  at  23  NM  004523  KIF11 
member  11 
1e-04  9  204709  s  at  49  NM  004856  KIF23 
kinesin  family 
.  member  23 
snow  she  whole  8e-05  2  209408  at  68  U63743  KIF2C 
kin  esin  family 
group  .  member  2C 
775- 
chromosome,  8  5e-03  204162  at  9  NM  006101  KNTC2 
kinetochore 
pericentric  .  associated  2 
region 
--  _-_-- 
11  NM  0 
-- 
centromere  4.3e-05  204962  s  at  01809  CC  ENPA 
I  protein  A,  17kDa 
show  the  whole  8e-05  2  209408  at  68  U  63743  KIF2C 
kinesin  family 
.  member  2C 
3777-  6.3e-02  1  204444  at  23  NM  004523  KIF11 
kinesin  family 
microtubule  member  11 Susan  M  Graham  2005  Appendix  1.29 
iGA  report  on  the  differentially  expressed  functional  gene 
classes:  up-regulated  CML  Divided  vs  CML  GO 
General  Information 
Mode 
Number  of  genes  on  chip 
Number  of  annotated  genes 
Number  of  groups 
Number  of  singletons 
Significance  threshold 
File  name 
I  Representative 
12698 
9531 
3990 
1648 
2.5e-04 
ICML  GO  vs  CML  DIV 
Grou  Changed  P-Value  Percent 
Top  Changed  Groups 
Members  Members  Changed  Chanqed 
7067  -  mitosis  74  10  1.5e-10  13.51 
5819  -spi4e  11  5  5.7e-09  45.45 
5871  -  kinesin  complex  9  3  2.8e-05  33.33 
775  -  chromosome,  9  3  2.8e-05  33.33 
pericentric  region 
3777  -  microtubule  motor 
1 
4  4  5  05  1  27  e-  . 
4.81 
activit 
4869  -  cysteine  protease  16  3  4  6  05  18  75 
inhibitor  activity 
e-  .  . 
278  -  mitotic  cell  cycle  3  2  7.1e-05  66.67 
776  -  kinetochore  14  3  1  1e-04  21.43 
5876  -  spindle  microtubule  4  3  2.1  e-04  75.00 
22  -  mitotic  spindle  2  2  2.2e-04  100.00 
elongation 
Changed  group  br  eakdown: 
Group 
P-value  e-set  Prob 
Rank  Gene  ID  Gene  Title 
D  Sy 
cell  division  cycle 
7067  -  mitosis  5.3e-02  203213  at  i7  AL524035  CDC2  2,  G1  to  S  and 
G2toM 
2.1  e-03  204162  at  9I  NM  006101  KNTC2 
kmetochore 
associated  2 
ubiquitin- 
5.2e-05  202954  at  10  NM  007019  UBE2C  conjugating 
enzyme  E2C Susan  M  Graham  2005 
motor  activity 
8.4e-03 
, 
204709  s  at 
9.0e-04  1  209408  at 
whole  show  the 
5.4e-05  218355  at  75  NM  012310  KIF4A  kinesin  family 
O1  p  member  4A 
4869  - 
cysteine 
c  statin  A  (stefin 
protease  5.0e-03  204971  at  3  NM  005213  CSTA  y 
A) 
inhibitor 
activity 
2  5e-03  210140  at  45  AF031824  CST7  cystatin  F 
.  (leukocystatin) 
show  the  whole 
baculoviral  IAP 
6.4e-05  202095  s  at  48  NM  001168  BIRC5  repeat-containing  group 
5  (survivin) 
chromosome  278  -  mitotic  1.  Oe-02  218663  at  32  NM  022346  HCAP-G  condensation 
cell  cycle  , 
protein  G 
show  the  whole  7  1e-05  212949  at  47  D38553  BRRN1 
barren  homolog 
4rOUp  .  (Drosophila) 
BUB1  budding 
776  7  1e-02  209642  at  50  AF043294  BUB1  uninhibited  by 
kinetochore  .  benzimidazoles  1 
homolog  (yeast) 
MAD2  mitotic 
3.6e-03  11203362  s  at!  62  NM  002358  MAD2L1  I  arrest  deficient- 
like  1  (yeast) 
BUB1  budding 
uninhibited  by 
up  hole  show  rh 
1.1e-04  203755  at  66  NM  001211  BUB1  B  benzimidazoles  I 
o 
1  homolog  beta 
(yeast) 
baculoviral  IAP 
5876  -  spindle  2.  Oe-02  202095  s  at  ,  48  I  NM  001168  I  BIRC5  repeat-containing 
microtubule  5  (survivin) 
kinesin  family 
3.6e-04  218355  at  75  NM  012310  KIF4A 
member  4A 
show  the  whole  1  e-04  2  1218009  s  at  104  NM  003981  PRC1  protein  regulator 
group  ,  of  cytokinesis  1 
22  -  mitotic 
spindle  1.  Oe-02  204709  s  at  49  NM  004856  KIF23 
kinesin  family 
member  23 
elongation 
1  protein  regulator  2.2e-04  218009  s  at  04  NM  003981  PRC1 
of  cytokinesis  1 
Appendix  1.31 
I 
49  NM  004856  KI  F23 
menesin 
fa 
mber  23 
68  U63743  KIF2C 
kinesin  family 
member  2C Susan  M  Graham  2005  Appendix  1.32 
iGA  report  on  the  differentially  expressed  functional  gene 
classes:  up-regulated  CML  GO  vs  CML  Divided 
General  Information 
Mode  Representative 
Number  of  genes  on  chip  12698 
Number  of  annotated  genes  9532 
Number  of  groups  3991 
Number  of  singletons  1649 
Significance  threshold  [  2.5e-04 
File  name 
I  ICML  GO  vs  CML  DIV 
Group  Changed  P-Value  Percent 
Top  Changed  Groups  Members  Members  Changed  Changed 
8009  -  chemokine  activity 
I  40  7  4.  Oe-11  I-17.50 
6935  -  chemotaxis  86  9  F  2.0e-08  [10.47 
5833  -  hemoglobin  complex  9  3  5.7e-05  33.33 
47115  -  trans-1,2-dihydrobenzene-  3  2  1.3e-04  66  67 
1  2-diol  dehydrogenase  activity  . 
15125  -  bile  acid  transporter  3  2  1.3e-04  66  67 
activity  . 
Changed  group  breakdown: 
Group  P-value 
Probe-set  Rank  Gene  ID 
Gene 
Title 
ID  Symbol 
8009  -  chemokine  (C-X- 
chemokine  11.7e-02  210163  at  4  AF030514  CXCL11  C  motif)  ligand 
activity  11 
chemokine  (C-X- 
2.5e-04  204533  at  6  NM  001565  CXCL10  C  motif)  ligand 
10 
interleukin  ý2.4e-06  [202859 
x  at  ;7  NM  000584  IL8  8 
chemokine  (C-X- 
1.3e07  207850  at  12  NM  002090  CXCL3 
C  motif)  ligand  3 
chemokine  (C-X- 
C  motif)  ligand  1 
9e-09  204470  at  15  NM  001511  CXCL1  (melanoma  2 
.  growth 
stimulating 
activity,  alpha) 
05114  s  at  18  NM  002983  '',  MGC12815  rhamnkine  (C-('  8.7e-11  :  205114-s- Susan  M  Graham  2005  Appendix  1.33 
motif)  ligand  3- 
like,  centromeric 
show  the  whole  group  4.  Oe-11  209774  x  at  24  M57731  CXCL2  chemokine  (C-X- 
C  motif)  ligand  2 
6935  - 
chemotaxis 
3.6e-02  210163  at  4  AF030514  CXCL11  C  motif)  ligand 
11 
chemokine  (C-X- 
1.2e-03  204533  at  6I  NM  001565  CXCL10  C  motif)  ligand 
10 
ý2  4e-05  202859  x  at  7  NM  000584  r  IL8  interleukin  8 
2.9e-06  207850  at  chemokine  (C-X-  12  NM  002090  CXCL3 
C  motif)  ligand  3 
chemokine  (C-X- 
1.5e-07  1  204470  at 
C  motif)  ligand  1 
15  NM  001511  CXCL1  (melanoma 
growth 
stimulating 
activity,  alpha) 
X-  [5.  -4e-08 
209774  x  at  24  M57731  CXCL2 
C 
che 
motif) 
mokine  (C- 
ligand  2 
chemokine  (C-X- 
C  motif)  ligand  6 
1.3e-07  206336  at  45  I  NM  002993  CXCL6  (granulocyte 
chemotactic 
protein  2) 
chemokine  (C-X-  3.7e-08  214974  x  at  57  AK026546  CXCL5 
C  motif)  ligand  5 
r-  - 
chemokine  (C-X- 
show  the  whole  group  2.0e-08  205242  at  75  NM  006419  CXCL13 
C  motif)  ligand 
13  (B-cell 
chemoattractant) 
5833- 
hemoglobin  2.8e-02  209116  x  at  30  M25079  HBB 
beta 
complex 
hemoglobin, 
2.7e-03  204419  x  at 
!  85  NM  000184  HBG1 
gamma  A 
erythroid 
show  the  whole  group  5.7e-05  219672  at  86  NM  016633  ERAF  associated 
factor 
47115  -  trans- 
1,2- 
dihydrobenzene- 
1,2-diol 
dehydrogenase 
activity 
1.2e-02  !  204151  x  at  37  I  NM  001353 
aldo-keto 
reductase  family 
1,  member  C1 
(dihydrodiol 
AKR1C1  dehydrogenase 
1;  20-alpha  (3- 
alpha)- 
hydroxysteroid 
dehydrogenase) 
show  the  whole  group  1.3e-04  216594  x  at  64  S68290  AKR  1  C1 
AKR1C2 
chemokine  (C-X- 
C  motif)  ligand 
11 
aldo-keto 
rpdiiu:  taca  family Susan  M  Graham  2005  Appendix  1.34 
1,  member  C1 
(dihydrodiol 
dehydrogenase 
1;  20-alpha  (3- 
alpha)- 
hydroxysteroid 
dehydrogenase) 
///  aldo-keto 
reductase  family 
1,  member  C2 
(dihydrodiol 
dehydrogenase 
2;  bile  acid 
binding  protein; 
3-alpha 
hydroxysteroid 
dehydrogenase, 
type  III) 
aldo-keto 
reductase  family 
1,  member  Cl 
(dihydrodiol 
dehydrogenase 
1;  20-alpha  (3- 
alpha)- 
hydroxysteroid 
dehydrogenase) 
[-F-  Fi- 
15125  -  bile  acid 
transporter  1.2e-02  204151  x  at  37  jNM  001353  AKR1C1 
activity 
show  the  whole  group  1.3e-04  ý  216594  x  at  64  S68290 
AKR  1C1 
AKR1C2 
aldo-keto 
reductase  family 
1,  member  C1 
(dihydrodiol 
dehydrogenase 
1;  20-alpha  (3- 
alpha)- 
hydroxysteroid 
dehydrogenase) 
///  aldo-keto 
reductase  family 
1,  member  C2 
(dihydrodiol 
dehydrogenase 
2;  bile  acid 
binding  protein; 
3-alpha 
hydroxysteroid 
dehydrogenase, 
type  III) 